<!DOCTYPE html >
<html lang="en">
<head>
    <meta charset="UTF-8">
    <link rel="stylesheet" type="text/css" href='https://code.jquery.com/ui/1.11.4/themes/smoothness/jquery-ui.css'/>
    <link rel="stylesheet"
          href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
    <link rel="stylesheet"
          href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/4.0.0-alpha.6/css/bootstrap.min.css"/>
    <style>
        .link_continuous {
            fill: none;
            stroke-width: 1px;
        }

        .link_dashed {
            fill: none;
            stroke-width: 1px;
            stroke-dasharray: 4, 4;

        }

        .Pathology {
            fill: #FF7F0E;
        }

        .Abundance {
            fill: #AEC7E8;
        }

        .Gene {
            fill: #FFBB78;
        }

        .miRNA {
            fill: #D62728;
        }

        .Protein {
            fill: #1F77B4;
        }

        .RNA {
            fill: #FF9896;
        }

        .BiologicalProcess {
            fill: #2CA02C;
        }

        .Pathology {
            fill: #FF7F0E;
        }

        .Complex {
            fill: #98DF8A;
        }

        .Composite {
            fill: #9467BD;
        }

    </style>
    <script type="text/javascript">
        window.graph = {"directed": true, "multigraph": true, "graph": {"pybel_version": "0.4.1", "annotation_list": {}}, "nodes": [{"function": "Protein", "namespace": "HGNC", "name": "GRIN2B", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": ["Protein", "HGNC", "GRIN2B", ["pmod", ["bel", "Ph"]]]}, {"function": "Abundance", "namespace": "CHEBI", "name": "ATP", "id": ["Abundance", "CHEBI", "ATP"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "electron transport chain", "id": ["BiologicalProcess", "GOBP", "electron transport chain"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "mitochondrial calcium ion homeostasis", "id": ["BiologicalProcess", "GOBP", "mitochondrial calcium ion homeostasis"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "mitochondria-nucleus signaling pathway", "id": ["BiologicalProcess", "GOBP", "mitochondria-nucleus signaling pathway"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "apoptotic process", "id": ["BiologicalProcess", "GOBP", "apoptotic process"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "reactive oxygen species metabolic process", "id": ["BiologicalProcess", "GOBP", "reactive oxygen species metabolic process"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "positive regulation of neuron apoptotic process", "id": ["BiologicalProcess", "GOBP", "positive regulation of neuron apoptotic process"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "calcium(2+)", "id": ["Abundance", "CHEBI", "calcium(2+)"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron projection development", "id": ["BiologicalProcess", "GOBP", "neuron projection development"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cell-cell adhesion involved in synapse maturation", "id": ["BiologicalProcess", "GOBP", "cell-cell adhesion involved in synapse maturation"]}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "frag", "start": 672, "stop": 713}], "id": ["Protein", "HGNC", "APP", ["frag", [672, 713]]]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "calcium ion homeostasis", "id": ["BiologicalProcess", "GOBP", "calcium ion homeostasis"]}, {"function": "Abundance", "namespace": "BRCO", "name": "Microglia", "id": ["Abundance", "BRCO", "Microglia"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Neurogenic Inflammation", "id": ["Pathology", "MESHD", "Neurogenic Inflammation"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "nitric oxide", "id": ["Abundance", "CHEBI", "nitric oxide"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of synaptic transmission, cholinergic", "id": ["BiologicalProcess", "GOBP", "regulation of synaptic transmission, cholinergic"]}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": ["Protein", "HGNC", "MAPT", ["pmod", ["bel", "Ph"]]]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "synaptic transmission", "id": ["BiologicalProcess", "GOBP", "synaptic transmission"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "negative regulation of neuron projection regeneration", "id": ["BiologicalProcess", "GOBP", "negative regulation of neuron projection regeneration"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron apoptotic process", "id": ["BiologicalProcess", "GOBP", "neuron apoptotic process"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron death", "id": ["BiologicalProcess", "GOBP", "neuron death"]}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR181C", "id": ["miRNA", "HGNC", "MIR181C"]}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR9-1", "id": ["miRNA", "HGNC", "MIR9-1"]}, {"function": "Abundance", "namespace": "SCHEM", "name": "Calcium", "id": ["Abundance", "SCHEM", "Calcium"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "inflammatory response", "id": ["BiologicalProcess", "GOBP", "inflammatory response"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Inflammation", "id": ["Pathology", "MESHD", "Inflammation"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Hypertension", "id": ["Pathology", "MESHD", "Hypertension"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Cerebral Amyloid Angiopathy", "id": ["Pathology", "MESHD", "Cerebral Amyloid Angiopathy"]}, {"function": "Abundance", "namespace": "SCHEM", "name": "sulfatide", "id": ["Abundance", "SCHEM", "sulfatide"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "reactive oxygen species", "id": ["Abundance", "CHEBI", "reactive oxygen species"]}, {"function": "Protein", "namespace": "HGNC", "name": "H3F3A", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ac"}}], "id": ["Protein", "HGNC", "H3F3A", ["pmod", ["bel", "Ac"]]]}, {"function": "Abundance", "namespace": "SCHEM", "name": "Glatiramer acetate", "id": ["Abundance", "SCHEM", "Glatiramer acetate"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Alzheimer Disease", "id": ["Pathology", "MESHD", "Alzheimer Disease"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "synaptic transmission, cholinergic", "id": ["BiologicalProcess", "GOBP", "synaptic transmission, cholinergic"]}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR29A", "id": ["miRNA", "HGNC", "MIR29A"]}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR107", "id": ["miRNA", "HGNC", "MIR107"]}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR124-1", "id": ["miRNA", "HGNC", "MIR124-1"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "acetylcholine", "id": ["Abundance", "CHEBI", "acetylcholine"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "cortisol", "id": ["Abundance", "CHEBI", "cortisol"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Wounds and Injuries", "id": ["Pathology", "MESHD", "Wounds and Injuries"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cytokine production involved in inflammatory response", "id": ["BiologicalProcess", "GOBP", "cytokine production involved in inflammatory response"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "production of molecular mediator involved in inflammatory response", "id": ["BiologicalProcess", "GOBP", "production of molecular mediator involved in inflammatory response"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "microglial cell activation involved in immune response", "id": ["BiologicalProcess", "GOBP", "microglial cell activation involved in immune response"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cognition", "id": ["BiologicalProcess", "GOBP", "cognition"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "learning", "id": ["BiologicalProcess", "GOBP", "learning"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "memory", "id": ["BiologicalProcess", "GOBP", "memory"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "gamma-aminobutyric acid", "id": ["Abundance", "CHEBI", "gamma-aminobutyric acid"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "glutamate(1-)", "id": ["Abundance", "CHEBI", "glutamate(1-)"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "calcium ion import", "id": ["BiologicalProcess", "GOBP", "calcium ion import"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "galanthamine", "id": ["Abundance", "CHEBI", "galanthamine"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "1-(3-chlorophenyl)piperazine", "id": ["Abundance", "CHEBI", "1-(3-chlorophenyl)piperazine"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cAMP catabolic process", "id": ["BiologicalProcess", "GOBP", "cAMP catabolic process"]}, {"function": "Abundance", "namespace": "CHEMBL", "name": "Nefiracetam", "id": ["Abundance", "CHEMBL", "Nefiracetam"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "long-term synaptic potentiation", "id": ["BiologicalProcess", "GOBP", "long-term synaptic potentiation"]}, {"function": "Complex", "namespace": "SCOMP", "name": "CAMK2 Complex", "id": ["Complex", "SCOMP", "CAMK2 Complex"]}, {"function": "Complex", "id": ["Complex", ["Abundance", "CHEMBL", "Nefiracetam"], ["Protein", "HGNC", "PRKCA"]]}, {"function": "Protein", "namespace": "HGNC", "name": "GRIA1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 831}], "id": ["Protein", "HGNC", "GRIA1", ["pmod", ["bel", "Ph"], "Ser", 831]]}, {"function": "Complex", "id": ["Complex", ["Protein", "HGNC", "EGR1"], ["Protein", "HGNC", "PSEN2"]]}, {"function": "Abundance", "namespace": "CHEBI", "name": "copper sulphate(5.H2O)", "id": ["Abundance", "CHEBI", "copper sulphate(5.H2O)"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "estradiol", "id": ["Abundance", "CHEBI", "estradiol"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of neuronal synaptic plasticity", "id": ["BiologicalProcess", "GOBP", "regulation of neuronal synaptic plasticity"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of synaptic plasticity", "id": ["BiologicalProcess", "GOBP", "regulation of synaptic plasticity"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of N-methyl-D-aspartate selective glutamate receptor activity", "id": ["BiologicalProcess", "GOBP", "regulation of N-methyl-D-aspartate selective glutamate receptor activity"]}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ub"}}], "id": ["Protein", "HGNC", "APP", ["pmod", ["bel", "Ub"]]]}, {"function": "Composite", "id": ["Composite", ["Protein", "HGNC", "IFNG"], ["Protein", "HGNC", "TNF"]]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "endocytosis", "id": ["BiologicalProcess", "GOBP", "endocytosis"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "metformin", "id": ["Abundance", "CHEBI", "metformin"]}, {"function": "Gene", "namespace": "HGNC", "name": "APP", "id": ["Gene", "HGNC", "APP"]}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR101-1", "id": ["miRNA", "HGNC", "MIR101-1"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "rivastigmine", "id": ["Abundance", "CHEBI", "rivastigmine"]}, {"function": "Abundance", "namespace": "BRCO", "name": "Astrocyte", "id": ["Abundance", "BRCO", "Astrocyte"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "cholesterol", "id": ["Abundance", "CHEBI", "cholesterol"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "donepezil", "id": ["Abundance", "CHEBI", "donepezil"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "minocycline", "id": ["Abundance", "CHEBI", "minocycline"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "resveratrol", "id": ["Abundance", "CHEBI", "resveratrol"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "rosiglitazone", "id": ["Abundance", "CHEBI", "rosiglitazone"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "simvastatin", "id": ["Abundance", "CHEBI", "simvastatin"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "streptozocin", "id": ["Abundance", "CHEBI", "streptozocin"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "vitamin E", "id": ["Abundance", "CHEBI", "vitamin E"]}, {"function": "Complex", "namespace": "SCOMP", "name": "gamma Secretase Complex", "id": ["Complex", "SCOMP", "gamma Secretase Complex"]}, {"function": "Protein", "namespace": "HGNC", "name": "APOE", "variants": [{"kind": "hgvs", "identifier": "p.Arg132Ser"}], "id": ["Protein", "HGNC", "APOE", ["hgvs", "p.Arg132Ser"]]}, {"function": "Abundance", "namespace": "CHEBI", "name": "hydrogen peroxide", "id": ["Abundance", "CHEBI", "hydrogen peroxide"]}, {"function": "Abundance", "namespace": "SCHEM", "name": "isoprostane", "id": ["Abundance", "SCHEM", "isoprostane"]}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "hgvs", "identifier": "p.Asn10Tyr"}], "id": ["Protein", "HGNC", "APP", ["hgvs", "p.Asn10Tyr"]]}, {"function": "Abundance", "namespace": "SCHEM", "name": "Probucol", "id": ["Abundance", "SCHEM", "Probucol"]}, {"function": "Complex", "id": ["Complex", ["Protein", "HGNC", "ACHE"], ["Protein", "HGNC", "APP", ["frag", [672, 713]]]]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of ryanodine-sensitive calcium-release channel activity", "id": ["BiologicalProcess", "GOBP", "regulation of ryanodine-sensitive calcium-release channel activity"]}, {"function": "Complex", "id": ["Complex", ["Protein", "HGNC", "APBB1"], ["Protein", "HGNC", "APP"], ["Protein", "HGNC", "LRP1"]]}, {"function": "Gene", "namespace": "HGNC", "name": "APOE", "id": ["Gene", "HGNC", "APOE"]}, {"function": "Gene", "namespace": "HGNC", "name": "PSEN1", "id": ["Gene", "HGNC", "PSEN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PSEN2", "id": ["Gene", "HGNC", "PSEN2"]}, {"function": "Gene", "namespace": "HGNC", "name": "PPARG", "id": ["Gene", "HGNC", "PPARG"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "maintenance of blood-brain barrier", "id": ["BiologicalProcess", "GOBP", "maintenance of blood-brain barrier"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "insulin receptor signaling pathway", "id": ["BiologicalProcess", "GOBP", "insulin receptor signaling pathway"]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "negative regulation of insulin receptor signaling pathway", "id": ["BiologicalProcess", "GOBP", "negative regulation of insulin receptor signaling pathway"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "memantine", "id": ["Abundance", "CHEBI", "memantine"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "paroxetine", "id": ["Abundance", "CHEBI", "paroxetine"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "(R)-flurbiprofen", "id": ["Abundance", "CHEBI", "(R)-flurbiprofen"]}, {"function": "Composite", "id": ["Composite", ["Protein", "HGNC", "NOS3"], ["Protein", "HGNC", "PIN1"]]}, {"function": "Abundance", "namespace": "CHEBI", "name": "pioglitazone", "id": ["Abundance", "CHEBI", "pioglitazone"]}, {"function": "Abundance", "namespace": "ADO", "name": "neuroprotectin", "id": ["Abundance", "ADO", "neuroprotectin"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "acrolein", "id": ["Abundance", "CHEBI", "acrolein"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "5-chloro-7-iodoquinolin-8-ol", "id": ["Abundance", "CHEBI", "5-chloro-7-iodoquinolin-8-ol"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "curcumin", "id": ["Abundance", "CHEBI", "curcumin"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "indometacin", "id": ["Abundance", "CHEBI", "indometacin"]}, {"function": "Protein", "namespace": "HGNC", "name": "A2M", "variants": [{"kind": "hgvs", "identifier": "p.Val1000Ile"}], "id": ["Protein", "HGNC", "A2M", ["hgvs", "p.Val1000Ile"]]}, {"function": "Gene", "namespace": "HGNC", "name": "BIN1", "id": ["Gene", "HGNC", "BIN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CR1", "id": ["Gene", "HGNC", "CR1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CLU", "id": ["Gene", "HGNC", "CLU"]}, {"function": "Gene", "namespace": "HGNC", "name": "PICALM", "id": ["Gene", "HGNC", "PICALM"]}, {"function": "Gene", "namespace": "HGNC", "name": "CD33", "id": ["Gene", "HGNC", "CD33"]}, {"function": "Gene", "namespace": "HGNC", "name": "CD2AP", "id": ["Gene", "HGNC", "CD2AP"]}, {"function": "Gene", "namespace": "HGNC", "name": "GAB2", "id": ["Gene", "HGNC", "GAB2"]}, {"function": "Complex", "id": ["Complex", ["Protein", "HGNC", "APOE"], ["Protein", "HGNC", "APP", ["frag", [672, 713]]]]}, {"function": "Gene", "namespace": "dbSNP", "name": "rs610932", "id": ["Gene", "dbSNP", "rs610932"]}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Oxidative Stress", "id": ["BiologicalProcess", "MESHPP", "Oxidative Stress"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "physostigmine", "id": ["Abundance", "CHEBI", "physostigmine"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "androgen", "id": ["Abundance", "CHEBI", "androgen"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Hypercholesterolemia", "id": ["Pathology", "MESHD", "Hypercholesterolemia"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "melatonin", "id": ["Abundance", "CHEBI", "melatonin"]}, {"function": "Complex", "id": ["Complex", ["Protein", "HGNC", "APOE"], ["Protein", "HGNC", "APP"]]}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "chemokine biosynthetic process", "id": ["BiologicalProcess", "GOBP", "chemokine biosynthetic process"]}, {"function": "Pathology", "namespace": "MESHD", "name": "Diabetes Mellitus, Type 2", "id": ["Pathology", "MESHD", "Diabetes Mellitus, Type 2"]}, {"function": "Abundance", "namespace": "SCHEM", "name": "Lithium", "id": ["Abundance", "SCHEM", "Lithium"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "carvedilol", "id": ["Abundance", "CHEBI", "carvedilol"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "celecoxib", "id": ["Abundance", "CHEBI", "celecoxib"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "folic acid", "id": ["Abundance", "CHEBI", "folic acid"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "glucocorticoid", "id": ["Abundance", "CHEBI", "glucocorticoid"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "ibuprofen", "id": ["Abundance", "CHEBI", "ibuprofen"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "mifepristone", "id": ["Abundance", "CHEBI", "mifepristone"]}, {"function": "Abundance", "namespace": "SCHEM", "name": "Niacin", "id": ["Abundance", "SCHEM", "Niacin"]}, {"function": "Abundance", "namespace": "CHEBI", "name": "thalidomide", "id": ["Abundance", "CHEBI", "thalidomide"]}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Insulin Resistance", "id": ["BiologicalProcess", "MESHPP", "Insulin Resistance"]}, {"function": "Protein", "namespace": "SFAM", "name": "MAPK Erk1/2 Family", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": ["Protein", "SFAM", "MAPK Erk1/2 Family", ["pmod", ["bel", "Ph"]]]}, {"function": "Abundance", "namespace": "SCHEM", "name": "Riluzole", "id": ["Abundance", "SCHEM", "Riluzole"]}, {"function": "Gene", "namespace": "HGNC", "name": "INSR", "id": ["Gene", "HGNC", "INSR"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRA5", "id": ["Gene", "HGNC", "GABRA5"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRB3", "id": ["Gene", "HGNC", "GABRB3"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRA3", "id": ["Gene", "HGNC", "GABRA3"]}, {"function": "Gene", "namespace": "HGNC", "name": "TNF", "id": ["Gene", "HGNC", "TNF"]}, {"function": "Gene", "namespace": "HGNC", "name": "BACE1", "id": ["Gene", "HGNC", "BACE1"]}, {"function": "Gene", "namespace": "HGNC", "name": "FOS", "id": ["Gene", "HGNC", "FOS"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASP3", "id": ["Gene", "HGNC", "CASP3"]}, {"function": "Gene", "namespace": "HGNC", "name": "CAPN2", "id": ["Gene", "HGNC", "CAPN2"]}, {"function": "Gene", "namespace": "HGNC", "name": "NAE1", "id": ["Gene", "HGNC", "NAE1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASR", "id": ["Gene", "HGNC", "CASR"]}, {"function": "Gene", "namespace": "HGNC", "name": "RELN", "id": ["Gene", "HGNC", "RELN"]}, {"function": "Gene", "namespace": "HGNC", "name": "ITGB1BP1", "id": ["Gene", "HGNC", "ITGB1BP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "EGF", "id": ["Gene", "HGNC", "EGF"]}, {"function": "Gene", "namespace": "HGNC", "name": "GRIA2", "id": ["Gene", "HGNC", "GRIA2"]}, {"function": "Gene", "namespace": "HGNC", "name": "NOTCH1", "id": ["Gene", "HGNC", "NOTCH1"]}, {"function": "Gene", "namespace": "HGNC", "name": "NOTCH2", "id": ["Gene", "HGNC", "NOTCH2"]}, {"function": "Gene", "namespace": "HGNC", "name": "BACE2", "id": ["Gene", "HGNC", "BACE2"]}, {"function": "Gene", "namespace": "HGNC", "name": "GSK3B", "id": ["Gene", "HGNC", "GSK3B"]}, {"function": "Gene", "namespace": "HGNC", "name": "SOD2", "id": ["Gene", "HGNC", "SOD2"]}, {"function": "Gene", "namespace": "HGNC", "name": "S100A9", "id": ["Gene", "HGNC", "S100A9"]}, {"function": "Gene", "namespace": "HGNC", "name": "BDNF", "id": ["Gene", "HGNC", "BDNF"]}, {"function": "Gene", "namespace": "HGNC", "name": "ARC", "id": ["Gene", "HGNC", "ARC"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASP4", "id": ["Gene", "HGNC", "CASP4"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL1B", "id": ["Gene", "HGNC", "IL1B"]}, {"function": "Gene", "namespace": "SFAM", "name": "GSK3 Family", "id": ["Gene", "SFAM", "GSK3 Family"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASP2", "id": ["Gene", "HGNC", "CASP2"]}, {"function": "Gene", "namespace": "HGNC", "name": "JAK2", "id": ["Gene", "HGNC", "JAK2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CKB", "id": ["Gene", "HGNC", "CKB"]}, {"function": "Gene", "namespace": "HGNC", "name": "SCARB1", "id": ["Gene", "HGNC", "SCARB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "MTOR", "id": ["Gene", "HGNC", "MTOR"]}, {"function": "Gene", "namespace": "HGNC", "name": "CREBBP", "id": ["Gene", "HGNC", "CREBBP"]}, {"function": "Gene", "namespace": "HGNC", "name": "DYRK1A", "id": ["Gene", "HGNC", "DYRK1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "ADAM10", "id": ["Gene", "HGNC", "ADAM10"]}, {"function": "Gene", "namespace": "HGNC", "name": "GRIN1", "id": ["Gene", "HGNC", "GRIN1"]}, {"function": "Gene", "namespace": "SFAM", "name": "MAPK JNK Family", "id": ["Gene", "SFAM", "MAPK JNK Family"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSD17B10", "id": ["Gene", "HGNC", "HSD17B10"]}, {"function": "Gene", "namespace": "HGNC", "name": "VEGFA", "id": ["Gene", "HGNC", "VEGFA"]}, {"function": "Gene", "namespace": "HGNC", "name": "MMP2", "id": ["Gene", "HGNC", "MMP2"]}, {"function": "Gene", "namespace": "HGNC", "name": "BCL2L1", "id": ["Gene", "HGNC", "BCL2L1"]}, {"function": "Gene", "namespace": "HGNC", "name": "NOS3", "id": ["Gene", "HGNC", "NOS3"]}, {"function": "Gene", "namespace": "HGNC", "name": "FASLG", "id": ["Gene", "HGNC", "FASLG"]}, {"function": "Gene", "namespace": "HGNC", "name": "PLAT", "id": ["Gene", "HGNC", "PLAT"]}, {"function": "Gene", "namespace": "HGNC", "name": "THBS1", "id": ["Gene", "HGNC", "THBS1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ECE1", "id": ["Gene", "HGNC", "ECE1"]}, {"function": "Gene", "namespace": "HGNC", "name": "EDN1", "id": ["Gene", "HGNC", "EDN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "DDIT3", "id": ["Gene", "HGNC", "DDIT3"]}, {"function": "Gene", "namespace": "HGNC", "name": "XBP1", "id": ["Gene", "HGNC", "XBP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PLAUR", "id": ["Gene", "HGNC", "PLAUR"]}, {"function": "Gene", "namespace": "HGNC", "name": "PLAU", "id": ["Gene", "HGNC", "PLAU"]}, {"function": "Gene", "namespace": "HGNC", "name": "MARCKS", "id": ["Gene", "HGNC", "MARCKS"]}, {"function": "Gene", "namespace": "HGNC", "name": "RPS6KB1", "id": ["Gene", "HGNC", "RPS6KB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "AGER", "id": ["Gene", "HGNC", "AGER"]}, {"function": "Gene", "namespace": "HGNC", "name": "CSF1", "id": ["Gene", "HGNC", "CSF1"]}, {"function": "Gene", "namespace": "HGNC", "name": "IFNG", "id": ["Gene", "HGNC", "IFNG"]}, {"function": "Gene", "namespace": "HGNC", "name": "STAT3", "id": ["Gene", "HGNC", "STAT3"]}, {"function": "Gene", "namespace": "HGNC", "name": "NFKB1", "id": ["Gene", "HGNC", "NFKB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "BCL2L11", "id": ["Gene", "HGNC", "BCL2L11"]}, {"function": "Gene", "namespace": "HGNC", "name": "NGFR", "id": ["Gene", "HGNC", "NGFR"]}, {"function": "Gene", "namespace": "HGNC", "name": "EGR1", "id": ["Gene", "HGNC", "EGR1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CDK5", "id": ["Gene", "HGNC", "CDK5"]}, {"function": "Gene", "namespace": "HGNC", "name": "NOS2", "id": ["Gene", "HGNC", "NOS2"]}, {"function": "Gene", "namespace": "HGNC", "name": "GSS", "id": ["Gene", "HGNC", "GSS"]}, {"function": "Gene", "namespace": "SFAM", "name": "PRKA Family", "id": ["Gene", "SFAM", "PRKA Family"]}, {"function": "Gene", "namespace": "HGNC", "name": "TGFB1", "id": ["Gene", "HGNC", "TGFB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GRIN2A", "id": ["Gene", "HGNC", "GRIN2A"]}, {"function": "Gene", "namespace": "HGNC", "name": "TFAM", "id": ["Gene", "HGNC", "TFAM"]}, {"function": "Gene", "namespace": "HGNC", "name": "INS", "id": ["Gene", "HGNC", "INS"]}, {"function": "Gene", "namespace": "HGNC", "name": "IGF1", "id": ["Gene", "HGNC", "IGF1"]}, {"function": "Gene", "namespace": "HGNC", "name": "MDM2", "id": ["Gene", "HGNC", "MDM2"]}, {"function": "Gene", "namespace": "HGNC", "name": "MPO", "id": ["Gene", "HGNC", "MPO"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL2", "id": ["Gene", "HGNC", "IL2"]}, {"function": "Gene", "namespace": "HGNC", "name": "SERPINI1", "id": ["Gene", "HGNC", "SERPINI1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PTGS1", "id": ["Gene", "HGNC", "PTGS1"]}, {"function": "Gene", "namespace": "HGNC", "name": "NR3C1", "id": ["Gene", "HGNC", "NR3C1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CDKN1B", "id": ["Gene", "HGNC", "CDKN1B"]}, {"function": "Gene", "namespace": "HGNC", "name": "ALOX5", "id": ["Gene", "HGNC", "ALOX5"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHI3L1", "id": ["Gene", "HGNC", "CHI3L1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CRH", "id": ["Gene", "HGNC", "CRH"]}, {"function": "Gene", "namespace": "HGNC", "name": "EIF2AK3", "id": ["Gene", "HGNC", "EIF2AK3"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRA1", "id": ["Gene", "HGNC", "GABRA1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRA2", "id": ["Gene", "HGNC", "GABRA2"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRA4", "id": ["Gene", "HGNC", "GABRA4"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRA6", "id": ["Gene", "HGNC", "GABRA6"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRB1", "id": ["Gene", "HGNC", "GABRB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRB2", "id": ["Gene", "HGNC", "GABRB2"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRG1", "id": ["Gene", "HGNC", "GABRG1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRG2", "id": ["Gene", "HGNC", "GABRG2"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRG3", "id": ["Gene", "HGNC", "GABRG3"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRD", "id": ["Gene", "HGNC", "GABRD"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRE", "id": ["Gene", "HGNC", "GABRE"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRP", "id": ["Gene", "HGNC", "GABRP"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABRQ", "id": ["Gene", "HGNC", "GABRQ"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABBR1", "id": ["Gene", "HGNC", "GABBR1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP27B1", "id": ["Gene", "HGNC", "CYP27B1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GRIA1", "id": ["Gene", "HGNC", "GRIA1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GNRH1", "id": ["Gene", "HGNC", "GNRH1"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL4", "id": ["Gene", "HGNC", "IL4"]}, {"function": "Gene", "namespace": "HGNC", "name": "NFKB2", "id": ["Gene", "HGNC", "NFKB2"]}, {"function": "Gene", "namespace": "HGNC", "name": "GRIN2B", "id": ["Gene", "HGNC", "GRIN2B"]}, {"function": "Gene", "namespace": "HGNC", "name": "ADAM9", "id": ["Gene", "HGNC", "ADAM9"]}, {"function": "Gene", "namespace": "HGNC", "name": "ADAM17", "id": ["Gene", "HGNC", "ADAM17"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA4", "id": ["Gene", "HGNC", "CHRNA4"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNB2", "id": ["Gene", "HGNC", "CHRNB2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA2", "id": ["Gene", "HGNC", "CHRNA2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA3", "id": ["Gene", "HGNC", "CHRNA3"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA5", "id": ["Gene", "HGNC", "CHRNA5"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA6", "id": ["Gene", "HGNC", "CHRNA6"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA7", "id": ["Gene", "HGNC", "CHRNA7"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA9", "id": ["Gene", "HGNC", "CHRNA9"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNA10", "id": ["Gene", "HGNC", "CHRNA10"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNB3", "id": ["Gene", "HGNC", "CHRNB3"]}, {"function": "Gene", "namespace": "HGNC", "name": "CHRNB4", "id": ["Gene", "HGNC", "CHRNB4"]}, {"function": "Gene", "namespace": "HGNC", "name": "ACHE", "id": ["Gene", "HGNC", "ACHE"]}, {"function": "Gene", "namespace": "HGNC", "name": "PRL", "id": ["Gene", "HGNC", "PRL"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP3A4", "id": ["Gene", "HGNC", "CYP3A4"]}, {"function": "Gene", "namespace": "HGNC", "name": "GABBR2", "id": ["Gene", "HGNC", "GABBR2"]}, {"function": "Gene", "namespace": "HGNC", "name": "PRKCA", "id": ["Gene", "HGNC", "PRKCA"]}, {"function": "Gene", "namespace": "HGNC", "name": "A2M", "id": ["Gene", "HGNC", "A2M"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABAT", "id": ["Gene", "HGNC", "ABAT"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCA1", "id": ["Gene", "HGNC", "ABCA1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCA7", "id": ["Gene", "HGNC", "ABCA7"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCC1", "id": ["Gene", "HGNC", "ABCC1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCC2", "id": ["Gene", "HGNC", "ABCC2"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCC3", "id": ["Gene", "HGNC", "ABCC3"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCD3", "id": ["Gene", "HGNC", "ABCD3"]}, {"function": "Gene", "namespace": "HGNC", "name": "ADCK3", "id": ["Gene", "HGNC", "ADCK3"]}, {"function": "Gene", "namespace": "HGNC", "name": "ADD3", "id": ["Gene", "HGNC", "ADD3"]}, {"function": "Gene", "namespace": "HGNC", "name": "ADM", "id": ["Gene", "HGNC", "ADM"]}, {"function": "Gene", "namespace": "HGNC", "name": "AGT", "id": ["Gene", "HGNC", "AGT"]}, {"function": "Gene", "namespace": "HGNC", "name": "AHR", "id": ["Gene", "HGNC", "AHR"]}, {"function": "Gene", "namespace": "HGNC", "name": "AIFM1", "id": ["Gene", "HGNC", "AIFM1"]}, {"function": "Gene", "namespace": "HGNC", "name": "AKT1", "id": ["Gene", "HGNC", "AKT1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ALAD", "id": ["Gene", "HGNC", "ALAD"]}, {"function": "Gene", "namespace": "HGNC", "name": "ALB", "id": ["Gene", "HGNC", "ALB"]}, {"function": "Gene", "namespace": "HGNC", "name": "ANG", "id": ["Gene", "HGNC", "ANG"]}, {"function": "Gene", "namespace": "HGNC", "name": "APOB", "id": ["Gene", "HGNC", "APOB"]}, {"function": "Gene", "namespace": "HGNC", "name": "ARG1", "id": ["Gene", "HGNC", "ARG1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ATF3", "id": ["Gene", "HGNC", "ATF3"]}, {"function": "Gene", "namespace": "HGNC", "name": "ATXN1", "id": ["Gene", "HGNC", "ATXN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "AURKA", "id": ["Gene", "HGNC", "AURKA"]}, {"function": "Gene", "namespace": "HGNC", "name": "BAG3", "id": ["Gene", "HGNC", "BAG3"]}, {"function": "Gene", "namespace": "HGNC", "name": "BCL2", "id": ["Gene", "HGNC", "BCL2"]}, {"function": "Gene", "namespace": "HGNC", "name": "BUB1B", "id": ["Gene", "HGNC", "BUB1B"]}, {"function": "Gene", "namespace": "HGNC", "name": "CA2", "id": ["Gene", "HGNC", "CA2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CACNB4", "id": ["Gene", "HGNC", "CACNB4"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASP1", "id": ["Gene", "HGNC", "CASP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASP8", "id": ["Gene", "HGNC", "CASP8"]}, {"function": "Gene", "namespace": "HGNC", "name": "CASP9", "id": ["Gene", "HGNC", "CASP9"]}, {"function": "Gene", "namespace": "HGNC", "name": "CAT", "id": ["Gene", "HGNC", "CAT"]}, {"function": "Gene", "namespace": "HGNC", "name": "CCNA2", "id": ["Gene", "HGNC", "CCNA2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CCND1", "id": ["Gene", "HGNC", "CCND1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CD24", "id": ["Gene", "HGNC", "CD24"]}, {"function": "Gene", "namespace": "HGNC", "name": "CD68", "id": ["Gene", "HGNC", "CD68"]}, {"function": "Gene", "namespace": "HGNC", "name": "CD83", "id": ["Gene", "HGNC", "CD83"]}, {"function": "Gene", "namespace": "HGNC", "name": "CDKN1A", "id": ["Gene", "HGNC", "CDKN1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "CDKN2A", "id": ["Gene", "HGNC", "CDKN2A"]}, {"function": "Gene", "namespace": "HGNC", "name": "CEBPB", "id": ["Gene", "HGNC", "CEBPB"]}, {"function": "Gene", "namespace": "HGNC", "name": "CFB", "id": ["Gene", "HGNC", "CFB"]}, {"function": "Gene", "namespace": "HGNC", "name": "CITED2", "id": ["Gene", "HGNC", "CITED2"]}, {"function": "Gene", "namespace": "HGNC", "name": "COL18A1", "id": ["Gene", "HGNC", "COL18A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CRIP1", "id": ["Gene", "HGNC", "CRIP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CRP", "id": ["Gene", "HGNC", "CRP"]}, {"function": "Gene", "namespace": "HGNC", "name": "CTSB", "id": ["Gene", "HGNC", "CTSB"]}, {"function": "Gene", "namespace": "HGNC", "name": "CXCL10", "id": ["Gene", "HGNC", "CXCL10"]}, {"function": "Gene", "namespace": "HGNC", "name": "CXCL2", "id": ["Gene", "HGNC", "CXCL2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CXCR4", "id": ["Gene", "HGNC", "CXCR4"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP19A1", "id": ["Gene", "HGNC", "CYP19A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP1A2", "id": ["Gene", "HGNC", "CYP1A2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP24A1", "id": ["Gene", "HGNC", "CYP24A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "DDIT4", "id": ["Gene", "HGNC", "DDIT4"]}, {"function": "Gene", "namespace": "HGNC", "name": "DHCR24", "id": ["Gene", "HGNC", "DHCR24"]}, {"function": "Gene", "namespace": "HGNC", "name": "DKK1", "id": ["Gene", "HGNC", "DKK1"]}, {"function": "Gene", "namespace": "HGNC", "name": "EGR2", "id": ["Gene", "HGNC", "EGR2"]}, {"function": "Gene", "namespace": "HGNC", "name": "EHMT1", "id": ["Gene", "HGNC", "EHMT1"]}, {"function": "Gene", "namespace": "HGNC", "name": "EP300", "id": ["Gene", "HGNC", "EP300"]}, {"function": "Gene", "namespace": "HGNC", "name": "ERBB2", "id": ["Gene", "HGNC", "ERBB2"]}, {"function": "Gene", "namespace": "HGNC", "name": "ESR1", "id": ["Gene", "HGNC", "ESR1"]}, {"function": "Gene", "namespace": "HGNC", "name": "FAS", "id": ["Gene", "HGNC", "FAS"]}, {"function": "Gene", "namespace": "HGNC", "name": "FBP1", "id": ["Gene", "HGNC", "FBP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "FGB", "id": ["Gene", "HGNC", "FGB"]}, {"function": "Gene", "namespace": "HGNC", "name": "FGFR3", "id": ["Gene", "HGNC", "FGFR3"]}, {"function": "Gene", "namespace": "HGNC", "name": "FKBP5", "id": ["Gene", "HGNC", "FKBP5"]}, {"function": "Gene", "namespace": "HGNC", "name": "FLNA", "id": ["Gene", "HGNC", "FLNA"]}, {"function": "Gene", "namespace": "HGNC", "name": "FOSB", "id": ["Gene", "HGNC", "FOSB"]}, {"function": "Gene", "namespace": "HGNC", "name": "FSHB", "id": ["Gene", "HGNC", "FSHB"]}, {"function": "Gene", "namespace": "HGNC", "name": "FYN", "id": ["Gene", "HGNC", "FYN"]}, {"function": "Gene", "namespace": "HGNC", "name": "GCH1", "id": ["Gene", "HGNC", "GCH1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GLB1", "id": ["Gene", "HGNC", "GLB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GPX3", "id": ["Gene", "HGNC", "GPX3"]}, {"function": "Gene", "namespace": "HGNC", "name": "GSK3A", "id": ["Gene", "HGNC", "GSK3A"]}, {"function": "Gene", "namespace": "HGNC", "name": "GSR", "id": ["Gene", "HGNC", "GSR"]}, {"function": "Gene", "namespace": "HGNC", "name": "HES1", "id": ["Gene", "HGNC", "HES1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HP", "id": ["Gene", "HGNC", "HP"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSPA1A", "id": ["Gene", "HGNC", "HSPA1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSPB1", "id": ["Gene", "HGNC", "HSPB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSPB8", "id": ["Gene", "HGNC", "HSPB8"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSPD1", "id": ["Gene", "HGNC", "HSPD1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ICAM1", "id": ["Gene", "HGNC", "ICAM1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ID2", "id": ["Gene", "HGNC", "ID2"]}, {"function": "Gene", "namespace": "HGNC", "name": "IER3", "id": ["Gene", "HGNC", "IER3"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL18", "id": ["Gene", "HGNC", "IL18"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL1R1", "id": ["Gene", "HGNC", "IL1R1"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL1RN", "id": ["Gene", "HGNC", "IL1RN"]}, {"function": "Gene", "namespace": "HGNC", "name": "CXCL8", "id": ["Gene", "HGNC", "CXCL8"]}, {"function": "Gene", "namespace": "HGNC", "name": "IP6K2", "id": ["Gene", "HGNC", "IP6K2"]}, {"function": "Gene", "namespace": "HGNC", "name": "ITGA2", "id": ["Gene", "HGNC", "ITGA2"]}, {"function": "Gene", "namespace": "HGNC", "name": "ITPR1", "id": ["Gene", "HGNC", "ITPR1"]}, {"function": "Gene", "namespace": "HGNC", "name": "JAG1", "id": ["Gene", "HGNC", "JAG1"]}, {"function": "Gene", "namespace": "HGNC", "name": "JUN", "id": ["Gene", "HGNC", "JUN"]}, {"function": "Gene", "namespace": "HGNC", "name": "JUND", "id": ["Gene", "HGNC", "JUND"]}, {"function": "Gene", "namespace": "HGNC", "name": "KYNU", "id": ["Gene", "HGNC", "KYNU"]}, {"function": "Gene", "namespace": "HGNC", "name": "LDLR", "id": ["Gene", "HGNC", "LDLR"]}, {"function": "Gene", "namespace": "HGNC", "name": "LOX", "id": ["Gene", "HGNC", "LOX"]}, {"function": "Gene", "namespace": "HGNC", "name": "LRP1", "id": ["Gene", "HGNC", "LRP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "MAOA", "id": ["Gene", "HGNC", "MAOA"]}, {"function": "Gene", "namespace": "HGNC", "name": "MAP2K1", "id": ["Gene", "HGNC", "MAP2K1"]}, {"function": "Gene", "namespace": "HGNC", "name": "MAPK1", "id": ["Gene", "HGNC", "MAPK1"]}, {"function": "Gene", "namespace": "HGNC", "name": "MAPK3", "id": ["Gene", "HGNC", "MAPK3"]}, {"function": "Gene", "namespace": "HGNC", "name": "MMP3", "id": ["Gene", "HGNC", "MMP3"]}, {"function": "Gene", "namespace": "HGNC", "name": "MRAS", "id": ["Gene", "HGNC", "MRAS"]}, {"function": "Gene", "namespace": "HGNC", "name": "NCSTN", "id": ["Gene", "HGNC", "NCSTN"]}, {"function": "Gene", "namespace": "HGNC", "name": "NEFH", "id": ["Gene", "HGNC", "NEFH"]}, {"function": "Gene", "namespace": "HGNC", "name": "NFE2L2", "id": ["Gene", "HGNC", "NFE2L2"]}, {"function": "Gene", "namespace": "HGNC", "name": "NFKBIA", "id": ["Gene", "HGNC", "NFKBIA"]}, {"function": "Gene", "namespace": "HGNC", "name": "PAFAH1B1", "id": ["Gene", "HGNC", "PAFAH1B1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PAK3", "id": ["Gene", "HGNC", "PAK3"]}, {"function": "Gene", "namespace": "HGNC", "name": "PCNA", "id": ["Gene", "HGNC", "PCNA"]}, {"function": "Gene", "namespace": "HGNC", "name": "PCSK5", "id": ["Gene", "HGNC", "PCSK5"]}, {"function": "Gene", "namespace": "HGNC", "name": "PDE4D", "id": ["Gene", "HGNC", "PDE4D"]}, {"function": "Gene", "namespace": "HGNC", "name": "PDGFA", "id": ["Gene", "HGNC", "PDGFA"]}, {"function": "Gene", "namespace": "HGNC", "name": "PHGDH", "id": ["Gene", "HGNC", "PHGDH"]}, {"function": "Gene", "namespace": "HGNC", "name": "PLD1", "id": ["Gene", "HGNC", "PLD1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PLEC", "id": ["Gene", "HGNC", "PLEC"]}, {"function": "Gene", "namespace": "HGNC", "name": "PNP", "id": ["Gene", "HGNC", "PNP"]}, {"function": "Gene", "namespace": "HGNC", "name": "PRNP", "id": ["Gene", "HGNC", "PRNP"]}, {"function": "Gene", "namespace": "HGNC", "name": "PROS1", "id": ["Gene", "HGNC", "PROS1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PSAT1", "id": ["Gene", "HGNC", "PSAT1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PTEN", "id": ["Gene", "HGNC", "PTEN"]}, {"function": "Gene", "namespace": "HGNC", "name": "RAB7A", "id": ["Gene", "HGNC", "RAB7A"]}, {"function": "Gene", "namespace": "HGNC", "name": "RASGRP1", "id": ["Gene", "HGNC", "RASGRP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "RGS2", "id": ["Gene", "HGNC", "RGS2"]}, {"function": "Gene", "namespace": "HGNC", "name": "RORA", "id": ["Gene", "HGNC", "RORA"]}, {"function": "Gene", "namespace": "HGNC", "name": "RPS6KA3", "id": ["Gene", "HGNC", "RPS6KA3"]}, {"function": "Gene", "namespace": "HGNC", "name": "S100A4", "id": ["Gene", "HGNC", "S100A4"]}, {"function": "Gene", "namespace": "HGNC", "name": "S100A6", "id": ["Gene", "HGNC", "S100A6"]}, {"function": "Gene", "namespace": "HGNC", "name": "SC5D", "id": ["Gene", "HGNC", "SC5D"]}, {"function": "Gene", "namespace": "HGNC", "name": "SEPP1", "id": ["Gene", "HGNC", "SEPP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SERPINA1", "id": ["Gene", "HGNC", "SERPINA1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SERPINE1", "id": ["Gene", "HGNC", "SERPINE1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SGK1", "id": ["Gene", "HGNC", "SGK1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC12A2", "id": ["Gene", "HGNC", "SLC12A2"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC1A2", "id": ["Gene", "HGNC", "SLC1A2"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC25A19", "id": ["Gene", "HGNC", "SLC25A19"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC25A4", "id": ["Gene", "HGNC", "SLC25A4"]}, {"function": "Gene", "namespace": "HGNC", "name": "SMOX", "id": ["Gene", "HGNC", "SMOX"]}, {"function": "Gene", "namespace": "HGNC", "name": "SOCS2", "id": ["Gene", "HGNC", "SOCS2"]}, {"function": "Gene", "namespace": "HGNC", "name": "SOD1", "id": ["Gene", "HGNC", "SOD1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SORL1", "id": ["Gene", "HGNC", "SORL1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SPP1", "id": ["Gene", "HGNC", "SPP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SQSTM1", "id": ["Gene", "HGNC", "SQSTM1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SRC", "id": ["Gene", "HGNC", "SRC"]}, {"function": "Gene", "namespace": "HGNC", "name": "STAT1", "id": ["Gene", "HGNC", "STAT1"]}, {"function": "Gene", "namespace": "HGNC", "name": "TERT", "id": ["Gene", "HGNC", "TERT"]}, {"function": "Gene", "namespace": "HGNC", "name": "TGFBI", "id": ["Gene", "HGNC", "TGFBI"]}, {"function": "Gene", "namespace": "HGNC", "name": "TGIF1", "id": ["Gene", "HGNC", "TGIF1"]}, {"function": "Gene", "namespace": "HGNC", "name": "TH", "id": ["Gene", "HGNC", "TH"]}, {"function": "Gene", "namespace": "HGNC", "name": "TIMP3", "id": ["Gene", "HGNC", "TIMP3"]}, {"function": "Gene", "namespace": "HGNC", "name": "TLN2", "id": ["Gene", "HGNC", "TLN2"]}, {"function": "Gene", "namespace": "HGNC", "name": "TNFRSF1A", "id": ["Gene", "HGNC", "TNFRSF1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "TP53", "id": ["Gene", "HGNC", "TP53"]}, {"function": "Gene", "namespace": "HGNC", "name": "TRPV1", "id": ["Gene", "HGNC", "TRPV1"]}, {"function": "Gene", "namespace": "HGNC", "name": "TYMS", "id": ["Gene", "HGNC", "TYMS"]}, {"function": "Gene", "namespace": "HGNC", "name": "VDR", "id": ["Gene", "HGNC", "VDR"]}, {"function": "Gene", "namespace": "HGNC", "name": "ABCB1", "id": ["Gene", "HGNC", "ABCB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "AGTR1", "id": ["Gene", "HGNC", "AGTR1"]}, {"function": "Gene", "namespace": "HGNC", "name": "AKR1C3", "id": ["Gene", "HGNC", "AKR1C3"]}, {"function": "Gene", "namespace": "HGNC", "name": "APOBEC3B", "id": ["Gene", "HGNC", "APOBEC3B"]}, {"function": "Gene", "namespace": "HGNC", "name": "AR", "id": ["Gene", "HGNC", "AR"]}, {"function": "Gene", "namespace": "HGNC", "name": "AREG", "id": ["Gene", "HGNC", "AREG"]}, {"function": "Gene", "namespace": "HGNC", "name": "AURKB", "id": ["Gene", "HGNC", "AURKB"]}, {"function": "Gene", "namespace": "HGNC", "name": "BRCA1", "id": ["Gene", "HGNC", "BRCA1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CCNB2", "id": ["Gene", "HGNC", "CCNB2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CDC6", "id": ["Gene", "HGNC", "CDC6"]}, {"function": "Gene", "namespace": "HGNC", "name": "CDK1", "id": ["Gene", "HGNC", "CDK1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CGB", "id": ["Gene", "HGNC", "CGB"]}, {"function": "Gene", "namespace": "HGNC", "name": "CKS1B", "id": ["Gene", "HGNC", "CKS1B"]}, {"function": "Gene", "namespace": "HGNC", "name": "CLSTN1", "id": ["Gene", "HGNC", "CLSTN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "COMT", "id": ["Gene", "HGNC", "COMT"]}, {"function": "Gene", "namespace": "HGNC", "name": "PTGS2", "id": ["Gene", "HGNC", "PTGS2"]}, {"function": "Gene", "namespace": "HGNC", "name": "CTSD", "id": ["Gene", "HGNC", "CTSD"]}, {"function": "Gene", "namespace": "HGNC", "name": "CXCL12", "id": ["Gene", "HGNC", "CXCL12"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP11A1", "id": ["Gene", "HGNC", "CYP11A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP1A1", "id": ["Gene", "HGNC", "CYP1A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "DBN1", "id": ["Gene", "HGNC", "DBN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ERRFI1", "id": ["Gene", "HGNC", "ERRFI1"]}, {"function": "Gene", "namespace": "HGNC", "name": "ESRRA", "id": ["Gene", "HGNC", "ESRRA"]}, {"function": "Gene", "namespace": "HGNC", "name": "FGF9", "id": ["Gene", "HGNC", "FGF9"]}, {"function": "Gene", "namespace": "HGNC", "name": "GNRHR", "id": ["Gene", "HGNC", "GNRHR"]}, {"function": "Gene", "namespace": "HGNC", "name": "GREB1", "id": ["Gene", "HGNC", "GREB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HMOX1", "id": ["Gene", "HGNC", "HMOX1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSD17B1", "id": ["Gene", "HGNC", "HSD17B1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HSPA1B", "id": ["Gene", "HGNC", "HSPA1B"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL6", "id": ["Gene", "HGNC", "IL6"]}, {"function": "Gene", "namespace": "HGNC", "name": "IRS2", "id": ["Gene", "HGNC", "IRS2"]}, {"function": "Gene", "namespace": "HGNC", "name": "KLK3", "id": ["Gene", "HGNC", "KLK3"]}, {"function": "Gene", "namespace": "HGNC", "name": "KRT19", "id": ["Gene", "HGNC", "KRT19"]}, {"function": "Gene", "namespace": "HGNC", "name": "LHB", "id": ["Gene", "HGNC", "LHB"]}, {"function": "Gene", "namespace": "HGNC", "name": "MAPT", "id": ["Gene", "HGNC", "MAPT"]}, {"function": "Gene", "namespace": "HGNC", "name": "MCM2", "id": ["Gene", "HGNC", "MCM2"]}, {"function": "Gene", "namespace": "HGNC", "name": "MMP1", "id": ["Gene", "HGNC", "MMP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "MMP9", "id": ["Gene", "HGNC", "MMP9"]}, {"function": "Gene", "namespace": "HGNC", "name": "MYC", "id": ["Gene", "HGNC", "MYC"]}, {"function": "Gene", "namespace": "HGNC", "name": "NQO1", "id": ["Gene", "HGNC", "NQO1"]}, {"function": "Gene", "namespace": "HGNC", "name": "NR5A1", "id": ["Gene", "HGNC", "NR5A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PAWR", "id": ["Gene", "HGNC", "PAWR"]}, {"function": "Gene", "namespace": "HGNC", "name": "PDGFB", "id": ["Gene", "HGNC", "PDGFB"]}, {"function": "Gene", "namespace": "HGNC", "name": "PGR", "id": ["Gene", "HGNC", "PGR"]}, {"function": "Gene", "namespace": "HGNC", "name": "PON1", "id": ["Gene", "HGNC", "PON1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PRSS23", "id": ["Gene", "HGNC", "PRSS23"]}, {"function": "Gene", "namespace": "HGNC", "name": "RAF1", "id": ["Gene", "HGNC", "RAF1"]}, {"function": "Gene", "namespace": "HGNC", "name": "RB1", "id": ["Gene", "HGNC", "RB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "RRM2", "id": ["Gene", "HGNC", "RRM2"]}, {"function": "Gene", "namespace": "HGNC", "name": "SERPINB9", "id": ["Gene", "HGNC", "SERPINB9"]}, {"function": "Gene", "namespace": "HGNC", "name": "SHBG", "id": ["Gene", "HGNC", "SHBG"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC2A1", "id": ["Gene", "HGNC", "SLC2A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC6A14", "id": ["Gene", "HGNC", "SLC6A14"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC6A6", "id": ["Gene", "HGNC", "SLC6A6"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC7A5", "id": ["Gene", "HGNC", "SLC7A5"]}, {"function": "Gene", "namespace": "HGNC", "name": "SULT1E1", "id": ["Gene", "HGNC", "SULT1E1"]}, {"function": "Gene", "namespace": "HGNC", "name": "TFF1", "id": ["Gene", "HGNC", "TFF1"]}, {"function": "Gene", "namespace": "HGNC", "name": "TGFB3", "id": ["Gene", "HGNC", "TGFB3"]}, {"function": "Gene", "namespace": "HGNC", "name": "TIMP1", "id": ["Gene", "HGNC", "TIMP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "TSC22D3", "id": ["Gene", "HGNC", "TSC22D3"]}, {"function": "Gene", "namespace": "HGNC", "name": "UBB", "id": ["Gene", "HGNC", "UBB"]}, {"function": "Gene", "namespace": "HGNC", "name": "VCAM1", "id": ["Gene", "HGNC", "VCAM1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GSTP1", "id": ["Gene", "HGNC", "GSTP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HIF1A", "id": ["Gene", "HGNC", "HIF1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "LEP", "id": ["Gene", "HGNC", "LEP"]}, {"function": "Gene", "namespace": "HGNC", "name": "LEPR", "id": ["Gene", "HGNC", "LEPR"]}, {"function": "Gene", "namespace": "HGNC", "name": "MKI67", "id": ["Gene", "HGNC", "MKI67"]}, {"function": "Gene", "namespace": "HGNC", "name": "PENK", "id": ["Gene", "HGNC", "PENK"]}, {"function": "Gene", "namespace": "HGNC", "name": "SLC31A1", "id": ["Gene", "HGNC", "SLC31A1"]}, {"function": "Gene", "namespace": "HGNC", "name": "PIN1", "id": ["Gene", "HGNC", "PIN1"]}, {"function": "Gene", "namespace": "HGNC", "name": "GCG", "id": ["Gene", "HGNC", "GCG"]}, {"function": "Gene", "namespace": "HGNC", "name": "APBB1", "id": ["Gene", "HGNC", "APBB1"]}, {"function": "Gene", "namespace": "HGNC", "name": "APH1A", "id": ["Gene", "HGNC", "APH1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "IL1A", "id": ["Gene", "HGNC", "IL1A"]}, {"function": "Gene", "namespace": "HGNC", "name": "CCR2", "id": ["Gene", "HGNC", "CCR2"]}, {"function": "Gene", "namespace": "HGNC", "name": "IDE", "id": ["Gene", "HGNC", "IDE"]}, {"function": "Gene", "namespace": "HGNC", "name": "ACE", "id": ["Gene", "HGNC", "ACE"]}, {"function": "Gene", "namespace": "HGNC", "name": "RELA", "id": ["Gene", "HGNC", "RELA"]}, {"function": "Gene", "namespace": "HGNC", "name": "MMP7", "id": ["Gene", "HGNC", "MMP7"]}, {"function": "Gene", "namespace": "SFAM", "name": "MMP Family", "id": ["Gene", "SFAM", "MMP Family"]}, {"function": "Gene", "namespace": "HGNC", "name": "QPCT", "id": ["Gene", "HGNC", "QPCT"]}, {"function": "Gene", "namespace": "HGNC", "name": "CAST", "id": ["Gene", "HGNC", "CAST"]}, {"function": "Gene", "namespace": "HGNC", "name": "APBA1", "id": ["Gene", "HGNC", "APBA1"]}, {"function": "Gene", "namespace": "HGNC", "name": "SP1", "id": ["Gene", "HGNC", "SP1"]}, {"function": "Gene", "namespace": "HGNC", "name": "HTR4", "id": ["Gene", "HGNC", "HTR4"]}, {"function": "Gene", "namespace": "HGNC", "name": "LRP8", "id": ["Gene", "HGNC", "LRP8"]}, {"function": "Gene", "namespace": "HGNC", "name": "LPL", "id": ["Gene", "HGNC", "LPL"]}, {"function": "Gene", "namespace": "HGNC", "name": "CPE", "id": ["Gene", "HGNC", "CPE"]}, {"function": "Gene", "namespace": "SFAM", "name": "MAPK Erk1/2 Family", "id": ["Gene", "SFAM", "MAPK Erk1/2 Family"]}, {"function": "Gene", "namespace": "HGNC", "name": "CYP2D6", "id": ["Gene", "HGNC", "CYP2D6"]}], "links": [{"relation": "increases", "evidence": "Protein kinase C: PKC is part of a multigene family of serine-threonine kinases central to many signal transduction pathways [138] with a prominent role in memory [139]. It is likely that A-induced increases in cytosolic Ca2+ signals are transmitted to PKC for PKC-mediated transcriptional activation. In addition, PKC activates ERK by interacting with Ras or Raf-1 [140] to initiate CREB phosphorylation. While PKC levels decline in AD [141], their activation restores K+ channel function in cells from AD patients [142]. In addition, activation of PKC directly or indirectly enhances the a-processing cleavage of APP [143].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 8, "target": 253, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 11, "target": 3, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 3, "key": 1}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 3, "key": 2}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 3, "key": 3}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 11, "target": 2, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 2, "key": 1}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 2, "key": 2}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 11, "target": 2, "key": 3}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 2, "key": 4}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 2, "key": 5}, {"relation": "decreases", "evidence": "Biochemical and morphological alterations of mitochondria may play an important role in the pathogenesis of Alzheimer's disease (AD). Particularly, mitochondrial dysfunction is a hallmark of amyloid-beta-induced neuronal toxicity in Alzheimer's disease. The recent emphasis on the intracellular biology of amyloid-beta and its precursor protein (APP) has led researchers to consider the possibility that mitochondria-associated and mitochondrial amyloid-beta may directly cause neurotoxicity. Both proteins are known to localize to mitochondrial membranes, block the transport of nuclear-encoded mitochondrial proteins to mitochondria, interact with mitochondrial proteins, disrupt the electron transport chain, increase reactive oxygen species production, cause mitochondrial damage, and prevent neurons from functioning normally. ", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 2, "key": 6}, {"relation": "decreases", "evidence": "Biochemical and morphological alterations of mitochondria may play an important role in the pathogenesis of Alzheimer's disease (AD). Particularly, mitochondrial dysfunction is a hallmark of amyloid-beta-induced neuronal toxicity in Alzheimer's disease. The recent emphasis on the intracellular biology of amyloid-beta and its precursor protein (APP) has led researchers to consider the possibility that mitochondria-associated and mitochondrial amyloid-beta may directly cause neurotoxicity. Both proteins are known to localize to mitochondrial membranes, block the transport of nuclear-encoded mitochondrial proteins to mitochondria, interact with mitochondrial proteins, disrupt the electron transport chain, increase reactive oxygen species production, cause mitochondrial damage, and prevent neurons from functioning normally. ", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 2, "key": 7}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 2, "key": 8}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 2, "key": 9}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 11, "target": 1, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 1, "key": 1}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 1, "key": 2}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 1, "key": 3}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 11, "target": 12, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 12, "key": 1}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 11, "target": 12, "key": 2}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 12, "key": 3}, {"relation": "decreases", "evidence": "A can also interact with Fe2+ and Cu+ to generate hydrogen peroxide and hydroxyl radical (OH.) resulting in membrane lipid peroxidation which generates toxic aldehydes that impair the function of membrane ion-motive ATPases (Na+ and Ca2+ pumps)", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Cell Membrane", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 12, "key": 4}, {"relation": "decreases", "evidence": "A can also interact with Fe2+ and Cu+ to generate hydrogen peroxide and hydroxyl radical (OH.) resulting in membrane lipid peroxidation which generates toxic aldehydes that impair the function of membrane ion-motive ATPases (Na+ and Ca2+ pumps)", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Cell Membrane", "Subgraph": "Calcium-dependent signal transduction"}, "source": 11, "target": 12, "key": 5}, {"relation": "increases", "evidence": "CD40 ligation in the presence of Abeta(1-42) leads to adaptive activation of microglia, as evidenced by increased co-localization of MHC class II with Abeta. ", "citation": {"type": "PubMed", "name": "Eur J Immunol2005", "reference": "15688347"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 11, "target": 13, "key": 4}, {"relation": "increases", "evidence": "CD40 ligation in the presence of Abeta(1-42) leads to adaptive activation of microglia, as evidenced by increased co-localization of MHC class II with Abeta. ", "citation": {"type": "PubMed", "name": "Eur J Immunol2005", "reference": "15688347"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 13, "key": 5}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 6, "key": 0}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Reactive oxygen species subgraph"}, "source": 11, "target": 6, "key": 1}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 14, "key": 0}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Reactive oxygen species subgraph"}, "source": 11, "target": 14, "key": 1}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Nitric oxide subgraph"}, "source": 11, "target": 15, "key": 0}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 15, "key": 1}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Reactive oxygen species subgraph"}, "source": 11, "target": 15, "key": 2}, {"relation": "increases", "evidence": "We have shown with cultured cerebral cortical normal (i.e., untransformed) adult human astrocytes (NAHAs) that exogenous amyloid- peptides (As) stimulate the astrocytes to make and secrete large amounts of As and nitric oxide by a mechanism mediated through the calcium-sensing receptor (CaSR).", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2014 Jun 20", "reference": "24948534"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Subgraph": "Nitric oxide subgraph", "Species": "9606", "NervousSystem": "Astrocytes"}, "source": 11, "target": 15, "key": 3}, {"relation": "increases", "evidence": "We have shown with cultured cerebral cortical normal (i.e., untransformed) adult human astrocytes (NAHAs) that exogenous amyloid- peptides (As) stimulate the astrocytes to make and secrete large amounts of As and nitric oxide by a mechanism mediated through the calcium-sensing receptor (CaSR).", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2014 Jun 20", "reference": "24948534"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Subgraph": "Nitric oxide subgraph", "Species": "9606", "NervousSystem": "Cerebral Cortex"}, "source": 11, "target": 15, "key": 4}, {"relation": "increases", "evidence": "beta amyloid peptides cause an elevation in intracellular calcium levels and enhance calcium responses to depolarization and calcium ion-ophore.", "citation": {"type": "PubMed", "name": "J Neurosci. 1992 Feb;12(2):376-89", "reference": "1346802"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Intracellular Space"}}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 8, "key": 0}, {"relation": "increases", "evidence": " Transcriptional activation of CREB recruits a multiprotein assembly called a transcriptional co-activator complex. These often include proteins with intrinsic acetyltransferase activity. Among the best characterized transcriptional co-activator proteins is CREB binding protein (CBP). There is no direct evidence indicating how lower levels of A might initiate CREB phosphorylation principally by Ca2+ signaling and/or through PKA/Atk/ERK pathways. However, exceeding physiological levels of A could deregulate Ca2+ signaling mechanism by excessive accumulation of Ca2+ in the cytoplasm and cytoplasmic organelles such as mitochondria. Since hippocampal neuronal calcium is one of the most potent signals in neuronal gene expression [149], A-induced Ca2+ deregulation may lead to compromised synaptic function. Consistence with this hypothesis, AD has been associated with impaired cAMP signaling which may contribute to the pathophysiology of the disease. Levels of the activated (i.e. phosphorylated) form of CREB are reduced in AD compared to that of an age-matched healthy control group [164]. Calcium signaling to the cell nucleus is the key inducer of CREB phosphorylation on its activator site serine 133 [165]. Experiments in aged neurons show altered calcium signaling at the level of either calcium signal generation and/or calcium signal propagation [166]. These studies indicate a critical role of calcium in A-induced synaptic activity and memory formation by regulating specific signal transduction pathways.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "Disease": "Alzheimer's disease"}, "source": 11, "target": 8, "key": 1}, {"relation": "decreases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 11, "target": 16, "key": 0}, {"relation": "decreases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 16, "key": 1}, {"relation": "increases", "evidence": "Recent studies have shown increased expression of select active kinases, including stress-activated kinase, c-Jun N-terminal kinase (SAPK/JNK) and kinase p38 in brain homogenates in all the tauopathies. Strong active SAPK/JNK and p38 immunoreactivity has been observed restricted to neurons and glial cells containing hyperphosphorylated tau, as well as in dystrophic neurites of senile plaques in AD", "citation": {"type": "PubMed", "name": "Neurotox Res. 2004;6(6):469-75", "reference": "15658002"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tau protein subgraph"}, "source": 11, "target": 17, "key": 0}, {"relation": "increases", "evidence": "Recent studies have shown increased expression of select active kinases, including stress-activated kinase, c-Jun N-terminal kinase (SAPK/JNK) and kinase p38 in brain homogenates in all the tauopathies. Strong active SAPK/JNK and p38 immunoreactivity has been observed restricted to neurons and glial cells containing hyperphosphorylated tau, as well as in dystrophic neurites of senile plaques in AD", "citation": {"type": "PubMed", "name": "Neurotox Res. 2004;6(6):469-75", "reference": "15658002"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "JAK-STAT signaling subgraph"}, "source": 11, "target": 17, "key": 1}, {"relation": "increases", "evidence": "Two possible models for involvement of HRD1 in the pathogenesis of AD. Model 1 (cause of AD): Unknown stress initiates insolubilization of HRD1 protein, resulting in a decrease in the functional HRD1 protein in the ER membrane. Subsequently, APP accumulates in the ER and is processed into A that induces hyperphosphorylation of tau protein (ptau). Finally, accumulated A and/or p-tau causes neurodegeneration leading to AD.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Endoplasmic Reticulum", "Subgraph": "Tau protein subgraph"}, "source": 11, "target": 17, "key": 2}, {"relation": "increases", "evidence": "Two possible models for involvement of HRD1 in the pathogenesis of AD. Model 1 (cause of AD): Unknown stress initiates insolubilization of HRD1 protein, resulting in a decrease in the functional HRD1 protein in the ER membrane. Subsequently, APP accumulates in the ER and is processed into A that induces hyperphosphorylation of tau protein (ptau). Finally, accumulated A and/or p-tau causes neurodegeneration leading to AD.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Endoplasmic Reticulum", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 17, "key": 3}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 11, "target": 17, "key": 4}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 17, "key": 5}, {"relation": "increases", "evidence": "We have shown that interaction of CD40 with CD40L enables microglial activation in response to amyloid-beta peptide (Abeta), which is associated with Alzheimer's disease (AD)-like neuronal tau hyperphosphorylation in vivo.", "citation": {"type": "PubMed", "name": "Nat Neurosci2002", "reference": "12402041"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 11, "target": 17, "key": 6}, {"relation": "increases", "evidence": "We have shown that interaction of CD40 with CD40L enables microglial activation in response to amyloid-beta peptide (Abeta), which is associated with Alzheimer's disease (AD)-like neuronal tau hyperphosphorylation in vivo.", "citation": {"type": "PubMed", "name": "Nat Neurosci2002", "reference": "12402041"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 17, "key": 7}, {"relation": "increases", "evidence": "We have shown that interaction of CD40 with CD40L enables microglial activation in response to amyloid-beta peptide (Abeta), which is associated with Alzheimer's disease (AD)-like neuronal tau hyperphosphorylation in vivo.", "citation": {"type": "PubMed", "name": "Nat Neurosci2002", "reference": "12402041"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 11, "target": 17, "key": 8}, {"relation": "increases", "evidence": "We further observed that treatment with Abeta(42) decreased cellular N-cadherin expression through NMDA receptors accompanied by increased phosphorylation of both p38 MAPK and Tau in murine primary neurons. ", "citation": {"type": "PubMed", "name": "J Biol Chem2011", "reference": "21177868"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 11, "target": 17, "key": 9}, {"relation": "increases", "evidence": "We further observed that treatment with Abeta(42) decreased cellular N-cadherin expression through NMDA receptors accompanied by increased phosphorylation of both p38 MAPK and Tau in murine primary neurons. ", "citation": {"type": "PubMed", "name": "J Biol Chem2011", "reference": "21177868"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 17, "key": 10}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 4, "key": 0}, {"relation": "decreases", "evidence": "Amyloid-beta accumulation in the synapses directly disturbs mitochondrial function, causing oxidative stress, decreased ATP, and increased Ca2+ influx. Furthermore, the interaction of mitochondrial amyloid-beta with its binding proteins, such as ABAD and CypD, exacerbates amyloid-beta-induced mitochondria and neuronal stress and malfunction.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Synapses", "Subgraph": "Response to oxidative stress"}, "source": 11, "target": 4, "key": 1}, {"relation": "decreases", "evidence": "Amyloid-beta accumulation in the synapses directly disturbs mitochondrial function, causing oxidative stress, decreased ATP, and increased Ca2+ influx. Furthermore, the interaction of mitochondrial amyloid-beta with its binding proteins, such as ABAD and CypD, exacerbates amyloid-beta-induced mitochondria and neuronal stress and malfunction.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Synapses", "Subgraph": "Reactive oxygen species subgraph"}, "source": 11, "target": 4, "key": 2}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Apoptosis signaling subgraph"}, "source": 11, "target": 5, "key": 0}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 5, "key": 1}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "miRNA subgraph"}, "source": 11, "target": 5, "key": 2}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 5, "key": 3}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 11, "target": 5, "key": 4}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 11, "target": 5, "key": 5}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 5, "key": 6}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 11, "target": 18, "key": 0}, {"relation": "increases", "evidence": "Two possible models for involvement of HRD1 in the pathogenesis of AD. Model 1 (cause of AD): Unknown stress initiates insolubilization of HRD1 protein, resulting in a decrease in the functional HRD1 protein in the ER membrane. Subsequently, APP accumulates in the ER and is processed into A that induces hyperphosphorylation of tau protein (ptau). Finally, accumulated A and/or p-tau causes neurodegeneration leading to AD.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Endoplasmic Reticulum", "Subgraph": "Tau protein subgraph"}, "source": 11, "target": 19, "key": 0}, {"relation": "increases", "evidence": "Two possible models for involvement of HRD1 in the pathogenesis of AD. Model 1 (cause of AD): Unknown stress initiates insolubilization of HRD1 protein, resulting in a decrease in the functional HRD1 protein in the ER membrane. Subsequently, APP accumulates in the ER and is processed into A that induces hyperphosphorylation of tau protein (ptau). Finally, accumulated A and/or p-tau causes neurodegeneration leading to AD.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Endoplasmic Reticulum", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 19, "key": 1}, {"relation": "increases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "GSK3 subgraph"}, "source": 11, "target": 20, "key": 0}, {"relation": "increases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 20, "key": 1}, {"relation": "increases", "evidence": "The present investigation reports that clinically relevant concentrations of tarenflurbil (i.e., 1-5 microM) protect both cultured human neuroblastoma cell lines and primary neurons from cytotoxicity associated with exposure to Abeta_{42} or H_{2}O_{2}. In concert with this protection, there is an upregulation of neurotrophins [i.e., nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)]. Furthermore, blocking exogenous NGF or BDNF by binding it to antibody prevents tarenflurbil from protecting human neuronal cells from Abeta_{42} and H_{2}O_{2} cytotoxicity. These findings suggest that up-regulation of neurotrophins might represent an underlying mechanism contributing to the beneficial effects seen with tarenflurbil in AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Nov;15(3):397-407", "reference": "18997293"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 11, "target": 20, "key": 2}, {"relation": "increases", "evidence": "The present investigation reports that clinically relevant concentrations of tarenflurbil (i.e., 1-5 microM) protect both cultured human neuroblastoma cell lines and primary neurons from cytotoxicity associated with exposure to Abeta_{42} or H_{2}O_{2}. In concert with this protection, there is an upregulation of neurotrophins [i.e., nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)]. Furthermore, blocking exogenous NGF or BDNF by binding it to antibody prevents tarenflurbil from protecting human neuronal cells from Abeta_{42} and H_{2}O_{2} cytotoxicity. These findings suggest that up-regulation of neurotrophins might represent an underlying mechanism contributing to the beneficial effects seen with tarenflurbil in AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Nov;15(3):397-407", "reference": "18997293"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 11, "target": 20, "key": 3}, {"relation": "increases", "evidence": "The present investigation reports that clinically relevant concentrations of tarenflurbil (i.e., 1-5 microM) protect both cultured human neuroblastoma cell lines and primary neurons from cytotoxicity associated with exposure to Abeta_{42} or H_{2}O_{2}. In concert with this protection, there is an upregulation of neurotrophins [i.e., nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)]. Furthermore, blocking exogenous NGF or BDNF by binding it to antibody prevents tarenflurbil from protecting human neuronal cells from Abeta_{42} and H_{2}O_{2} cytotoxicity. These findings suggest that up-regulation of neurotrophins might represent an underlying mechanism contributing to the beneficial effects seen with tarenflurbil in AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Nov;15(3):397-407", "reference": "18997293"}, "annotations": {"Subgraph": "Hydrogen peroxide subgraph"}, "source": 11, "target": 20, "key": 4}, {"relation": "increases", "evidence": "DYRK1A phosphorylates APP at Thr688 and enhances APP amyloidogenic cleavage, resulting in increased level of A40/42, formation of toxic A oligomers and deposition of fibrillar amyloid in plaques. Brain amyloidosis contributes to loss of neuronal function and possibly also to neuronal loss. Moreover, elevated levels of A may up-regulate DYRK1A expression and enhance the contribution of overexpressed DYRK1A to neurofibrillary degeneration and -amyloidosis.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 11, "target": 21, "key": 0}, {"relation": "increases", "evidence": "DYRK1A phosphorylates APP at Thr688 and enhances APP amyloidogenic cleavage, resulting in increased level of A40/42, formation of toxic A oligomers and deposition of fibrillar amyloid in plaques. Brain amyloidosis contributes to loss of neuronal function and possibly also to neuronal loss. Moreover, elevated levels of A may up-regulate DYRK1A expression and enhance the contribution of overexpressed DYRK1A to neurofibrillary degeneration and -amyloidosis.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 21, "key": 1}, {"relation": "decreases", "evidence": "Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-. MicroRNAs (miRNAs) are small non-coding RNA regulators of protein synthesis that are essential for normal\\ brain development and function. Their profiles are significantly altered in neurodegenerative diseases such as Alzheimer's\\ disease (AD) that is characterized by amyloid- (A) and tau deposition in brain. How deregulated miRNAs contribute to AD\\ is not understood, as their dysfunction could be both a cause and a consequence of disease. To address this question we\\ had previously profiled miRNAs in models of AD. This identified miR-9 and -181c as being down-regulated by A in\\ hippocampal cultures. Interestingly, there was a remarkable overlap with those miRNAs that are deregulated in A-depositing APP23 transgenic mice and in human AD tissue. While the A precursor protein APP itself is a target of miRNA regulation, the challenge resides in identifying further targets. Here, we expand the repertoire of miRNA target genes by identifying the 3' untranslated regions (3' UTRs) of TGFBI, TRIM2, SIRT1 and BTBD3 as being repressed by miR-9 and -181c, either alone or in combination. Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2012 Feb;46(2):324-35. doi: 10.1007/s12031-011-9587-2. Epub 2011 Jul 1.", "reference": "21720722"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 11, "target": 22, "key": 2}, {"relation": "decreases", "evidence": "Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-. MicroRNAs (miRNAs) are small non-coding RNA regulators of protein synthesis that are essential for normal\\ brain development and function. Their profiles are significantly altered in neurodegenerative diseases such as Alzheimer's\\ disease (AD) that is characterized by amyloid- (A) and tau deposition in brain. How deregulated miRNAs contribute to AD\\ is not understood, as their dysfunction could be both a cause and a consequence of disease. To address this question we\\ had previously profiled miRNAs in models of AD. This identified miR-9 and -181c as being down-regulated by A in\\ hippocampal cultures. Interestingly, there was a remarkable overlap with those miRNAs that are deregulated in A-depositing APP23 transgenic mice and in human AD tissue. While the A precursor protein APP itself is a target of miRNA regulation, the challenge resides in identifying further targets. Here, we expand the repertoire of miRNA target genes by identifying the 3' untranslated regions (3' UTRs) of TGFBI, TRIM2, SIRT1 and BTBD3 as being repressed by miR-9 and -181c, either alone or in combination. Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2012 Feb;46(2):324-35. doi: 10.1007/s12031-011-9587-2. Epub 2011 Jul 1.", "reference": "21720722"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 22, "key": 3}, {"relation": "decreases", "evidence": "Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-. MicroRNAs (miRNAs) are small non-coding RNA regulators of protein synthesis that are essential for normal\\ brain development and function. Their profiles are significantly altered in neurodegenerative diseases such as Alzheimer's\\ disease (AD) that is characterized by amyloid- (A) and tau deposition in brain. How deregulated miRNAs contribute to AD\\ is not understood, as their dysfunction could be both a cause and a consequence of disease. To address this question we\\ had previously profiled miRNAs in models of AD. This identified miR-9 and -181c as being down-regulated by A in\\ hippocampal cultures. Interestingly, there was a remarkable overlap with those miRNAs that are deregulated in A-depositing APP23 transgenic mice and in human AD tissue. While the A precursor protein APP itself is a target of miRNA regulation, the challenge resides in identifying further targets. Here, we expand the repertoire of miRNA target genes by identifying the 3' untranslated regions (3' UTRs) of TGFBI, TRIM2, SIRT1 and BTBD3 as being repressed by miR-9 and -181c, either alone or in combination. Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2012 Feb;46(2):324-35. doi: 10.1007/s12031-011-9587-2. Epub 2011 Jul 1.", "reference": "21720722"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 11, "target": 23, "key": 2}, {"relation": "decreases", "evidence": "Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-. MicroRNAs (miRNAs) are small non-coding RNA regulators of protein synthesis that are essential for normal\\ brain development and function. Their profiles are significantly altered in neurodegenerative diseases such as Alzheimer's\\ disease (AD) that is characterized by amyloid- (A) and tau deposition in brain. How deregulated miRNAs contribute to AD\\ is not understood, as their dysfunction could be both a cause and a consequence of disease. To address this question we\\ had previously profiled miRNAs in models of AD. This identified miR-9 and -181c as being down-regulated by A in\\ hippocampal cultures. Interestingly, there was a remarkable overlap with those miRNAs that are deregulated in A-depositing APP23 transgenic mice and in human AD tissue. While the A precursor protein APP itself is a target of miRNA regulation, the challenge resides in identifying further targets. Here, we expand the repertoire of miRNA target genes by identifying the 3' untranslated regions (3' UTRs) of TGFBI, TRIM2, SIRT1 and BTBD3 as being repressed by miR-9 and -181c, either alone or in combination. Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2012 Feb;46(2):324-35. doi: 10.1007/s12031-011-9587-2. Epub 2011 Jul 1.", "reference": "21720722"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 23, "key": 3}, {"relation": "increases", "evidence": "Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2000 May 12;275(19):14077-83.", "reference": "10799482"}, "annotations": {"NervousSystem": "Hypothalamus", "Subgraph": "Calcium-dependent signal transduction"}, "source": 11, "target": 24, "key": 0}, {"relation": "increases", "evidence": "A1-42 and human amylin (hAmylin) increase cytosolic cAMP and Ca(2+), trigger multiple pathways involving the signal transduction mediators protein kinase A, MAPK, Akt, and cFos.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 May 25;287(22):18820-30. doi: 10.1074/jbc.M111.331181. Epub 2012 Apr 12.", "reference": "22500019"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 24, "key": 1}, {"relation": "increases", "evidence": "A1-42 and human amylin (hAmylin) increase cytosolic cAMP and Ca(2+), trigger multiple pathways involving the signal transduction mediators protein kinase A, MAPK, Akt, and cFos.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 May 25;287(22):18820-30. doi: 10.1074/jbc.M111.331181. Epub 2012 Apr 12.", "reference": "22500019"}, "annotations": {"Subgraph": "Calcium-dependent signal transduction"}, "source": 11, "target": 24, "key": 2}, {"relation": "increases", "evidence": "Moreover, in examination of this pathway in another cell type pertinent to AD, we find that A induces a proinflammatory response in microglia as evidenced by increased leukotriene B4 release. We show that both dipyridamole and compounds which increase cGMP levels prevent Abeta-induced microglial inflammation. Our results suggest that therapeutic intervention aimed at reduction of microglial-mediated inflammation via inhibition of cGMP-PDE or elevation of cGMP may be beneficial in the treatment of AD.", "citation": {"type": "PubMed", "name": "Exp Neurol. 1999 May;157(1):211-21", "reference": "10222124"}, "annotations": {"NervousSystem": "Microglia", "Subgraph": "Inflammatory response subgraph"}, "source": 11, "target": 25, "key": 0}, {"relation": "increases", "evidence": "Moreover, in examination of this pathway in another cell type pertinent to AD, we find that A induces a proinflammatory response in microglia as evidenced by increased leukotriene B4 release. We show that both dipyridamole and compounds which increase cGMP levels prevent Abeta-induced microglial inflammation. Our results suggest that therapeutic intervention aimed at reduction of microglial-mediated inflammation via inhibition of cGMP-PDE or elevation of cGMP may be beneficial in the treatment of AD.", "citation": {"type": "PubMed", "name": "Exp Neurol. 1999 May;157(1):211-21", "reference": "10222124"}, "annotations": {"NervousSystem": "Microglia", "Subgraph": "Blood vessel dilation subgraph"}, "source": 11, "target": 25, "key": 1}, {"relation": "increases", "evidence": "In disease state, LPS (lipoploysacharide) induces TLR4, which increases NFKB1 activities. NFKB1 increases MIR34A which targets TREM2, decreasing normal TREM2 and increases the mutant variant. Recent GWAS studies associated SNP rs75932628 with TREM2 in LOAD patients. Also there are studies suggesting the link of this TREM2 variant with certain clinical and neuroimaging AD features such as frontobasal gray atrophy. Moreover, in disease brain TREM2 forms complex with TYROBP which triggers immune responses through activating macrophages and dendritic cells which leads to chronic neuroinflammation.", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Condition": "Normal Healthy State", "Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 11, "target": 25, "key": 2}, {"relation": "increases", "evidence": "In disease state, LPS (lipoploysacharide) induces TLR4, which increases NFKB1 activities. NFKB1 increases MIR34A which targets TREM2, decreasing normal TREM2 and increases the mutant variant. Recent GWAS studies associated SNP rs75932628 with TREM2 in LOAD patients. Also there are studies suggesting the link of this TREM2 variant with certain clinical and neuroimaging AD features such as frontobasal gray atrophy. Moreover, in disease brain TREM2 forms complex with TYROBP which triggers immune responses through activating macrophages and dendritic cells which leads to chronic neuroinflammation.", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Condition": "Normal Healthy State", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 25, "key": 3}, {"relation": "increases", "evidence": "Moreover, in examination of this pathway in another cell type pertinent to AD, we find that A induces a proinflammatory response in microglia as evidenced by increased leukotriene B4 release. We show that both dipyridamole and compounds which increase cGMP levels prevent Abeta-induced microglial inflammation. Our results suggest that therapeutic intervention aimed at reduction of microglial-mediated inflammation via inhibition of cGMP-PDE or elevation of cGMP may be beneficial in the treatment of AD.", "citation": {"type": "PubMed", "name": "Exp Neurol. 1999 May;157(1):211-21", "reference": "10222124"}, "annotations": {"NervousSystem": "Microglia", "Subgraph": "Inflammatory response subgraph"}, "source": 11, "target": 26, "key": 0}, {"relation": "increases", "evidence": "Moreover, in examination of this pathway in another cell type pertinent to AD, we find that A induces a proinflammatory response in microglia as evidenced by increased leukotriene B4 release. We show that both dipyridamole and compounds which increase cGMP levels prevent Abeta-induced microglial inflammation. Our results suggest that therapeutic intervention aimed at reduction of microglial-mediated inflammation via inhibition of cGMP-PDE or elevation of cGMP may be beneficial in the treatment of AD.", "citation": {"type": "PubMed", "name": "Exp Neurol. 1999 May;157(1):211-21", "reference": "10222124"}, "annotations": {"NervousSystem": "Microglia", "Subgraph": "Blood vessel dilation subgraph"}, "source": 11, "target": 26, "key": 1}, {"relation": "increases", "evidence": "In disease state, LPS (lipoploysacharide) induces TLR4, which increases NFKB1 activities. NFKB1 increases MIR34A which targets TREM2, decreasing normal TREM2 and increases the mutant variant. Recent GWAS studies associated SNP rs75932628 with TREM2 in LOAD patients. Also there are studies suggesting the link of this TREM2 variant with certain clinical and neuroimaging AD features such as frontobasal gray atrophy. Moreover, in disease brain TREM2 forms complex with TYROBP which triggers immune responses through activating macrophages and dendritic cells which leads to chronic neuroinflammation.", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Condition": "Normal Healthy State", "Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 11, "target": 26, "key": 4}, {"relation": "increases", "evidence": "In disease state, LPS (lipoploysacharide) induces TLR4, which increases NFKB1 activities. NFKB1 increases MIR34A which targets TREM2, decreasing normal TREM2 and increases the mutant variant. Recent GWAS studies associated SNP rs75932628 with TREM2 in LOAD patients. Also there are studies suggesting the link of this TREM2 variant with certain clinical and neuroimaging AD features such as frontobasal gray atrophy. Moreover, in disease brain TREM2 forms complex with TYROBP which triggers immune responses through activating macrophages and dendritic cells which leads to chronic neuroinflammation.", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Condition": "Normal Healthy State", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 26, "key": 5}, {"relation": "increases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 11, "target": 27, "key": 0}, {"relation": "increases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 11, "target": 27, "key": 1}, {"relation": "increases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 11, "target": 28, "key": 0}, {"relation": "increases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 11, "target": 28, "key": 1}, {"relation": "decreases", "evidence": "Moreover, our recent studies further demonstrated that (1) apoE mediates sulfatide depletion in amyloid-beta precursor protein transgenic mice; (2) sulfatides enhance amyloid beta (Abeta) peptides binding to apoE-associated particles; (3) Abeta42 content notably correlates with sulfatide content in CSF;(4) sulfatides markedly enhance the uptake of Abeta peptides; and (5) abnormal sulfatide-facilitated Abeta uptake results in the accumulation of Abeta in lysosomes.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2010", "reference": "20052565"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 11, "target": 29, "key": 0}, {"relation": "decreases", "evidence": "Moreover, our recent studies further demonstrated that (1) apoE mediates sulfatide depletion in amyloid-beta precursor protein transgenic mice; (2) sulfatides enhance amyloid beta (Abeta) peptides binding to apoE-associated particles; (3) Abeta42 content notably correlates with sulfatide content in CSF;(4) sulfatides markedly enhance the uptake of Abeta peptides; and (5) abnormal sulfatide-facilitated Abeta uptake results in the accumulation of Abeta in lysosomes.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2010", "reference": "20052565"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 29, "key": 1}, {"relation": "increases", "evidence": " Increased A levels promoted the production of reactive oxygen species (ROS)", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.", "reference": "19245828"}, "annotations": {"Species": "10090"}, "source": 11, "target": 30, "key": 0}, {"relation": "increases", "evidence": " hypomethylation of the APP promoter for example can increase the ceiling of expression of the APP gene in response to aging processes driving overproduction of APP and A levels. The increased A levels then facilitate ROS production with their pro-oxidant properties, damaging the DNA. ", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.", "reference": "19245828"}, "annotations": {"Species": "10090", "Encode_Feature_Types": "Promoter"}, "source": 11, "target": 30, "key": 1}, {"relation": "increases", "evidence": "Developmental exposure to lead (Pb) has been shown to elevate the Alzheimer's disease (AD) related beta-amyloid peptide (Abeta), which is known to generate reactive oxygen species in the aging brain. This study measures the lifetime cerebral 8-hydroxy-2'-deoxyguanosine (oxo8dG) levels and the activity of the DNA repair enzyme 8-oxoguanine DNA glycosylase (Ogg1) in rats developmentally exposed to Pb.", "citation": {"type": "PubMed", "name": "FASEB J. 2006 Apr;20(6):788-90. Epub 2006 Feb 16.", "reference": "16484331"}, "annotations": {"Species": "10116", "Developmental_Phase__of_patient": "Old"}, "source": 11, "target": 30, "key": 2}, {"relation": "increases", "evidence": "Passage of A through the Tom40 import pore increases Reactive Oxygen Species (ROS) within the organelle.", "citation": {"type": "PubMed", "name": "Int J Alzheimers Dis. 2012;2012:421452. doi: 10.1155/2012/421452. Epub 2012 Apr 9.", "reference": "22550605"}, "annotations": {"Subgraph": "AD T2DM SNPs"}, "source": 11, "target": 30, "key": 3}, {"relation": "increases", "evidence": " We found that bilateral microinjection of amyloid beta (A)1-40 fibrils into the hippocampal CA1 area of resulted in significant upregulation of CX3CR1 messenger RNA (mRNA) and protein expression (via increasing histone H3 acetylation in the Cx3cr1 promoter region), synaptic dysfunction, and cognitive impairment,", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Dec;34(12):2843-52. doi: 10.1016/j.neurobiolaging.2013.06.003. Epub 2013 Jul 12.", "reference": "23855980"}, "annotations": {"NervousSystem": "Hippocampus", "Encode_Feature_Types": "Promoter"}, "source": 11, "target": 31, "key": 0}, {"relation": "increases", "evidence": "abaton et al. have presented a pmodel of both non-pathological and pathological Abeta activities and suggest potential therapeutic pathways based on their proposed framework of Abeta acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1.", "citation": {"type": "PubMed", "name": "Exp Neurol2010", "reference": "20451519"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 11, "target": 141, "key": 0}, {"relation": "increases", "evidence": "abaton et al. have presented a pmodel of both non-pathological and pathological Abeta activities and suggest potential therapeutic pathways based on their proposed framework of Abeta acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1.", "citation": {"type": "PubMed", "name": "Exp Neurol2010", "reference": "20451519"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 141, "key": 1}, {"relation": "increases", "evidence": "Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 11, "target": 141, "key": 2}, {"relation": "increases", "evidence": "Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 141, "key": 3}, {"relation": "increases", "evidence": "Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 11, "target": 141, "key": 4}, {"relation": "increases", "evidence": "Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 141, "key": 5}, {"relation": "increases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 11, "target": 141, "key": 6}, {"relation": "increases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 141, "key": 7}, {"relation": "increases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 11, "target": 141, "key": 8}, {"relation": "increases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Calpastatin-calpain subgraph"}, "source": 11, "target": 141, "key": 9}, {"relation": "increases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 11, "target": 141, "key": 10}, {"relation": "increases", "evidence": "A1-42 and human amylin (hAmylin) increase cytosolic cAMP and Ca(2+), trigger multiple pathways involving the signal transduction mediators protein kinase A, MAPK, Akt, and cFos.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 May 25;287(22):18820-30. doi: 10.1074/jbc.M111.331181. Epub 2012 Apr 12.", "reference": "22500019"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 142, "key": 0}, {"relation": "increases", "evidence": "A1-42 and human amylin (hAmylin) increase cytosolic cAMP and Ca(2+), trigger multiple pathways involving the signal transduction mediators protein kinase A, MAPK, Akt, and cFos.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 May 25;287(22):18820-30. doi: 10.1074/jbc.M111.331181. Epub 2012 Apr 12.", "reference": "22500019"}, "annotations": {"Subgraph": "JAK-STAT signaling subgraph"}, "source": 11, "target": 142, "key": 1}, {"relation": "increases", "evidence": "The A Peptides-Activated Calcium-Sensing Receptor Stimulates the Production and Secretion of Vascular Endothelial Growth Factor-A by Normoxic Adult Human Cortical Astrocytes.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2014 Jun 20", "reference": "24948534"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Astrocytes", "FluidAndSecretion": "Bodily Secretions", "Subgraph": "Vascular endothelial growth factor subgraph", "Species": "9606"}, "source": 11, "target": 146, "key": 0}, {"relation": "decreases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "object": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "Reelin subgraph"}, "source": 11, "target": 147, "key": 0}, {"relation": "decreases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "object": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 147, "key": 1}, {"relation": "increases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "GSK3 subgraph"}, "source": 11, "target": 154, "key": 0}, {"relation": "increases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 154, "key": 1}, {"relation": "increases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "GSK3 subgraph"}, "source": 11, "target": 154, "key": 2}, {"relation": "increases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 154, "key": 3}, {"relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "GSK3 subgraph"}, "source": 11, "target": 154, "key": 4}, {"relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 11, "target": 154, "key": 5}, {"relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 154, "key": 6}, {"relation": "decreases", "evidence": "Although there are numerous studies regarding Alzheimer's disease (AD), the cause and progression of AD are still not well understood. The researches in the past decade implicated amyloid-beta (A) overproduction as a causative event in disease pathogenesis, but still failed to clarify the mechanism of pathology from A production to central neural system defects in AD. The present review raises the hypothesis that the onset of AD pathology is closely related with mitochondrial dysfunction induced by A and brain-derived neurotrophic factor (BDNF) axonal transport deficits. It is well-known that axonal transport defect and attenuation of BDNF-neurotrophic tyrosine receptor kinase 2 (TrkB) signal are fatal to neuronal function and survival.We hypothesized that abnormal amyloid precursor protein (APP) processing and A production in mitochondria disturb the axonal transport by impairing mitochondrial function and attenuate BDNF-neurotrophic tyrosine receptor kinase 2 signal subsequently.For this hypothesis, the factors related with the initiation of AD pathology are not only limited to the neurons per se but also expanded to the microenvironment around neurons, such as the secretion of BDNF from astrocytes. The modification of the origin in this pathway may contribute to slow down the disease progression of AD.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2012 Jun;33(6):1122.e1-1122.e10. Epub 2011 Dec 31.", "reference": "22212405"}, "object": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Axonal transport subgraph"}, "source": 11, "target": 157, "key": 0}, {"relation": "decreases", "evidence": "Although there are numerous studies regarding Alzheimer's disease (AD), the cause and progression of AD are still not well understood. The researches in the past decade implicated amyloid-beta (A) overproduction as a causative event in disease pathogenesis, but still failed to clarify the mechanism of pathology from A production to central neural system defects in AD. The present review raises the hypothesis that the onset of AD pathology is closely related with mitochondrial dysfunction induced by A and brain-derived neurotrophic factor (BDNF) axonal transport deficits. It is well-known that axonal transport defect and attenuation of BDNF-neurotrophic tyrosine receptor kinase 2 (TrkB) signal are fatal to neuronal function and survival.We hypothesized that abnormal amyloid precursor protein (APP) processing and A production in mitochondria disturb the axonal transport by impairing mitochondrial function and attenuate BDNF-neurotrophic tyrosine receptor kinase 2 signal subsequently.For this hypothesis, the factors related with the initiation of AD pathology are not only limited to the neurons per se but also expanded to the microenvironment around neurons, such as the secretion of BDNF from astrocytes. The modification of the origin in this pathway may contribute to slow down the disease progression of AD.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2012 Jun;33(6):1122.e1-1122.e10. Epub 2011 Dec 31.", "reference": "22212405"}, "object": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 157, "key": 1}, {"relation": "decreases", "evidence": "Glial activation and increased inflammation characterize neuropathology in Alzheimer's disease (AD). The aim was to develop a model for studying phagocytosis of beta-amyloid (Abeta) peptide by human microglia and to test effects thereupon by immunomodulatory substances. Human CHME3 microglia showed intracellular Abeta(1-42) colocalized with lysosome-associated membrane protein-2, indicating phagocytosis. This was increased by interferon-gamma, and to a lesser degree with Protollin, a proteosome-based adjuvant. Secretion of brain-derived neurotrophic factor (BDNF) was decreased by Abeta(1-42) and by interferon-gamma and interleukin-1beta. These cytokines, but not Abeta(1-42), stimulated interleukin-6 release. Microglia which phagocytosed Abeta(1-42) exhibited a higher degree of expression of interleukin-1 receptor type I and inducible nitric oxide synthase. In conclusion, we show that human microglia are able to phagocytose Abeta(1-42) and that this is associated with expression of inflammatory markers. Abeta(1-42) and interferon-gamma decreased BDNF secretion suggesting a new neuropathological role for Abeta(1-42) and the inflammation accompanying AD.", "citation": {"type": "PubMed", "name": "Int J Alzheimers Dis. 2010 May 20;2010. pii: 798424. doi: 10.4061/2010/798424.", "reference": "20798889"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"NervousSystem": "Microglia", "Subgraph": "Chaperone subgraph"}, "source": 11, "target": 157, "key": 2}, {"relation": "increases", "evidence": "The extracellular A oligomers may activate caspases through activation of cell surface death receptors", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "object": {"modifier": "Activity", "effect": {"name": "cat", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 159, "key": 0}, {"relation": "increases", "evidence": "The extracellular A oligomers may activate caspases through activation of cell surface death receptors", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "object": {"modifier": "Activity", "effect": {"name": "cat", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Caspase subgraph"}, "source": 11, "target": 159, "key": 1}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 160, "key": 0}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Interleukin signaling subgraph"}, "source": 11, "target": 160, "key": 1}, {"relation": "increases", "evidence": "A temporal sequence was observed whereby A accumulation is followed by expression of IL-1 and eventually, of CXCL1, in the hippocampus and olfactory bulb but not the cortex.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2011 Mar 29;492(1):5-10. Epub 2011 Feb 2", "reference": "21295112"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "NervousSystem": "Hippocampus", "Subgraph": "Chemokine signaling subgraph"}, "source": 11, "target": 160, "key": 2}, {"relation": "increases", "evidence": "A temporal sequence was observed whereby A accumulation is followed by expression of IL-1 and eventually, of CXCL1, in the hippocampus and olfactory bulb but not the cortex.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2011 Mar 29;492(1):5-10. Epub 2011 Feb 2", "reference": "21295112"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "NervousSystem": "Hippocampus", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 160, "key": 3}, {"relation": "increases", "evidence": "In Alzheimer disease, it has been proposed that the peptide beta amyloid promotes GSK3 activation, resulting in tau phosphorylation", "citation": {"type": "PubMed", "name": "Exp Neurol. 2010 Jun;223(2):322-5. Epub 2009 Sep 24.", "reference": "19782073"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "GSK3 subgraph"}, "source": 11, "target": 161, "key": 0}, {"relation": "increases", "evidence": "In Alzheimer disease, it has been proposed that the peptide beta amyloid promotes GSK3 activation, resulting in tau phosphorylation", "citation": {"type": "PubMed", "name": "Exp Neurol. 2010 Jun;223(2):322-5. Epub 2009 Sep 24.", "reference": "19782073"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tau protein subgraph"}, "source": 11, "target": 161, "key": 1}, {"relation": "increases", "evidence": "In Alzheimer disease, it has been proposed that the peptide beta amyloid promotes GSK3 activation, resulting in tau phosphorylation", "citation": {"type": "PubMed", "name": "Exp Neurol. 2010 Jun;223(2):322-5. Epub 2009 Sep 24.", "reference": "19782073"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 161, "key": 2}, {"relation": "increases", "evidence": "Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.", "citation": {"type": "PubMed", "name": "Neurobiology of Disease2009", "reference": "19038340"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "GSK3 subgraph"}, "source": 11, "target": 161, "key": 3}, {"relation": "increases", "evidence": "Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.", "citation": {"type": "PubMed", "name": "Neurobiology of Disease2009", "reference": "19038340"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 161, "key": 4}, {"relation": "increases", "evidence": "Caspase-2 mediates neuronal cell death induced by beta-amyloid", "citation": {"type": "PubMed", "name": "J Neurosci. 2000 Feb 15;20(4):1386-92", "reference": "10662829"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Apoptosis signaling subgraph"}, "source": 11, "target": 162, "key": 0}, {"relation": "increases", "evidence": "Caspase-2 mediates neuronal cell death induced by beta-amyloid", "citation": {"type": "PubMed", "name": "J Neurosci. 2000 Feb 15;20(4):1386-92", "reference": "10662829"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 162, "key": 1}, {"relation": "increases", "evidence": "Caspase-2 mediates neuronal cell death induced by beta-amyloid", "citation": {"type": "PubMed", "name": "J Neurosci. 2000 Feb 15;20(4):1386-92", "reference": "10662829"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Caspase subgraph"}, "source": 11, "target": 162, "key": 2}, {"relation": "decreases", "evidence": "Abeta-dependent inactivation of the JAK2/STAT3 axis causes memory loss through cholinergic dysfunction.", "citation": {"type": "PubMed", "name": "Mol Psychiatry. 2009 Feb;14(2):206-22. Epub 2008 Sep 23", "reference": "18813209"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "JAK-STAT signaling subgraph", "Disease": "Alzheimer's disease"}, "source": 11, "target": 163, "key": 0}, {"relation": "decreases", "evidence": "Creatine kinase(CK) and beta-actin have increased carbonyl groups, an index of protein oxidation, and Glt-1, the principal glutamate transporter, has increased binding of the lipid peroxidation product, 4-hydroxy-2-nonenal (HNE). Abeta inhibits CK and causes lipid peroxidation, leading to HNE formation.", "citation": {"type": "PubMed", "name": "Free Radic Res. 2002 Dec;36(12):1307-13", "reference": "12607822"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Lipid peroxidation subgraph"}, "source": 11, "target": 164, "key": 0}, {"relation": "increases", "evidence": "Our results suggest that SRs play a role on inflammatory activation, inducing production of NO and IL1, and show potentiation by A. Potentiation of the inflammatory response of A could be meaningful for the activation of glia observed in AD.We propose that scavenger receptors (SR) participate in the activation of glia by A.", "citation": {"type": "PubMed", "name": "Neurotox Res. 2012 Jan 12. [Epub ahead of print]", "reference": "22237943"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Binding and Uptake of Ligands by Scavenger Receptors"}, "source": 11, "target": 165, "key": 0}, {"relation": "increases", "evidence": "Here we show that the buildup of Abeta increases the mammalian target of rapamycin (mTOR) signaling, whereas decreasing mTOR signaling reduces Abeta levels, thereby highlighting an interrelation between mTOR signaling and Abeta. The mTOR pathway plays a central role in controlling protein homeostasis and hence, neuronal functions; indeed mTOR signaling regulates different forms of learning and memory.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 23;285(17):13107-20. Epub 2010 Feb 23.", "reference": "20178983"}, "object": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 166, "key": 0}, {"relation": "increases", "evidence": "Here we show that the buildup of Abeta increases the mammalian target of rapamycin (mTOR) signaling, whereas decreasing mTOR signaling reduces Abeta levels, thereby highlighting an interrelation between mTOR signaling and Abeta. The mTOR pathway plays a central role in controlling protein homeostasis and hence, neuronal functions; indeed mTOR signaling regulates different forms of learning and memory.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 23;285(17):13107-20. Epub 2010 Feb 23.", "reference": "20178983"}, "object": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "mTOR signaling subgraph"}, "source": 11, "target": 166, "key": 1}, {"relation": "decreases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "object": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "GSK3 subgraph"}, "source": 11, "target": 167, "key": 0}, {"relation": "decreases", "evidence": "-Amyloid (A) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of A, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3 after exposure to oligomeric A in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3, even in the absence of A, is sufficient to produce a phenocopy of A-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3 prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3 inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3 inhibition robustly decreased the oligomeric A load in the mouse brain. All these findings support the idea that GSK3 is aberrantly activated by the presence of A, and contributes, at least in part, to the neuronal anatomical derangement associated with A plaques in AD brains and to A pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "object": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 167, "key": 1}, {"relation": "increases", "evidence": "DYRK1A phosphorylates APP at Thr688 and enhances APP amyloidogenic cleavage, resulting in increased level of A40/42, formation of toxic A oligomers and deposition of fibrillar amyloid in plaques. Brain amyloidosis contributes to loss of neuronal function and possibly also to neuronal loss. Moreover, elevated levels of A may up-regulate DYRK1A expression and enhance the contribution of overexpressed DYRK1A to neurofibrillary degeneration and -amyloidosis.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 11, "target": 168, "key": 0}, {"relation": "increases", "evidence": "DYRK1A phosphorylates APP at Thr688 and enhances APP amyloidogenic cleavage, resulting in increased level of A40/42, formation of toxic A oligomers and deposition of fibrillar amyloid in plaques. Brain amyloidosis contributes to loss of neuronal function and possibly also to neuronal loss. Moreover, elevated levels of A may up-regulate DYRK1A expression and enhance the contribution of overexpressed DYRK1A to neurofibrillary degeneration and -amyloidosis.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 168, "key": 1}, {"relation": "directlyDecreases", "evidence": "Amyloidogenic APP processing may prevent a-secretase (a) cleavage of APP which would otherwise generate a secreted form of APP (sAPPa).", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 169, "key": 0}, {"relation": "directlyDecreases", "evidence": "Amyloidogenic APP processing may prevent a-secretase (a) cleavage of APP which would otherwise generate a secreted form of APP (sAPPa).", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 11, "target": 169, "key": 1}, {"relation": "increases", "evidence": "A oligomers have been found to cause an increase in NMDAR activity, which might require direct association between A oligomers and the NR1 subunit of NMDAR [131]. There is also evidence that glutamate or other endogenous glutamate receptor agonists are increased in AD. Furthermore, NMDAR subunits NR1, NR2A, and NR2B protein levels and phosphorylation are selectively reduced in AD and these abnormalities correlate with the cognitive impairments.", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Glutamatergic subgraph", "Disease": "Alzheimer's disease"}, "source": 11, "target": 170, "key": 0}, {"relation": "increases", "evidence": "Soluble Abeta oligomers can rapidly disrupt synaptic memory mechanisms at extremely low concentrations via stress-activated kinases and oxidative/nitrosative stress mediators.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2007 Nov;35(Pt 5):1219-23.", "reference": "17956317"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "Disease": "Alzheimer's disease"}, "source": 11, "target": 171, "key": 0}, {"relation": "directlyDecreases", "evidence": "Mitochondrial A-binding alcohol dehydrogenase (ABAD): ABAD is a member of the short chain dehydrogenase reductase family in mitochondria that binds A. Binding of A to ABAD distorts the enzymes structure, rendering it inactive. In neurons, ABAD is predominately localized to mitochondria. Upon binding ABAD, A triggers events leading to neuronal apoptosis through a mitochondrial pathway.Interestingly, mitochondrial ABAD is upregulated in neurons from AD patients. The ABAD-A complex has been hypothesized to induce oxidant stress and mitochondrial dysfunction. Increased expression of ABAD exacerbates A-mediated mitochondrial and neuronal stress. A binding to ABAD causes free radical production and neuronal apoptosis", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity", "effect": {"name": "cat", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Mitochondrial translocation subgraph"}, "source": 11, "target": 172, "key": 0}, {"relation": "directlyDecreases", "evidence": "Mitochondrial A-binding alcohol dehydrogenase (ABAD): ABAD is a member of the short chain dehydrogenase reductase family in mitochondria that binds A. Binding of A to ABAD distorts the enzymes structure, rendering it inactive. In neurons, ABAD is predominately localized to mitochondria. Upon binding ABAD, A triggers events leading to neuronal apoptosis through a mitochondrial pathway.Interestingly, mitochondrial ABAD is upregulated in neurons from AD patients. The ABAD-A complex has been hypothesized to induce oxidant stress and mitochondrial dysfunction. Increased expression of ABAD exacerbates A-mediated mitochondrial and neuronal stress. A binding to ABAD causes free radical production and neuronal apoptosis", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity", "effect": {"name": "cat", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Free radical formation subgraph"}, "source": 11, "target": 172, "key": 1}, {"relation": "directlyDecreases", "evidence": "Mitochondrial A-binding alcohol dehydrogenase (ABAD): ABAD is a member of the short chain dehydrogenase reductase family in mitochondria that binds A. Binding of A to ABAD distorts the enzymes structure, rendering it inactive. In neurons, ABAD is predominately localized to mitochondria. Upon binding ABAD, A triggers events leading to neuronal apoptosis through a mitochondrial pathway.Interestingly, mitochondrial ABAD is upregulated in neurons from AD patients. The ABAD-A complex has been hypothesized to induce oxidant stress and mitochondrial dysfunction. Increased expression of ABAD exacerbates A-mediated mitochondrial and neuronal stress. A binding to ABAD causes free radical production and neuronal apoptosis", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity", "effect": {"name": "cat", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Metabolism of steroid hormones subgraph"}, "source": 11, "target": 172, "key": 2}, {"relation": "increases", "evidence": "Here, we report that exogenous As stimulate the NAHAs to produce and secrete even VEGF-A through a CaSR-mediated mechanism.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2014 Jun 20", "reference": "24948534"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Subgraph": "Vascular endothelial growth factor subgraph", "NervousSystem": "Astrocytes"}, "source": 11, "target": 173, "key": 0}, {"relation": "increases", "evidence": "Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells.", "citation": {"type": "PubMed", "name": "J Neurochem. 2003 Jun;85(5):1208-15.", "reference": "12753080"}, "object": {"modifier": "Activity"}, "annotations": {"Cell": "regular cardiac myocyte", "Subgraph": "Matrix metalloproteinase subgraph", "Species": "9606"}, "source": 11, "target": 174, "key": 0}, {"relation": "increases", "evidence": "Up-regulation of Bcl-xL in response to subtoxic beta-amyloid: role in neuronal resistance against apoptotic and oxidative injury.", "citation": {"type": "PubMed", "name": "Neuroscience. 2001;102(1):139-50", "reference": "11226677"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 175, "key": 0}, {"relation": "increases", "evidence": "Up-regulation of Bcl-xL in response to subtoxic beta-amyloid: role in neuronal resistance against apoptotic and oxidative injury.", "citation": {"type": "PubMed", "name": "Neuroscience. 2001;102(1):139-50", "reference": "11226677"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "Subgraph": "Bcl-2 subgraph"}, "source": 11, "target": 175, "key": 1}, {"relation": "increases", "evidence": "Exposure of neuronal cultures to subtoxic concentrations of beta-amyloid peptide 1-40 (1-10microM) or the fragment 25-35 up-regulated both bcl-xL mRNA and Bcl-xL protein levels, determined by reverse transcriptase-polymerase chain reaction and western blot analysis.", "citation": {"type": "PubMed", "name": "Neuroscience. 2001;102(1):139-50", "reference": "11226677"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "Species": "9606", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 175, "key": 2}, {"relation": "increases", "evidence": "Exposure of neuronal cultures to subtoxic concentrations of beta-amyloid peptide 1-40 (1-10microM) or the fragment 25-35 up-regulated both bcl-xL mRNA and Bcl-xL protein levels, determined by reverse transcriptase-polymerase chain reaction and western blot analysis.", "citation": {"type": "PubMed", "name": "Neuroscience. 2001;102(1):139-50", "reference": "11226677"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "Species": "9606", "Subgraph": "Bcl-2 subgraph"}, "source": 11, "target": 175, "key": 3}, {"relation": "decreases", "evidence": "-amyloid decreases detectable endothelial nitric oxide synthase in human erythrocytes: a role for membrane acetylcholinesterase.", "citation": {"type": "PubMed", "name": "Cell Biochem Funct. 2012 Aug;30(6):474-9", "reference": "22431227"}, "annotations": {"Species": "9606", "Tissue": "Endothelium", "Cell": "erythrocyte", "Subgraph": "Nitric oxide subgraph"}, "source": 11, "target": 176, "key": 0}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 11, "target": 176, "key": 1}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 11, "target": 176, "key": 2}, {"relation": "increases", "evidence": "Neurons in both AD brain and Abeta-treated cultures exhibited FasL upregulation and changes in immunoreactivity for Fas receptor.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Apr;12(3):182-93", "reference": "12742739"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 11, "target": 177, "key": 0}, {"relation": "increases", "evidence": "Neurons in both AD brain and Abeta-treated cultures exhibited FasL upregulation and changes in immunoreactivity for Fas receptor.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Apr;12(3):182-93", "reference": "12742739"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 177, "key": 1}, {"relation": "increases", "evidence": "Assembled A beta is a potent stimulator of tissue-type plasminogen activator (tPA) in vitro.", "citation": {"type": "PubMed", "name": "Biochemistry. 1999 Aug 31;38(35):11570-6", "reference": "10471309"}, "annotations": {"Subgraph": "Plasminogen activator subgraph"}, "source": 11, "target": 178, "key": 0}, {"relation": "increases", "evidence": "Our results indicate that beta-sheet secondary structure of A beta, which can be promoted by plasmin cleavage, stimulates tPA activity.", "citation": {"type": "PubMed", "name": "Biochemistry. 1999 Aug 31;38(35):11570-6", "reference": "10471309"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 11, "target": 178, "key": 1}, {"relation": "increases", "evidence": "Our results indicate that beta-sheet secondary structure of A beta, which can be promoted by plasmin cleavage, stimulates tPA activity.", "citation": {"type": "PubMed", "name": "Biochemistry. 1999 Aug 31;38(35):11570-6", "reference": "10471309"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Plasminogen activator subgraph"}, "source": 11, "target": 178, "key": 2}, {"relation": "decreases", "evidence": "Amyloid- inhibits thrombospondin 1 release from cultured astrocytes: effects on synaptic protein expression.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2013 Aug;72(8):735-44", "reference": "23860027"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"NervousSystem": "Astrocytes", "Subgraph": "Cell adhesion subgraph"}, "source": 11, "target": 179, "key": 0}, {"relation": "decreases", "evidence": "These findings suggest that A-mediated reduction in astrocytic TSP-1 release, possibly related to oxidative stress, contributes to the loss of synaptophysin in neurons.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2013 Aug;72(8):735-44", "reference": "23860027"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Cell adhesion subgraph"}, "source": 11, "target": 179, "key": 1}, {"relation": "decreases", "evidence": "These findings suggest that A-mediated reduction in astrocytic TSP-1 release, possibly related to oxidative stress, contributes to the loss of synaptophysin in neurons.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2013 Aug;72(8):735-44", "reference": "23860027"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Response to oxidative stress"}, "source": 11, "target": 179, "key": 2}, {"relation": "increases", "evidence": "We previously showed ECE-2 and ET-1 to be elevated in postmortem temporal cortex from AD patients, and ECE-2 expression and ET-1 release to be upregulated by A42 in vitro.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;36(3):577-87", "reference": "23629587"}, "annotations": {"Subgraph": "Endothelin subgraph", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Cerebral Cortex", "Species": "9606"}, "source": 11, "target": 180, "key": 0}, {"relation": "increases", "evidence": "We previously showed ECE-2 and ET-1 to be elevated in postmortem temporal cortex from AD patients, and ECE-2 expression and ET-1 release to be upregulated by A42 in vitro.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;36(3):577-87", "reference": "23629587"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Subgraph": "Endothelin subgraph", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Cerebral Cortex", "Species": "9606"}, "source": 11, "target": 181, "key": 0}, {"relation": "increases", "evidence": "In primary cultures of human brain endothelial cells, both A40 and A42 caused a significant increase in ET-1 release, the increase being particularly pronounced with A40.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;36(3):577-87", "reference": "23629587"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Subgraph": "Endothelin subgraph", "NervousSystem": "Brain", "Cell": "endothelial cell", "Species": "9606"}, "source": 11, "target": 181, "key": 1}, {"relation": "increases", "evidence": "A42 causes increased neuronal production and release of endothelin-1 (ET-1), a potent vasoconstrictor, and upregulation of endothelin-converting enzyme-2 (ECE-2), the enzyme which cleaves ET-1 from its inactive precursor.", "citation": {"type": "PubMed", "name": "Pharmacol Res. 2011 Jun;63(6):525-31", "reference": "21193044"}, "annotations": {"Subgraph": "Endothelin subgraph"}, "source": 11, "target": 181, "key": 2}, {"relation": "increases", "evidence": "A42 causes increased neuronal production and release of endothelin-1 (ET-1), a potent vasoconstrictor, and upregulation of endothelin-converting enzyme-2 (ECE-2), the enzyme which cleaves ET-1 from its inactive precursor.", "citation": {"type": "PubMed", "name": "Pharmacol Res. 2011 Jun;63(6):525-31", "reference": "21193044"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 181, "key": 3}, {"relation": "increases", "evidence": "C/EBP homologous protein (CHOP), a pro-apoptotic ER stress protein, was expressed at high levels but glucose-regulated protein 78 (GRP78), an anti-apoptotic ER stress protein with chaperone activity, was only slightly affected by treatment with -amyloid.", "citation": {"type": "PubMed", "name": "Biol Res. 2012;45(4):403-10", "reference": "23558999"}, "annotations": {"Subgraph": "Unfolded protein response subgraph"}, "source": 11, "target": 182, "key": 0}, {"relation": "increases", "evidence": "C/EBP homologous protein (CHOP), a pro-apoptotic ER stress protein, was expressed at high levels but glucose-regulated protein 78 (GRP78), an anti-apoptotic ER stress protein with chaperone activity, was only slightly affected by treatment with -amyloid.", "citation": {"type": "PubMed", "name": "Biol Res. 2012;45(4):403-10", "reference": "23558999"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 182, "key": 1}, {"relation": "increases", "evidence": "We report here that A activates the ER stress response factor X-box binding protein 1 (XBP1) in transgenic flies and in mammalian cultured neurons, yielding its active form, the transcription factor XBP1s. XBP1s shows neuroprotective activity in two different AD models, flies expressing A and mammalian cultured neurons treated with A oligomers.", "citation": {"type": "PubMed", "name": "Hum Mol Genet. 2011 Jun 1;20(11):2144-60", "reference": "21389082"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Neurons", "Subgraph": "Neuroprotection subgraph"}, "source": 11, "target": 183, "key": 0}, {"relation": "increases", "evidence": "We report here that A activates the ER stress response factor X-box binding protein 1 (XBP1) in transgenic flies and in mammalian cultured neurons, yielding its active form, the transcription factor XBP1s. XBP1s shows neuroprotective activity in two different AD models, flies expressing A and mammalian cultured neurons treated with A oligomers.", "citation": {"type": "PubMed", "name": "Hum Mol Genet. 2011 Jun 1;20(11):2144-60", "reference": "21389082"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Neurons", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 183, "key": 1}, {"relation": "increases", "evidence": "We report here that A activates the ER stress response factor X-box binding protein 1 (XBP1) in transgenic flies and in mammalian cultured neurons, yielding its active form, the transcription factor XBP1s. XBP1s shows neuroprotective activity in two different AD models, flies expressing A and mammalian cultured neurons treated with A oligomers.", "citation": {"type": "PubMed", "name": "Hum Mol Genet. 2011 Jun 1;20(11):2144-60", "reference": "21389082"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Neurons", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 11, "target": 183, "key": 2}, {"relation": "increases", "evidence": "In this study we demonstrate that uPAR mRNA and protein expression is induced following incubation of human post-mortem brain-derived microglia with fibrillar amyloid beta (Abeta) peptide.", "citation": {"type": "PubMed", "name": "Brain Res. 2002 Feb 1;926(1-2):69-79", "reference": "11814408"}, "annotations": {"Species": "9606", "Subgraph": "Plasminogen activator subgraph", "NervousSystem": "Brain"}, "source": 11, "target": 184, "key": 0}, {"relation": "increases", "evidence": "In this study we demonstrate that uPAR mRNA and protein expression is induced following incubation of human post-mortem brain-derived microglia with fibrillar amyloid beta (Abeta) peptide.", "citation": {"type": "PubMed", "name": "Brain Res. 2002 Feb 1;926(1-2):69-79", "reference": "11814408"}, "annotations": {"Species": "9606", "Subgraph": "Plasminogen activator subgraph", "NervousSystem": "Microglia"}, "source": 11, "target": 184, "key": 1}, {"relation": "increases", "evidence": "Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2003 May 23;278(21):19054-61", "reference": "12754271"}, "annotations": {"Cell": "regular cardiac myocyte", "Species": "9606", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 184, "key": 2}, {"relation": "increases", "evidence": "Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2003 May 23;278(21):19054-61", "reference": "12754271"}, "annotations": {"Cell": "regular cardiac myocyte", "Species": "9606", "Subgraph": "Plasminogen activator subgraph"}, "source": 11, "target": 184, "key": 3}, {"relation": "increases", "evidence": "Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2003 May 23;278(21):19054-61", "reference": "12754271"}, "annotations": {"Cell": "regular cardiac myocyte", "Species": "9606", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 185, "key": 0}, {"relation": "increases", "evidence": "Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2003 May 23;278(21):19054-61", "reference": "12754271"}, "annotations": {"Cell": "regular cardiac myocyte", "Species": "9606", "Subgraph": "Plasminogen activator subgraph"}, "source": 11, "target": 185, "key": 1}, {"relation": "increases", "evidence": "Abeta induced translocation of MARCKS from the membrane fraction to the cytosolic fraction.", "citation": {"type": "PubMed", "name": "Neurochem Int. 2001 Jun;38(7):593-600", "reference": "11290384"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Cytosol"}}}, "annotations": {"Subgraph": "Phosphatidylinositol 3 subgraph", "CellStructure": "Cell Membrane"}, "source": 11, "target": 186, "key": 0}, {"relation": "increases", "evidence": "Abeta induced translocation of MARCKS from the membrane fraction to the cytosolic fraction.", "citation": {"type": "PubMed", "name": "Neurochem Int. 2001 Jun;38(7):593-600", "reference": "11290384"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Cytosol"}}}, "annotations": {"Subgraph": "Phosphatidylinositol 3 subgraph", "CellStructure": "Cytosol"}, "source": 11, "target": 186, "key": 1}, {"relation": "increases", "evidence": "The extracellular amyloid-beta deposition in AD brains could be a causative factor that activates p70S6K. We hypothesized that amyloid-beta deposition activates p70S6K whose anti-apoptotic property subsequently keeps neurons from entering into the apoptotic process.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Aug;14(4):385-92", "reference": "18688088"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Brain", "Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 187, "key": 0}, {"relation": "increases", "evidence": "The extracellular amyloid-beta deposition in AD brains could be a causative factor that activates p70S6K. We hypothesized that amyloid-beta deposition activates p70S6K whose anti-apoptotic property subsequently keeps neurons from entering into the apoptotic process.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Aug;14(4):385-92", "reference": "18688088"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Brain", "Subgraph": "mTOR signaling subgraph"}, "source": 11, "target": 187, "key": 1}, {"relation": "increases", "evidence": "The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid beta-peptide.", "citation": {"type": "PubMed", "name": "Curr Med Chem. 2006;13(17):1971-8.", "reference": "16842191"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Immunoglobulin subgraph"}, "source": 11, "target": 188, "key": 0}, {"relation": "increases", "evidence": "The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid beta-peptide.", "citation": {"type": "PubMed", "name": "Curr Med Chem2006", "reference": "16842191"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Immunoglobulin subgraph"}, "source": 11, "target": 188, "key": 1}, {"relation": "increases", "evidence": "The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid beta-peptide.", "citation": {"type": "PubMed", "name": "Curr Med Chem2006", "reference": "16842191"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Cytokine signaling subgraph"}, "source": 11, "target": 188, "key": 2}, {"relation": "increases", "evidence": "Direct addition of Ab(1 42) to the microglia increased their expression of M-CSF. ", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2005", "reference": "15882940"}, "annotations": {"Subgraph": "Cytokine signaling subgraph"}, "source": 11, "target": 189, "key": 0}, {"relation": "increases", "evidence": "Direct addition of Ab(1 42) to the microglia increased their expression of M-CSF. ", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2005", "reference": "15882940"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 189, "key": 1}, {"relation": "increases", "evidence": " In each case, the Abstimulation of M-CSF secretion was significantly blocked by treatment of cultures with anti-RAGE F(ab')2.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2005", "reference": "15882940"}, "annotations": {"Subgraph": "Cytokine signaling subgraph"}, "source": 11, "target": 189, "key": 2}, {"relation": "increases", "evidence": " In each case, the Abstimulation of M-CSF secretion was significantly blocked by treatment of cultures with anti-RAGE F(ab')2.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2005", "reference": "15882940"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 189, "key": 3}, {"relation": "increases", "evidence": "Aggregated Abeta induced IFN-gamma production from co-culture of astrocytes and microglia, and IFN-gamma elicited tumor necrosis factor (TNF)-alpha secretion in wild type (WT) but not GRKO microglia co-cultured with astrocytes. ", "citation": {"type": "PubMed", "name": "Am J Pathol2007", "reference": "17255335"}, "annotations": {"Subgraph": "Interferon signaling"}, "source": 11, "target": 190, "key": 0}, {"relation": "increases", "evidence": "Aggregated Abeta induced IFN-gamma production from co-culture of astrocytes and microglia, and IFN-gamma elicited tumor necrosis factor (TNF)-alpha secretion in wild type (WT) but not GRKO microglia co-cultured with astrocytes. ", "citation": {"type": "PubMed", "name": "Am J Pathol2007", "reference": "17255335"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 190, "key": 1}, {"relation": "decreases", "evidence": " Intracerebroventricular administration of Abeta1-42 downregulated p-STAT3 whereas passive immunization with anti-Abeta antibody conversely restored hippocampal p-STAT3 levels in Tg2576 mice, paralleling the decrease in the brain Abeta burden. Abeta1-42 consistently pmodulated p-STAT3 levels in primary neurons.", "citation": {"type": "PubMed", "name": "Mol Psychiatry2009", "reference": "18813209"}, "annotations": {"Subgraph": "Serotonergic subgraph"}, "source": 11, "target": 191, "key": 0}, {"relation": "decreases", "evidence": " Intracerebroventricular administration of Abeta1-42 downregulated p-STAT3 whereas passive immunization with anti-Abeta antibody conversely restored hippocampal p-STAT3 levels in Tg2576 mice, paralleling the decrease in the brain Abeta burden. Abeta1-42 consistently pmodulated p-STAT3 levels in primary neurons.", "citation": {"type": "PubMed", "name": "Mol Psychiatry2009", "reference": "18813209"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 191, "key": 1}, {"relation": "decreases", "evidence": " Intracerebroventricular administration of Abeta1-42 downregulated p-STAT3 whereas passive immunization with anti-Abeta antibody conversely restored hippocampal p-STAT3 levels in Tg2576 mice, paralleling the decrease in the brain Abeta burden. Abeta1-42 consistently pmodulated p-STAT3 levels in primary neurons.", "citation": {"type": "PubMed", "name": "Mol Psychiatry2009", "reference": "18813209"}, "annotations": {"Subgraph": "JAK-STAT signaling subgraph"}, "source": 11, "target": 191, "key": 2}, {"relation": "increases", "evidence": "Likewise, Abeta(1-40) led to activation of both JNK (c-Jun-NH2-terminal kinase)/c-Jun and nuclear factor-kappaB, resulting in iNOS upregulation in both brain structures.", "citation": {"type": "PubMed", "name": "Journal of Neuroscience2007", "reference": "17507561"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 192, "key": 0}, {"relation": "increases", "evidence": "Likewise, Abeta(1-40) led to activation of both JNK (c-Jun-NH2-terminal kinase)/c-Jun and nuclear factor-kappaB, resulting in iNOS upregulation in both brain structures.", "citation": {"type": "PubMed", "name": "Journal of Neuroscience2007", "reference": "17507561"}, "annotations": {"Subgraph": "Caspase subgraph"}, "source": 11, "target": 192, "key": 1}, {"relation": "increases", "evidence": "We report that beta-amyloid (Abeta), a death-promoting peptide implicated in the pathophysiology of AD, induces the proapoptotic protein Bcl-2 interacting mediator of cell death (Bim) in cultured hippocampal and cortical neurons. ", "citation": {"type": "PubMed", "name": "The journal of neuroscience2007", "reference": "17251431"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 193, "key": 0}, {"relation": "increases", "evidence": "We report that beta-amyloid (Abeta), a death-promoting peptide implicated in the pathophysiology of AD, induces the proapoptotic protein Bcl-2 interacting mediator of cell death (Bim) in cultured hippocampal and cortical neurons. ", "citation": {"type": "PubMed", "name": "The journal of neuroscience2007", "reference": "17251431"}, "annotations": {"Subgraph": "Bcl-2 subgraph"}, "source": 11, "target": 193, "key": 1}, {"relation": "increases", "evidence": "Soluble Abeta40, the major amyloid precursor protein cleavage product, by itself stimulates astrocytes to express NOS-2 and make NO, possibly by activating p75(NTR) receptors, which they share with neurons, and can considerably amplify NOS-2 expression by the pro-inflammatory cytokine trio. ", "citation": {"type": "PubMed", "name": "Italian journal of anatomy and embryologyNA", "reference": "17385278"}, "annotations": {"Subgraph": "Nitric oxide subgraph"}, "source": 11, "target": 194, "key": 0}, {"relation": "increases", "evidence": "Soluble Abeta40, the major amyloid precursor protein cleavage product, by itself stimulates astrocytes to express NOS-2 and make NO, possibly by activating p75(NTR) receptors, which they share with neurons, and can considerably amplify NOS-2 expression by the pro-inflammatory cytokine trio. ", "citation": {"type": "PubMed", "name": "Italian journal of anatomy and embryologyNA", "reference": "17385278"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 11, "target": 194, "key": 1}, {"relation": "increases", "evidence": "Soluble Abeta40, the major amyloid precursor protein cleavage product, by itself stimulates astrocytes to express NOS-2 and make NO, possibly by activating p75(NTR) receptors, which they share with neurons, and can considerably amplify NOS-2 expression by the pro-inflammatory cytokine trio. ", "citation": {"type": "PubMed", "name": "Italian journal of anatomy and embryologyNA", "reference": "17385278"}, "annotations": {"Subgraph": "Nerve growth factor subgraph"}, "source": 11, "target": 194, "key": 2}, {"relation": "decreases", "evidence": "CCR2 deficiency leads to lower microglia accumulation and higher brain beta-amyloid (Abeta) levels, indicating that early microglial accumulation promotes Abeta clearance.", "citation": {"type": "PubMed", "name": "Trends Pharmacol Sci. 2008 Dec;29(12):626-32. Epub 2008 Oct 1.", "reference": "18835047"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Complement system subgraph"}, "source": 13, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "CCR2 deficiency leads to lower microglia accumulation and higher brain beta-amyloid (Abeta) levels, indicating that early microglial accumulation promotes Abeta clearance.", "citation": {"type": "PubMed", "name": "Trends Pharmacol Sci. 2008 Dec;29(12):626-32. Epub 2008 Oct 1.", "reference": "18835047"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 13, "target": 11, "key": 3}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Endothelin subgraph"}, "source": 13, "target": 11, "key": 6}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 13, "target": 11, "key": 7}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 13, "target": 11, "key": 8}, {"relation": "increases", "evidence": "Microglia, macrophage-like resident immune cells in the brain, possess both neurotoxic and neuroprotective properties and have a critical role in the development of Alzheimer's disease (AD)", "citation": {"type": "PubMed", "name": "Am J Pathol. 2011 Oct;179(4):2016-27. Epub 2011 Aug 26.", "reference": "21872563"}, "annotations": {"Disease": "Alzheimer's disease"}, "source": 13, "target": 33, "key": 0}, {"relation": "increases", "evidence": "In disease state, LPS (lipoploysacharide) induces TLR4, which increases NFKB1 activities. NFKB1 increases MIR34A which targets TREM2, decreasing normal TREM2 and increases the mutant variant. Recent GWAS studies associated SNP rs75932628 with TREM2 in LOAD patients. Also there are studies suggesting the link of this TREM2 variant with certain clinical and neuroimaging AD features such as frontobasal gray atrophy. Moreover, in disease brain TREM2 forms complex with TYROBP which triggers immune responses through activating macrophages and dendritic cells which leads to chronic neuroinflammation.", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Inflammatory response subgraph", "Condition": "Normal Healthy State", "Disease": "Alzheimer's disease"}, "source": 13, "target": 140, "key": 0}, {"relation": "increases", "evidence": "Neuroinflammation contributes to the pathogenesis of sporadic Alzheimer's disease (AD)", "citation": {"type": "PubMed", "name": "Int J Mol Epidemiol Genet. 2012;3(1):39-47. Epub 2012 Feb 23.", "reference": "22493750"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 14, "target": 33, "key": 0}, {"relation": "decreases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 14, "target": 44, "key": 0}, {"relation": "decreases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 14, "target": 44, "key": 1}, {"relation": "increases", "evidence": "NGF increases APP levels through enhanced translation rate and that NO, which modulates the NGF-induced increase in APP protein, also regulates APP mRNA levels and could play a role in APP processing Interestingly, we also found that this inhibition of NOS only partially attenuated the increase in APP promoter activation mediated by NGF [7] suggesting that NGF- signal transduction pathways and NO may be influencing the rate of APP mRNA or protein synthesis or degradation in addition to altering gene transcription.", "citation": {"type": "PubMed", "name": "Open Biochem J. 2012;6:31-9. Epub 2012 Apr 19", "reference": "22550546"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Nitric oxide subgraph"}, "source": 15, "target": 68, "key": 0}, {"relation": "increases", "evidence": "NGF increases APP levels through enhanced translation rate and that NO, which modulates the NGF-induced increase in APP protein, also regulates APP mRNA levels and could play a role in APP processing Interestingly, we also found that this inhibition of NOS only partially attenuated the increase in APP promoter activation mediated by NGF [7] suggesting that NGF- signal transduction pathways and NO may be influencing the rate of APP mRNA or protein synthesis or degradation in addition to altering gene transcription.", "citation": {"type": "PubMed", "name": "Open Biochem J. 2012;6:31-9. Epub 2012 Apr 19", "reference": "22550546"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 15, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10205228"}, "annotations": {}, "source": 15, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10792026"}, "annotations": {}, "source": 15, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11250657"}, "annotations": {}, "source": 15, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223066"}, "annotations": {}, "source": 15, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16168523"}, "annotations": {}, "source": 15, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18041089"}, "annotations": {}, "source": 15, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18335517"}, "annotations": {}, "source": 15, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20188080"}, "annotations": {}, "source": 15, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7534305"}, "annotations": {}, "source": 15, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9706149"}, "annotations": {}, "source": 15, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9758726"}, "annotations": {}, "source": 15, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10909967"}, "annotations": {}, "source": 15, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12723939"}, "annotations": {}, "source": 15, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "13678430"}, "annotations": {}, "source": 15, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16492401"}, "annotations": {}, "source": 15, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16968468"}, "annotations": {}, "source": 15, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17026986"}, "annotations": {}, "source": 15, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17157857"}, "annotations": {}, "source": 15, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18206661"}, "annotations": {}, "source": 15, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11063824"}, "annotations": {}, "source": 15, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12612912"}, "annotations": {}, "source": 15, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14617770"}, "annotations": {}, "source": 15, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14623498"}, "annotations": {}, "source": 15, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17067557"}, "annotations": {}, "source": 15, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17729120"}, "annotations": {}, "source": 15, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18207479"}, "annotations": {}, "source": 15, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18369347"}, "annotations": {}, "source": 15, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20626112"}, "annotations": {}, "source": 15, "target": 140, "key": 27}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20627362"}, "annotations": {}, "source": 15, "target": 140, "key": 28}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20708382"}, "annotations": {}, "source": 15, "target": 140, "key": 29}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21943492"}, "annotations": {}, "source": 15, "target": 140, "key": 30}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8341679"}, "annotations": {}, "source": 15, "target": 140, "key": 31}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8975779"}, "annotations": {}, "source": 15, "target": 140, "key": 32}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9388267"}, "annotations": {}, "source": 15, "target": 140, "key": 33}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10706834"}, "annotations": {}, "source": 15, "target": 140, "key": 34}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11282106"}, "annotations": {}, "source": 15, "target": 140, "key": 35}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223066"}, "annotations": {}, "source": 15, "target": 140, "key": 36}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15451797"}, "annotations": {}, "source": 15, "target": 140, "key": 37}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15485488"}, "annotations": {}, "source": 15, "target": 140, "key": 38}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16366677"}, "annotations": {}, "source": 15, "target": 140, "key": 39}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16754782"}, "annotations": {}, "source": 15, "target": 140, "key": 40}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19393675"}, "annotations": {}, "source": 15, "target": 140, "key": 41}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21943492"}, "annotations": {}, "source": 15, "target": 140, "key": 42}, {"relation": "decreases", "evidence": "Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7519435"}, "annotations": {}, "source": 15, "target": 140, "key": 43}, {"relation": "increases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 16, "target": 44, "key": 0}, {"relation": "increases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 16, "target": 44, "key": 1}, {"relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 16, "target": 44, "key": 2}, {"relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 16, "target": 45, "key": 0}, {"relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 16, "target": 46, "key": 0}, {"relation": "increases", "evidence": "During the course of AD tau becomes hyperphosphorylated and dissociates from microtubules which then depolymerize. The hyperphosphorylated tau self-aggregates and accumulates in the cell body where it forms paired-helical filaments (neurofibrillary tangles). As a consequence of accumulation of A at synapses, Ca2+ regulation is impaired", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "annotations": {"NervousSystem": "Neurons", "Disease": "Alzheimer's disease", "Subgraph": "Tau protein subgraph"}, "source": 17, "target": 11, "key": 0}, {"relation": "increases", "evidence": "During the course of AD tau becomes hyperphosphorylated and dissociates from microtubules which then depolymerize. The hyperphosphorylated tau self-aggregates and accumulates in the cell body where it forms paired-helical filaments (neurofibrillary tangles). As a consequence of accumulation of A at synapses, Ca2+ regulation is impaired", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "annotations": {"NervousSystem": "Neurons", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 17, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The pathogenic correlation between Shc/Grb2 binding to APP during AD development is supported by the observation that the complexes APP (or CTFs)/ShcA or Grb2 are significantly increased in AD brain as compared to controls [55]. The increased phosphorylation/activation of ERK1/2, often described in AD brain, is also observed in thrombin-activated astrocytes, suggesting that, in this model, ERK1/2 may be activated by APP through ShcA. These data give prominence to the biological importance of APP phosphorylation for its functions and the regulation of intracellular adaptor binding as events responsible for the induction of glial-associated mitogenic pathway. Furthermore, ERK1/2, activated by Ain vitro, plays a role in APP processing and phosphorylates Tau in a PHF-Tau similar manner. However, it is conceivable that a different signaling A-independent might as well activate tau phosphorylation by ERK1/2 via the intracellular signaling regulated by the APP/CTFs-Shc-Grb2 pathway", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tau protein subgraph"}, "source": 17, "target": 33, "key": 0}, {"relation": "increases", "evidence": "The pathogenic correlation between Shc/Grb2 binding to APP during AD development is supported by the observation that the complexes APP (or CTFs)/ShcA or Grb2 are significantly increased in AD brain as compared to controls [55]. The increased phosphorylation/activation of ERK1/2, often described in AD brain, is also observed in thrombin-activated astrocytes, suggesting that, in this model, ERK1/2 may be activated by APP through ShcA. These data give prominence to the biological importance of APP phosphorylation for its functions and the regulation of intracellular adaptor binding as events responsible for the induction of glial-associated mitogenic pathway. Furthermore, ERK1/2, activated by Ain vitro, plays a role in APP processing and phosphorylates Tau in a PHF-Tau similar manner. However, it is conceivable that a different signaling A-independent might as well activate tau phosphorylation by ERK1/2 via the intracellular signaling regulated by the APP/CTFs-Shc-Grb2 pathway", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "MAPK-ERK subgraph"}, "source": 17, "target": 33, "key": 1}, {"relation": "increases", "evidence": "During the course of AD tau becomes hyperphosphorylated and dissociates from microtubules which then depolymerize. The hyperphosphorylated tau self-aggregates and accumulates in the cell body where it forms paired-helical filaments (neurofibrillary tangles). As a consequence of accumulation of A at synapses, Ca2+ regulation is impaired", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Tau protein subgraph", "Disease": "Alzheimer's disease"}, "source": 17, "target": 33, "key": 3}, {"relation": "increases", "evidence": "Abnormal phosphorylation of tau and activation of -calpain are two key events in the pathology of AD. Importantly, these two events are also related with GCs and IR Importantly, these two events are also related with GCs and IR. We therefore speculate that tau phosphorylation and  -calpain activation may mediate the GCs-induced IR. Akt phosphorylation at Ser-473 (pAkt) is commonly used as a marker for assessing IR.", "citation": {"type": "PubMed", "name": "2012;7(4):e35783. doi: 10.1371/journal.pone.0035783. Epub 2012 Apr 20.", "reference": "22536436"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tau protein subgraph"}, "source": 17, "target": 33, "key": 4}, {"relation": "increases", "evidence": "Abnormal phosphorylation of tau and activation of -calpain are two key events in the pathology of AD. Importantly, these two events are also related with GCs and IR Importantly, these two events are also related with GCs and IR. We therefore speculate that tau phosphorylation and  -calpain activation may mediate the GCs-induced IR. Akt phosphorylation at Ser-473 (pAkt) is commonly used as a marker for assessing IR.", "citation": {"type": "PubMed", "name": "2012;7(4):e35783. doi: 10.1371/journal.pone.0035783. Epub 2012 Apr 20.", "reference": "22536436"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Insulin signal transduction"}, "source": 17, "target": 33, "key": 5}, {"relation": "increases", "evidence": "Abnormal regulation of tau phosphorylation and/or alternative splicing is associated with the development of a large (>20) group of neurodegenerative disorders collectively known as tauopathies, the most common being Alzheimer's disease. Despite intensive research, little is known about the molecular mechanisms that participate in the transcriptional and posttranscriptional regulation of endogenous tau, especially in neurons. We identified miR-16 and miR-132 as putative endogenous modulators of neuronal tau phosphorylation and tau exon 10 splicing, respectively. Interestingly, these miRNAs have been implicated in cell survival and function, whereas changes in miR-16/132 levels correlate with tau pathology in human neurodegenerative disorders. Thus, understanding how miRNA networks influence tau metabolism and possibly other biological systems might provide important clues into the molecular causes of tauopathies, particularly the more common but less understood sporadic forms.", "citation": {"type": "PubMed", "name": "Int J Alzheimers Dis. 2012;2012:406561. doi: 10.1155/2012/406561. Epub 2012 Jun 5.", "reference": "22720189"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 17, "target": 33, "key": 7}, {"relation": "increases", "evidence": "Abnormal regulation of tau phosphorylation and/or alternative splicing is associated with the development of a large (>20) group of neurodegenerative disorders collectively known as tauopathies, the most common being Alzheimer's disease. Despite intensive research, little is known about the molecular mechanisms that participate in the transcriptional and posttranscriptional regulation of endogenous tau, especially in neurons. We identified miR-16 and miR-132 as putative endogenous modulators of neuronal tau phosphorylation and tau exon 10 splicing, respectively. Interestingly, these miRNAs have been implicated in cell survival and function, whereas changes in miR-16/132 levels correlate with tau pathology in human neurodegenerative disorders. Thus, understanding how miRNA networks influence tau metabolism and possibly other biological systems might provide important clues into the molecular causes of tauopathies, particularly the more common but less understood sporadic forms.", "citation": {"type": "PubMed", "name": "Int J Alzheimers Dis. 2012;2012:406561. doi: 10.1155/2012/406561. Epub 2012 Jun 5.", "reference": "22720189"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 17, "target": 33, "key": 8}, {"relation": "increases", "evidence": "The pathogenic correlation between Shc/Grb2 binding to APP during AD development is supported by the observation that the complexes APP (or CTFs)/ShcA or Grb2 are significantly increased in AD brain as compared to controls [55]. The increased phosphorylation/activation of ERK1/2, often described in AD brain, is also observed in thrombin-activated astrocytes, suggesting that, in this model, ERK1/2 may be activated by APP through ShcA. These data give prominence to the biological importance of APP phosphorylation for its functions and the regulation of intracellular adaptor binding as events responsible for the induction of glial-associated mitogenic pathway. Furthermore, ERK1/2, activated by Ain vitro, plays a role in APP processing and phosphorylates Tau in a PHF-Tau similar manner. However, it is conceivable that a different signaling A-independent might as well activate tau phosphorylation by ERK1/2 via the intracellular signaling regulated by the APP/CTFs-Shc-Grb2 pathway", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 17, "target": 33, "key": 21}, {"relation": "increases", "evidence": "The pathogenic correlation between Shc/Grb2 binding to APP during AD development is supported by the observation that the complexes APP (or CTFs)/ShcA or Grb2 are significantly increased in AD brain as compared to controls [55]. The increased phosphorylation/activation of ERK1/2, often described in AD brain, is also observed in thrombin-activated astrocytes, suggesting that, in this model, ERK1/2 may be activated by APP through ShcA. These data give prominence to the biological importance of APP phosphorylation for its functions and the regulation of intracellular adaptor binding as events responsible for the induction of glial-associated mitogenic pathway. Furthermore, ERK1/2, activated by Ain vitro, plays a role in APP processing and phosphorylates Tau in a PHF-Tau similar manner. However, it is conceivable that a different signaling A-independent might as well activate tau phosphorylation by ERK1/2 via the intracellular signaling regulated by the APP/CTFs-Shc-Grb2 pathway", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 17, "target": 33, "key": 22}, {"relation": "decreases", "evidence": "Hyperphosphorylated tau protein is the basic structural component of the neurofibrillary tangle, a histopathological hallmark of Alzheimers disease. The formation of hyperphosphorylated tau protein may impair learning and the synaptic plasticity of neurons. Tau is a protein that is associated with and stabilizes microtubules; hyperphosphorylated tau protein is unable to perform this stabilization function.", "citation": {"type": "PubMed", "name": "Eur Neuropsychopharmacol. 2006 Dec;16(8):547-51. Epub 2006 Feb 28.", "reference": "16504486"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 17, "target": 62, "key": 0}, {"relation": "decreases", "evidence": "Hyperphosphorylated tau protein is the basic structural component of the neurofibrillary tangle, a histopathological hallmark of Alzheimers disease. The formation of hyperphosphorylated tau protein may impair learning and the synaptic plasticity of neurons. Tau is a protein that is associated with and stabilizes microtubules; hyperphosphorylated tau protein is unable to perform this stabilization function.", "citation": {"type": "PubMed", "name": "Eur Neuropsychopharmacol. 2006 Dec;16(8):547-51. Epub 2006 Feb 28.", "reference": "16504486"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 17, "target": 45, "key": 0}, {"relation": "decreases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53 expression, as well as p53-mediated apoptosis, can be enhanced by AICD. Another AICD target gene, GSK3-b, may also contribute to AICD-related cytotoxicity by up-regulating tau hyperphosphorylation. GSK-3b activation and collapsin response mediator protein 2 (CRMP2) phosphorylation, along with downstream tau hyper-phosphorylation/aggregation, neurodegeneration and memory loss", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Tau protein subgraph"}, "source": 17, "target": 46, "key": 0}, {"relation": "decreases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53 expression, as well as p53-mediated apoptosis, can be enhanced by AICD. Another AICD target gene, GSK3-b, may also contribute to AICD-related cytotoxicity by up-regulating tau hyperphosphorylation. GSK-3b activation and collapsin response mediator protein 2 (CRMP2) phosphorylation, along with downstream tau hyper-phosphorylation/aggregation, neurodegeneration and memory loss", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 17, "target": 46, "key": 1}, {"relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "name": "Psychoneuroendocrinology. 1995;20(6):623-36", "reference": "8584603"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 18, "target": 44, "key": 0}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "MAPK-ERK subgraph"}, "source": 19, "target": 46, "key": 0}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Calcium-dependent signal transduction"}, "source": 19, "target": 46, "key": 1}, {"relation": "decreases", "evidence": "Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {}, "source": 19, "target": 46, "key": 2}, {"relation": "increases", "evidence": "Mn neurotoxicity is also known to contribute to the development of multiple neurodegenerative disorders including AD,", "citation": {"type": "PubMed", "name": "Neurochem Res. 2015 Feb;40(2):380-8. doi: 10.1007/s11064-014-1391-2. Epub 2014 Jul 27.", "reference": "25064045"}, "annotations": {}, "source": 21, "target": 33, "key": 6}, {"relation": "increases", "evidence": "Recently, there have been increasing evidences that microRNA-146 (miR-146) is related to up-regulated immune and inflammatory signaling through its target genes, such as IRAK1 and TRAF6. Additionally, abundant data continue to support the hypothesis that progressive up-regulation of inflammatory gene expression and elevated inflammatory signaling facilitate the development and progression of Alzheimer's disease (AD). This review focuses on the recent findings regarding the role of miR-146 in modulating immune response and its subsequent effects in the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2012 Mar;78(3):398-401. doi: 10.1016/j.mehy.2011.11.019. Epub 2011 Dec 29.", "reference": "22209051"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 25, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Recently, there have been increasing evidences that microRNA-146 (miR-146) is related to up-regulated immune and inflammatory signaling through its target genes, such as IRAK1 and TRAF6. Additionally, abundant data continue to support the hypothesis that progressive up-regulation of inflammatory gene expression and elevated inflammatory signaling facilitate the development and progression of Alzheimer's disease (AD). This review focuses on the recent findings regarding the role of miR-146 in modulating immune response and its subsequent effects in the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2012 Mar;78(3):398-401. doi: 10.1016/j.mehy.2011.11.019. Epub 2011 Dec 29.", "reference": "22209051"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 25, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Accumulating data indicate that astrocytes play an important role in the neuroinflammation related to the/ pathogenesis of AD. It has been shown that microglia and astrocytes are activated in AD brain and amyloid-beta (Abeta)/ can increase the expression of cyclooxygenase 2 (COX-2), interleukin-1, and interleukin-6.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;20(4):1189-99. doi: 10.3233/JAD-2010-091336.", "reference": "20413894"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 25, "target": 33, "key": 3}, {"relation": "decreases", "evidence": "Chronic neuroinflammation correlates with cognitive decline and brain atrophy in Alzheimer's disease (AD),/ and cytokines and chemokines mediate the inflammatory response. However, quantitation of cytokines and chemokines in AD/ brain tissue has only been carried out for a small number of mediators with variable results. We simultaneously quantified / 17 cytokines and chemokines in brain tissue extracts from controls (n = 10) and from patients with and without genetic / forms of AD (n = 12). Group comparisons accounting for multiple testing revealed that monocyte chemoattractant protein-1/ (MCP-1), interleukin-6 (IL-6) and interleukin-8 (IL-8) were consistently upregulated in AD brain tissue. / Immunohistochemistry for MCP-1, IL-6 and IL-8 confirmed this increase and determined localization of these factors/ in neurons (MCP-1, IL-6, IL-8), astrocytes (MCP-1, IL-6) and plaque pathology (MCP-1, IL-8). Logistic linear regression/ modeling determined that MCP-1 was the most reliable predictor of disease. Our data support previous work on significant / increases in IL-6 and IL-8 in AD but indicate that MCP-1 may play a more dominant role in chronic inflammation in AD.", "citation": {"type": "PubMed", "name": "Brain Pathol. 2009 Jul;19(3):392-8. doi: 10.1111/j.1750-3639.2008.00188.x. Epub 2008 Jul 10.", "reference": "18637012"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 25, "target": 44, "key": 0}, {"relation": "increases", "evidence": "The serum IL-1 and TNF- level were significantly increased, and the expressions of TLR4 and NF-B p65 mRNA and protein in the brain were up-regulated, indicating inflammation response was initiated following administration of A1-42.", "citation": {"type": "PubMed", "name": "Int J Dev Neurosci. 2011 Aug;29(5):537-42", "reference": "21515354"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph", "NervousSystem": "Brain", "FluidAndSecretion": "Serum"}, "source": 25, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Cytokines, particularly tumor necrosis factor  (TNF-) and interleukin 1 (IL-1), can induce chronic inflammation that may promote the loss of synapses, cognitive dysfunction, and eventually neuronal death [19] and [20].", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2014 Jun 21. pii: S0891-5849(14)00265-2", "reference": "24960578"}, "annotations": {"Subgraph": "Synapse assembly subgraph"}, "source": 26, "target": 44, "key": 0}, {"relation": "decreases", "evidence": "Cytokines, particularly tumor necrosis factor  (TNF-) and interleukin 1 (IL-1), can induce chronic inflammation that may promote the loss of synapses, cognitive dysfunction, and eventually neuronal death [19] and [20].", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2014 Jun 21. pii: S0891-5849(14)00265-2", "reference": "24960578"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 26, "target": 44, "key": 1}, {"relation": "increases", "evidence": "Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Hypertension"}, "source": 27, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Hypercholesterolemia"}, "source": 27, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 27, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Increased ROS levels act at multiple levels to impair mitochondrial function: they induce mtDNA mutations that consequently negatively influence mitochondrial function, enhance amyloid-beta production by guiding APP cleavage pathway toward the amyloidogenesis, increase lipid peroxidation, activate mitophagy, leading to a reduced mitochondrial number, and augment tau hyperphosphorylation and NFT formation impairing organelle trafficking and neuronal function finally leading to apoptosis.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Reactive oxygen species subgraph"}, "source": 30, "target": 11, "key": 0}, {"relation": "increases", "evidence": "presenilin-1 (PS-1) promote Alzheimer's disease (AD) by increasing reactive oxygen species, at least part of which is derived by an accompanying increase in generation of amyloid-beta (Abeta).", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2006 Dec;10(4):353-8.", "reference": "17183144"}, "annotations": {}, "source": 30, "target": 33, "key": 1}, {"relation": "decreases", "evidence": "Redox and phosphorylative energetic exhaustion: A-induced mitochondrial and synaptic dysfunction:Increasing evidence indicates that the mitochondrial dysfunction is an important early factor in the development of AD-like pathology. Mitochondria are known to accumulate in synapses and mitochondrial trafficking to synapses is dynamic and regulated by synaptic activity. However, increasing evidence indicates that accumulation of A in mitochondria occurs before extracellular amyloid deposition and increases with age. APP and its derivatives, monomeric and oligomeric forms of A, interact with mitochondrial membranes or mitochondrial matrix protein ABAD leading to mitochondrial dysfunction.Substantial evidence indicates that mitochondria serve as direct targets for A protein mediated neuronal toxicity. Lower levels of ROS are required for synaptic signaling with ROS acting as messenger molecules in the process of LTP. However, high levels of ROS have been implicated as damaging toxic molecules in the age-related impairments of LTP. Our previous work shows that ROS levels increase with age of neurons in parallel with an age-related decline in transmembrane potential. As mitochondrial transmembrane potential is a driving force for cellular production of ATP, its decline in neurons will have a long term effect in many important energy driven reactions. Increased oxidative stress, coupled with dysregulation of calcium homeostasis and resulting apoptosis of vulnerable neuronal populations, are proposed to underlie the loss of synaptic activity and associated cognitive decline. From these deficiencies emerges the concept of synaptic energy exhaustion in AD, both phosphorylative (ATP) and redox (NAD[P]H) energies. Our previous work shows that hippocampal NAD(P)H and glutathione (GSH) decline with age in association with increased susceptibility to glutamate toxicity in neurons of old-age. Thus, an age-related decline in neuronal reducing currency (NAD[P]H) and reducing buffer (GSH) will surely promote oxidative stress and excess ROS. It is noteworthy that in the early stages of AD, there is already a reduction in the number of mitochondria and the activities of tricarboxylic acid cycle enzymes and cytochrome C oxidase. However, how ROS are produced at the synapse in response to A oligomers is not fully known. Excessive ROS are locally generated in response to synaptic A oligomer binding. This ROS formation can be totally blocked by the mitochondrial uncoupler, 2,4-dinitrophenol which suggests a central role of mitochondria in A-induced oxidative stress. Many studies suggest the possible involvement of oxidative stress and calcium dysfunction in A toxicity.The question as to why brain synaptic ROS levels increase with age is uncertain, but may involve lack of use followed by acute overstimulation of excitatory NMDARs that leads to excessive ROS, related to excess Ca2+ entry into mitochondria. Dysregulation of NMDAR function induced by A binding to neuronal synapses may lead to synaptic mitochondrial dysfunction and excessive ROS formation. Memory mechanisms might be directly compromised by elevated ROS, which could explain the connection between AD and oxidative stress. The increase in oxidative damage exhibited by synaptic mitochondria will damage synapses, affect neurotransmission and might be ultimately responsible for cognitive decline in AD patients. Taken together these studies provide convincing evidence for the concept that mitochondria have a pivotal role in A-induced synaptic dysfunction and neuronal stress. Improved function of mitochondria is an effective way of reducing effects of aging and may inhibit neuronal cell death in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Reactive oxygen species subgraph", "Condition": "Normal Healthy State"}, "source": 30, "target": 54, "key": 0}, {"relation": "increases", "evidence": "We also found that the increasing trend of cellular histone H3 acetylation is consistent with the increased expression of A1-42 and A1-40 peptides in N2a/APPswe and N2a/APPwt cells. This data suggested that the cellular histone hyperacetylation may regulate the genes that produce the A peptides", "citation": {"type": "PubMed", "name": "PLoS One. 2014 Jul 22;9(7):e103067. doi: 10.1371/journal.pone.0103067. eCollection 2014.", "reference": "25051175"}, "annotations": {"Encode_Feature_Types": "Promoter"}, "source": 31, "target": 11, "key": 0}, {"relation": "increases", "evidence": "show that T3 treatment decreases both histone H3 acetylation and histone H3 lysine 4 methylation at the APP promoter and that chemical inhibitors of histone deacetylases and histone lysine demethylase abrogate T3-dependent APP silencing.", "citation": {"type": "PubMed", "name": "Mol Cell Endocrinol. 2011 Jun 6;339(1-2):72-80. doi: 10.1016/j.mce.2011.03.016. Epub 2011 Mar 31.", "reference": "21458529"}, "annotations": {"Encode_Feature_Types": "Promoter"}, "source": 31, "target": 68, "key": 0}, {"relation": "increases", "evidence": "In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46", "reference": "21969301"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Hippocampus", "Species": "10090", "Subgraph": "GABA subgraph"}, "source": 32, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 33, "target": 34, "key": 2}, {"relation": "decreases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 33, "target": 16, "key": 0}, {"relation": "decreases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 33, "target": 16, "key": 1}, {"relation": "decreases", "evidence": "In Alzheimers disease (AD), the most common age-related primary dementing disorder, degeneration of the cholinergic neurons of the basal forebrain (Whitehouse et al., 1982) occurs. Additionally, cholinergic dysfunction may lead to endocrine abnormalities including altered plasma and cerebrospinal fluid (CSF) concentrations of various neuropeptides. Vasopressin, CRF and ACTH levels are reportedly reduced in the CSF of subjects with AD, whereas plasma cortisol levels are elevated in AD and are not suppressed by dexamethasone.", "citation": {"type": "PubMed", "name": "Psychoneuroendocrinology. 1995;20(6):623-36", "reference": "8584603"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 33, "target": 16, "key": 2}, {"relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 33, "target": 16, "key": 3}, {"relation": "increases", "evidence": " Alzheimer's disease (AD) is an age-related disorder characterized by deposition of Amyloid beta and degeneration of neurons in brain regions such as the hippocampus, resulting in progressive cognitive dysfunction. The pathogenesis of AD is tightly linked to Amyloid beta deposition and oxidative stress, but it remains unclear as to how these factors result in neuronal dysfunction and death. We report alterations in sphingolipid and cholesterol metabolism during normal brain aging and in the brains of AD patients that result in accumulation of long chain ceramides and cholesterol. Membrane associated oxidative stress occurs in association with the lipid alterations, and exposure of hippocampal neurons to Amyloid beta induces membrane oxidative stress and the accumulation of ceramide species and cholesterol. Treatment of neurons with alpha-tocopherol or an inhibitor of sphingomyelin synthesis prevents accumulation of ceramides and cholesterol and protects them against death induced by Amyloid beta. Our findings suggest a sequence of events in the pathogenesis of AD in which Amyloid beta induces membrane-associated oxidative stress, resulting in perturbed ceramide and cholesterol metabolism which, in turn, triggers a neurodegenerative cascade that leads to clinical disease.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2004 Feb 17; 101(7): 20702075.", "reference": "14970312"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph", "BRCO": "Hippocampus"}, "source": 33, "target": 21, "key": 6}, {"relation": "decreases", "evidence": "Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia", "citation": {"type": "PubMed", "name": "J Neurosci. 2006 May 10;26(19):5167-79", "reference": "16687508"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Response to oxidative stress"}, "source": 33, "target": 4, "key": 0}, {"relation": "decreases", "evidence": "Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia", "citation": {"type": "PubMed", "name": "J Neurosci. 2006 May 10;26(19):5167-79", "reference": "16687508"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 33, "target": 4, "key": 1}, {"relation": "decreases", "evidence": " The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. Loss of microRNA cluster miR-29a/b-1 in sporadic\\ Alzheimer's disease correlates with increased BACE1/beta-secretase expression.We show here that miR-29a,\\ -29b-1, and -9 can regulate BACE1 expression in vitro.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23.", "reference": "18434550"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 33, "target": 35, "key": 0}, {"relation": "decreases", "evidence": " The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. Loss of microRNA cluster miR-29a/b-1 in sporadic\\ Alzheimer's disease correlates with increased BACE1/beta-secretase expression.We show here that miR-29a,\\ -29b-1, and -9 can regulate BACE1 expression in vitro.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23.", "reference": "18434550"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 33, "target": 35, "key": 1}, {"relation": "decreases", "evidence": "Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains. The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains. MiR-29a-mediated down-regulation of NAV3 was verified by the luciferase reporter assay. By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.", "citation": {"type": "PubMed", "name": "Neuropathol Appl Neurobiol. 2010 Jun;36(4):320-30. doi: 10.1111/j.1365-2990.2010.01076.x. Epub 2010 Feb 25.", "reference": "20202123"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 33, "target": 35, "key": 2}, {"relation": "decreases", "evidence": "Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains. The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains. MiR-29a-mediated down-regulation of NAV3 was verified by the luciferase reporter assay. By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.", "citation": {"type": "PubMed", "name": "Neuropathol Appl Neurobiol. 2010 Jun;36(4):320-30. doi: 10.1111/j.1365-2990.2010.01076.x. Epub 2010 Feb 25.", "reference": "20202123"}, "annotations": {"Subgraph": "Axonal guidance subgraph"}, "source": 33, "target": 35, "key": 3}, {"relation": "decreases", "evidence": "HAT activity of p300 stimulates the PS1 and BACE1 promoter histone hyperacetylation", "citation": {"type": "PubMed", "name": "PLoS One. 2014 Jul 22;9(7):e103067. doi: 10.1371/journal.pone.0103067. eCollection 2014.", "reference": "25051175"}, "annotations": {"Encode_Feature_Types": "Promoter"}, "source": 33, "target": 35, "key": 4}, {"relation": "decreases", "evidence": "AD frontal cortex showed disease-specific hypermethylation in the promoter region of CREB, which may exacerbate reduced BDNF. Hypomethylation of NF-B in the AD cortex may explain reported increased neuroinflammation due to upregulated NF-B activity associated with its reduced methylation state. Furthermore, altered synaptic plasticity in AD is associated with reduced protein and mRNA levels of synaptophysin, which may be due to the hypermethylated state of its promoter region in AD brain samples. ", "citation": {"type": "PubMed", "name": "Transl Psychiatry. 2012 Jul 3;2:e132. doi: 10.1038/tp.2012.55.", "reference": "22760556"}, "annotations": {"Encode_Feature_Types": "Promoter"}, "source": 33, "target": 35, "key": 5}, {"relation": "decreases", "evidence": "MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD). Here we study a new group of well-characterized human temporal cortex samples (N=19). MiR-107 expression was assessed, normalized to miR-124 and let-7a. Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P< 0.05) and neurofibrillary tangle counts (P< 0.02) in adjacent brain tissue. Adjusted miR-107 and BACE1 mRNA levels tended to correlate negatively (trend with regression P< 0.07). In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(1):75-9. doi: 10.3233/JAD-2010-091603.", "reference": "20413881"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 33, "target": 36, "key": 0}, {"relation": "decreases", "evidence": "MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD). Here we study a new group of well-characterized human temporal cortex samples (N=19). MiR-107 expression was assessed, normalized to miR-124 and let-7a. Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P< 0.05) and neurofibrillary tangle counts (P< 0.02) in adjacent brain tissue. Adjusted miR-107 and BACE1 mRNA levels tended to correlate negatively (trend with regression P< 0.07). In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(1):75-9. doi: 10.3233/JAD-2010-091603.", "reference": "20413881"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 33, "target": 36, "key": 1}, {"relation": "decreases", "evidence": "Most genes such as APP, NCSTN, BACE, SIN3A, APH1B, HTATIP or DNMT1 revealed the hypermethylation patterns in the majority of brain tissues and in the lymphocytes in AD", "citation": {"type": "PubMed", "name": "PLoS One. 2008 Jul 16;3(7):e2698. doi: 10.1371/journal.pone.0002698.", "reference": "18628954"}, "annotations": {"Cell": "lymphocyte", "NervousSystem": "Brain"}, "source": 33, "target": 36, "key": 5}, {"relation": "decreases", "evidence": "Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing. Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons. Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene. Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation. Finally, we show that miR-124 is down-regulated in AD brain. In sum, our results suggest that specific miRNAs are involved in the fine-tuning of APP alternative splicing in neurons. Since abnormal neuronal splicing of APP affects -amyloid peptide production, these results could contribute to the understanding of the implication of miRNAs in brain health and disease.", "citation": {"type": "PubMed", "name": "J Neurochem. 2011 Jan;116(2):240-7. doi: 10.1111/j.1471-4159.2010.07097.x. Epub 2010 Dec 2.", "reference": "21062284"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 33, "target": 37, "key": 0}, {"relation": "decreases", "evidence": "Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing. Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons. Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene. Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation. Finally, we show that miR-124 is down-regulated in AD brain. In sum, our results suggest that specific miRNAs are involved in the fine-tuning of APP alternative splicing in neurons. Since abnormal neuronal splicing of APP affects -amyloid peptide production, these results could contribute to the understanding of the implication of miRNAs in brain health and disease.", "citation": {"type": "PubMed", "name": "J Neurochem. 2011 Jan;116(2):240-7. doi: 10.1111/j.1471-4159.2010.07097.x. Epub 2010 Dec 2.", "reference": "21062284"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 33, "target": 37, "key": 1}, {"relation": "decreases", "evidence": "In Alzheimers disease (AD), the most common age-related primary dementing disorder, degeneration of the cholinergic neurons of the basal forebrain (Whitehouse et al., 1982) occurs. Additionally, cholinergic dysfunction may lead to endocrine abnormalities including altered plasma and cerebrospinal fluid (CSF) concentrations of various neuropeptides. Vasopressin, CRF and ACTH levels are reportedly reduced in the CSF of subjects with AD, whereas plasma cortisol levels are elevated in AD and are not suppressed by dexamethasone.", "citation": {"type": "PubMed", "name": "Psychoneuroendocrinology. 1995;20(6):623-36", "reference": "8584603"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Acetylcholine signaling subgraph", "FluidAndSecretion": "Cerebrospinal Fluid"}, "source": 33, "target": 38, "key": 1}, {"relation": "increases", "evidence": "In Alzheimers disease (AD), the most common age-related primary dementing disorder, degeneration of the cholinergic neurons of the basal forebrain (Whitehouse et al., 1982) occurs. Additionally, cholinergic dysfunction may lead to endocrine abnormalities including altered plasma and cerebrospinal fluid (CSF) concentrations of various neuropeptides. Vasopressin, CRF and ACTH levels are reportedly reduced in the CSF of subjects with AD, whereas plasma cortisol levels are elevated in AD and are not suppressed by dexamethasone.", "citation": {"type": "PubMed", "name": "Psychoneuroendocrinology. 1995;20(6):623-36", "reference": "8584603"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Cortisol subgraph", "FluidAndSecretion": "Plasma"}, "source": 33, "target": 39, "key": 0}, {"relation": "increases", "evidence": "Hippocampal neurons are vulnerable to injury induced by Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2008 Oct 10;443(3):188-92", "reference": "18687381"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "NervousSystem": "Neurons"}, "source": 33, "target": 40, "key": 0}, {"relation": "increases", "evidence": "Hippocampal neurons are vulnerable to injury induced by Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2008 Oct 10;443(3):188-92", "reference": "18687381"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "NervousSystem": "Hippocampus"}, "source": 33, "target": 40, "key": 1}, {"relation": "increases", "evidence": "Hippocampal neurons are vulnerable to injury induced by Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2008 Oct 10;443(3):188-92", "reference": "18687381"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Neurons"}, "source": 33, "target": 40, "key": 2}, {"relation": "increases", "evidence": "Hippocampal neurons are vulnerable to injury induced by Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2008 Oct 10;443(3):188-92", "reference": "18687381"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Hippocampus"}, "source": 33, "target": 40, "key": 3}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is associated with an altered immune response, resulting in chronic increased/ inflammatory cytokine production with a prominent role of TNF-. TNF- signals are mediated by two receptors: TNF/ receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Signaling through TNFR2 is associated with neuroprotection, whereas/ signaling through TNFR1 is generally proinflammatory and proapoptotic. Here, we have identified a TNF--induced/ proinflammatory agent, lipocalin 2 (Lcn2) via gene array in murine primary cortical neurons. Further investigation/ showed that Lcn2 protein production and secretion were activated solely upon TNFR1 stimulation when primary murine neurons,/ astrocytes, and microglia were treated with TNFR1 and TNFR2 agonistic antibodies. Lcn2 was found to be significantly/ decreased in CSF of human patients with mild cognitive impairment and AD and increased in brain regions associated with/ AD pathology in human postmortem brain tissue. Mechanistic studies in cultures of primary cortical neurons showed that/ Lcn2 sensitizes nerve cells to -amyloid toxicity. Moreover, Lcn2 silences a TNFR2-mediated protective neuronal signaling/ cascade in neurons, pivotal for TNF--mediated neuroprotection. The present study introduces Lcn2 as a molecular actor in/ neuroinflammation in early clinical stages of AD.", "citation": {"type": "PubMed", "name": "FASEB J. 2012 Jul;26(7):2811-23. doi: 10.1096/fj.11-202457. Epub 2012 Mar 21.", "reference": "22441986"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 33, "target": 41, "key": 0}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is associated with an altered immune response, resulting in chronic increased/ inflammatory cytokine production with a prominent role of TNF-. TNF- signals are mediated by two receptors: TNF/ receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Signaling through TNFR2 is associated with neuroprotection, whereas/ signaling through TNFR1 is generally proinflammatory and proapoptotic. Here, we have identified a TNF--induced/ proinflammatory agent, lipocalin 2 (Lcn2) via gene array in murine primary cortical neurons. Further investigation/ showed that Lcn2 protein production and secretion were activated solely upon TNFR1 stimulation when primary murine neurons,/ astrocytes, and microglia were treated with TNFR1 and TNFR2 agonistic antibodies. Lcn2 was found to be significantly/ decreased in CSF of human patients with mild cognitive impairment and AD and increased in brain regions associated with/ AD pathology in human postmortem brain tissue. Mechanistic studies in cultures of primary cortical neurons showed that/ Lcn2 sensitizes nerve cells to -amyloid toxicity. Moreover, Lcn2 silences a TNFR2-mediated protective neuronal signaling/ cascade in neurons, pivotal for TNF--mediated neuroprotection. The present study introduces Lcn2 as a molecular actor in/ neuroinflammation in early clinical stages of AD.", "citation": {"type": "PubMed", "name": "FASEB J. 2012 Jul;26(7):2811-23. doi: 10.1096/fj.11-202457. Epub 2012 Mar 21.", "reference": "22441986"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 33, "target": 41, "key": 1}, {"relation": "increases", "evidence": "In AD, an increased ApoE mRNA was reported in the hippocampus. The risk for AD has been reported to correlate with transcriptional activity of the ApoE gene. Binding sites for putative transcriptional factors (TF), such\\ as AP-1, AP-2 and NF-kappaB, are present in the ApoE promoter. The promoter also contains sites for the inflammatory response transcription factors IL-6 RE-BP, MED1, STAT1 and STAT2. A functional peroxisome-proliferator-activated receptor gamma (PPARgamma) has been detected in the ApoE/ApoCI intergenic region.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2004;23(3):225-33.", "reference": "15181251"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 33, "target": 89, "key": 0}, {"relation": "decreases", "evidence": "Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) brain.Mitochondrial biogenesis is regulated by the peroxisome proliferator activator receptor gamma-coactivator 1a (PGC-1a)-nuclear respiratory factor (NRF)-mitochondrial transcription factor A pathway. Expression levels of PGC-1a, NRF 1, NRF 2, and mitochondrial transcription factor A were significantly decreased in both AD hippocampal tissues and APPswe M17 cells, suggesting a reduced mitochondrial biogenesis. Indeed, APPswe M17 cells demonstrated decreased mitochondrial DNA/nuclear DNA ratio, correlated with reduced ATP content, and decreased cytochrome C oxidase activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Feb;120(3):419-29. doi: 10.1111/j.1471-4159.2011.07581.x. Epub 2011 Dec 8", "reference": "22077634"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 92, "key": 0}, {"relation": "decreases", "evidence": "Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) brain.Mitochondrial biogenesis is regulated by the peroxisome proliferator activator receptor gamma-coactivator 1a (PGC-1a)-nuclear respiratory factor (NRF)-mitochondrial transcription factor A pathway. Expression levels of PGC-1a, NRF 1, NRF 2, and mitochondrial transcription factor A were significantly decreased in both AD hippocampal tissues and APPswe M17 cells, suggesting a reduced mitochondrial biogenesis. Indeed, APPswe M17 cells demonstrated decreased mitochondrial DNA/nuclear DNA ratio, correlated with reduced ATP content, and decreased cytochrome C oxidase activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Feb;120(3):419-29. doi: 10.1111/j.1471-4159.2011.07581.x. Epub 2011 Dec 8", "reference": "22077634"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 33, "target": 92, "key": 1}, {"relation": "decreases", "evidence": "Alzheimer's disease (AD) is linked to CNS insulin resistance, decreased expression of insulin and insulin receptor genes, and lower cerebrospinal insulin levels.", "citation": {"type": "PubMed", "name": "Expert Rev Clin Pharmacol. 2012 Jan;5(1):17-20", "reference": "22142155"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Insulin Resistance"}, "source": 33, "target": 136, "key": 0}, {"relation": "decreases", "evidence": "Alzheimer's disease (AD) is linked to CNS insulin resistance, decreased expression of insulin and insulin receptor genes, and lower cerebrospinal insulin levels.", "citation": {"type": "PubMed", "name": "Expert Rev Clin Pharmacol. 2012 Jan;5(1):17-20", "reference": "22142155"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Alzheimer Disease"}, "source": 33, "target": 136, "key": 1}, {"relation": "decreases", "evidence": "IR  and  IGF-1 R  sign a ling  is  markedly  disturbed  in  the CNS  of  AD  patients  (54, 76, 77].  Postmortem studies have show n that mRNA  levels of insulin  and  its receptor decrease w ith a n a lm ost 80%  reduced  1R expression in severe  AD [15, 78].  Accordingly, Frolich  et a/. [54]  found  that  neuronal ty ros ine kinase  activity  is decreased  in AD  patients compared to age-matched controls. The overall  expression of  IGF- I R is  redu ced   in  AD  brains  d ependent   on  the  severity of the disease. However, in some  cases  IGF-1 R density was found to be increased   i n n eurons next  to amyloid  plaques [77,  78]. Bra in IGF-1  mRNA  levels  diminish in severe AD,  w hereas I GF-1  serum  leve ls a re increased   in early  stages  of  disease, suggesting that  IGF-1 resistance  plays  a role  in  the  patho genesis  of  AD  [78, 79].  IRS-1 /-2 protei n  ex pression   is  re duced  in AD  brains  and  in activatin g Serine-phosphorylation oflRS-l at Ser3 12  and Ser616  is increased  lead ing to impaired IR and IGF-1 R signa ling [77]. Thus,  lRIIGF-1 R downstream sig n al  transd uction  is impaired in A D brains, leading  to the hypoth es is  that  cerebral   insulin/IG F-1  resistance  might be involved  in the path ogen esis of AD.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 33, "target": 136, "key": 2}, {"relation": "increases", "evidence": " The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. Loss of microRNA cluster miR-29a/b-1 in sporadic\\ Alzheimer's disease correlates with increased BACE1/beta-secretase expression.We show here that miR-29a,\\ -29b-1, and -9 can regulate BACE1 expression in vitro.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23.", "reference": "18434550"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 33, "target": 141, "key": 0}, {"relation": "increases", "evidence": " The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. Loss of microRNA cluster miR-29a/b-1 in sporadic\\ Alzheimer's disease correlates with increased BACE1/beta-secretase expression.We show here that miR-29a,\\ -29b-1, and -9 can regulate BACE1 expression in vitro.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23.", "reference": "18434550"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 33, "target": 141, "key": 1}, {"relation": "decreases", "evidence": "Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients.Our data show a significant decrease in the levels of epidermal growth factor (EGF) and of MMP-2 in platelets of AD patients and decreased levels of MMP-2 in MCI.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2012 Oct;9(8):982-9", "reference": "21875409"}, "annotations": {"HemicAndImmuneSystem": "Blood Platelets", "Species": "9606", "Subgraph": "Matrix metalloproteinase subgraph"}, "source": 33, "target": 149, "key": 0}, {"relation": "decreases", "evidence": "Akt substrates such as mammalian target of rapamycin (mTOR; Ser2448) and decreased levels of cell-cycle inhibitors (p27kip1) are found in AD temporal cortex when compared to controls . GSK-3a has been implicated in the production of A peptide while increased GSK-3 activity has been implicated in tau hyperphosphorylation and neuronal cell death", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "mTOR signaling subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 166, "key": 0}, {"relation": "increases", "evidence": "Dual-specificity tyrosine(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) is a protein kinase that might be responsible for mental retardation and early onset of Alzheimer's disease in Down's syndrome patients. Dyrk1A plays a role in many cellular pathways through phosphorylation of diverse substrate proteins; however, its role in synaptic vesicle exocytosis is poorly understood. Munc18-1, a central regulator of neurotransmitter release, interacts with Syntaxin 1 and X11-alpha. Syntaxin 1 is a key soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein involved in synaptic vesicle docking/fusion events, and X11-alpha modulates amyloid precursor protein processing and beta amyloid generation. In this study, we demonstrate that Dyrk1A interacts with and phosphorylates Munc18-1 at the Thr(479) residue. The phosphorylation of Munc18-1 at Thr(479) by Dyrk1A stimulated binding of Munc18-1 to Syntaxin 1 and X11-alpha. ", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Sep;122(5):1081-91. doi: 10.1111/j.1471-4159.2012.07861.x. Epub 2012 Aug 3.", "reference": "22765017"}, "annotations": {"Subgraph": "DYRK1A subgraph"}, "source": 33, "target": 168, "key": 0}, {"relation": "increases", "evidence": "Dual-specificity tyrosine(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) is a protein kinase that might be responsible for mental retardation and early onset of Alzheimer's disease in Down's syndrome patients. Dyrk1A plays a role in many cellular pathways through phosphorylation of diverse substrate proteins; however, its role in synaptic vesicle exocytosis is poorly understood. Munc18-1, a central regulator of neurotransmitter release, interacts with Syntaxin 1 and X11-alpha. Syntaxin 1 is a key soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein involved in synaptic vesicle docking/fusion events, and X11-alpha modulates amyloid precursor protein processing and beta amyloid generation. In this study, we demonstrate that Dyrk1A interacts with and phosphorylates Munc18-1 at the Thr(479) residue. The phosphorylation of Munc18-1 at Thr(479) by Dyrk1A stimulated binding of Munc18-1 to Syntaxin 1 and X11-alpha. ", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Sep;122(5):1081-91. doi: 10.1111/j.1471-4159.2012.07861.x. Epub 2012 Aug 3.", "reference": "22765017"}, "annotations": {"Subgraph": "Synaptic vesicle endocytosis subgraph"}, "source": 33, "target": 168, "key": 1}, {"relation": "decreases", "evidence": "In Alzheimer's disease (AD), disturbed homeostasis of the proteases competing for amyloid precursor protein processing has been reported: a disintegrin and metalloproteinase 10 (ADAM10), the physiological -secretase, is decreased in favor of the amyloid--generating enzyme BACE-1.", "citation": {"type": "PubMed", "name": "FASEB J. 2014 Feb;28(2):978-97", "reference": "24165480"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 33, "target": 169, "key": 0}, {"relation": "decreases", "evidence": "A oligomers have been found to cause an increase in NMDAR activity, which might require direct association between A oligomers and the NR1 subunit of NMDAR [131]. There is also evidence that glutamate or other endogenous glutamate receptor agonists are increased in AD. Furthermore, NMDAR subunits NR1, NR2A, and NR2B protein levels and phosphorylation are selectively reduced in AD and these abnormalities correlate with the cognitive impairments.", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Subgraph": "Glutamatergic subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 170, "key": 0}, {"relation": "decreases", "evidence": "Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients.Our data show a significant decrease in the levels of epidermal growth factor (EGF) and of MMP-2 in platelets of AD patients and decreased levels of MMP-2 in MCI.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2012 Oct;9(8):982-9", "reference": "21875409"}, "annotations": {"HemicAndImmuneSystem": "Blood Platelets", "Species": "9606", "Subgraph": "Matrix metalloproteinase subgraph"}, "source": 33, "target": 174, "key": 0}, {"relation": "decreases", "evidence": "There was a significant 1.5-fold decrease in MMP-2 activity in the AD group compared to HC (p < 0.001) and a 1.4-fold decrease compared to MCI (p < 0.01).", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2011;26(4):779-86", "reference": "21694463"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Matrix metalloproteinase subgraph", "NervousSystem": "Brain"}, "source": 33, "target": 174, "key": 1}, {"relation": "decreases", "evidence": "There was a significant 1.5-fold decrease in MMP-2 activity in the AD group compared to HC (p < 0.001) and a 1.4-fold decrease compared to MCI (p < 0.01).", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2011;26(4):779-86", "reference": "21694463"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Matrix metalloproteinase subgraph", "NervousSystem": "Astrocytes"}, "source": 33, "target": 174, "key": 2}, {"relation": "increases", "evidence": "Neurons in both AD brain and Abeta-treated cultures exhibited FasL upregulation and changes in immunoreactivity for Fas receptor.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Apr;12(3):182-93", "reference": "12742739"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 33, "target": 177, "key": 0}, {"relation": "increases", "evidence": "Neurons in both AD brain and Abeta-treated cultures exhibited FasL upregulation and changes in immunoreactivity for Fas receptor.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Apr;12(3):182-93", "reference": "12742739"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Amyloidogenic subgraph"}, "source": 33, "target": 177, "key": 1}, {"relation": "decreases", "evidence": "Decreased tPA activity was detected in the cortex and subcortex of AD mice, whereas increased tPA activity was found in the cerebellum of SCA1 mice.", "citation": {"type": "PubMed", "name": "Lab Invest. 2011 Jul;91(7):1079-91", "reference": "21519332"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Plasminogen activator subgraph", "Species": "10090", "NervousSystem": "Cerebral Cortex"}, "source": 33, "target": 178, "key": 0}, {"relation": "decreases", "evidence": "In this study, zymography, immunocapture, and ELISAs were utilized to show that tissue plasminogen activator activity in frontal cortex tissue of Alzheimer patients is dramatically reduced compared with age-matched controls, while tissue plasminogen activator and plasminogen protein levels are unchanged; suggesting that plasminogen activator activity is inhibited in the Alzheimer brain.", "citation": {"type": "PubMed", "name": "J Neurochem. 2009 Apr;109(2):303-15", "reference": "19222708"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Plasminogen activator subgraph", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Brain", "Species": "9606"}, "source": 33, "target": 178, "key": 1}, {"relation": "increases", "evidence": "We have now studied isolated leptomeningeal blood vessels from postmortem brains and found that although ECE-1 level is reduced, ECE-1 activity and ET-1 level are significantly elevated in AD vessels.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;36(3):577-87", "reference": "23629587"}, "annotations": {"Subgraph": "Endothelin subgraph", "NervousSystem": "Brain", "CardiovascularSystem": "Blood Vessels"}, "source": 33, "target": 180, "key": 0}, {"relation": "increases", "evidence": "We have now studied isolated leptomeningeal blood vessels from postmortem brains and found that although ECE-1 level is reduced, ECE-1 activity and ET-1 level are significantly elevated in AD vessels.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;36(3):577-87", "reference": "23629587"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Endothelin subgraph", "NervousSystem": "Brain", "CardiovascularSystem": "Blood Vessels"}, "source": 33, "target": 181, "key": 0}, {"relation": "increases", "evidence": "Part of the inflammatory response in Alzheimer's disease (AD) is the upregulation of the inducible nitric oxide synthase (NOS2) resulting in increased NO production.", "citation": {"type": "PubMed", "name": "Neuron. 2011 Sep 8;71(5):833-44.", "reference": "21903077"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Nitric oxide subgraph"}, "source": 33, "target": 197, "key": 0}, {"relation": "decreases", "evidence": "Oxidative stress-mediated neuronal death may be initiated by a decrease in glutathione (GSH), whose levels are reduced in mitochondrial and synaptosomal fractions of specific CNS regions in Alzheimer disease (AD) patients", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2012 Jan 27. [Epub ahead of print]", "reference": "22326489"}, "object": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Response to oxidative stress"}, "source": 33, "target": 198, "key": 0}, {"relation": "decreases", "evidence": "Oxidative stress-mediated neuronal death may be initiated by a decrease in glutathione (GSH), whose levels are reduced in mitochondrial and synaptosomal fractions of specific CNS regions in Alzheimer disease (AD) patients", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2012 Jan 27. [Epub ahead of print]", "reference": "22326489"}, "object": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Glutathione reductase subgraph"}, "source": 33, "target": 198, "key": 1}, {"relation": "decreases", "evidence": "AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include -amyloid protein (A) generation and tau phosphorylation. In particular, AMPK may regulate A generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating A generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "object": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 199, "key": 0}, {"relation": "decreases", "evidence": "In Alzheimer's disease (AD), affected neurons accumulate beta amyloid protein, components of which can induce mouse microglia to express the high-output isoform of nitric oxide synthase (NOS2) in vitro. Products of NOS2 can be neurotoxic. In mice, NOS2 is normally suppressed by transforming growth factor beta 1 (TGF-beta 1). Expression of TGF-beta 1 is decreased in brains from AD patients, a situation that might be permissive for accumulation of NOS2.", "citation": {"type": "PubMed", "name": "J Exp Med. 1996 Oct 1;184(4):1425-33", "reference": "8879214"}, "annotations": {"Subgraph": "Nitric oxide subgraph"}, "source": 33, "target": 200, "key": 0}, {"relation": "decreases", "evidence": "In Alzheimer's disease (AD), affected neurons accumulate beta amyloid protein, components of which can induce mouse microglia to express the high-output isoform of nitric oxide synthase (NOS2) in vitro. Products of NOS2 can be neurotoxic. In mice, NOS2 is normally suppressed by transforming growth factor beta 1 (TGF-beta 1). Expression of TGF-beta 1 is decreased in brains from AD patients, a situation that might be permissive for accumulation of NOS2.", "citation": {"type": "PubMed", "name": "J Exp Med. 1996 Oct 1;184(4):1425-33", "reference": "8879214"}, "annotations": {"Subgraph": "TGF-Beta subgraph"}, "source": 33, "target": 200, "key": 1}, {"relation": "decreases", "evidence": "In Alzheimer's disease (AD), affected neurons accumulate beta amyloid protein, components of which can induce mouse microglia to express the high-output isoform of nitric oxide synthase (NOS2) in vitro. Products of NOS2 can be neurotoxic. In mice, NOS2 is normally suppressed by transforming growth factor beta 1 (TGF-beta 1). Expression of TGF-beta 1 is decreased in brains from AD patients, a situation that might be permissive for accumulation of NOS2.", "citation": {"type": "PubMed", "name": "J Exp Med. 1996 Oct 1;184(4):1425-33", "reference": "8879214"}, "annotations": {"Subgraph": "TGF-Beta subgraph"}, "source": 33, "target": 200, "key": 2}, {"relation": "decreases", "evidence": "A oligomers have been found to cause an increase in NMDAR activity, which might require direct association between A oligomers and the NR1 subunit of NMDAR [131]. There is also evidence that glutamate or other endogenous glutamate receptor agonists are increased in AD. Furthermore, NMDAR subunits NR1, NR2A, and NR2B protein levels and phosphorylation are selectively reduced in AD and these abnormalities correlate with the cognitive impairments.", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Subgraph": "Glutamatergic subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 201, "key": 0}, {"relation": "decreases", "evidence": "Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) brain.Mitochondrial biogenesis is regulated by the peroxisome proliferator activator receptor gamma-coactivator 1a (PGC-1a)-nuclear respiratory factor (NRF)-mitochondrial transcription factor A pathway. Expression levels of PGC-1a, NRF 1, NRF 2, and mitochondrial transcription factor A were significantly decreased in both AD hippocampal tissues and APPswe M17 cells, suggesting a reduced mitochondrial biogenesis. Indeed, APPswe M17 cells demonstrated decreased mitochondrial DNA/nuclear DNA ratio, correlated with reduced ATP content, and decreased cytochrome C oxidase activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Feb;120(3):419-29. doi: 10.1111/j.1471-4159.2011.07581.x. Epub 2011 Dec 8", "reference": "22077634"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 202, "key": 0}, {"relation": "decreases", "evidence": "In that study, we demonstrated advanced AD to be associated with strikingly reduced levels of insulin and IGF-1 polypeptide and receptor genes in the brain (Figure 1). In addition, all the signaling pathways that mediate insulin and IGF-1-stimulated neuronal survival, tau expression, energy metabolism, and mitochondrial function were perturbed in AD.", "citation": {"type": "PubMed", "name": "J Diabetes Sci Technol. Nov 2008; 2(6): 11011113.", "reference": "19885299"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Diabetes Mellitus, Type 2"}, "source": 33, "target": 203, "key": 0}, {"relation": "decreases", "evidence": "Alzheimer's disease (AD) is linked to CNS insulin resistance, decreased expression of insulin and insulin receptor genes, and lower cerebrospinal insulin levels.", "citation": {"type": "PubMed", "name": "Expert Rev Clin Pharmacol. 2012 Jan;5(1):17-20", "reference": "22142155"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Insulin Resistance"}, "source": 33, "target": 203, "key": 1}, {"relation": "decreases", "evidence": "Alzheimer's disease (AD) is linked to CNS insulin resistance, decreased expression of insulin and insulin receptor genes, and lower cerebrospinal insulin levels.", "citation": {"type": "PubMed", "name": "Expert Rev Clin Pharmacol. 2012 Jan;5(1):17-20", "reference": "22142155"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Alzheimer Disease"}, "source": 33, "target": 203, "key": 2}, {"relation": "decreases", "evidence": "In that study, we demonstrated advanced AD to be associated with strikingly reduced levels of insulin and IGF-1 polypeptide and receptor genes in the brain (Figure 1). In addition, all the signaling pathways that mediate insulin and IGF-1-stimulated neuronal survival, tau expression, energy metabolism, and mitochondrial function were perturbed in AD.", "citation": {"type": "PubMed", "name": "J Diabetes Sci Technol. Nov 2008; 2(6): 11011113.", "reference": "19885299"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Diabetes Mellitus, Type 2"}, "source": 33, "target": 204, "key": 0}, {"relation": "decreases", "evidence": "Murine double minute 2 (MDM2) protein levels were decreased in AD cells relative to control lymphoblasts, suggesting an impairment of FOXO3a degradation.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Apr;34(4):1090-100", "reference": "23153928"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Species": "10090"}, "source": 33, "target": 205, "key": 0}, {"relation": "increases", "evidence": "Neuronal expression of myeloperoxidase is increased in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem. 2004 Aug;90(3):724-33", "reference": "15255951"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Myeloperoxidase subgraph"}, "source": 33, "target": 206, "key": 0}, {"relation": "increases", "evidence": "Increased myeloperoxidase plasma levels in patients with Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2014;39(3):557-64", "reference": "24217274"}, "annotations": {"Species": "9606", "MeSHDisease": "Alzheimer Disease", "FluidAndSecretion": "Plasma", "Subgraph": "Myeloperoxidase subgraph"}, "source": 33, "target": 206, "key": 1}, {"relation": "increases", "evidence": "ResULTS: AD patients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean  SD): 132.8  114.8 ng/mL versus 55.0  42.6 ng/mL; p = 0.002).", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2014;39(3):557-64", "reference": "24217274"}, "annotations": {"Subgraph": "Myeloperoxidase subgraph", "MeSHDisease": "Alzheimer Disease", "FluidAndSecretion": "Plasma"}, "source": 33, "target": 206, "key": 2}, {"relation": "increases", "evidence": "MPO is similarly expressed in astrocytes in human AD tissue.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2009 Jan 30;284(5):3158-69", "reference": "19059911"}, "annotations": {"Subgraph": "Myeloperoxidase subgraph", "Species": "9606", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Astrocytes"}, "source": 33, "target": 206, "key": 3}, {"relation": "increases", "evidence": "Neuronal expression of myeloperoxidase is increased in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem. 2004 Aug;90(3):724-33", "reference": "15255951"}, "annotations": {"Subgraph": "Myeloperoxidase subgraph", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Neurons"}, "source": 33, "target": 206, "key": 4}, {"relation": "decreases", "evidence": "The production of superoxide anions was increased only by monocytes from the elderly groups.The results suggest that although the impaired immune function in patients with Alzheimer's disease is related to the aging process, the significant low IL-2 production in these patients may play a role in their increased susceptibility to infections.", "citation": {"type": "PubMed", "name": "Gerontology. 2002 May-Jun;48(3):128-32", "reference": "11961364"}, "annotations": {"Subgraph": "Interleukin signaling subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 33, "target": 207, "key": 0}, {"relation": "decreases", "evidence": "The production of superoxide anions was increased only by monocytes from the elderly groups.The results suggest that although the impaired immune function in patients with Alzheimer's disease is related to the aging process, the significant low IL-2 production in these patients may play a role in their increased susceptibility to infections.", "citation": {"type": "PubMed", "name": "Gerontology. 2002 May-Jun;48(3):128-32", "reference": "11961364"}, "annotations": {"Subgraph": "Interleukin signaling subgraph", "MeSHDisease": "Infection"}, "source": 33, "target": 207, "key": 1}, {"relation": "increases", "evidence": "Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.", "citation": {"type": "PubMed", "name": "J Neurochem. 2009 Apr;109(2):303-15", "reference": "19222708"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Brain", "Subgraph": "Plasminogen activator subgraph"}, "source": 33, "target": 208, "key": 0}, {"relation": "increases", "evidence": "This pattern suggests an overall increase of COX-1 expression in AD. The present study shows that COX-1 is widely expressed in human brain, and raises the possibility that COX-1 may contribute to CNS pathology.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 1999 Nov;58(11):1135-46", "reference": "10560656"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Prostaglandin subgraph", "NervousSystem": "Brain"}, "source": 33, "target": 209, "key": 0}, {"relation": "decreases", "evidence": "Given the capacity of glucocorticoids and corticotropin-releasing hormone to induce AD-associated pathologies, I suggest a role for circadian cortisol hypersecretion in the initiation of sporadic AD; and propose a temporal mechanism for AD development featuring neuroinflammation- mediated suppression of central glucocorticoid receptor (GR) signaling.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2013 Sep;10(7):714-31", "reference": "23906001"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease"}, "source": 33, "target": 210, "key": 0}, {"relation": "decreases", "evidence": "In Alzheimer's disease (AD), the hypothalamic-pituitary-adrenal (HPA) axis is hyperactive and the sensitivity to dexamethasone is decreased, suggesting a possible involvement of glucocorticoid receptor alpha (GRalpha) defects in the aetiopathology of the disease.We, therefore, searched for the presence of mutations in the human GRalpha (hGRalpha) gene, focusing on the hormone-binding domain due to its importance in mediating glucocorticoids' effects.", "citation": {"type": "PubMed", "name": "Clin Chim Acta. 2004 Nov;349(1-2):167-72", "reference": "15469870"}, "object": {"modifier": "Activity"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Hypothalamus", "Species": "9606"}, "source": 33, "target": 210, "key": 1}, {"relation": "decreases", "evidence": "However, lymphoblasts derived from AD patients showed reduced levels of the Cdk inhibitor p27(kip1), which were restored after anti-calmodulin treatment of the cultures.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Aug;13(3):254-63", "reference": "12901840"}, "annotations": {"Cell": "lymphocyte", "Subgraph": "Cyclin-CDK subgraph", "MeSHDisease": "Alzheimer Disease", "Species": "9606"}, "source": 33, "target": 211, "key": 0}, {"relation": "increases", "evidence": "We found a significant increase in 5-LOX gene expression in AD subjects compared to healthy controls, paralleled by increased 5-LOX protein and leukotriene B4, the 5-LOX product.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;37(1):3-8", "reference": "23727898"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Eicosanoids signaling subgraph"}, "source": 33, "target": 212, "key": 0}, {"relation": "increases", "evidence": "We found a significant increase in 5-LOX gene expression in AD subjects compared to healthy controls, paralleled by increased 5-LOX protein and leukotriene B4, the 5-LOX product.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;37(1):3-8", "reference": "23727898"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Inflammatory response subgraph"}, "source": 33, "target": 212, "key": 1}, {"relation": "increases", "evidence": "We found a significant increase in 5-LOX gene expression in AD subjects compared to healthy controls, paralleled by increased 5-LOX protein and leukotriene B4, the 5-LOX product.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;37(1):3-8", "reference": "23727898"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Eicosanoids signaling subgraph"}, "source": 33, "target": 212, "key": 2}, {"relation": "increases", "evidence": "We found a significant increase in 5-LOX gene expression in AD subjects compared to healthy controls, paralleled by increased 5-LOX protein and leukotriene B4, the 5-LOX product.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2013;37(1):3-8", "reference": "23727898"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Inflammatory response subgraph"}, "source": 33, "target": 212, "key": 3}, {"relation": "increases", "evidence": "Discovery and validation cohorts, showed higher mean CSF YKL-40 in very mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) versus control subjects (CDR 0) and PSP subjects. Importantly, CSF YKL-40/A42 ratio predicted risk of developing cognitive impairment (CDR 0 to CDR > 0 conversion), as well as the best CSF biomarkers identified to date, tau/A42 and p-tau 181/A42. Mean plasma YKL-40 was higher in CDR 0.5 and 1 versus CDR 0, and correlated with CSF levels. YKL-40 immunoreactivity labeled astrocytes near a subset of amyloid plaques, implicating YKL-40 in the neuroinflammatory response to A deposition. CONCLUSIONS: These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with A42, has potential prognostic utility as a biomarker for preclinical AD.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025.", "reference": "21035623"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 33, "target": 213, "key": 0}, {"relation": "decreases", "evidence": "Hypersecretion of CRF in the brain may contribute to the symptomatology seen in neuropsychiatric disorders, such as depression, anxiety-related disorders and anorexia nervosa. Furthermore, overproduction of CRF at peripheral inflammatory sites, such as synovial joints may contribute to autoimmune diseases such as rheumatoid arthritis. In contrast, deficits in brain CRF are apparent in neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, as they relate to dysfunction of CRF neurons in the brain areas affected in the particular disorder. Strategies directed at developing CRF-related agents may hold promise for novel therapies for the treatment of these various disorders.", "citation": {"type": "PubMed", "name": "Psychoneuroendocrinology. 1995;20(8):789-819.", "reference": "8834089"}, "annotations": {"Species": "9606", "Subgraph": "CRH subgraph", "Disease": "Alzheimer's disease"}, "source": 33, "target": 214, "key": 0}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "miRNA subgraph"}, "source": 37, "target": 11, "key": 0}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 37, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 37, "target": 11, "key": 2}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 37, "target": 11, "key": 3}, {"relation": "increases", "evidence": "The role of miR-124 on the expression of -site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the -amyloid production, was studied in this paper using cellular models for Alzheimer' disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by A neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.", "citation": {"type": "PubMed", "name": "Toxicol Lett. 2012 Feb 25;209(1):94-105. Epub 2011 Dec 8.", "reference": "22178568"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 37, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "name": "Psychoneuroendocrinology. 1995;20(6):623-36", "reference": "8584603"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 39, "target": 44, "key": 0}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 42, "target": 44, "key": 0}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Chemokine signaling subgraph"}, "source": 42, "target": 44, "key": 1}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Interleukin signaling subgraph"}, "source": 42, "target": 44, "key": 2}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 42, "target": 44, "key": 3}, {"relation": "increases", "evidence": "Microglia are activated in response to a number of different pathological states within the CNS including injury, ischemia, and infection. Microglial activation results in their production of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-a. While release of these factors is typically intended to prevent further damage to CNS tissue, they may also be toxic to neurons and other glial cells. Mounting evidence indicates that chronic microglial activation may also contribute to the development and progression of neurodegenerative disorders.", "citation": {"type": "PubMed", "name": "Brain Res Bull. 2012 Jan 4;87(1):10-20. Epub 2011 Oct 18.", "reference": "22024597"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 43, "target": 140, "key": 0}, {"relation": "increases", "evidence": "Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD) Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process.These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC) BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Aug;20(0):5-36", "reference": "18715507"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 43, "target": 140, "key": 1}, {"relation": "increases", "evidence": "Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD) Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process.These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC) BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Aug;20(0):5-36", "reference": "18715507"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 43, "target": 140, "key": 2}, {"relation": "increases", "evidence": "APP processing can be regulated by calcium signaling and inversely, APP metabolism can influence calcium signaling. It was shown that calcium influx mediated by calcium ionophores or by membrane depolarization and channel opening, leads to increased production of A. Conversly, inhibition of SERCA pumps with thapsigargin and increased cytosolic calcium levels from ER calcium depletion, diminished A generation", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 49, "target": 11, "key": 0}, {"relation": "increases", "evidence": "APP processing can be regulated by calcium signaling and inversely, APP metabolism can influence calcium signaling. It was shown that calcium influx mediated by calcium ionophores or by membrane depolarization and channel opening, leads to increased production of A. Conversly, inhibition of SERCA pumps with thapsigargin and increased cytosolic calcium levels from ER calcium depletion, diminished A generation", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Calcium-dependent signal transduction"}, "source": 49, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Redox and phosphorylative energetic exhaustion: A-induced mitochondrial and synaptic dysfunction:Increasing evidence indicates that the mitochondrial dysfunction is an important early factor in the development of AD-like pathology. Mitochondria are known to accumulate in synapses and mitochondrial trafficking to synapses is dynamic and regulated by synaptic activity. However, increasing evidence indicates that accumulation of A in mitochondria occurs before extracellular amyloid deposition and increases with age. APP and its derivatives, monomeric and oligomeric forms of A, interact with mitochondrial membranes or mitochondrial matrix protein ABAD leading to mitochondrial dysfunction.Substantial evidence indicates that mitochondria serve as direct targets for A protein mediated neuronal toxicity. Lower levels of ROS are required for synaptic signaling with ROS acting as messenger molecules in the process of LTP. However, high levels of ROS have been implicated as damaging toxic molecules in the age-related impairments of LTP. Our previous work shows that ROS levels increase with age of neurons in parallel with an age-related decline in transmembrane potential. As mitochondrial transmembrane potential is a driving force for cellular production of ATP, its decline in neurons will have a long term effect in many important energy driven reactions. Increased oxidative stress, coupled with dysregulation of calcium homeostasis and resulting apoptosis of vulnerable neuronal populations, are proposed to underlie the loss of synaptic activity and associated cognitive decline. From these deficiencies emerges the concept of synaptic energy exhaustion in AD, both phosphorylative (ATP) and redox (NAD[P]H) energies. Our previous work shows that hippocampal NAD(P)H and glutathione (GSH) decline with age in association with increased susceptibility to glutamate toxicity in neurons of old-age. Thus, an age-related decline in neuronal reducing currency (NAD[P]H) and reducing buffer (GSH) will surely promote oxidative stress and excess ROS. It is noteworthy that in the early stages of AD, there is already a reduction in the number of mitochondria and the activities of tricarboxylic acid cycle enzymes and cytochrome C oxidase. However, how ROS are produced at the synapse in response to A oligomers is not fully known. Excessive ROS are locally generated in response to synaptic A oligomer binding. This ROS formation can be totally blocked by the mitochondrial uncoupler, 2,4-dinitrophenol which suggests a central role of mitochondria in A-induced oxidative stress. Many studies suggest the possible involvement of oxidative stress and calcium dysfunction in A toxicity.The question as to why brain synaptic ROS levels increase with age is uncertain, but may involve lack of use followed by acute overstimulation of excitatory NMDARs that leads to excessive ROS, related to excess Ca2+ entry into mitochondria. Dysregulation of NMDAR function induced by A binding to neuronal synapses may lead to synaptic mitochondrial dysfunction and excessive ROS formation. Memory mechanisms might be directly compromised by elevated ROS, which could explain the connection between AD and oxidative stress. The increase in oxidative damage exhibited by synaptic mitochondria will damage synapses, affect neurotransmission and might be ultimately responsible for cognitive decline in AD patients. Taken together these studies provide convincing evidence for the concept that mitochondria have a pivotal role in A-induced synaptic dysfunction and neuronal stress. Improved function of mitochondria is an effective way of reducing effects of aging and may inhibit neuronal cell death in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Glutamatergic subgraph"}, "source": 49, "target": 235, "key": 0}, {"relation": "increases", "evidence": "Redox and phosphorylative energetic exhaustion: A-induced mitochondrial and synaptic dysfunction:Increasing evidence indicates that the mitochondrial dysfunction is an important early factor in the development of AD-like pathology. Mitochondria are known to accumulate in synapses and mitochondrial trafficking to synapses is dynamic and regulated by synaptic activity. However, increasing evidence indicates that accumulation of A in mitochondria occurs before extracellular amyloid deposition and increases with age. APP and its derivatives, monomeric and oligomeric forms of A, interact with mitochondrial membranes or mitochondrial matrix protein ABAD leading to mitochondrial dysfunction.Substantial evidence indicates that mitochondria serve as direct targets for A protein mediated neuronal toxicity. Lower levels of ROS are required for synaptic signaling with ROS acting as messenger molecules in the process of LTP. However, high levels of ROS have been implicated as damaging toxic molecules in the age-related impairments of LTP. Our previous work shows that ROS levels increase with age of neurons in parallel with an age-related decline in transmembrane potential. As mitochondrial transmembrane potential is a driving force for cellular production of ATP, its decline in neurons will have a long term effect in many important energy driven reactions. Increased oxidative stress, coupled with dysregulation of calcium homeostasis and resulting apoptosis of vulnerable neuronal populations, are proposed to underlie the loss of synaptic activity and associated cognitive decline. From these deficiencies emerges the concept of synaptic energy exhaustion in AD, both phosphorylative (ATP) and redox (NAD[P]H) energies. Our previous work shows that hippocampal NAD(P)H and glutathione (GSH) decline with age in association with increased susceptibility to glutamate toxicity in neurons of old-age. Thus, an age-related decline in neuronal reducing currency (NAD[P]H) and reducing buffer (GSH) will surely promote oxidative stress and excess ROS. It is noteworthy that in the early stages of AD, there is already a reduction in the number of mitochondria and the activities of tricarboxylic acid cycle enzymes and cytochrome C oxidase. However, how ROS are produced at the synapse in response to A oligomers is not fully known. Excessive ROS are locally generated in response to synaptic A oligomer binding. This ROS formation can be totally blocked by the mitochondrial uncoupler, 2,4-dinitrophenol which suggests a central role of mitochondria in A-induced oxidative stress. Many studies suggest the possible involvement of oxidative stress and calcium dysfunction in A toxicity.The question as to why brain synaptic ROS levels increase with age is uncertain, but may involve lack of use followed by acute overstimulation of excitatory NMDARs that leads to excessive ROS, related to excess Ca2+ entry into mitochondria. Dysregulation of NMDAR function induced by A binding to neuronal synapses may lead to synaptic mitochondrial dysfunction and excessive ROS formation. Memory mechanisms might be directly compromised by elevated ROS, which could explain the connection between AD and oxidative stress. The increase in oxidative damage exhibited by synaptic mitochondria will damage synapses, affect neurotransmission and might be ultimately responsible for cognitive decline in AD patients. Taken together these studies provide convincing evidence for the concept that mitochondria have a pivotal role in A-induced synaptic dysfunction and neuronal stress. Improved function of mitochondria is an effective way of reducing effects of aging and may inhibit neuronal cell death in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Calcium-dependent signal transduction"}, "source": 49, "target": 235, "key": 1}, {"relation": "increases", "evidence": "Redox and phosphorylative energetic exhaustion: A-induced mitochondrial and synaptic dysfunction:Increasing evidence indicates that the mitochondrial dysfunction is an important early factor in the development of AD-like pathology. Mitochondria are known to accumulate in synapses and mitochondrial trafficking to synapses is dynamic and regulated by synaptic activity. However, increasing evidence indicates that accumulation of A in mitochondria occurs before extracellular amyloid deposition and increases with age. APP and its derivatives, monomeric and oligomeric forms of A, interact with mitochondrial membranes or mitochondrial matrix protein ABAD leading to mitochondrial dysfunction.Substantial evidence indicates that mitochondria serve as direct targets for A protein mediated neuronal toxicity. Lower levels of ROS are required for synaptic signaling with ROS acting as messenger molecules in the process of LTP. However, high levels of ROS have been implicated as damaging toxic molecules in the age-related impairments of LTP. Our previous work shows that ROS levels increase with age of neurons in parallel with an age-related decline in transmembrane potential. As mitochondrial transmembrane potential is a driving force for cellular production of ATP, its decline in neurons will have a long term effect in many important energy driven reactions. Increased oxidative stress, coupled with dysregulation of calcium homeostasis and resulting apoptosis of vulnerable neuronal populations, are proposed to underlie the loss of synaptic activity and associated cognitive decline. From these deficiencies emerges the concept of synaptic energy exhaustion in AD, both phosphorylative (ATP) and redox (NAD[P]H) energies. Our previous work shows that hippocampal NAD(P)H and glutathione (GSH) decline with age in association with increased susceptibility to glutamate toxicity in neurons of old-age. Thus, an age-related decline in neuronal reducing currency (NAD[P]H) and reducing buffer (GSH) will surely promote oxidative stress and excess ROS. It is noteworthy that in the early stages of AD, there is already a reduction in the number of mitochondria and the activities of tricarboxylic acid cycle enzymes and cytochrome C oxidase. However, how ROS are produced at the synapse in response to A oligomers is not fully known. Excessive ROS are locally generated in response to synaptic A oligomer binding. This ROS formation can be totally blocked by the mitochondrial uncoupler, 2,4-dinitrophenol which suggests a central role of mitochondria in A-induced oxidative stress. Many studies suggest the possible involvement of oxidative stress and calcium dysfunction in A toxicity.The question as to why brain synaptic ROS levels increase with age is uncertain, but may involve lack of use followed by acute overstimulation of excitatory NMDARs that leads to excessive ROS, related to excess Ca2+ entry into mitochondria. Dysregulation of NMDAR function induced by A binding to neuronal synapses may lead to synaptic mitochondrial dysfunction and excessive ROS formation. Memory mechanisms might be directly compromised by elevated ROS, which could explain the connection between AD and oxidative stress. The increase in oxidative damage exhibited by synaptic mitochondria will damage synapses, affect neurotransmission and might be ultimately responsible for cognitive decline in AD patients. Taken together these studies provide convincing evidence for the concept that mitochondria have a pivotal role in A-induced synaptic dysfunction and neuronal stress. Improved function of mitochondria is an effective way of reducing effects of aging and may inhibit neuronal cell death in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Reactive oxygen species subgraph"}, "source": 49, "target": 235, "key": 2}, {"relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 50, "target": 38, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 238, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 239, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 240, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 241, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 242, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 243, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 244, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 245, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 246, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 247, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 50, "target": 248, "key": 0}, {"relation": "decreases", "evidence": "Galantamine is a phenanthrene alkaloid (similar to codeine) and acts as a reversible inhibitor of AChE with a competitive action. In addition, galantamine's nicotinic agonist properties may provide an additional therapeutic mechanism to AChE inhibition.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):136-40", "reference": "15530663"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 50, "target": 249, "key": 0}, {"relation": "increases", "evidence": "1-(3-chlorophenyl)piperazine results in increased expression of PRL protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17000009"}, "annotations": {"Species": "9606", "Subgraph": "Calcium-dependent signal transduction"}, "source": 51, "target": 250, "key": 0}, {"relation": "increases", "evidence": "1-(3-chlorophenyl)piperazine results in increased expression of PRL protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16418827"}, "annotations": {"Species": "9606"}, "source": 51, "target": 250, "key": 1}, {"relation": "increases", "evidence": "1-(3-chlorophenyl)piperazine results in increased expression of PRL protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9598218"}, "annotations": {"Species": "9606"}, "source": 51, "target": 250, "key": 2}, {"relation": "increases", "evidence": "1-(3-chlorophenyl)piperazine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21402137"}, "annotations": {}, "source": 51, "target": 251, "key": 0}, {"relation": "increases", "evidence": "Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Psychopharmacology (Berl). 1997 May;131(2):130-9", "reference": "9201800"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 44, "key": 0}, {"relation": "increases", "evidence": "The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.", "citation": {"type": "PubMed", "name": "Psychopharmacology (Berl). 1994 Mar;114(2):200-8", "reference": "7838908"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 44, "key": 2}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 44, "key": 4}, {"relation": "increases", "evidence": "Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. ", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 53, "target": 54, "key": 0}, {"relation": "increases", "evidence": "Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. ", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 53, "target": 55, "key": 0}, {"relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 53, "target": 55, "key": 1}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 56, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 235, "key": 0}, {"relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 53, "target": 235, "key": 1}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 238, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 239, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 240, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 241, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 242, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 243, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 244, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 245, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 246, "key": 0}, {"relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 247, "key": 0}, {"relation": "increases", "evidence": "In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 53, "target": 253, "key": 0}, {"relation": "increases", "evidence": "Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. ", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 55, "target": 57, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 238, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 239, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 240, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 241, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 242, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 243, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 244, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 245, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 246, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 247, "key": 0}, {"relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 56, "target": 248, "key": 0}, {"relation": "increases", "evidence": "We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 58, "target": 91, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PSEN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 90, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of BIN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 107, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of GABRA5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606", "Subgraph": "GABA subgraph"}, "source": 59, "target": 137, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of GABRB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606", "Subgraph": "GABA subgraph"}, "source": 59, "target": 138, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FOS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10362023"}, "annotations": {"Species": "9606"}, "source": 59, "target": 142, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FOS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 142, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of CASP3 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640809"}, "annotations": {}, "source": 59, "target": 143, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of CASP3 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 143, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of CASP3 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18369385"}, "annotations": {}, "source": 59, "target": 143, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of CASP3 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20946909"}, "annotations": {}, "source": 59, "target": 143, "key": 3}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of RELN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 147, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of GSK3B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 154, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SOD2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 155, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SOD2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11299314"}, "annotations": {}, "source": 59, "target": 155, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SOD2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19715684"}, "annotations": {}, "source": 59, "target": 155, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ARC mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 158, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CASP4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 159, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SCARB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 165, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CREBBP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 167, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 173, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of PLAT mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 178, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of THBS1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 179, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of EDN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 181, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of DDIT3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 182, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of XBP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 183, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PLAUR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 184, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PLAU mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 185, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of RPS6KB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 187, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [CNTF protein results in increased phosphorylation of STAT3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10364193"}, "annotations": {"Species": "9606"}, "source": 59, "target": 191, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [CNTF protein results in increased phosphorylation of STAT3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16896058"}, "annotations": {"Species": "9606"}, "source": 59, "target": 191, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [CNTF protein results in increased phosphorylation of STAT3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 191, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of NFKB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 192, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CDK5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 196, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of NOS2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 197, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of TGFB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 200, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TFAM mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 202, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SERPINI1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 208, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of NR3C1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 210, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CRH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 214, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of EIF2AK3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 215, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of ACHE protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16828738"}, "annotations": {}, "source": 59, "target": 249, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of ACHE protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16023296"}, "annotations": {}, "source": 59, "target": 249, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of ACHE protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 249, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of A2M mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 254, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABAT mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 255, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ABCA1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 256, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABCA7 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 257, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABCA7 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18579281"}, "annotations": {}, "source": 59, "target": 257, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABCC1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 258, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABCC2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 259, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABCC3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16283523"}, "annotations": {"Species": "9606"}, "source": 59, "target": 260, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ABCC3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 260, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ABCD3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 261, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ADCK3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 262, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ADD3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 263, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ADM mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 264, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of AGT mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 265, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of AHR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 266, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of AIFM1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 267, "key": 0}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15001399"}, "annotations": {"Species": "9606"}, "source": 59, "target": 268, "key": 0}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16973122"}, "annotations": {"Species": "9606"}, "source": 59, "target": 268, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ALAD mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 269, "key": 0}, {"relation": "increases", "evidence": "ALB protein promotes the reaction [Copper Sulfate results in increased abundance of Malondialdehyde]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11487471"}, "annotations": {}, "source": 59, "target": 270, "key": 0}, {"relation": "increases", "evidence": "ALB protein promotes the reaction [Copper Sulfate results in increased abundance of Malondialdehyde]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16327069"}, "annotations": {}, "source": 59, "target": 270, "key": 1}, {"relation": "increases", "evidence": "ALB protein promotes the reaction [Copper Sulfate results in increased abundance of Malondialdehyde]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16327069"}, "annotations": {}, "source": 59, "target": 270, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ANG mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 271, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of APOB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 272, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ARG1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 273, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16283523"}, "annotations": {"Species": "9606"}, "source": 59, "target": 274, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 274, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ATXN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 275, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 276, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of BAG3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 277, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [Trientine results in increased expression of BCL2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14513838"}, "annotations": {"Species": "9606"}, "source": 59, "target": 278, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [Trientine results in increased expression of BCL2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 278, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of BUB1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 279, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CA2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 280, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CACNB4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 281, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CASP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 282, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CASP8 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 283, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CASP8 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20946909"}, "annotations": {}, "source": 59, "target": 283, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of CASP9 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640809"}, "annotations": {}, "source": 59, "target": 284, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of CASP9 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20946909"}, "annotations": {}, "source": 59, "target": 284, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12175101"}, "annotations": {}, "source": 59, "target": 285, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16828738"}, "annotations": {}, "source": 59, "target": 285, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16828738"}, "annotations": {}, "source": 59, "target": 285, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16023296"}, "annotations": {}, "source": 59, "target": 285, "key": 3}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640809"}, "annotations": {}, "source": 59, "target": 285, "key": 4}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 285, "key": 5}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11299314"}, "annotations": {}, "source": 59, "target": 285, "key": 6}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CCNA2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 286, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CCND1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 287, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CD24 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 288, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CD68 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 289, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CD83 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16099135"}, "annotations": {"Species": "9606"}, "source": 59, "target": 290, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CD83 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 290, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CDKN1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15001399"}, "annotations": {"Species": "9606"}, "source": 59, "target": 291, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CDKN1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 291, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CDKN2A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 292, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CEBPB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 293, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CEBPB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19020976"}, "annotations": {}, "source": 59, "target": 293, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CFB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 294, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CITED2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 295, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of COL18A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19789285"}, "annotations": {}, "source": 59, "target": 296, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CRIP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 297, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CRP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 298, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CTSB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 299, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CXCL10 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 300, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CXCL2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 301, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CXCL2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11708899"}, "annotations": {}, "source": 59, "target": 301, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CXCR4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 302, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CYP19A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 303, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CYP1A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 304, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of CYP24A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 305, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of DDIT4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21595052"}, "annotations": {}, "source": 59, "target": 306, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of DDIT4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16283523"}, "annotations": {}, "source": 59, "target": 306, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of DDIT4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 306, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of DHCR24 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 307, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of DKK1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 308, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of EGR2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 309, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of EHMT1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 310, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of EP300 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 311, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ERBB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 312, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ESR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19789285"}, "annotations": {}, "source": 59, "target": 313, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of FAS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12175101"}, "annotations": {"Species": "9606"}, "source": 59, "target": 314, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of FAS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 314, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of FBP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 315, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of FGB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 316, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of FGFR3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 317, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FKBP5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 318, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FKBP5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18579281"}, "annotations": {}, "source": 59, "target": 318, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FLNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 319, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FOSB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 320, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of FSHB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 321, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of FYN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 322, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of GCH1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 323, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of GLB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 324, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of GPX3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 325, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of GSK3A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21595052"}, "annotations": {}, "source": 59, "target": 326, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of GSR protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640809"}, "annotations": {}, "source": 59, "target": 327, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of GSR protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 327, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of GSR protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19945177"}, "annotations": {}, "source": 59, "target": 327, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HES1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 328, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of HP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 329, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16283523"}, "annotations": {"Species": "9606"}, "source": 59, "target": 330, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16730829"}, "annotations": {"Species": "9606"}, "source": 59, "target": 330, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17244614"}, "annotations": {"Species": "9606"}, "source": 59, "target": 330, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 330, "key": 3}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 331, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18579281"}, "annotations": {}, "source": 59, "target": 331, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of HSPB8 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 332, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of HSPD1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19789285"}, "annotations": {}, "source": 59, "target": 333, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of HSPD1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 333, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of HSPD1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20599845"}, "annotations": {}, "source": 59, "target": 333, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ICAM1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 334, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ID2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 335, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of IER3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 336, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of IL18 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 337, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of IL1R1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 338, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of IL1R1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18579281"}, "annotations": {}, "source": 59, "target": 338, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of IL1RN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 339, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate promotes the reaction [Homocysteine results in increased expression of IL8 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12964812"}, "annotations": {"Species": "9606"}, "source": 59, "target": 340, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate promotes the reaction [Homocysteine results in increased expression of IL8 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16099135"}, "annotations": {"Species": "9606"}, "source": 59, "target": 340, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate promotes the reaction [Homocysteine results in increased expression of IL8 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 340, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of IP6K2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 341, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of ITGA2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 342, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of ITPR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 343, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of JAG1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 344, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of JUN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 345, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of JUN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9728050"}, "annotations": {"Species": "9606"}, "source": 59, "target": 345, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of JUND mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 346, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of KYNU mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 347, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of LDLR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12860252"}, "annotations": {"Species": "9606"}, "source": 59, "target": 348, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of LDLR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 348, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of LOX mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 349, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of LOX mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20599845"}, "annotations": {"Species": "9606"}, "source": 59, "target": 349, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of LRP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 350, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of MAOA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 351, "key": 0}, {"relation": "decreases", "evidence": "4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAP2K1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10564177"}, "annotations": {"Species": "9606"}, "source": 59, "target": 352, "key": 0}, {"relation": "decreases", "evidence": "4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAP2K1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 352, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10564177"}, "annotations": {"Species": "9606"}, "source": 59, "target": 353, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 353, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9728050"}, "annotations": {"Species": "9606"}, "source": 59, "target": 353, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10564177"}, "annotations": {"Species": "9606"}, "source": 59, "target": 354, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of MMP3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 355, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of MRAS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 356, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of NCSTN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 357, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of NEFH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 358, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of NFE2L2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 359, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of NFE2L2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22003191"}, "annotations": {}, "source": 59, "target": 359, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of NFKBIA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 360, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PAFAH1B1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 361, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of PAK3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 362, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 363, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PCSK5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 364, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PDE4D mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 365, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PDGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 366, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PHGDH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 367, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of PLD1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 368, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PLEC mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 369, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 370, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PRNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11994310"}, "annotations": {}, "source": 59, "target": 371, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PRNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16847141"}, "annotations": {}, "source": 59, "target": 371, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PRNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 371, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PRNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11994310"}, "annotations": {}, "source": 59, "target": 371, "key": 3}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PRNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16787422"}, "annotations": {}, "source": 59, "target": 371, "key": 4}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PRNP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14713301"}, "annotations": {}, "source": 59, "target": 371, "key": 5}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of PROS1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 372, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of PSAT1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 373, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of PTEN mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 374, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of RAB7A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 375, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of RASGRP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 376, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of RGS2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 377, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of RORA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 378, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of RPS6KA3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20599845"}, "annotations": {"Species": "9606"}, "source": 59, "target": 379, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of S100A4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 380, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of S100A6 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 381, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SC5D mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12860252"}, "annotations": {}, "source": 59, "target": 382, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SC5D mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 382, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SC5D mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18579281"}, "annotations": {}, "source": 59, "target": 382, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SEPP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 383, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SERPINA1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 384, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SERPINE1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16283523"}, "annotations": {"Species": "9606"}, "source": 59, "target": 385, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SGK1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 386, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SLC12A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 387, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SLC1A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 388, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SLC25A19 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 389, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SLC25A4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 390, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SMOX mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 391, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SOCS2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 392, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16023296"}, "annotations": {}, "source": 59, "target": 393, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640809"}, "annotations": {}, "source": 59, "target": 393, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14513838"}, "annotations": {}, "source": 59, "target": 393, "key": 2}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17683925"}, "annotations": {}, "source": 59, "target": 393, "key": 3}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16045547"}, "annotations": {}, "source": 59, "target": 393, "key": 4}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19945177"}, "annotations": {}, "source": 59, "target": 393, "key": 5}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11299314"}, "annotations": {}, "source": 59, "target": 393, "key": 6}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12899943"}, "annotations": {}, "source": 59, "target": 393, "key": 7}, {"relation": "increases", "evidence": "Copper Sulfate results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19715684"}, "annotations": {}, "source": 59, "target": 393, "key": 8}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of SORL1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 394, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SPP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 395, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SQSTM1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 396, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SQSTM1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19070373"}, "annotations": {}, "source": 59, "target": 396, "key": 1}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of SRC mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 397, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [CNTF protein results in increased phosphorylation of STAT1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16896058"}, "annotations": {"Species": "9606"}, "source": 59, "target": 398, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TERT mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 399, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TGFBI mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 400, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of TGIF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 401, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of TH protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20184101"}, "annotations": {}, "source": 59, "target": 402, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of TH protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18369385"}, "annotations": {}, "source": 59, "target": 402, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of TH protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20184101"}, "annotations": {"Subgraph": "Dopaminergic subgraph"}, "source": 59, "target": 402, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TIMP3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 403, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TLN2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 404, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased expression of TNFRSF1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 405, "key": 0}, {"relation": "increases", "evidence": "Copper Sulfate results in increased phosphorylation of and results in increased expression of TP53 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15001399"}, "annotations": {"Species": "9606"}, "source": 59, "target": 406, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TRPV1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17567713"}, "annotations": {}, "source": 59, "target": 407, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TRPV1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {}, "source": 59, "target": 407, "key": 1}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TRPV1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19244541"}, "annotations": {}, "source": 59, "target": 407, "key": 2}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of TYMS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 408, "key": 0}, {"relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of VDR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": "9606"}, "source": 59, "target": 409, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15964169"}, "annotations": {}, "source": 60, "target": 92, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 92, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 92, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632903"}, "annotations": {}, "source": 60, "target": 92, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21734263"}, "annotations": {}, "source": 60, "target": 92, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18359623"}, "annotations": {}, "source": 60, "target": 92, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15964169"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 60, "target": 92, "key": 6}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PPARG protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15964169"}, "annotations": {"Subgraph": "Estrogen subgraph"}, "source": 60, "target": 92, "key": 7}, {"relation": "increases", "evidence": "Estradiol results in increased expression of GABRA3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16000229"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 60, "target": 139, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12963085"}, "annotations": {}, "source": 60, "target": 143, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16924424"}, "annotations": {}, "source": 60, "target": 143, "key": 1}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19095654"}, "annotations": {}, "source": 60, "target": 143, "key": 2}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19347870"}, "annotations": {}, "source": 60, "target": 143, "key": 3}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20945400"}, "annotations": {}, "source": 60, "target": 143, "key": 4}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15964511"}, "annotations": {}, "source": 60, "target": 143, "key": 5}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19095654"}, "annotations": {}, "source": 60, "target": 143, "key": 6}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 143, "key": 7}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22465879"}, "annotations": {}, "source": 60, "target": 143, "key": 8}, {"relation": "decreases", "evidence": "[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of S100A9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {"Subgraph": "Toll like receptor subgraph"}, "source": 60, "target": 156, "key": 0}, {"relation": "decreases", "evidence": "[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of S100A9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {"Subgraph": "Estrogen subgraph"}, "source": 60, "target": 156, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of BDNF mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 157, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of BDNF mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15570173"}, "annotations": {}, "source": 60, "target": 157, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ARC mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20068009"}, "annotations": {}, "source": 60, "target": 158, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ARC mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19420261"}, "annotations": {}, "source": 60, "target": 158, "key": 1}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16298037"}, "annotations": {}, "source": 60, "target": 160, "key": 0}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16934544"}, "annotations": {}, "source": 60, "target": 160, "key": 1}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17266178"}, "annotations": {}, "source": 60, "target": 160, "key": 2}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17636213"}, "annotations": {}, "source": 60, "target": 160, "key": 3}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20600708"}, "annotations": {}, "source": 60, "target": 160, "key": 4}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20621171"}, "annotations": {}, "source": 60, "target": 160, "key": 5}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22219637"}, "annotations": {}, "source": 60, "target": 160, "key": 6}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12072388"}, "annotations": {}, "source": 60, "target": 160, "key": 7}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21501669"}, "annotations": {}, "source": 60, "target": 160, "key": 8}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17068060"}, "annotations": {}, "source": 60, "target": 160, "key": 9}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21127968"}, "annotations": {}, "source": 60, "target": 160, "key": 10}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16298037"}, "annotations": {}, "source": 60, "target": 160, "key": 11}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [Ritonavir results in increased expression of SCARB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17879945"}, "annotations": {}, "source": 60, "target": 165, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [Ritonavir results in increased expression of SCARB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 165, "key": 1}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [Ritonavir results in increased expression of SCARB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17673517"}, "annotations": {}, "source": 60, "target": 165, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16807025"}, "annotations": {}, "source": 60, "target": 173, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17275223"}, "annotations": {}, "source": 60, "target": 173, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16299233"}, "annotations": {}, "source": 60, "target": 173, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17289903"}, "annotations": {}, "source": 60, "target": 173, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18252963"}, "annotations": {}, "source": 60, "target": 173, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19148513"}, "annotations": {}, "source": 60, "target": 173, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 173, "key": 6}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19828145"}, "annotations": {}, "source": 60, "target": 173, "key": 7}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19838210"}, "annotations": {}, "source": 60, "target": 173, "key": 8}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11985600"}, "annotations": {}, "source": 60, "target": 173, "key": 9}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15591033"}, "annotations": {}, "source": 60, "target": 173, "key": 10}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 173, "key": 11}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640349"}, "annotations": {}, "source": 60, "target": 173, "key": 12}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19693291"}, "annotations": {}, "source": 60, "target": 173, "key": 13}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20025956"}, "annotations": {}, "source": 60, "target": 173, "key": 14}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15774498"}, "annotations": {}, "source": 60, "target": 173, "key": 15}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12810170"}, "annotations": {}, "source": 60, "target": 173, "key": 16}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 173, "key": 17}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21277368"}, "annotations": {}, "source": 60, "target": 173, "key": 18}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8344219"}, "annotations": {}, "source": 60, "target": 173, "key": 19}, {"relation": "increases", "evidence": "Estradiol results in increased expression of VEGFA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9214597"}, "annotations": {}, "source": 60, "target": 173, "key": 20}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19956873"}, "annotations": {}, "source": 60, "target": 174, "key": 0}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22219637"}, "annotations": {}, "source": 60, "target": 174, "key": 1}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19279558"}, "annotations": {}, "source": 60, "target": 174, "key": 2}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 174, "key": 3}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15653758"}, "annotations": {}, "source": 60, "target": 174, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15956360"}, "annotations": {}, "source": 60, "target": 176, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15615701"}, "annotations": {}, "source": 60, "target": 176, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11583108"}, "annotations": {}, "source": 60, "target": 176, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14742696"}, "annotations": {}, "source": 60, "target": 176, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15358673"}, "annotations": {}, "source": 60, "target": 176, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16840783"}, "annotations": {}, "source": 60, "target": 176, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18296501"}, "annotations": {}, "source": 60, "target": 176, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21513769"}, "annotations": {}, "source": 60, "target": 176, "key": 7}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17873880"}, "annotations": {}, "source": 60, "target": 176, "key": 8}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18628394"}, "annotations": {}, "source": 60, "target": 176, "key": 9}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12020746"}, "annotations": {}, "source": 60, "target": 176, "key": 10}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16436525"}, "annotations": {}, "source": 60, "target": 176, "key": 11}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11583108"}, "annotations": {}, "source": 60, "target": 176, "key": 12}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11779577"}, "annotations": {}, "source": 60, "target": 176, "key": 13}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12810170"}, "annotations": {}, "source": 60, "target": 176, "key": 14}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15358673"}, "annotations": {}, "source": 60, "target": 176, "key": 15}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21092740"}, "annotations": {}, "source": 60, "target": 176, "key": 16}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15653758"}, "annotations": {}, "source": 60, "target": 176, "key": 17}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15967841"}, "annotations": {}, "source": 60, "target": 176, "key": 18}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16680078"}, "annotations": {}, "source": 60, "target": 176, "key": 19}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17618301"}, "annotations": {}, "source": 60, "target": 176, "key": 20}, {"relation": "decreases", "evidence": "2,3,7,8-tetrachlorodibenzofuran inhibits the reaction [Estradiol results in increased secretion of PLAT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15219790"}, "annotations": {"Species": "9606"}, "source": 60, "target": 178, "key": 0}, {"relation": "decreases", "evidence": "2,3,7,8-tetrachlorodibenzofuran inhibits the reaction [Estradiol results in increased secretion of PLAT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17393018"}, "annotations": {"Species": "9606"}, "source": 60, "target": 178, "key": 1}, {"relation": "decreases", "evidence": "2,3,7,8-tetrachlorodibenzofuran inhibits the reaction [Estradiol results in increased secretion of PLAT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {"Species": "9606"}, "source": 60, "target": 178, "key": 2}, {"relation": "decreases", "evidence": "2,3,7,8-tetrachlorodibenzofuran inhibits the reaction [Estradiol results in increased secretion of PLAT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {"Species": "9606"}, "source": 60, "target": 178, "key": 3}, {"relation": "decreases", "evidence": "2,3,7,8-tetrachlorodibenzofuran inhibits the reaction [Estradiol results in increased secretion of PLAT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {"Species": "9606"}, "source": 60, "target": 178, "key": 4}, {"relation": "decreases", "evidence": "2,3,7,8-tetrachlorodibenzofuran inhibits the reaction [Estradiol results in increased secretion of PLAT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3119194"}, "annotations": {"Species": "9606"}, "source": 60, "target": 178, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of ECE1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19943105"}, "annotations": {}, "source": 60, "target": 180, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of ECE1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 180, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of ECE1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11375906"}, "annotations": {}, "source": 60, "target": 180, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of DDIT3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19153601"}, "annotations": {}, "source": 60, "target": 182, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of DDIT3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 182, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of DDIT3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 182, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of DDIT3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17522070"}, "annotations": {}, "source": 60, "target": 182, "key": 3}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased expression of AGER protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15878629"}, "annotations": {"Species": "9606"}, "source": 60, "target": 188, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of NGFR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 194, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of NGFR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {"Species": "9606"}, "source": 60, "target": 194, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of NGFR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {"Species": "9606"}, "source": 60, "target": 194, "key": 2}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17873880"}, "annotations": {}, "source": 60, "target": 197, "key": 0}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11583108"}, "annotations": {}, "source": 60, "target": 197, "key": 1}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11063824"}, "annotations": {}, "source": 60, "target": 197, "key": 2}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15256495"}, "annotations": {}, "source": 60, "target": 197, "key": 3}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17873880"}, "annotations": {}, "source": 60, "target": 197, "key": 4}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21512103"}, "annotations": {}, "source": 60, "target": 197, "key": 5}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12020746"}, "annotations": {}, "source": 60, "target": 197, "key": 6}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17068060"}, "annotations": {}, "source": 60, "target": 197, "key": 7}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11583108"}, "annotations": {}, "source": 60, "target": 197, "key": 8}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12810170"}, "annotations": {}, "source": 60, "target": 197, "key": 9}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16006544"}, "annotations": {}, "source": 60, "target": 197, "key": 10}, {"relation": "decreases", "evidence": "27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17053178"}, "annotations": {}, "source": 60, "target": 197, "key": 11}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of GSS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16705744"}, "annotations": {}, "source": 60, "target": 198, "key": 0}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19307427"}, "annotations": {}, "source": 60, "target": 200, "key": 0}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16403803"}, "annotations": {}, "source": 60, "target": 200, "key": 1}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18635743"}, "annotations": {}, "source": 60, "target": 200, "key": 2}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19264808"}, "annotations": {}, "source": 60, "target": 200, "key": 3}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21826169"}, "annotations": {}, "source": 60, "target": 200, "key": 4}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11861973"}, "annotations": {}, "source": 60, "target": 200, "key": 5}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12469912"}, "annotations": {}, "source": 60, "target": 200, "key": 6}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19279558"}, "annotations": {}, "source": 60, "target": 200, "key": 7}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20962747"}, "annotations": {}, "source": 60, "target": 200, "key": 8}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8390853"}, "annotations": {}, "source": 60, "target": 200, "key": 9}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11498938"}, "annotations": {}, "source": 60, "target": 200, "key": 10}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12378635"}, "annotations": {}, "source": 60, "target": 200, "key": 11}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15618244"}, "annotations": {}, "source": 60, "target": 200, "key": 12}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16284289"}, "annotations": {}, "source": 60, "target": 200, "key": 13}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19453300"}, "annotations": {}, "source": 60, "target": 200, "key": 14}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21129541"}, "annotations": {}, "source": 60, "target": 200, "key": 15}, {"relation": "increases", "evidence": "TGFB1 protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7585526"}, "annotations": {}, "source": 60, "target": 200, "key": 16}, {"relation": "decreases", "evidence": "Estradiol promotes the reaction [INS protein results in decreased oxidation of Palmitates]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632903"}, "annotations": {"Species": "9606"}, "source": 60, "target": 203, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19920132"}, "annotations": {}, "source": 60, "target": 204, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23548939"}, "annotations": {}, "source": 60, "target": 204, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20467862"}, "annotations": {}, "source": 60, "target": 204, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21315524"}, "annotations": {}, "source": 60, "target": 204, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22811575"}, "annotations": {}, "source": 60, "target": 204, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21885231"}, "annotations": {}, "source": 60, "target": 204, "key": 5}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "1332906"}, "annotations": {}, "source": 60, "target": 204, "key": 6}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15762036"}, "annotations": {}, "source": 60, "target": 204, "key": 7}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15809018"}, "annotations": {}, "source": 60, "target": 204, "key": 8}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15855258"}, "annotations": {}, "source": 60, "target": 204, "key": 9}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15969240"}, "annotations": {}, "source": 60, "target": 204, "key": 10}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17484513"}, "annotations": {}, "source": 60, "target": 204, "key": 11}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17872375"}, "annotations": {}, "source": 60, "target": 204, "key": 12}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21795739"}, "annotations": {}, "source": 60, "target": 204, "key": 13}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21826169"}, "annotations": {}, "source": 60, "target": 204, "key": 14}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22798350"}, "annotations": {}, "source": 60, "target": 204, "key": 15}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21276474"}, "annotations": {}, "source": 60, "target": 204, "key": 16}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23041725"}, "annotations": {}, "source": 60, "target": 204, "key": 17}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11509743"}, "annotations": {}, "source": 60, "target": 204, "key": 18}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11985600"}, "annotations": {}, "source": 60, "target": 204, "key": 19}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14664709"}, "annotations": {}, "source": 60, "target": 204, "key": 20}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19031445"}, "annotations": {}, "source": 60, "target": 204, "key": 21}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19341330"}, "annotations": {}, "source": 60, "target": 204, "key": 22}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19920132"}, "annotations": {}, "source": 60, "target": 204, "key": 23}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22467019"}, "annotations": {}, "source": 60, "target": 204, "key": 24}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8390853"}, "annotations": {}, "source": 60, "target": 204, "key": 25}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21703268"}, "annotations": {}, "source": 60, "target": 204, "key": 26}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19101654"}, "annotations": {}, "source": 60, "target": 204, "key": 27}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11408345"}, "annotations": {}, "source": 60, "target": 204, "key": 28}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15979666"}, "annotations": {}, "source": 60, "target": 204, "key": 29}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16414171"}, "annotations": {}, "source": 60, "target": 204, "key": 30}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20381596"}, "annotations": {}, "source": 60, "target": 204, "key": 31}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7684602"}, "annotations": {}, "source": 60, "target": 204, "key": 32}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of IGF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17656051"}, "annotations": {}, "source": 60, "target": 204, "key": 33}, {"relation": "decreases", "evidence": "Dexamethasone promotes the reaction [Estradiol results in decreased expression of NR3C1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {"Species": "9606"}, "source": 60, "target": 210, "key": 0}, {"relation": "decreases", "evidence": "Dexamethasone promotes the reaction [Estradiol results in decreased expression of NR3C1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23183181"}, "annotations": {"Species": "9606"}, "source": 60, "target": 210, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17283133"}, "annotations": {}, "source": 60, "target": 211, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22064387"}, "annotations": {}, "source": 60, "target": 211, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23029392"}, "annotations": {}, "source": 60, "target": 211, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9705214"}, "annotations": {}, "source": 60, "target": 211, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 211, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased degradation of CDKN1B protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640349"}, "annotations": {}, "source": 60, "target": 211, "key": 5}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of EIF2AK3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {"Species": "9606"}, "source": 60, "target": 215, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of EIF2AK3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 215, "key": 1}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10566683"}, "annotations": {}, "source": 60, "target": 232, "key": 0}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17054466"}, "annotations": {}, "source": 60, "target": 232, "key": 1}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9588692"}, "annotations": {}, "source": 60, "target": 232, "key": 2}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10537130"}, "annotations": {}, "source": 60, "target": 232, "key": 3}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16439454"}, "annotations": {}, "source": 60, "target": 232, "key": 4}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8812359"}, "annotations": {}, "source": 60, "target": 232, "key": 5}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22497783"}, "annotations": {}, "source": 60, "target": 232, "key": 6}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17596564"}, "annotations": {}, "source": 60, "target": 232, "key": 7}, {"relation": "increases", "evidence": "Estradiol results in increased expression of NFKB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 234, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of ACHE mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 249, "key": 0}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18617618"}, "annotations": {}, "source": 60, "target": 250, "key": 0}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22785235"}, "annotations": {}, "source": 60, "target": 250, "key": 1}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12650681"}, "annotations": {}, "source": 60, "target": 250, "key": 2}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15950373"}, "annotations": {}, "source": 60, "target": 250, "key": 3}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17054466"}, "annotations": {}, "source": 60, "target": 250, "key": 4}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17187171"}, "annotations": {}, "source": 60, "target": 250, "key": 5}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20074812"}, "annotations": {}, "source": 60, "target": 250, "key": 6}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22064387"}, "annotations": {}, "source": 60, "target": 250, "key": 7}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2943108"}, "annotations": {}, "source": 60, "target": 250, "key": 8}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7506205"}, "annotations": {}, "source": 60, "target": 250, "key": 9}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3346359"}, "annotations": {}, "source": 60, "target": 250, "key": 10}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3964786"}, "annotations": {}, "source": 60, "target": 250, "key": 11}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23041725"}, "annotations": {}, "source": 60, "target": 250, "key": 12}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11786374"}, "annotations": {}, "source": 60, "target": 250, "key": 13}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20950447"}, "annotations": {}, "source": 60, "target": 250, "key": 14}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16188257"}, "annotations": {}, "source": 60, "target": 250, "key": 15}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10652244"}, "annotations": {}, "source": 60, "target": 250, "key": 16}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11408345"}, "annotations": {}, "source": 60, "target": 250, "key": 17}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11498938"}, "annotations": {}, "source": 60, "target": 250, "key": 18}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12030773"}, "annotations": {}, "source": 60, "target": 250, "key": 19}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12804517"}, "annotations": {}, "source": 60, "target": 250, "key": 20}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12824819"}, "annotations": {}, "source": 60, "target": 250, "key": 21}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12897383"}, "annotations": {}, "source": 60, "target": 250, "key": 22}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "1534540"}, "annotations": {}, "source": 60, "target": 250, "key": 23}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15811834"}, "annotations": {}, "source": 60, "target": 250, "key": 24}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16522720"}, "annotations": {}, "source": 60, "target": 250, "key": 25}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16614383"}, "annotations": {}, "source": 60, "target": 250, "key": 26}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17033158"}, "annotations": {}, "source": 60, "target": 250, "key": 27}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17174995"}, "annotations": {}, "source": 60, "target": 250, "key": 28}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17909072"}, "annotations": {}, "source": 60, "target": 250, "key": 29}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19400946"}, "annotations": {}, "source": 60, "target": 250, "key": 30}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19479013"}, "annotations": {}, "source": 60, "target": 250, "key": 31}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21187122"}, "annotations": {}, "source": 60, "target": 250, "key": 32}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22104698"}, "annotations": {}, "source": 60, "target": 250, "key": 33}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22785235"}, "annotations": {}, "source": 60, "target": 250, "key": 34}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23458715"}, "annotations": {}, "source": 60, "target": 250, "key": 35}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2446353"}, "annotations": {}, "source": 60, "target": 250, "key": 36}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3141044"}, "annotations": {}, "source": 60, "target": 250, "key": 37}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3613869"}, "annotations": {}, "source": 60, "target": 250, "key": 38}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3658230"}, "annotations": {}, "source": 60, "target": 250, "key": 39}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3780563"}, "annotations": {}, "source": 60, "target": 250, "key": 40}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "6588219"}, "annotations": {}, "source": 60, "target": 250, "key": 41}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "6743839"}, "annotations": {}, "source": 60, "target": 250, "key": 42}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7306549"}, "annotations": {}, "source": 60, "target": 250, "key": 43}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7585526"}, "annotations": {}, "source": 60, "target": 250, "key": 44}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8674863"}, "annotations": {}, "source": 60, "target": 250, "key": 45}, {"relation": "decreases", "evidence": "Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9112368"}, "annotations": {}, "source": 60, "target": 250, "key": 46}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12505310"}, "annotations": {}, "source": 60, "target": 251, "key": 0}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9047321"}, "annotations": {}, "source": 60, "target": 251, "key": 1}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15650019"}, "annotations": {}, "source": 60, "target": 251, "key": 2}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16790556"}, "annotations": {}, "source": 60, "target": 251, "key": 3}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2271712"}, "annotations": {}, "source": 60, "target": 251, "key": 4}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9714305"}, "annotations": {}, "source": 60, "target": 251, "key": 5}, {"relation": "decreases", "evidence": "Chlorpyrifos inhibits the reaction [CYP3A4 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22837389"}, "annotations": {}, "source": 60, "target": 251, "key": 6}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ABCA1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 256, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ABCC1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11080590"}, "annotations": {}, "source": 60, "target": 258, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ABCC1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19580841"}, "annotations": {}, "source": 60, "target": 258, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ABCC1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 258, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ADD3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {"Species": "9606"}, "source": 60, "target": 263, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ADD3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {"Species": "9606"}, "source": 60, "target": 263, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ADD3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {"Species": "9606"}, "source": 60, "target": 263, "key": 2}, {"relation": "decreases", "evidence": "CALCA protein modified form inhibits the reaction [ADM protein inhibits the reaction [FSHB protein results in increased secretion of Estradiol]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18401014"}, "annotations": {}, "source": 60, "target": 264, "key": 0}, {"relation": "decreases", "evidence": "CALCA protein modified form inhibits the reaction [ADM protein inhibits the reaction [FSHB protein results in increased secretion of Estradiol]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {}, "source": 60, "target": 264, "key": 1}, {"relation": "decreases", "evidence": "CALCA protein modified form inhibits the reaction [ADM protein inhibits the reaction [FSHB protein results in increased secretion of Estradiol]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {}, "source": 60, "target": 264, "key": 2}, {"relation": "decreases", "evidence": "CALCA protein modified form inhibits the reaction [ADM protein inhibits the reaction [FSHB protein results in increased secretion of Estradiol]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 264, "key": 3}, {"relation": "decreases", "evidence": "CALCA protein modified form inhibits the reaction [ADM protein inhibits the reaction [FSHB protein results in increased secretion of Estradiol]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18401014"}, "annotations": {}, "source": 60, "target": 264, "key": 4}, {"relation": "decreases", "evidence": "CALCA protein modified form inhibits the reaction [ADM protein inhibits the reaction [FSHB protein results in increased secretion of Estradiol]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21824440"}, "annotations": {}, "source": 60, "target": 264, "key": 5}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17912697"}, "annotations": {}, "source": 60, "target": 272, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11076531"}, "annotations": {}, "source": 60, "target": 272, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16192472"}, "annotations": {}, "source": 60, "target": 272, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21984479"}, "annotations": {}, "source": 60, "target": 272, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ARG1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 273, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ARG1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 273, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ARG1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15289156"}, "annotations": {}, "source": 60, "target": 273, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ARG1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 273, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 274, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16516039"}, "annotations": {}, "source": 60, "target": 274, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19153601"}, "annotations": {}, "source": 60, "target": 274, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 274, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 274, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ATF3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 274, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 276, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16514628"}, "annotations": {}, "source": 60, "target": 276, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17268063"}, "annotations": {}, "source": 60, "target": 276, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 276, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 276, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18497064"}, "annotations": {}, "source": 60, "target": 276, "key": 5}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of BAG3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 277, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of BAG3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 277, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of BAG3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 277, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of BAG3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 277, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of BAG3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 277, "key": 4}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10455518"}, "annotations": {}, "source": 60, "target": 278, "key": 0}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10545406"}, "annotations": {}, "source": 60, "target": 278, "key": 1}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11356682"}, "annotations": {}, "source": 60, "target": 278, "key": 2}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11896290"}, "annotations": {}, "source": 60, "target": 278, "key": 3}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15870704"}, "annotations": {}, "source": 60, "target": 278, "key": 4}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15897899"}, "annotations": {}, "source": 60, "target": 278, "key": 5}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16051634"}, "annotations": {}, "source": 60, "target": 278, "key": 6}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18174961"}, "annotations": {}, "source": 60, "target": 278, "key": 7}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 278, "key": 8}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19264808"}, "annotations": {}, "source": 60, "target": 278, "key": 9}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19698761"}, "annotations": {}, "source": 60, "target": 278, "key": 10}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19796866"}, "annotations": {}, "source": 60, "target": 278, "key": 11}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20305694"}, "annotations": {}, "source": 60, "target": 278, "key": 12}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20945400"}, "annotations": {}, "source": 60, "target": 278, "key": 13}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22403704"}, "annotations": {}, "source": 60, "target": 278, "key": 14}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22609851"}, "annotations": {}, "source": 60, "target": 278, "key": 15}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23052036"}, "annotations": {}, "source": 60, "target": 278, "key": 16}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 278, "key": 17}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17578864"}, "annotations": {}, "source": 60, "target": 278, "key": 18}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14659978"}, "annotations": {}, "source": 60, "target": 278, "key": 19}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 278, "key": 20}, {"relation": "decreases", "evidence": "ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22465879"}, "annotations": {}, "source": 60, "target": 278, "key": 21}, {"relation": "increases", "evidence": "Estradiol results in increased expression of BUB1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 279, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of BUB1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 279, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of BUB1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15721199"}, "annotations": {}, "source": 60, "target": 279, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of BUB1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 279, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CASP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 282, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CASP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {"Species": "9606"}, "source": 60, "target": 282, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CASP8 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19095654"}, "annotations": {}, "source": 60, "target": 283, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CASP8 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19095654"}, "annotations": {}, "source": 60, "target": 283, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CASP8 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 283, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CASP8 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22465879"}, "annotations": {}, "source": 60, "target": 283, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CASP9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19095654"}, "annotations": {}, "source": 60, "target": 284, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CASP9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 284, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CASP9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19095654"}, "annotations": {}, "source": 60, "target": 284, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CASP9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 284, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11762696"}, "annotations": {}, "source": 60, "target": 285, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16584521"}, "annotations": {}, "source": 60, "target": 285, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17522070"}, "annotations": {}, "source": 60, "target": 285, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19526586"}, "annotations": {}, "source": 60, "target": 285, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21966433"}, "annotations": {}, "source": 60, "target": 285, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased activity of CAT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22142692"}, "annotations": {}, "source": 60, "target": 285, "key": 5}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11896290"}, "annotations": {}, "source": 60, "target": 287, "key": 0}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15297603"}, "annotations": {}, "source": 60, "target": 287, "key": 1}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15897899"}, "annotations": {}, "source": 60, "target": 287, "key": 2}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16061635"}, "annotations": {}, "source": 60, "target": 287, "key": 3}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16328721"}, "annotations": {}, "source": 60, "target": 287, "key": 4}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16839579"}, "annotations": {}, "source": 60, "target": 287, "key": 5}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17266178"}, "annotations": {}, "source": 60, "target": 287, "key": 6}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18275596"}, "annotations": {}, "source": 60, "target": 287, "key": 7}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18997820"}, "annotations": {}, "source": 60, "target": 287, "key": 8}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19079715"}, "annotations": {}, "source": 60, "target": 287, "key": 9}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19361625"}, "annotations": {}, "source": 60, "target": 287, "key": 10}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19496085"}, "annotations": {}, "source": 60, "target": 287, "key": 11}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19584281"}, "annotations": {}, "source": 60, "target": 287, "key": 12}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19800779"}, "annotations": {}, "source": 60, "target": 287, "key": 13}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19838210"}, "annotations": {}, "source": 60, "target": 287, "key": 14}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20204298"}, "annotations": {}, "source": 60, "target": 287, "key": 15}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20206645"}, "annotations": {}, "source": 60, "target": 287, "key": 16}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20208560"}, "annotations": {}, "source": 60, "target": 287, "key": 17}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20228224"}, "annotations": {}, "source": 60, "target": 287, "key": 18}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20302909"}, "annotations": {}, "source": 60, "target": 287, "key": 19}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20372779"}, "annotations": {}, "source": 60, "target": 287, "key": 20}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 287, "key": 21}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21041310"}, "annotations": {}, "source": 60, "target": 287, "key": 22}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21826169"}, "annotations": {}, "source": 60, "target": 287, "key": 23}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22113133"}, "annotations": {}, "source": 60, "target": 287, "key": 24}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22534328"}, "annotations": {}, "source": 60, "target": 287, "key": 25}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22552626"}, "annotations": {}, "source": 60, "target": 287, "key": 26}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {}, "source": 60, "target": 287, "key": 27}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23052036"}, "annotations": {}, "source": 60, "target": 287, "key": 28}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23229410"}, "annotations": {}, "source": 60, "target": 287, "key": 29}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23328252"}, "annotations": {}, "source": 60, "target": 287, "key": 30}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23524099"}, "annotations": {}, "source": 60, "target": 287, "key": 31}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8927716"}, "annotations": {}, "source": 60, "target": 287, "key": 32}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9049186"}, "annotations": {}, "source": 60, "target": 287, "key": 33}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9705214"}, "annotations": {}, "source": 60, "target": 287, "key": 34}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11861973"}, "annotations": {}, "source": 60, "target": 287, "key": 35}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 287, "key": 36}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15845746"}, "annotations": {}, "source": 60, "target": 287, "key": 37}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640349"}, "annotations": {}, "source": 60, "target": 287, "key": 38}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9094091"}, "annotations": {}, "source": 60, "target": 287, "key": 39}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of CCND1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 287, "key": 40}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11896290"}, "annotations": {}, "source": 60, "target": 291, "key": 0}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12154049"}, "annotations": {}, "source": 60, "target": 291, "key": 1}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12473173"}, "annotations": {}, "source": 60, "target": 291, "key": 2}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15757668"}, "annotations": {}, "source": 60, "target": 291, "key": 3}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15870704"}, "annotations": {}, "source": 60, "target": 291, "key": 4}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 291, "key": 5}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18174961"}, "annotations": {}, "source": 60, "target": 291, "key": 6}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19434490"}, "annotations": {}, "source": 60, "target": 291, "key": 7}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 291, "key": 8}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20696891"}, "annotations": {}, "source": 60, "target": 291, "key": 9}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 291, "key": 10}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22534328"}, "annotations": {}, "source": 60, "target": 291, "key": 11}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23229410"}, "annotations": {}, "source": 60, "target": 291, "key": 12}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23328252"}, "annotations": {}, "source": 60, "target": 291, "key": 13}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9705214"}, "annotations": {}, "source": 60, "target": 291, "key": 14}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 291, "key": 15}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16977382"}, "annotations": {}, "source": 60, "target": 291, "key": 16}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640349"}, "annotations": {}, "source": 60, "target": 291, "key": 17}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 291, "key": 18}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19654927"}, "annotations": {}, "source": 60, "target": 291, "key": 19}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20667977"}, "annotations": {}, "source": 60, "target": 291, "key": 20}, {"relation": "decreases", "evidence": "Benzo(a)pyrene inhibits the reaction [Estradiol results in decreased expression of CDKN1A protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20826375"}, "annotations": {}, "source": 60, "target": 291, "key": 21}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CDKN2A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19027819"}, "annotations": {"Species": "9606"}, "source": 60, "target": 292, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CTSB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11509743"}, "annotations": {}, "source": 60, "target": 299, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CTSB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15289156"}, "annotations": {}, "source": 60, "target": 299, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CTSB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23219593"}, "annotations": {}, "source": 60, "target": 299, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CXCL10 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15557169"}, "annotations": {}, "source": 60, "target": 300, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CXCL10 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 300, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CXCL10 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19533603"}, "annotations": {}, "source": 60, "target": 300, "key": 2}, {"relation": "decreases", "evidence": "CXCR4 protein results in decreased susceptibility to Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 302, "key": 0}, {"relation": "decreases", "evidence": "CXCR4 protein results in decreased susceptibility to Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 302, "key": 1}, {"relation": "decreases", "evidence": "CXCR4 protein results in decreased susceptibility to Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22549810"}, "annotations": {}, "source": 60, "target": 302, "key": 2}, {"relation": "decreases", "evidence": "CXCR4 protein results in decreased susceptibility to Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17578864"}, "annotations": {}, "source": 60, "target": 302, "key": 3}, {"relation": "decreases", "evidence": "Carbaryl inhibits the reaction [CYP1A2 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10910964"}, "annotations": {"Species": "9606"}, "source": 60, "target": 304, "key": 0}, {"relation": "decreases", "evidence": "Carbaryl inhibits the reaction [CYP1A2 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15961252"}, "annotations": {"Species": "9606"}, "source": 60, "target": 304, "key": 1}, {"relation": "decreases", "evidence": "Carbaryl inhibits the reaction [CYP1A2 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16790556"}, "annotations": {"Species": "9606"}, "source": 60, "target": 304, "key": 2}, {"relation": "decreases", "evidence": "Carbaryl inhibits the reaction [CYP1A2 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {"Species": "9606"}, "source": 60, "target": 304, "key": 3}, {"relation": "decreases", "evidence": "Carbaryl inhibits the reaction [CYP1A2 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {"Species": "9606"}, "source": 60, "target": 304, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DHCR24 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15585566"}, "annotations": {}, "source": 60, "target": 307, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DHCR24 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18260696"}, "annotations": {}, "source": 60, "target": 307, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DHCR24 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 307, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DHCR24 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20826375"}, "annotations": {}, "source": 60, "target": 307, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of FAS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19139166"}, "annotations": {}, "source": 60, "target": 314, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of FAS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 314, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of FAS mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18359623"}, "annotations": {}, "source": 60, "target": 314, "key": 2}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16641147"}, "annotations": {}, "source": 60, "target": 321, "key": 0}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16967098"}, "annotations": {}, "source": 60, "target": 321, "key": 1}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21315524"}, "annotations": {}, "source": 60, "target": 321, "key": 2}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22129622"}, "annotations": {}, "source": 60, "target": 321, "key": 3}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22281079"}, "annotations": {}, "source": 60, "target": 321, "key": 4}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21885231"}, "annotations": {}, "source": 60, "target": 321, "key": 5}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15781295"}, "annotations": {}, "source": 60, "target": 321, "key": 6}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16584521"}, "annotations": {}, "source": 60, "target": 321, "key": 7}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17028438"}, "annotations": {}, "source": 60, "target": 321, "key": 8}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18401014"}, "annotations": {}, "source": 60, "target": 321, "key": 9}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18535249"}, "annotations": {}, "source": 60, "target": 321, "key": 10}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18635743"}, "annotations": {}, "source": 60, "target": 321, "key": 11}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19501113"}, "annotations": {}, "source": 60, "target": 321, "key": 12}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20064783"}, "annotations": {}, "source": 60, "target": 321, "key": 13}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21734263"}, "annotations": {}, "source": 60, "target": 321, "key": 14}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22366471"}, "annotations": {}, "source": 60, "target": 321, "key": 15}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22451503"}, "annotations": {}, "source": 60, "target": 321, "key": 16}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22798350"}, "annotations": {}, "source": 60, "target": 321, "key": 17}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23254195"}, "annotations": {}, "source": 60, "target": 321, "key": 18}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8263139"}, "annotations": {}, "source": 60, "target": 321, "key": 19}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19456401"}, "annotations": {}, "source": 60, "target": 321, "key": 20}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20647052"}, "annotations": {}, "source": 60, "target": 321, "key": 21}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23041725"}, "annotations": {}, "source": 60, "target": 321, "key": 22}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17255206"}, "annotations": {}, "source": 60, "target": 321, "key": 23}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21586554"}, "annotations": {}, "source": 60, "target": 321, "key": 24}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22366471"}, "annotations": {}, "source": 60, "target": 321, "key": 25}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23536570"}, "annotations": {}, "source": 60, "target": 321, "key": 26}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8977383"}, "annotations": {}, "source": 60, "target": 321, "key": 27}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18511507"}, "annotations": {}, "source": 60, "target": 321, "key": 28}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18635743"}, "annotations": {}, "source": 60, "target": 321, "key": 29}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22366471"}, "annotations": {}, "source": 60, "target": 321, "key": 30}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15878966"}, "annotations": {}, "source": 60, "target": 321, "key": 31}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15936871"}, "annotations": {}, "source": 60, "target": 321, "key": 32}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16522720"}, "annotations": {}, "source": 60, "target": 321, "key": 33}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16574160"}, "annotations": {}, "source": 60, "target": 321, "key": 34}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16737795"}, "annotations": {}, "source": 60, "target": 321, "key": 35}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16760380"}, "annotations": {}, "source": 60, "target": 321, "key": 36}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18401014"}, "annotations": {}, "source": 60, "target": 321, "key": 37}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22948218"}, "annotations": {}, "source": 60, "target": 321, "key": 38}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23137853"}, "annotations": {}, "source": 60, "target": 321, "key": 39}, {"relation": "decreases", "evidence": "2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [FSHB protein results in increased secretion of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17656051"}, "annotations": {}, "source": 60, "target": 321, "key": 40}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of GLB1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17075048"}, "annotations": {}, "source": 60, "target": 324, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of GLB1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15289156"}, "annotations": {}, "source": 60, "target": 324, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of GPX3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18191855"}, "annotations": {}, "source": 60, "target": 325, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of GPX3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11509743"}, "annotations": {}, "source": 60, "target": 325, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of GPX3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 325, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of GPX3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19693291"}, "annotations": {}, "source": 60, "target": 325, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased activity of GSR protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11762696"}, "annotations": {}, "source": 60, "target": 327, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased activity of GSR protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15289156"}, "annotations": {}, "source": 60, "target": 327, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased activity of GSR protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19945177"}, "annotations": {}, "source": 60, "target": 327, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 330, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 330, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPA1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15860553"}, "annotations": {}, "source": 60, "target": 330, "key": 2}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of HSPB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11174852"}, "annotations": {}, "source": 60, "target": 331, "key": 0}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of HSPB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {}, "source": 60, "target": 331, "key": 1}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of HSPB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19698761"}, "annotations": {}, "source": 60, "target": 331, "key": 2}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of HSPB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11375906"}, "annotations": {}, "source": 60, "target": 331, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPD1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14605097"}, "annotations": {"Species": "9606"}, "source": 60, "target": 333, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPD1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16514628"}, "annotations": {"Species": "9606"}, "source": 60, "target": 333, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of IL18 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22226936"}, "annotations": {}, "source": 60, "target": 337, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of IL18 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {}, "source": 60, "target": 337, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of IL18 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 337, "key": 2}, {"relation": "decreases", "evidence": "ESR2 protein promotes the reaction [Estradiol results in decreased expression of ITPR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {"Species": "9606"}, "source": 60, "target": 343, "key": 0}, {"relation": "decreases", "evidence": "ESR2 protein promotes the reaction [Estradiol results in decreased expression of ITPR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19426747"}, "annotations": {"Species": "9606"}, "source": 60, "target": 343, "key": 1}, {"relation": "decreases", "evidence": "ESR2 protein promotes the reaction [Estradiol results in decreased expression of ITPR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {"Species": "9606"}, "source": 60, "target": 343, "key": 2}, {"relation": "decreases", "evidence": "ESR2 protein promotes the reaction [Estradiol results in decreased expression of ITPR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {"Species": "9606"}, "source": 60, "target": 343, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15930183"}, "annotations": {}, "source": 60, "target": 345, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17088408"}, "annotations": {}, "source": 60, "target": 345, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17266178"}, "annotations": {}, "source": 60, "target": 345, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17395694"}, "annotations": {}, "source": 60, "target": 345, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19153601"}, "annotations": {}, "source": 60, "target": 345, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 345, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 345, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11285193"}, "annotations": {}, "source": 60, "target": 345, "key": 7}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11473722"}, "annotations": {}, "source": 60, "target": 345, "key": 8}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11506814"}, "annotations": {}, "source": 60, "target": 345, "key": 9}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 345, "key": 10}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17089059"}, "annotations": {}, "source": 60, "target": 345, "key": 11}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20025956"}, "annotations": {}, "source": 60, "target": 345, "key": 12}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7497467"}, "annotations": {}, "source": 60, "target": 345, "key": 13}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2118345"}, "annotations": {}, "source": 60, "target": 345, "key": 14}, {"relation": "increases", "evidence": "Estradiol results in increased expression of LDLR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {"Species": "9606"}, "source": 60, "target": 348, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased activity of MAP2K1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15615701"}, "annotations": {}, "source": 60, "target": 352, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased activity of MAP2K1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12154049"}, "annotations": {}, "source": 60, "target": 352, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased activity of MAP2K1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15615701"}, "annotations": {}, "source": 60, "target": 352, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased activity of MAP2K1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {}, "source": 60, "target": 352, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased activity of MAP2K1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14664709"}, "annotations": {}, "source": 60, "target": 352, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased activity of MAP2K1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 352, "key": 5}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15615701"}, "annotations": {}, "source": 60, "target": 353, "key": 0}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18296501"}, "annotations": {}, "source": 60, "target": 353, "key": 1}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12948864"}, "annotations": {}, "source": 60, "target": 353, "key": 2}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12967334"}, "annotations": {}, "source": 60, "target": 353, "key": 3}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14710592"}, "annotations": {}, "source": 60, "target": 353, "key": 4}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14975756"}, "annotations": {}, "source": 60, "target": 353, "key": 5}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15090535"}, "annotations": {}, "source": 60, "target": 353, "key": 6}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15185748"}, "annotations": {}, "source": 60, "target": 353, "key": 7}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15292328"}, "annotations": {}, "source": 60, "target": 353, "key": 8}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15319301"}, "annotations": {}, "source": 60, "target": 353, "key": 9}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15358673"}, "annotations": {}, "source": 60, "target": 353, "key": 10}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15930183"}, "annotations": {}, "source": 60, "target": 353, "key": 11}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16901965"}, "annotations": {}, "source": 60, "target": 353, "key": 12}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17088408"}, "annotations": {}, "source": 60, "target": 353, "key": 13}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17689939"}, "annotations": {}, "source": 60, "target": 353, "key": 14}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18544561"}, "annotations": {}, "source": 60, "target": 353, "key": 15}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18997820"}, "annotations": {}, "source": 60, "target": 353, "key": 16}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19041697"}, "annotations": {}, "source": 60, "target": 353, "key": 17}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19079715"}, "annotations": {}, "source": 60, "target": 353, "key": 18}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20206645"}, "annotations": {}, "source": 60, "target": 353, "key": 19}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20372779"}, "annotations": {}, "source": 60, "target": 353, "key": 20}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20875696"}, "annotations": {}, "source": 60, "target": 353, "key": 21}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 353, "key": 22}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23029392"}, "annotations": {}, "source": 60, "target": 353, "key": 23}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 353, "key": 24}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23409030"}, "annotations": {}, "source": 60, "target": 353, "key": 25}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17174166"}, "annotations": {}, "source": 60, "target": 353, "key": 26}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19279558"}, "annotations": {}, "source": 60, "target": 353, "key": 27}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19340542"}, "annotations": {}, "source": 60, "target": 353, "key": 28}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20950447"}, "annotations": {}, "source": 60, "target": 353, "key": 29}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21278053"}, "annotations": {}, "source": 60, "target": 353, "key": 30}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072920"}, "annotations": {}, "source": 60, "target": 353, "key": 31}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15531431"}, "annotations": {}, "source": 60, "target": 353, "key": 32}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16123166"}, "annotations": {}, "source": 60, "target": 353, "key": 33}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16713447"}, "annotations": {}, "source": 60, "target": 353, "key": 34}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17174995"}, "annotations": {}, "source": 60, "target": 353, "key": 35}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19111554"}, "annotations": {}, "source": 60, "target": 353, "key": 36}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19463694"}, "annotations": {}, "source": 60, "target": 353, "key": 37}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20870566"}, "annotations": {}, "source": 60, "target": 353, "key": 38}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20926581"}, "annotations": {}, "source": 60, "target": 353, "key": 39}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21152324"}, "annotations": {}, "source": 60, "target": 353, "key": 40}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22230296"}, "annotations": {}, "source": 60, "target": 353, "key": 41}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22465879"}, "annotations": {}, "source": 60, "target": 353, "key": 42}, {"relation": "increases", "evidence": "ESR1 protein promotes the reaction [Estradiol results in increased activity of MAPK1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23458715"}, "annotations": {}, "source": 60, "target": 353, "key": 43}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15615701"}, "annotations": {}, "source": 60, "target": 354, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12948864"}, "annotations": {}, "source": 60, "target": 354, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12967334"}, "annotations": {}, "source": 60, "target": 354, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14975756"}, "annotations": {}, "source": 60, "target": 354, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15090535"}, "annotations": {}, "source": 60, "target": 354, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15292328"}, "annotations": {}, "source": 60, "target": 354, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15319301"}, "annotations": {}, "source": 60, "target": 354, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15358673"}, "annotations": {}, "source": 60, "target": 354, "key": 7}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15615701"}, "annotations": {}, "source": 60, "target": 354, "key": 8}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15930183"}, "annotations": {}, "source": 60, "target": 354, "key": 9}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16901965"}, "annotations": {}, "source": 60, "target": 354, "key": 10}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17088408"}, "annotations": {}, "source": 60, "target": 354, "key": 11}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17689939"}, "annotations": {}, "source": 60, "target": 354, "key": 12}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18544561"}, "annotations": {}, "source": 60, "target": 354, "key": 13}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18997820"}, "annotations": {}, "source": 60, "target": 354, "key": 14}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19041697"}, "annotations": {}, "source": 60, "target": 354, "key": 15}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19079715"}, "annotations": {}, "source": 60, "target": 354, "key": 16}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20206645"}, "annotations": {}, "source": 60, "target": 354, "key": 17}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20372779"}, "annotations": {}, "source": 60, "target": 354, "key": 18}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20875696"}, "annotations": {}, "source": 60, "target": 354, "key": 19}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 354, "key": 20}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23029392"}, "annotations": {}, "source": 60, "target": 354, "key": 21}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23409030"}, "annotations": {}, "source": 60, "target": 354, "key": 22}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 354, "key": 23}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17174166"}, "annotations": {}, "source": 60, "target": 354, "key": 24}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19279558"}, "annotations": {}, "source": 60, "target": 354, "key": 25}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19340542"}, "annotations": {}, "source": 60, "target": 354, "key": 26}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20950447"}, "annotations": {}, "source": 60, "target": 354, "key": 27}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21278053"}, "annotations": {}, "source": 60, "target": 354, "key": 28}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072920"}, "annotations": {}, "source": 60, "target": 354, "key": 29}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15531431"}, "annotations": {}, "source": 60, "target": 354, "key": 30}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16123166"}, "annotations": {}, "source": 60, "target": 354, "key": 31}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16713447"}, "annotations": {}, "source": 60, "target": 354, "key": 32}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19111554"}, "annotations": {}, "source": 60, "target": 354, "key": 33}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19463694"}, "annotations": {}, "source": 60, "target": 354, "key": 34}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20870566"}, "annotations": {}, "source": 60, "target": 354, "key": 35}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20926581"}, "annotations": {}, "source": 60, "target": 354, "key": 36}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21152324"}, "annotations": {}, "source": 60, "target": 354, "key": 37}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22230296"}, "annotations": {}, "source": 60, "target": 354, "key": 38}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22465879"}, "annotations": {}, "source": 60, "target": 354, "key": 39}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23458715"}, "annotations": {}, "source": 60, "target": 354, "key": 40}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072547"}, "annotations": {}, "source": 60, "target": 363, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 363, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17268063"}, "annotations": {}, "source": 60, "target": 363, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15591033"}, "annotations": {}, "source": 60, "target": 363, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 363, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15845746"}, "annotations": {}, "source": 60, "target": 363, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16985261"}, "annotations": {}, "source": 60, "target": 363, "key": 6}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22414604"}, "annotations": {}, "source": 60, "target": 363, "key": 7}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16557470"}, "annotations": {}, "source": 60, "target": 363, "key": 8}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PCNA mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20600213"}, "annotations": {}, "source": 60, "target": 363, "key": 9}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC1A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 388, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC1A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 388, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC1A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22154832"}, "annotations": {}, "source": 60, "target": 388, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC1A2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22645130"}, "annotations": {}, "source": 60, "target": 388, "key": 3}, {"relation": "increases", "evidence": "[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11756571"}, "object": {"modifier": "Activity"}, "annotations": {}, "source": 60, "target": 393, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of SORL1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {"Species": "9606"}, "source": 60, "target": 394, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SQSTM1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {"Species": "9606"}, "source": 60, "target": 396, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SQSTM1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 396, "key": 1}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15585566"}, "annotations": {}, "source": 60, "target": 399, "key": 0}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16051634"}, "annotations": {}, "source": 60, "target": 399, "key": 1}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16327978"}, "annotations": {}, "source": 60, "target": 399, "key": 2}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16798746"}, "annotations": {}, "source": 60, "target": 399, "key": 3}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17075048"}, "annotations": {}, "source": 60, "target": 399, "key": 4}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19501078"}, "annotations": {}, "source": 60, "target": 399, "key": 5}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19561322"}, "annotations": {}, "source": 60, "target": 399, "key": 6}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23409030"}, "annotations": {}, "source": 60, "target": 399, "key": 7}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of TERT protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15590986"}, "annotations": {}, "source": 60, "target": 399, "key": 8}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16543374"}, "annotations": {}, "source": 60, "target": 402, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14699072"}, "annotations": {}, "source": 60, "target": 402, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {}, "source": 60, "target": 402, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TH mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16427766"}, "annotations": {}, "source": 60, "target": 402, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of TNFRSF1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12469912"}, "annotations": {}, "source": 60, "target": 405, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of TNFRSF1A mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11375906"}, "annotations": {}, "source": 60, "target": 405, "key": 1}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {"Species": "9606"}, "source": 60, "target": 408, "key": 0}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {"Species": "9606"}, "source": 60, "target": 408, "key": 1}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310284"}, "annotations": {"Species": "9606"}, "source": 60, "target": 408, "key": 2}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {"Species": "9606"}, "source": 60, "target": 408, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of VDR mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15930183"}, "annotations": {}, "source": 60, "target": 409, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of VDR mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17088408"}, "annotations": {}, "source": 60, "target": 409, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of VDR mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 409, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of VDR mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "1315250"}, "annotations": {}, "source": 60, "target": 409, "key": 3}, {"relation": "decreases", "evidence": "Dactinomycin inhibits the reaction [Estradiol results in increased expression of ABCB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15290871"}, "annotations": {"Species": "9606"}, "source": 60, "target": 410, "key": 0}, {"relation": "decreases", "evidence": "Dactinomycin inhibits the reaction [Estradiol results in increased expression of ABCB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16925584"}, "annotations": {"Species": "9606"}, "source": 60, "target": 410, "key": 1}, {"relation": "decreases", "evidence": "Dactinomycin inhibits the reaction [Estradiol results in increased expression of ABCB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19580841"}, "annotations": {"Species": "9606"}, "source": 60, "target": 410, "key": 2}, {"relation": "decreases", "evidence": "Dactinomycin inhibits the reaction [Estradiol results in increased expression of ABCB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19813763"}, "annotations": {"Species": "9606"}, "source": 60, "target": 410, "key": 3}, {"relation": "decreases", "evidence": "Dactinomycin inhibits the reaction [Estradiol results in increased expression of ABCB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 410, "key": 4}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [AGT protein results in increased expression of AGTR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15159206"}, "annotations": {}, "source": 60, "target": 411, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [AGT protein results in increased expression of AGTR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16097371"}, "annotations": {}, "source": 60, "target": 411, "key": 1}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [AGT protein results in increased expression of AGTR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 411, "key": 2}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [AGT protein results in increased expression of AGTR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 411, "key": 3}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [AGT protein results in increased expression of AGTR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17021606"}, "annotations": {}, "source": 60, "target": 411, "key": 4}, {"relation": "increases", "evidence": "[AKR1C3 protein results in increased metabolism of Estrone] which results in increased chemical synthesis of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19320734"}, "annotations": {}, "source": 60, "target": 412, "key": 0}, {"relation": "increases", "evidence": "[AKR1C3 protein results in increased metabolism of Estrone] which results in increased chemical synthesis of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20036328"}, "annotations": {}, "source": 60, "target": 412, "key": 1}, {"relation": "increases", "evidence": "[AKR1C3 protein results in increased metabolism of Estrone] which results in increased chemical synthesis of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 412, "key": 2}, {"relation": "increases", "evidence": "[AKR1C3 protein results in increased metabolism of Estrone] which results in increased chemical synthesis of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 412, "key": 3}, {"relation": "increases", "evidence": "[AKR1C3 protein results in increased metabolism of Estrone] which results in increased chemical synthesis of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19010312"}, "annotations": {}, "source": 60, "target": 412, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOBEC3B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19139166"}, "annotations": {}, "source": 60, "target": 413, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOBEC3B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 413, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOBEC3B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 413, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOBEC3B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 413, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of APOBEC3B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 413, "key": 4}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11861974"}, "annotations": {}, "source": 60, "target": 414, "key": 0}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11861975"}, "annotations": {}, "source": 60, "target": 414, "key": 1}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11867264"}, "annotations": {}, "source": 60, "target": 414, "key": 2}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12391264"}, "annotations": {}, "source": 60, "target": 414, "key": 3}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12676605"}, "annotations": {}, "source": 60, "target": 414, "key": 4}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14751673"}, "annotations": {}, "source": 60, "target": 414, "key": 5}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15026081"}, "annotations": {}, "source": 60, "target": 414, "key": 6}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15084347"}, "annotations": {}, "source": 60, "target": 414, "key": 7}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15159206"}, "annotations": {}, "source": 60, "target": 414, "key": 8}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15171712"}, "annotations": {}, "source": 60, "target": 414, "key": 9}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15849065"}, "annotations": {}, "source": 60, "target": 414, "key": 10}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15950459"}, "annotations": {}, "source": 60, "target": 414, "key": 11}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15994348"}, "annotations": {}, "source": 60, "target": 414, "key": 12}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17131305"}, "annotations": {}, "source": 60, "target": 414, "key": 13}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17823853"}, "annotations": {}, "source": 60, "target": 414, "key": 14}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18275596"}, "annotations": {}, "source": 60, "target": 414, "key": 15}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18324785"}, "annotations": {}, "source": 60, "target": 414, "key": 16}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20821581"}, "annotations": {}, "source": 60, "target": 414, "key": 17}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 414, "key": 18}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632903"}, "annotations": {}, "source": 60, "target": 414, "key": 19}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9073609"}, "annotations": {}, "source": 60, "target": 414, "key": 20}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9846162"}, "annotations": {}, "source": 60, "target": 414, "key": 21}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21276474"}, "annotations": {}, "source": 60, "target": 414, "key": 22}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11509743"}, "annotations": {}, "source": 60, "target": 414, "key": 23}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23144751"}, "annotations": {}, "source": 60, "target": 414, "key": 24}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15597887"}, "annotations": {}, "source": 60, "target": 414, "key": 25}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14565775"}, "annotations": {}, "source": 60, "target": 414, "key": 26}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16311018"}, "annotations": {}, "source": 60, "target": 414, "key": 27}, {"relation": "decreases", "evidence": "2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Estradiol results in increased activity of AR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17589598"}, "annotations": {}, "source": 60, "target": 414, "key": 28}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19772891"}, "annotations": {}, "source": 60, "target": 415, "key": 0}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16257430"}, "annotations": {}, "source": 60, "target": 415, "key": 1}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17450229"}, "annotations": {}, "source": 60, "target": 415, "key": 2}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20732338"}, "annotations": {}, "source": 60, "target": 415, "key": 3}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 415, "key": 4}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16202921"}, "annotations": {}, "source": 60, "target": 415, "key": 5}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21826169"}, "annotations": {}, "source": 60, "target": 415, "key": 6}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072547"}, "annotations": {}, "source": 60, "target": 415, "key": 7}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22643241"}, "annotations": {}, "source": 60, "target": 415, "key": 8}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22414604"}, "annotations": {}, "source": 60, "target": 415, "key": 9}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19022889"}, "annotations": {}, "source": 60, "target": 415, "key": 10}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 415, "key": 11}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16514628"}, "annotations": {}, "source": 60, "target": 415, "key": 12}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18556351"}, "annotations": {}, "source": 60, "target": 415, "key": 13}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 415, "key": 14}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19244106"}, "annotations": {}, "source": 60, "target": 415, "key": 15}, {"relation": "decreases", "evidence": "4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Estradiol results in increased expression of AREG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12432273"}, "annotations": {}, "source": 60, "target": 415, "key": 16}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 416, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 416, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18497064"}, "annotations": {}, "source": 60, "target": 416, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20826375"}, "annotations": {}, "source": 60, "target": 416, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 416, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 416, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of AURKB mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310284"}, "annotations": {}, "source": 60, "target": 416, "key": 6}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11110848"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 0}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12473173"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 1}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16061635"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 2}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16417649"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 3}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16489025"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 4}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17266178"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 5}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18997820"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 6}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20206645"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 7}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20631324"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 8}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22197621"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 9}, {"relation": "decreases", "evidence": "2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {"Species": "9606"}, "source": 60, "target": 417, "key": 10}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CCNB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15897899"}, "annotations": {}, "source": 60, "target": 418, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CCNB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20826375"}, "annotations": {}, "source": 60, "target": 418, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CCNB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 418, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CCNB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19693291"}, "annotations": {}, "source": 60, "target": 418, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CCNB2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 418, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDC6 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 419, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDC6 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17268063"}, "annotations": {}, "source": 60, "target": 419, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDC6 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310284"}, "annotations": {}, "source": 60, "target": 419, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDC6 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 419, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDC6 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 419, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDK1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20826375"}, "annotations": {}, "source": 60, "target": 420, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDK1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 420, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CDK1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 420, "key": 2}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8263139"}, "annotations": {}, "source": 60, "target": 421, "key": 0}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22429990"}, "annotations": {}, "source": 60, "target": 421, "key": 1}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16574160"}, "annotations": {}, "source": 60, "target": 421, "key": 2}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19766106"}, "annotations": {}, "source": 60, "target": 421, "key": 3}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23312234"}, "annotations": {}, "source": 60, "target": 421, "key": 4}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22461451"}, "annotations": {}, "source": 60, "target": 421, "key": 5}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20130263"}, "annotations": {}, "source": 60, "target": 421, "key": 6}, {"relation": "increases", "evidence": "CGB protein results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18191855"}, "annotations": {}, "source": 60, "target": 421, "key": 7}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17622325"}, "annotations": {}, "source": 60, "target": 422, "key": 0}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 422, "key": 1}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 422, "key": 2}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 422, "key": 3}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18556351"}, "annotations": {}, "source": 60, "target": 422, "key": 4}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 422, "key": 5}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {}, "source": 60, "target": 422, "key": 6}, {"relation": "decreases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23029392"}, "annotations": {}, "source": 60, "target": 422, "key": 7}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of CLSTN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16514628"}, "annotations": {"Subgraph": "Calsyntenin subgraph"}, "source": 60, "target": 423, "key": 0}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15292328"}, "annotations": {}, "source": 60, "target": 424, "key": 0}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18566989"}, "annotations": {}, "source": 60, "target": 424, "key": 1}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15288375"}, "annotations": {}, "source": 60, "target": 424, "key": 2}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18192686"}, "annotations": {}, "source": 60, "target": 424, "key": 3}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18497090"}, "annotations": {}, "source": 60, "target": 424, "key": 4}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22285433"}, "annotations": {}, "source": 60, "target": 424, "key": 5}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9683193"}, "annotations": {}, "source": 60, "target": 424, "key": 6}, {"relation": "decreases", "evidence": "COMT protein polymorphism results in decreased abundance of Estradiol analog", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20600213"}, "annotations": {}, "source": 60, "target": 424, "key": 7}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in decreased expression of COX2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {}, "source": 60, "target": 425, "key": 0}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10030690"}, "annotations": {}, "source": 60, "target": 426, "key": 0}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10411295"}, "annotations": {}, "source": 60, "target": 426, "key": 1}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10944450"}, "annotations": {}, "source": 60, "target": 426, "key": 2}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11165043"}, "annotations": {}, "source": 60, "target": 426, "key": 3}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {}, "source": 60, "target": 426, "key": 4}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14994273"}, "annotations": {}, "source": 60, "target": 426, "key": 5}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072547"}, "annotations": {}, "source": 60, "target": 426, "key": 6}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15090535"}, "annotations": {}, "source": 60, "target": 426, "key": 7}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15219790"}, "annotations": {}, "source": 60, "target": 426, "key": 8}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16257430"}, "annotations": {}, "source": 60, "target": 426, "key": 9}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19079715"}, "annotations": {}, "source": 60, "target": 426, "key": 10}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19365803"}, "annotations": {}, "source": 60, "target": 426, "key": 11}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19496085"}, "annotations": {}, "source": 60, "target": 426, "key": 12}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 426, "key": 13}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19654927"}, "annotations": {}, "source": 60, "target": 426, "key": 14}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19698761"}, "annotations": {}, "source": 60, "target": 426, "key": 15}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20372779"}, "annotations": {}, "source": 60, "target": 426, "key": 16}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 426, "key": 17}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22235307"}, "annotations": {}, "source": 60, "target": 426, "key": 18}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22403704"}, "annotations": {}, "source": 60, "target": 426, "key": 19}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22609851"}, "annotations": {}, "source": 60, "target": 426, "key": 20}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2278856"}, "annotations": {}, "source": 60, "target": 426, "key": 21}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23219593"}, "annotations": {}, "source": 60, "target": 426, "key": 22}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7498097"}, "annotations": {}, "source": 60, "target": 426, "key": 23}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7909315"}, "annotations": {}, "source": 60, "target": 426, "key": 24}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8384872"}, "annotations": {}, "source": 60, "target": 426, "key": 25}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8385571"}, "annotations": {}, "source": 60, "target": 426, "key": 26}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8524236"}, "annotations": {}, "source": 60, "target": 426, "key": 27}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8631852"}, "annotations": {}, "source": 60, "target": 426, "key": 28}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23041725"}, "annotations": {}, "source": 60, "target": 426, "key": 29}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16192472"}, "annotations": {}, "source": 60, "target": 426, "key": 30}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17823450"}, "annotations": {}, "source": 60, "target": 426, "key": 31}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18709148"}, "annotations": {}, "source": 60, "target": 426, "key": 32}, {"relation": "decreases", "evidence": "3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Estradiol results in increased expression of CTSD mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21984479"}, "annotations": {}, "source": 60, "target": 426, "key": 33}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17984146"}, "annotations": {}, "source": 60, "target": 427, "key": 0}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22549810"}, "annotations": {}, "source": 60, "target": 427, "key": 1}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {}, "source": 60, "target": 427, "key": 2}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 427, "key": 3}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22643241"}, "annotations": {}, "source": 60, "target": 427, "key": 4}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23384675"}, "annotations": {}, "source": 60, "target": 427, "key": 5}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20549624"}, "annotations": {}, "source": 60, "target": 427, "key": 6}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 427, "key": 7}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15913882"}, "annotations": {}, "source": 60, "target": 427, "key": 8}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17555868"}, "annotations": {}, "source": 60, "target": 427, "key": 9}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 427, "key": 10}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18692832"}, "annotations": {}, "source": 60, "target": 427, "key": 11}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18556351"}, "annotations": {}, "source": 60, "target": 427, "key": 12}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17872378"}, "annotations": {}, "source": 60, "target": 427, "key": 13}, {"relation": "decreases", "evidence": "afimoxifene inhibits the reaction [Estradiol results in increased secretion of CXCL12 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15986123"}, "annotations": {}, "source": 60, "target": 427, "key": 14}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of SDF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19797619"}, "annotations": {}, "source": 60, "target": 427, "key": 15}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of SDF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19584281"}, "annotations": {}, "source": 60, "target": 427, "key": 16}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12858341"}, "annotations": {}, "source": 60, "target": 428, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14648872"}, "annotations": {}, "source": 60, "target": 428, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16311018"}, "annotations": {}, "source": 60, "target": 428, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18191889"}, "annotations": {}, "source": 60, "target": 428, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20144698"}, "annotations": {}, "source": 60, "target": 428, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22771390"}, "annotations": {}, "source": 60, "target": 428, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of CYP11A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23209616"}, "annotations": {}, "source": 60, "target": 428, "key": 6}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 429, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15964790"}, "annotations": {}, "source": 60, "target": 429, "key": 1}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 429, "key": 2}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18497090"}, "annotations": {}, "source": 60, "target": 429, "key": 3}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15837795"}, "annotations": {}, "source": 60, "target": 429, "key": 4}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15142886"}, "annotations": {}, "source": 60, "target": 429, "key": 5}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 429, "key": 6}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8674863"}, "annotations": {}, "source": 60, "target": 429, "key": 7}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19416221"}, "annotations": {}, "source": 60, "target": 429, "key": 8}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15507517"}, "annotations": {}, "source": 60, "target": 429, "key": 9}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15377160"}, "annotations": {}, "source": 60, "target": 429, "key": 10}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18691609"}, "annotations": {}, "source": 60, "target": 429, "key": 11}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22127542"}, "annotations": {}, "source": 60, "target": 429, "key": 12}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10619402"}, "annotations": {}, "source": 60, "target": 429, "key": 13}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17555868"}, "annotations": {}, "source": 60, "target": 429, "key": 14}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21513769"}, "annotations": {}, "source": 60, "target": 429, "key": 15}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16029874"}, "annotations": {}, "source": 60, "target": 429, "key": 16}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12093619"}, "annotations": {}, "source": 60, "target": 429, "key": 17}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15805301"}, "annotations": {}, "source": 60, "target": 429, "key": 18}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 429, "key": 19}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10822009"}, "annotations": {}, "source": 60, "target": 429, "key": 20}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18456490"}, "annotations": {}, "source": 60, "target": 429, "key": 21}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16219370"}, "annotations": {}, "source": 60, "target": 429, "key": 22}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14691211"}, "annotations": {}, "source": 60, "target": 429, "key": 23}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11281733"}, "annotations": {}, "source": 60, "target": 429, "key": 24}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17919675"}, "annotations": {}, "source": 60, "target": 429, "key": 25}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15521013"}, "annotations": {}, "source": 60, "target": 429, "key": 26}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21047992"}, "annotations": {}, "source": 60, "target": 429, "key": 27}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22235307"}, "annotations": {}, "source": 60, "target": 429, "key": 28}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 429, "key": 29}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16327978"}, "annotations": {}, "source": 60, "target": 429, "key": 30}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15908097"}, "annotations": {}, "source": 60, "target": 429, "key": 31}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10072167"}, "annotations": {}, "source": 60, "target": 429, "key": 32}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 429, "key": 33}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15597882"}, "annotations": {}, "source": 60, "target": 429, "key": 34}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11186135"}, "annotations": {}, "source": 60, "target": 429, "key": 35}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9920887"}, "annotations": {}, "source": 60, "target": 429, "key": 36}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18493746"}, "annotations": {}, "source": 60, "target": 429, "key": 37}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16675542"}, "annotations": {}, "source": 60, "target": 429, "key": 38}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10910964"}, "annotations": {}, "source": 60, "target": 429, "key": 39}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15157572"}, "annotations": {}, "source": 60, "target": 429, "key": 40}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11358810"}, "annotations": {}, "source": 60, "target": 429, "key": 41}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23524099"}, "annotations": {}, "source": 60, "target": 429, "key": 42}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP1A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8631852"}, "annotations": {}, "source": 60, "target": 429, "key": 43}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DBN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 430, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DBN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 430, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of DBN1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 430, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ERRFI1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19153601"}, "annotations": {}, "source": 60, "target": 431, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ERRFI1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20826375"}, "annotations": {}, "source": 60, "target": 431, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ERRFI1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20667977"}, "annotations": {}, "source": 60, "target": 431, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ERRFI1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 431, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of ERRFI1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 431, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20211987"}, "annotations": {}, "source": 60, "target": 432, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15968320"}, "annotations": {}, "source": 60, "target": 432, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 432, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22574217"}, "annotations": {}, "source": 60, "target": 432, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15458797"}, "annotations": {}, "source": 60, "target": 432, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12193582"}, "annotations": {}, "source": 60, "target": 432, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of ESRRA mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223131"}, "annotations": {}, "source": 60, "target": 432, "key": 6}, {"relation": "increases", "evidence": "Estradiol results in increased expression of FGF9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22798350"}, "annotations": {}, "source": 60, "target": 433, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of FGF9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12072406"}, "annotations": {}, "source": 60, "target": 433, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of FGF9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 433, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of FGF9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21098263"}, "annotations": {}, "source": 60, "target": 433, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of FGF9 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14602803"}, "annotations": {}, "source": 60, "target": 433, "key": 4}, {"relation": "decreases", "evidence": "GNRHR protein inhibits the reaction [Estradiol promotes the reaction [TNF protein results in increased expression of IL8 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12574206"}, "annotations": {}, "source": 60, "target": 434, "key": 0}, {"relation": "decreases", "evidence": "GNRHR protein inhibits the reaction [Estradiol promotes the reaction [TNF protein results in increased expression of IL8 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16614383"}, "annotations": {}, "source": 60, "target": 434, "key": 1}, {"relation": "decreases", "evidence": "GNRHR protein inhibits the reaction [Estradiol promotes the reaction [TNF protein results in increased expression of IL8 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17185802"}, "annotations": {}, "source": 60, "target": 434, "key": 2}, {"relation": "decreases", "evidence": "GNRHR protein inhibits the reaction [Estradiol promotes the reaction [TNF protein results in increased expression of IL8 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16522720"}, "annotations": {}, "source": 60, "target": 434, "key": 3}, {"relation": "decreases", "evidence": "GNRHR protein inhibits the reaction [Estradiol promotes the reaction [TNF protein results in increased expression of IL8 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23041725"}, "annotations": {}, "source": 60, "target": 434, "key": 4}, {"relation": "decreases", "evidence": "GNRHR protein inhibits the reaction [Estradiol promotes the reaction [TNF protein results in increased expression of IL8 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18280221"}, "annotations": {}, "source": 60, "target": 434, "key": 5}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22494775"}, "annotations": {}, "source": 60, "target": 435, "key": 0}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20049119"}, "annotations": {}, "source": 60, "target": 435, "key": 1}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17283378"}, "annotations": {}, "source": 60, "target": 435, "key": 2}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 435, "key": 3}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 435, "key": 4}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 435, "key": 5}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 435, "key": 6}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 435, "key": 7}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23384675"}, "annotations": {}, "source": 60, "target": 435, "key": 8}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20846786"}, "annotations": {}, "source": 60, "target": 435, "key": 9}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 435, "key": 10}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 435, "key": 11}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20068169"}, "annotations": {}, "source": 60, "target": 435, "key": 12}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21795739"}, "annotations": {}, "source": 60, "target": 435, "key": 13}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14699072"}, "annotations": {}, "source": 60, "target": 435, "key": 14}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15849065"}, "annotations": {}, "source": 60, "target": 435, "key": 15}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {}, "source": 60, "target": 435, "key": 16}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of GREB1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15986123"}, "annotations": {}, "source": 60, "target": 435, "key": 17}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HMOX1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16298037"}, "annotations": {}, "source": 60, "target": 436, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HMOX1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 436, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HMOX1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 436, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HMOX1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16684588"}, "annotations": {}, "source": 60, "target": 436, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HMOX1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18691609"}, "annotations": {}, "source": 60, "target": 436, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HMOX1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 436, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSD17B1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16054388"}, "annotations": {}, "source": 60, "target": 437, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSD17B1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18855374"}, "annotations": {}, "source": 60, "target": 437, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSD17B1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12858341"}, "annotations": {}, "source": 60, "target": 437, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPA1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 438, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of HSPA1B mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12927369"}, "annotations": {}, "source": 60, "target": 438, "key": 1}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10731640"}, "annotations": {}, "source": 60, "target": 439, "key": 0}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15528032"}, "annotations": {}, "source": 60, "target": 439, "key": 1}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15983630"}, "annotations": {}, "source": 60, "target": 439, "key": 2}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16298037"}, "annotations": {}, "source": 60, "target": 439, "key": 3}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17266178"}, "annotations": {}, "source": 60, "target": 439, "key": 4}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17532054"}, "annotations": {}, "source": 60, "target": 439, "key": 5}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19401270"}, "annotations": {}, "source": 60, "target": 439, "key": 6}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {}, "source": 60, "target": 439, "key": 7}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20621171"}, "annotations": {}, "source": 60, "target": 439, "key": 8}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12538720"}, "annotations": {}, "source": 60, "target": 439, "key": 9}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17615358"}, "annotations": {}, "source": 60, "target": 439, "key": 10}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19533603"}, "annotations": {}, "source": 60, "target": 439, "key": 11}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21501669"}, "annotations": {}, "source": 60, "target": 439, "key": 12}, {"relation": "decreases", "evidence": "chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21277368"}, "annotations": {}, "source": 60, "target": 439, "key": 13}, {"relation": "increases", "evidence": "Estradiol promotes the reaction [Progesterone results in increased expression of IRS2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15949379"}, "annotations": {}, "source": 60, "target": 440, "key": 0}, {"relation": "increases", "evidence": "Estradiol promotes the reaction [Progesterone results in increased expression of IRS2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 440, "key": 1}, {"relation": "increases", "evidence": "Estradiol promotes the reaction [Progesterone results in increased expression of IRS2 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 440, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15994348"}, "annotations": {}, "source": 60, "target": 441, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17131305"}, "annotations": {}, "source": 60, "target": 441, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15950459"}, "annotations": {}, "source": 60, "target": 441, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404077"}, "annotations": {}, "source": 60, "target": 441, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18586690"}, "annotations": {}, "source": 60, "target": 441, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10687981"}, "annotations": {}, "source": 60, "target": 441, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15955889"}, "annotations": {}, "source": 60, "target": 441, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12391264"}, "annotations": {}, "source": 60, "target": 441, "key": 7}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17503469"}, "annotations": {}, "source": 60, "target": 441, "key": 8}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 442, "key": 0}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 442, "key": 1}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20160136"}, "annotations": {}, "source": 60, "target": 442, "key": 2}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15289156"}, "annotations": {}, "source": 60, "target": 442, "key": 3}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640349"}, "annotations": {}, "source": 60, "target": 442, "key": 4}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14699072"}, "annotations": {}, "source": 60, "target": 442, "key": 5}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {}, "source": 60, "target": 442, "key": 6}, {"relation": "decreases", "evidence": "diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {}, "source": 60, "target": 442, "key": 7}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23423282"}, "annotations": {}, "source": 60, "target": 443, "key": 0}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19394185"}, "annotations": {}, "source": 60, "target": 443, "key": 1}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "3299987"}, "annotations": {}, "source": 60, "target": 443, "key": 2}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8263139"}, "annotations": {}, "source": 60, "target": 443, "key": 3}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19456401"}, "annotations": {}, "source": 60, "target": 443, "key": 4}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20647052"}, "annotations": {}, "source": 60, "target": 443, "key": 5}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23041725"}, "annotations": {}, "source": 60, "target": 443, "key": 6}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15796768"}, "annotations": {}, "source": 60, "target": 443, "key": 7}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17629525"}, "annotations": {}, "source": 60, "target": 443, "key": 8}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20566471"}, "annotations": {}, "source": 60, "target": 443, "key": 9}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16522720"}, "annotations": {}, "source": 60, "target": 443, "key": 10}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16614383"}, "annotations": {}, "source": 60, "target": 443, "key": 11}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17596564"}, "annotations": {}, "source": 60, "target": 443, "key": 12}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640482"}, "annotations": {}, "source": 60, "target": 443, "key": 13}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18162529"}, "annotations": {}, "source": 60, "target": 443, "key": 14}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19215433"}, "annotations": {}, "source": 60, "target": 443, "key": 15}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20144698"}, "annotations": {}, "source": 60, "target": 443, "key": 16}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20951796"}, "annotations": {}, "source": 60, "target": 443, "key": 17}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2113863"}, "annotations": {}, "source": 60, "target": 443, "key": 18}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21187122"}, "annotations": {}, "source": 60, "target": 443, "key": 19}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21303948"}, "annotations": {}, "source": 60, "target": 443, "key": 20}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22247282"}, "annotations": {}, "source": 60, "target": 443, "key": 21}, {"relation": "increases", "evidence": "LHB protein results in increased secretion of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "909588"}, "annotations": {}, "source": 60, "target": 443, "key": 22}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MAPT protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20579400"}, "annotations": {"Species": "9606"}, "source": 60, "target": 444, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MCM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17268063"}, "annotations": {}, "source": 60, "target": 445, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MCM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16966611"}, "annotations": {}, "source": 60, "target": 445, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MCM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 445, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MCM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 445, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MCM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 445, "key": 4}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17157789"}, "annotations": {}, "source": 60, "target": 446, "key": 0}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 446, "key": 1}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 446, "key": 2}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 446, "key": 3}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22219637"}, "annotations": {}, "source": 60, "target": 446, "key": 4}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20600708"}, "annotations": {}, "source": 60, "target": 446, "key": 5}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21795739"}, "annotations": {}, "source": 60, "target": 446, "key": 6}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17157789"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 60, "target": 446, "key": 7}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12948864"}, "annotations": {}, "source": 60, "target": 447, "key": 0}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 447, "key": 1}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19956873"}, "annotations": {}, "source": 60, "target": 447, "key": 2}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20226447"}, "annotations": {}, "source": 60, "target": 447, "key": 3}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20951759"}, "annotations": {}, "source": 60, "target": 447, "key": 4}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21760532"}, "annotations": {}, "source": 60, "target": 447, "key": 5}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22219637"}, "annotations": {}, "source": 60, "target": 447, "key": 6}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19279558"}, "annotations": {}, "source": 60, "target": 447, "key": 7}, {"relation": "decreases", "evidence": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in decreased expression of MMP9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19416213"}, "annotations": {}, "source": 60, "target": 447, "key": 8}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 448, "key": 0}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 448, "key": 1}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20945400"}, "annotations": {}, "source": 60, "target": 448, "key": 2}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16093440"}, "annotations": {}, "source": 60, "target": 448, "key": 3}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16839579"}, "annotations": {}, "source": 60, "target": 448, "key": 4}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20204298"}, "annotations": {}, "source": 60, "target": 448, "key": 5}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2118345"}, "annotations": {}, "source": 60, "target": 448, "key": 6}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15528270"}, "annotations": {}, "source": 60, "target": 448, "key": 7}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 448, "key": 8}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19647730"}, "annotations": {}, "source": 60, "target": 448, "key": 9}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17266178"}, "annotations": {}, "source": 60, "target": 448, "key": 10}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19698761"}, "annotations": {}, "source": 60, "target": 448, "key": 11}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16155795"}, "annotations": {}, "source": 60, "target": 448, "key": 12}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20404318"}, "annotations": {}, "source": 60, "target": 448, "key": 13}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20049119"}, "annotations": {}, "source": 60, "target": 448, "key": 14}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18997820"}, "annotations": {}, "source": 60, "target": 448, "key": 15}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16327978"}, "annotations": {}, "source": 60, "target": 448, "key": 16}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21826169"}, "annotations": {}, "source": 60, "target": 448, "key": 17}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072547"}, "annotations": {}, "source": 60, "target": 448, "key": 18}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17157789"}, "annotations": {}, "source": 60, "target": 448, "key": 19}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15319301"}, "annotations": {}, "source": 60, "target": 448, "key": 20}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19838210"}, "annotations": {}, "source": 60, "target": 448, "key": 21}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11896290"}, "annotations": {}, "source": 60, "target": 448, "key": 22}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8390853"}, "annotations": {}, "source": 60, "target": 448, "key": 23}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19584281"}, "annotations": {}, "source": 60, "target": 448, "key": 24}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19139166"}, "annotations": {}, "source": 60, "target": 448, "key": 25}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23071688"}, "annotations": {}, "source": 60, "target": 448, "key": 26}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18556351"}, "annotations": {}, "source": 60, "target": 448, "key": 27}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16051634"}, "annotations": {}, "source": 60, "target": 448, "key": 28}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19244106"}, "annotations": {}, "source": 60, "target": 448, "key": 29}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15833885"}, "annotations": {}, "source": 60, "target": 448, "key": 30}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19654927"}, "annotations": {}, "source": 60, "target": 448, "key": 31}, {"relation": "decreases", "evidence": "4-fluorobenzoyl-TN-14003 inhibits the reaction [Estradiol results in increased expression of MYC mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12632255"}, "annotations": {}, "source": 60, "target": 448, "key": 32}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of NQO1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16219370"}, "annotations": {}, "source": 60, "target": 449, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of NQO1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18497090"}, "annotations": {}, "source": 60, "target": 449, "key": 1}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of NQO1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12088631"}, "annotations": {}, "source": 60, "target": 449, "key": 2}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of NQO1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15212807"}, "annotations": {}, "source": 60, "target": 449, "key": 3}, {"relation": "increases", "evidence": "[4-(heptyloxy)phenol results in increased activity of NR5A1 protein] which results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549922"}, "annotations": {}, "source": 60, "target": 450, "key": 0}, {"relation": "increases", "evidence": "[4-(heptyloxy)phenol results in increased activity of NR5A1 protein] which results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23481593"}, "annotations": {}, "source": 60, "target": 450, "key": 1}, {"relation": "increases", "evidence": "[4-(heptyloxy)phenol results in increased activity of NR5A1 protein] which results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20045459"}, "annotations": {}, "source": 60, "target": 450, "key": 2}, {"relation": "increases", "evidence": "[4-(heptyloxy)phenol results in increased activity of NR5A1 protein] which results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21610156"}, "annotations": {}, "source": 60, "target": 450, "key": 3}, {"relation": "increases", "evidence": "[4-(heptyloxy)phenol results in increased activity of NR5A1 protein] which results in increased abundance of Estradiol", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23481593"}, "annotations": {}, "source": 60, "target": 450, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PAWR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 451, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PAWR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20945400"}, "annotations": {}, "source": 60, "target": 451, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of PAWR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15964511"}, "annotations": {}, "source": 60, "target": 451, "key": 2}, {"relation": "decreases", "evidence": "[Estradiol co-treated with Medroxyprogesterone Acetate] results in decreased secretion of [PDGFA protein binds to PDGFB protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {"Subgraph": "Regulation of cytoskeleton subgraph"}, "source": 60, "target": 452, "key": 0}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21536273"}, "annotations": {}, "source": 60, "target": 453, "key": 0}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23306105"}, "annotations": {}, "source": 60, "target": 453, "key": 1}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21715713"}, "annotations": {}, "source": 60, "target": 453, "key": 2}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10411312"}, "annotations": {}, "source": 60, "target": 453, "key": 3}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10822009"}, "annotations": {}, "source": 60, "target": 453, "key": 4}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11014213"}, "annotations": {}, "source": 60, "target": 453, "key": 5}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {}, "source": 60, "target": 453, "key": 6}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11391616"}, "annotations": {}, "source": 60, "target": 453, "key": 7}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11507064"}, "annotations": {}, "source": 60, "target": 453, "key": 8}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11606380"}, "annotations": {}, "source": 60, "target": 453, "key": 9}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11693576"}, "annotations": {}, "source": 60, "target": 453, "key": 10}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11813992"}, "annotations": {}, "source": 60, "target": 453, "key": 11}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11867264"}, "annotations": {}, "source": 60, "target": 453, "key": 12}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11879974"}, "annotations": {}, "source": 60, "target": 453, "key": 13}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12429138"}, "annotations": {}, "source": 60, "target": 453, "key": 14}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12746304"}, "annotations": {}, "source": 60, "target": 453, "key": 15}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12753421"}, "annotations": {}, "source": 60, "target": 453, "key": 16}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12822488"}, "annotations": {}, "source": 60, "target": 453, "key": 17}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072547"}, "annotations": {}, "source": 60, "target": 453, "key": 18}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15218360"}, "annotations": {}, "source": 60, "target": 453, "key": 19}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15219790"}, "annotations": {}, "source": 60, "target": 453, "key": 20}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15319301"}, "annotations": {}, "source": 60, "target": 453, "key": 21}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15806153"}, "annotations": {}, "source": 60, "target": 453, "key": 22}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15913882"}, "annotations": {}, "source": 60, "target": 453, "key": 23}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16000229"}, "annotations": {}, "source": 60, "target": 453, "key": 24}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16202921"}, "annotations": {}, "source": 60, "target": 453, "key": 25}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16242299"}, "annotations": {}, "source": 60, "target": 453, "key": 26}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16257430"}, "annotations": {}, "source": 60, "target": 453, "key": 27}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16323292"}, "annotations": {}, "source": 60, "target": 453, "key": 28}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16393665"}, "annotations": {}, "source": 60, "target": 453, "key": 29}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16739346"}, "annotations": {}, "source": 60, "target": 453, "key": 30}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16892383"}, "annotations": {}, "source": 60, "target": 453, "key": 31}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17142977"}, "annotations": {}, "source": 60, "target": 453, "key": 32}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17872378"}, "annotations": {}, "source": 60, "target": 453, "key": 33}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17904202"}, "annotations": {}, "source": 60, "target": 453, "key": 34}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18677558"}, "annotations": {}, "source": 60, "target": 453, "key": 35}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18997820"}, "annotations": {}, "source": 60, "target": 453, "key": 36}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19041697"}, "annotations": {}, "source": 60, "target": 453, "key": 37}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19079715"}, "annotations": {}, "source": 60, "target": 453, "key": 38}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19434490"}, "annotations": {}, "source": 60, "target": 453, "key": 39}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19496085"}, "annotations": {}, "source": 60, "target": 453, "key": 40}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19584281"}, "annotations": {}, "source": 60, "target": 453, "key": 41}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 453, "key": 42}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19654927"}, "annotations": {}, "source": 60, "target": 453, "key": 43}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19772891"}, "annotations": {}, "source": 60, "target": 453, "key": 44}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19797619"}, "annotations": {}, "source": 60, "target": 453, "key": 45}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20172022"}, "annotations": {}, "source": 60, "target": 453, "key": 46}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20206645"}, "annotations": {}, "source": 60, "target": 453, "key": 47}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20302909"}, "annotations": {}, "source": 60, "target": 453, "key": 48}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20406620"}, "annotations": {}, "source": 60, "target": 453, "key": 49}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20423157"}, "annotations": {}, "source": 60, "target": 453, "key": 50}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20540524"}, "annotations": {}, "source": 60, "target": 453, "key": 51}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20550710"}, "annotations": {}, "source": 60, "target": 453, "key": 52}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "2079700"}, "annotations": {}, "source": 60, "target": 453, "key": 53}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 453, "key": 54}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21536273"}, "annotations": {}, "source": 60, "target": 453, "key": 55}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21795739"}, "annotations": {}, "source": 60, "target": 453, "key": 56}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22071320"}, "annotations": {}, "source": 60, "target": 453, "key": 57}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22403704"}, "annotations": {}, "source": 60, "target": 453, "key": 58}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22414680"}, "annotations": {}, "source": 60, "target": 453, "key": 59}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22609851"}, "annotations": {}, "source": 60, "target": 453, "key": 60}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22643241"}, "annotations": {}, "source": 60, "target": 453, "key": 61}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22728919"}, "annotations": {}, "source": 60, "target": 453, "key": 62}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22808167"}, "annotations": {}, "source": 60, "target": 453, "key": 63}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23026265"}, "annotations": {}, "source": 60, "target": 453, "key": 64}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23029392"}, "annotations": {}, "source": 60, "target": 453, "key": 65}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23052036"}, "annotations": {}, "source": 60, "target": 453, "key": 66}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23384675"}, "annotations": {}, "source": 60, "target": 453, "key": 67}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23524099"}, "annotations": {}, "source": 60, "target": 453, "key": 68}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7498097"}, "annotations": {}, "source": 60, "target": 453, "key": 69}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8504731"}, "annotations": {}, "source": 60, "target": 453, "key": 70}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8812239"}, "annotations": {}, "source": 60, "target": 453, "key": 71}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8919768"}, "annotations": {}, "source": 60, "target": 453, "key": 72}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9391166"}, "annotations": {}, "source": 60, "target": 453, "key": 73}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9449681"}, "annotations": {}, "source": 60, "target": 453, "key": 74}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11509743"}, "annotations": {}, "source": 60, "target": 453, "key": 75}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11985600"}, "annotations": {}, "source": 60, "target": 453, "key": 76}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15541753"}, "annotations": {}, "source": 60, "target": 453, "key": 77}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16985261"}, "annotations": {}, "source": 60, "target": 453, "key": 78}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18281260"}, "annotations": {}, "source": 60, "target": 453, "key": 79}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21195146"}, "annotations": {}, "source": 60, "target": 453, "key": 80}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23144751"}, "annotations": {}, "source": 60, "target": 453, "key": 81}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9607801"}, "annotations": {}, "source": 60, "target": 453, "key": 82}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16728199"}, "annotations": {}, "source": 60, "target": 453, "key": 83}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10397250"}, "annotations": {}, "source": 60, "target": 453, "key": 84}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11399792"}, "annotations": {}, "source": 60, "target": 453, "key": 85}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11474214"}, "annotations": {}, "source": 60, "target": 453, "key": 86}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12399409"}, "annotations": {}, "source": 60, "target": 453, "key": 87}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12535155"}, "annotations": {}, "source": 60, "target": 453, "key": 88}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12834913"}, "annotations": {}, "source": 60, "target": 453, "key": 89}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12858169"}, "annotations": {}, "source": 60, "target": 453, "key": 90}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15456929"}, "annotations": {}, "source": 60, "target": 453, "key": 91}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15914137"}, "annotations": {}, "source": 60, "target": 453, "key": 92}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15979666"}, "annotations": {}, "source": 60, "target": 453, "key": 93}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16311018"}, "annotations": {}, "source": 60, "target": 453, "key": 94}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16414171"}, "annotations": {}, "source": 60, "target": 453, "key": 95}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16522720"}, "annotations": {}, "source": 60, "target": 453, "key": 96}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16557470"}, "annotations": {}, "source": 60, "target": 453, "key": 97}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16607101"}, "annotations": {}, "source": 60, "target": 453, "key": 98}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16837883"}, "annotations": {}, "source": 60, "target": 453, "key": 99}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16837889"}, "annotations": {}, "source": 60, "target": 453, "key": 100}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17033158"}, "annotations": {}, "source": 60, "target": 453, "key": 101}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17049845"}, "annotations": {}, "source": 60, "target": 453, "key": 102}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18653720"}, "annotations": {}, "source": 60, "target": 453, "key": 103}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18790044"}, "annotations": {}, "source": 60, "target": 453, "key": 104}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19460436"}, "annotations": {}, "source": 60, "target": 453, "key": 105}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20381596"}, "annotations": {}, "source": 60, "target": 453, "key": 106}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22127542"}, "annotations": {}, "source": 60, "target": 453, "key": 107}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23209616"}, "annotations": {}, "source": 60, "target": 453, "key": 108}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7414049"}, "annotations": {}, "source": 60, "target": 453, "key": 109}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8812239"}, "annotations": {}, "source": 60, "target": 453, "key": 110}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9783916"}, "annotations": {}, "source": 60, "target": 453, "key": 111}, {"relation": "decreases", "evidence": "bisphenol A inhibits the reaction [Estradiol results in increased expression of PGR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16431846"}, "annotations": {}, "source": 60, "target": 453, "key": 112}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PON1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 454, "key": 0}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15913882"}, "annotations": {}, "source": 60, "target": 455, "key": 0}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20049119"}, "annotations": {}, "source": 60, "target": 455, "key": 1}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23384675"}, "annotations": {}, "source": 60, "target": 455, "key": 2}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 455, "key": 3}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 455, "key": 4}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 455, "key": 5}, {"relation": "decreases", "evidence": "ESR1 protein inhibits the reaction [Estradiol results in increased expression of PRSS23 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19619570"}, "annotations": {}, "source": 60, "target": 455, "key": 6}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RAF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12432273"}, "annotations": {"Species": "9606"}, "source": 60, "target": 456, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RAF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15930183"}, "annotations": {"Species": "9606"}, "source": 60, "target": 456, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RAF1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16029874"}, "annotations": {"Species": "9606"}, "source": 60, "target": 456, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15297603"}, "annotations": {}, "source": 60, "target": 457, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19027819"}, "annotations": {}, "source": 60, "target": 457, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9049186"}, "annotations": {}, "source": 60, "target": 457, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9705214"}, "annotations": {}, "source": 60, "target": 457, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15845746"}, "annotations": {}, "source": 60, "target": 457, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RRM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 458, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RRM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15598610"}, "annotations": {}, "source": 60, "target": 458, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RRM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 458, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RRM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 458, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RRM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 458, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of RRM2 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310284"}, "annotations": {}, "source": 60, "target": 458, "key": 5}, {"relation": "decreases", "evidence": "Butyrophenones inhibits the reaction [[Estradiol results in increased activity of ESR1 protein] which results in increased expression of SERPINB9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14617632"}, "annotations": {}, "source": 60, "target": 459, "key": 0}, {"relation": "decreases", "evidence": "Butyrophenones inhibits the reaction [[Estradiol results in increased activity of ESR1 protein] which results in increased expression of SERPINB9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17237823"}, "annotations": {}, "source": 60, "target": 459, "key": 1}, {"relation": "decreases", "evidence": "Butyrophenones inhibits the reaction [[Estradiol results in increased activity of ESR1 protein] which results in increased expression of SERPINB9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 459, "key": 2}, {"relation": "decreases", "evidence": "Butyrophenones inhibits the reaction [[Estradiol results in increased activity of ESR1 protein] which results in increased expression of SERPINB9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21041310"}, "annotations": {}, "source": 60, "target": 459, "key": 3}, {"relation": "decreases", "evidence": "Butyrophenones inhibits the reaction [[Estradiol results in increased activity of ESR1 protein] which results in increased expression of SERPINB9 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10681578"}, "annotations": {}, "source": 60, "target": 459, "key": 4}, {"relation": "increases", "evidence": "Copper promotes the reaction [Estradiol results in increased expression of SHBG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632903"}, "annotations": {}, "source": 60, "target": 460, "key": 0}, {"relation": "increases", "evidence": "Copper promotes the reaction [Estradiol results in increased expression of SHBG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19685012"}, "annotations": {}, "source": 60, "target": 460, "key": 1}, {"relation": "increases", "evidence": "Copper promotes the reaction [Estradiol results in increased expression of SHBG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15081833"}, "annotations": {}, "source": 60, "target": 460, "key": 2}, {"relation": "increases", "evidence": "Copper promotes the reaction [Estradiol results in increased expression of SHBG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15556074"}, "annotations": {}, "source": 60, "target": 460, "key": 3}, {"relation": "increases", "evidence": "Copper promotes the reaction [Estradiol results in increased expression of SHBG mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17484513"}, "annotations": {}, "source": 60, "target": 460, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of SLC2A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14605097"}, "annotations": {}, "source": 60, "target": 461, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of SLC2A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15350188"}, "annotations": {}, "source": 60, "target": 461, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of SLC2A1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18948400"}, "annotations": {}, "source": 60, "target": 461, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC6A14 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11331657"}, "annotations": {}, "source": 60, "target": 462, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC6A14 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 462, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC6A14 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 462, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC6A14 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 462, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC6A14 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 462, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC6A14 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 462, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of TAUT mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223131"}, "annotations": {}, "source": 60, "target": 463, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17555868"}, "annotations": {}, "source": 60, "target": 464, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 464, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 464, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22609851"}, "annotations": {}, "source": 60, "target": 464, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15757668"}, "annotations": {}, "source": 60, "target": 464, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14664709"}, "annotations": {}, "source": 60, "target": 464, "key": 5}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of SLC7A5 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 464, "key": 6}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19646966"}, "annotations": {}, "source": 60, "target": 465, "key": 0}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16914110"}, "annotations": {}, "source": 60, "target": 465, "key": 1}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11301044"}, "annotations": {}, "source": 60, "target": 465, "key": 2}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18161906"}, "annotations": {}, "source": 60, "target": 465, "key": 3}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11358677"}, "annotations": {}, "source": 60, "target": 465, "key": 4}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23144751"}, "annotations": {}, "source": 60, "target": 465, "key": 5}, {"relation": "decreases", "evidence": "2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SULT1E1 protein results in increased metabolism of Estradiol]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23209616"}, "annotations": {}, "source": 60, "target": 465, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11331657"}, "annotations": {}, "source": 60, "target": 466, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 466, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23026265"}, "annotations": {}, "source": 60, "target": 466, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310281"}, "annotations": {}, "source": 60, "target": 466, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16972788"}, "annotations": {}, "source": 60, "target": 466, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15525692"}, "annotations": {}, "source": 60, "target": 466, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15090535"}, "annotations": {}, "source": 60, "target": 466, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23183181"}, "annotations": {}, "source": 60, "target": 466, "key": 7}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23384675"}, "annotations": {}, "source": 60, "target": 466, "key": 8}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12753421"}, "annotations": {}, "source": 60, "target": 466, "key": 9}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19416221"}, "annotations": {}, "source": 60, "target": 466, "key": 10}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20206645"}, "annotations": {}, "source": 60, "target": 466, "key": 11}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20228224"}, "annotations": {}, "source": 60, "target": 466, "key": 12}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11580929"}, "annotations": {}, "source": 60, "target": 466, "key": 13}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20186393"}, "annotations": {}, "source": 60, "target": 466, "key": 14}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16242299"}, "annotations": {}, "source": 60, "target": 466, "key": 15}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14617632"}, "annotations": {}, "source": 60, "target": 466, "key": 16}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20097460"}, "annotations": {}, "source": 60, "target": 466, "key": 17}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22808167"}, "annotations": {}, "source": 60, "target": 466, "key": 18}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15528270"}, "annotations": {}, "source": 60, "target": 466, "key": 19}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474171"}, "annotations": {}, "source": 60, "target": 466, "key": 20}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10064545"}, "annotations": {}, "source": 60, "target": 466, "key": 21}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9166778"}, "annotations": {}, "source": 60, "target": 466, "key": 22}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19338011"}, "annotations": {}, "source": 60, "target": 466, "key": 23}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15986123"}, "annotations": {}, "source": 60, "target": 466, "key": 24}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11879974"}, "annotations": {}, "source": 60, "target": 466, "key": 25}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16797915"}, "annotations": {}, "source": 60, "target": 466, "key": 26}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 466, "key": 27}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 466, "key": 28}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12014631"}, "annotations": {}, "source": 60, "target": 466, "key": 29}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17904202"}, "annotations": {}, "source": 60, "target": 466, "key": 30}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19838210"}, "annotations": {}, "source": 60, "target": 466, "key": 31}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15219790"}, "annotations": {}, "source": 60, "target": 466, "key": 32}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19584281"}, "annotations": {}, "source": 60, "target": 466, "key": 33}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18677558"}, "annotations": {}, "source": 60, "target": 466, "key": 34}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16965913"}, "annotations": {}, "source": 60, "target": 466, "key": 35}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11693576"}, "annotations": {}, "source": 60, "target": 466, "key": 36}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8168101"}, "annotations": {}, "source": 60, "target": 466, "key": 37}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20397420"}, "annotations": {}, "source": 60, "target": 466, "key": 38}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18700809"}, "annotations": {}, "source": 60, "target": 466, "key": 39}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14605097"}, "annotations": {}, "source": 60, "target": 466, "key": 40}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15118252"}, "annotations": {}, "source": 60, "target": 466, "key": 41}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10620335"}, "annotations": {}, "source": 60, "target": 466, "key": 42}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19654927"}, "annotations": {}, "source": 60, "target": 466, "key": 43}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14706564"}, "annotations": {}, "source": 60, "target": 466, "key": 44}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19858209"}, "annotations": {}, "source": 60, "target": 466, "key": 45}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17453334"}, "annotations": {}, "source": 60, "target": 466, "key": 46}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16093440"}, "annotations": {}, "source": 60, "target": 466, "key": 47}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20302909"}, "annotations": {}, "source": 60, "target": 466, "key": 48}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22643241"}, "annotations": {}, "source": 60, "target": 466, "key": 49}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10811566"}, "annotations": {}, "source": 60, "target": 466, "key": 50}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22609851"}, "annotations": {}, "source": 60, "target": 466, "key": 51}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17872378"}, "annotations": {}, "source": 60, "target": 466, "key": 52}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22071320"}, "annotations": {}, "source": 60, "target": 466, "key": 53}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19593637"}, "annotations": {}, "source": 60, "target": 466, "key": 54}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19698761"}, "annotations": {}, "source": 60, "target": 466, "key": 55}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16155795"}, "annotations": {}, "source": 60, "target": 466, "key": 56}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19496085"}, "annotations": {}, "source": 60, "target": 466, "key": 57}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19772891"}, "annotations": {}, "source": 60, "target": 466, "key": 58}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22235307"}, "annotations": {}, "source": 60, "target": 466, "key": 59}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19079715"}, "annotations": {}, "source": 60, "target": 466, "key": 60}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12473173"}, "annotations": {}, "source": 60, "target": 466, "key": 61}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22562034"}, "annotations": {}, "source": 60, "target": 466, "key": 62}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15072547"}, "annotations": {}, "source": 60, "target": 466, "key": 63}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17157789"}, "annotations": {}, "source": 60, "target": 466, "key": 64}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20540524"}, "annotations": {}, "source": 60, "target": 466, "key": 65}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23056216"}, "annotations": {}, "source": 60, "target": 466, "key": 66}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9391166"}, "annotations": {}, "source": 60, "target": 466, "key": 67}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12429138"}, "annotations": {}, "source": 60, "target": 466, "key": 68}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21185374"}, "annotations": {}, "source": 60, "target": 466, "key": 69}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15913882"}, "annotations": {}, "source": 60, "target": 466, "key": 70}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20208560"}, "annotations": {}, "source": 60, "target": 466, "key": 71}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 466, "key": 72}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16514628"}, "annotations": {}, "source": 60, "target": 466, "key": 73}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16393665"}, "annotations": {}, "source": 60, "target": 466, "key": 74}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18275596"}, "annotations": {}, "source": 60, "target": 466, "key": 75}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9276643"}, "annotations": {}, "source": 60, "target": 466, "key": 76}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16892383"}, "annotations": {}, "source": 60, "target": 466, "key": 77}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20360387"}, "annotations": {}, "source": 60, "target": 466, "key": 78}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23524099"}, "annotations": {}, "source": 60, "target": 466, "key": 79}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11331657"}, "annotations": {}, "source": 60, "target": 467, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 467, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 467, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16202921"}, "annotations": {}, "source": 60, "target": 467, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11861973"}, "annotations": {}, "source": 60, "target": 467, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21586554"}, "annotations": {}, "source": 60, "target": 467, "key": 5}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10811566"}, "annotations": {}, "source": 60, "target": 467, "key": 6}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TGFB3 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8390853"}, "annotations": {}, "source": 60, "target": 467, "key": 7}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TIMP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20226447"}, "annotations": {}, "source": 60, "target": 468, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TIMP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {}, "source": 60, "target": 468, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TIMP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 468, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TIMP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21632981"}, "annotations": {}, "source": 60, "target": 468, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of TIMP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16202921"}, "annotations": {}, "source": 60, "target": 468, "key": 4}, {"relation": "decreases", "evidence": "ESR1 mutant form inhibits the reaction [Estradiol inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {}, "source": 60, "target": 469, "key": 0}, {"relation": "decreases", "evidence": "ESR1 mutant form inhibits the reaction [Estradiol inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20660070"}, "annotations": {}, "source": 60, "target": 469, "key": 1}, {"relation": "decreases", "evidence": "ESR1 mutant form inhibits the reaction [Estradiol inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23373633"}, "annotations": {}, "source": 60, "target": 469, "key": 2}, {"relation": "decreases", "evidence": "ESR1 mutant form inhibits the reaction [Estradiol inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17404688"}, "annotations": {}, "source": 60, "target": 469, "key": 3}, {"relation": "decreases", "evidence": "ESR1 mutant form inhibits the reaction [Estradiol inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23183181"}, "annotations": {}, "source": 60, "target": 469, "key": 4}, {"relation": "increases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in increased expression of UBB mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11179685"}, "annotations": {"Species": "9606"}, "source": 60, "target": 470, "key": 0}, {"relation": "increases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in increased expression of UBB mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20106945"}, "annotations": {"Species": "9606"}, "source": 60, "target": 470, "key": 1}, {"relation": "increases", "evidence": "diindolylmethane promotes the reaction [Estradiol results in increased expression of UBB mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23019147"}, "annotations": {"Species": "9606"}, "source": 60, "target": 470, "key": 2}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12547825"}, "annotations": {}, "source": 60, "target": 471, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17578864"}, "annotations": {}, "source": 60, "target": 471, "key": 1}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19553526"}, "annotations": {}, "source": 60, "target": 471, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of GSTP1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17982697"}, "annotations": {"Species": "9606"}, "source": 60, "target": 472, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [Progesterone results in increased expression of HIF1A mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17275223"}, "annotations": {}, "source": 60, "target": 473, "key": 0}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [Progesterone results in increased expression of HIF1A mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15774498"}, "annotations": {}, "source": 60, "target": 473, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of LEP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18359623"}, "annotations": {}, "source": 60, "target": 474, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of LEP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23153703"}, "annotations": {}, "source": 60, "target": 474, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of LEPR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 475, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of LEPR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14664709"}, "annotations": {}, "source": 60, "target": 475, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of LEPR mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15093691"}, "annotations": {}, "source": 60, "target": 475, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310284"}, "annotations": {}, "source": 60, "target": 476, "key": 0}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19167446"}, "annotations": {}, "source": 60, "target": 476, "key": 1}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15845746"}, "annotations": {}, "source": 60, "target": 476, "key": 2}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19654927"}, "annotations": {}, "source": 60, "target": 476, "key": 3}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21484412"}, "annotations": {}, "source": 60, "target": 476, "key": 4}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16607101"}, "annotations": {}, "source": 60, "target": 476, "key": 5}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16891317"}, "annotations": {}, "source": 60, "target": 476, "key": 6}, {"relation": "increases", "evidence": "Estradiol results in increased expression of MKI67 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20381596"}, "annotations": {}, "source": 60, "target": 476, "key": 7}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PENK mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14664709"}, "annotations": {}, "source": 60, "target": 477, "key": 0}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PENK mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19484750"}, "annotations": {}, "source": 60, "target": 477, "key": 1}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PENK mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19693291"}, "annotations": {}, "source": 60, "target": 477, "key": 2}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PENK mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11474214"}, "annotations": {}, "source": 60, "target": 477, "key": 3}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PENK mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12503826"}, "annotations": {}, "source": 60, "target": 477, "key": 4}, {"relation": "decreases", "evidence": "Estradiol results in decreased expression of PENK mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "8717366"}, "annotations": {}, "source": 60, "target": 477, "key": 5}, {"relation": "decreases", "evidence": "Estradiol inhibits the reaction [Copper results in decreased expression of SLC31A1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19685012"}, "annotations": {"Species": "9606"}, "source": 60, "target": 478, "key": 0}, {"relation": "decreases", "evidence": "Endoplasmic reticulum (ER)-associated degradation (ERAD) is a protective mechanism against ER stress in which unfolded proteins accumulated in the ER are selectively transported to the cytosol for degradation by the ubiquitin-proteasome system. We cloned the novel ubiquitin ligase HRD1, which is involved in ERAD, and showed that HRD1 promoted amyloid precursor protein (APP) ubiquitination and degradation, resulting in decreased generation of amyloid  (A). In addition, suppression of HRD1 expression caused APP accumulation and promoted A generation associated with ER stress and apoptosis. Interestingly, HRD1 levels were significantly decreased in the cerebral cortex of patients with Alzheimer's disease (AD), and the brains of these patients experienced ER stress. Our recent study revealed that this decrease in HRD1 was due to its insolubilization; however, controversy persists about whether the decrease in HRD1 protein promotes A generation or whether A neurotoxicity causes the decrease in HRD1 protein levels. Here, we review current findings on the mechanism of HRD1 protein loss in the AD brain and the involvement of HRD1 in the pathogenesis of AD. Furthermore, we propose that HRD1 may be a target for novel AD therapeutics.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Unfolded protein response subgraph"}, "source": 64, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Endoplasmic reticulum (ER)-associated degradation (ERAD) is a protective mechanism against ER stress in which unfolded proteins accumulated in the ER are selectively transported to the cytosol for degradation by the ubiquitin-proteasome system. We cloned the novel ubiquitin ligase HRD1, which is involved in ERAD, and showed that HRD1 promoted amyloid precursor protein (APP) ubiquitination and degradation, resulting in decreased generation of amyloid  (A). In addition, suppression of HRD1 expression caused APP accumulation and promoted A generation associated with ER stress and apoptosis. Interestingly, HRD1 levels were significantly decreased in the cerebral cortex of patients with Alzheimer's disease (AD), and the brains of these patients experienced ER stress. Our recent study revealed that this decrease in HRD1 was due to its insolubilization; however, controversy persists about whether the decrease in HRD1 protein promotes A generation or whether A neurotoxicity causes the decrease in HRD1 protein levels. Here, we review current findings on the mechanism of HRD1 protein loss in the AD brain and the involvement of HRD1 in the pathogenesis of AD. Furthermore, we propose that HRD1 may be a target for novel AD therapeutics.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 64, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Endoplasmic reticulum (ER)-associated degradation (ERAD) is a protective mechanism against ER stress in which unfolded proteins accumulated in the ER are selectively transported to the cytosol for degradation by the ubiquitin-proteasome system. We cloned the novel ubiquitin ligase HRD1, which is involved in ERAD, and showed that HRD1 promoted amyloid precursor protein (APP) ubiquitination and degradation, resulting in decreased generation of amyloid  (A). In addition, suppression of HRD1 expression caused APP accumulation and promoted A generation associated with ER stress and apoptosis. Interestingly, HRD1 levels were significantly decreased in the cerebral cortex of patients with Alzheimer's disease (AD), and the brains of these patients experienced ER stress. Our recent study revealed that this decrease in HRD1 was due to its insolubilization; however, controversy persists about whether the decrease in HRD1 protein promotes A generation or whether A neurotoxicity causes the decrease in HRD1 protein levels. Here, we review current findings on the mechanism of HRD1 protein loss in the AD brain and the involvement of HRD1 in the pathogenesis of AD. Furthermore, we propose that HRD1 may be a target for novel AD therapeutics.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 64, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "A possible model for involvement of HRD1 in Alzheimers disease (AD). Suppression of AD: Upregulation of HRD1 promotes the ubiquitination and degradation of APP in the ERAD pathway, resulting in decreased A generation.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Unfolded protein response subgraph"}, "source": 64, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "A possible model for involvement of HRD1 in Alzheimers disease (AD). Suppression of AD: Upregulation of HRD1 promotes the ubiquitination and degradation of APP in the ERAD pathway, resulting in decreased A generation.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 64, "target": 11, "key": 4}, {"relation": "increases", "evidence": "The ubiquitin-proteasome pathway is a major protein degradation pathway whose dysfunction is now widely accepted as a cause of neurodegenerative diseases, including Alzheimer's disease. Here we demonstrate that the F-box and leucine rich repeat protein2 (FBL2), a component of the E3 ubiquitin ligase complex, regulates amyloid precursor protein (APP) metabolism through APP ubiquitination.", "citation": {"type": "PubMed", "name": "J Neurosci. 2012 Mar 7;32(10):3352-65.", "reference": "22399757"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 64, "target": 68, "key": 0}, {"relation": "increases", "evidence": "The ubiquitin-proteasome pathway is a major protein degradation pathway whose dysfunction is now widely accepted as a cause of neurodegenerative diseases, including Alzheimer's disease. Here we demonstrate that the F-box and leucine rich repeat protein2 (FBL2), a component of the E3 ubiquitin ligase complex, regulates amyloid precursor protein (APP) metabolism through APP ubiquitination.", "citation": {"type": "PubMed", "name": "J Neurosci. 2012 Mar 7;32(10):3352-65.", "reference": "22399757"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Ubiquitin degradation subgraph"}, "source": 64, "target": 68, "key": 1}, {"relation": "increases", "evidence": "TNF-+IFN- stimulation significantly increased levels of astrocytic BACE1, APP, and secreted A40", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2011 Nov 2;8:150.", "reference": "22047170"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Disease": "Alzheimer's disease", "NervousSystem": "Astrocytes", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 65, "target": 11, "key": 0}, {"relation": "increases", "evidence": "TNF-+IFN- stimulation significantly increased levels of astrocytic BACE1, APP, and secreted A40", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2011 Nov 2;8:150.", "reference": "22047170"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"Disease": "Alzheimer's disease", "NervousSystem": "Astrocytes", "Subgraph": "Amyloidogenic subgraph"}, "source": 65, "target": 11, "key": 1}, {"relation": "increases", "evidence": "IFNgamma in combination with TNFalpha or IL-1beta seems to trigger Abeta production by supporting beta-secretase cleavage of the immature APP molecule.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2000", "reference": "11114266"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 65, "target": 11, "key": 2}, {"relation": "increases", "evidence": "IFNgamma in combination with TNFalpha or IL-1beta seems to trigger Abeta production by supporting beta-secretase cleavage of the immature APP molecule.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2000", "reference": "11114266"}, "annotations": {"Subgraph": "Interferon signaling"}, "source": 65, "target": 11, "key": 3}, {"relation": "increases", "evidence": "IFNgamma in combination with TNFalpha or IL-1beta seems to trigger Abeta production by supporting beta-secretase cleavage of the immature APP molecule.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2000", "reference": "11114266"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 65, "target": 11, "key": 4}, {"relation": "increases", "evidence": "TNF-+IFN- stimulation significantly increased levels of astrocytic BACE1, APP, and secreted A40", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2011 Nov 2;8:150.", "reference": "22047170"}, "annotations": {"Disease": "Alzheimer's disease", "NervousSystem": "Astrocytes", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 65, "target": 68, "key": 0}, {"relation": "increases", "evidence": "TNF-+IFN- stimulation significantly increased levels of astrocytic BACE1, APP, and secreted A40", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2011 Nov 2;8:150.", "reference": "22047170"}, "annotations": {"Disease": "Alzheimer's disease", "NervousSystem": "Astrocytes", "Subgraph": "Amyloidogenic subgraph"}, "source": 65, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Cirrito et al. [26] also show that synaptic activity-induced increase in endocytosis drives more APP into the endocytic compartment, ultimately resulting in increased A production and release. A produced in the endocytic pathway is then brought to the cell surface where it is released into the extracellular fluid [70]. Inhibition of endocytosis reduces APP internalization and reduces A production and release in cell lines", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 66, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Cirrito et al. [26] also show that synaptic activity-induced increase in endocytosis drives more APP into the endocytic compartment, ultimately resulting in increased A production and release. A produced in the endocytic pathway is then brought to the cell surface where it is released into the extracellular fluid [70]. Inhibition of endocytosis reduces APP internalization and reduces A production and release in cell lines", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Synaptic vesicle endocytosis subgraph"}, "source": 66, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Insulin modulates metabolism of -amyloid precursor protein (APP) in neurons, decreasing the intracellular accumulation of -amyloid (A) peptides, which are pivotal in AD pathogenesis. The present study investigates whether the widely prescribed insulin-sensitizing drug, metformin (GlucophageR), affects APP metabolism and A generation in various cell models. We demonstrate that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular A species", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 67, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Insulin modulates metabolism of -amyloid precursor protein (APP) in neurons, decreasing the intracellular accumulation of -amyloid (A) peptides, which are pivotal in AD pathogenesis. The present study investigates whether the widely prescribed insulin-sensitizing drug, metformin (GlucophageR), affects APP metabolism and A generation in various cell models. We demonstrate that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular A species", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Energy metabolism"}, "source": 67, "target": 11, "key": 1}, {"relation": "increases", "evidence": " Furthermore, the effect of metformin on A generation is mediated by transcriptional up-regulation of -secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on A degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on A. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on A generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on A generation, in combined use, metformin enhances insulin's effect in reducing A levels", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 67, "target": 11, "key": 2}, {"relation": "increases", "evidence": " Furthermore, the effect of metformin on A generation is mediated by transcriptional up-regulation of -secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on A degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on A. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on A generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on A generation, in combined use, metformin enhances insulin's effect in reducing A levels", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 67, "target": 11, "key": 3}, {"relation": "increases", "evidence": " Furthermore, the effect of metformin on A generation is mediated by transcriptional up-regulation of -secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on A degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on A. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on A generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on A generation, in combined use, metformin enhances insulin's effect in reducing A levels", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 67, "target": 11, "key": 4}, {"relation": "increases", "evidence": " Furthermore, the effect of metformin on A generation is mediated by transcriptional up-regulation of -secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on A degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on A. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on A generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on A generation, in combined use, metformin enhances insulin's effect in reducing A levels", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 67, "target": 11, "key": 8}, {"relation": "increases", "evidence": "We treated N2a695 cells with metformin and found that metformin increased levels of both extracellular (Fig. 1A) and intracellular (data not shown) A40/42 in dose-dependent manners, with the maximum effect (3-fold) seen after 24 h at 10 mM. Similar effects were seen in primary neurons at a much lower concentration of metformin (10 M) (Fig. 1B). To ascertain that the intracellular A measured from cell lysates did not include the secreted A that is often associated with cell membranes, we briefly treated cells with trypsin and then with trypsin inhibitors before lysis and found no significant difference in the intracellular A levels with or without trypsin cleavage", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"UserdefinedCellLine": "N2a695 cell", "Subgraph": "Insulin signal transduction"}, "source": 67, "target": 11, "key": 9}, {"relation": "increases", "evidence": "We treated N2a695 cells with metformin and found that metformin increased levels of both extracellular (Fig. 1A) and intracellular (data not shown) A40/42 in dose-dependent manners, with the maximum effect (3-fold) seen after 24 h at 10 mM. Similar effects were seen in primary neurons at a much lower concentration of metformin (10 M) (Fig. 1B). To ascertain that the intracellular A measured from cell lysates did not include the secreted A that is often associated with cell membranes, we briefly treated cells with trypsin and then with trypsin inhibitors before lysis and found no significant difference in the intracellular A levels with or without trypsin cleavage", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"UserdefinedCellLine": "N2a695 cell", "Subgraph": "Amyloidogenic subgraph"}, "source": 67, "target": 11, "key": 10}, {"relation": "increases", "evidence": "We examined whether metformin's A-increasing effect depended on activation of AMPK, a known molecular target of metformin. Phosphorylation of AMPK at Thr-172 and its substrate, acetyl CoA carboxylase (ACC), were found to be both induced by metformin in a dose-dependent manner (Fig. 4 A and B). We also observed a significant inhibition of metformin-stimulated A production by compound C, a specific AMPK inhibitor, in a dose-dependent manner. Compound C inhibited metformin's effect by 50% when used at a concentration (20 M) that is known to guarantee its specificity for AMPK (32) (Fig. 4C). These results indicate an AMPK-dependent mechanism for metformin's effect on A. Significantly, the antagonizing effect of compound C was largely attributed to suppression of BACE1 transcription because the mRNA was greatly reduced after treatment with the two drugs (Fig. 4D).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 67, "target": 11, "key": 11}, {"relation": "increases", "evidence": "We examined whether metformin's A-increasing effect depended on activation of AMPK, a known molecular target of metformin. Phosphorylation of AMPK at Thr-172 and its substrate, acetyl CoA carboxylase (ACC), were found to be both induced by metformin in a dose-dependent manner (Fig. 4 A and B). We also observed a significant inhibition of metformin-stimulated A production by compound C, a specific AMPK inhibitor, in a dose-dependent manner. Compound C inhibited metformin's effect by 50% when used at a concentration (20 M) that is known to guarantee its specificity for AMPK (32) (Fig. 4C). These results indicate an AMPK-dependent mechanism for metformin's effect on A. Significantly, the antagonizing effect of compound C was largely attributed to suppression of BACE1 transcription because the mRNA was greatly reduced after treatment with the two drugs (Fig. 4D).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 67, "target": 11, "key": 12}, {"relation": "decreases", "evidence": "The surface levels of both APP and LRP1 (low-density lipoprotein receptor-related protein 1), which are known to comigrate during trafficking, were dramatically reduced after metformin treatment as detected by biotinylation assays, whereas their total protein levels remained unchanged (Fig. 1D). However, the surface and the total BACE1 were markedly increased by metformin. Through further subfractionation, using sucrose gradients, we showed that metformin treatment caused changes in the compartmentalization of APP, as evidenced by increased distribution in trans-Golgi network (TGN) vesicles (fraction 2), including those trafficks en route to early endosomes and TGN (fraction 3), and decreased distribution in membranes (fraction 5) (Fig. S1 B and C). BACE1 protein levels were found to be elevated in all 3 fractions: 2, 3, and 5, with an 2-fold increase of the total protein. The increased distribution of both APP and BACE1 in fractions 2 and 3 are expected to favor A generation within TGN and/or endocytic compartments, the two compartments with mild acidic pH optimal for BACE1 activity (33, 34). Indeed, we detected increased immunofluorescent A40 signals after metformin treatment in TGN (Fig. 1E).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"CellStructure": "Cell Membrane", "Subgraph": "Insulin signal transduction"}, "source": 67, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "The surface levels of both APP and LRP1 (low-density lipoprotein receptor-related protein 1), which are known to comigrate during trafficking, were dramatically reduced after metformin treatment as detected by biotinylation assays, whereas their total protein levels remained unchanged (Fig. 1D). However, the surface and the total BACE1 were markedly increased by metformin. Through further subfractionation, using sucrose gradients, we showed that metformin treatment caused changes in the compartmentalization of APP, as evidenced by increased distribution in trans-Golgi network (TGN) vesicles (fraction 2), including those trafficks en route to early endosomes and TGN (fraction 3), and decreased distribution in membranes (fraction 5) (Fig. S1 B and C). BACE1 protein levels were found to be elevated in all 3 fractions: 2, 3, and 5, with an 2-fold increase of the total protein. The increased distribution of both APP and BACE1 in fractions 2 and 3 are expected to favor A generation within TGN and/or endocytic compartments, the two compartments with mild acidic pH optimal for BACE1 activity (33, 34). Indeed, we detected increased immunofluorescent A40 signals after metformin treatment in TGN (Fig. 1E).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"CellStructure": "Cell Membrane", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 67, "target": 68, "key": 1}, {"relation": "increases", "evidence": "The surface levels of both APP and LRP1 (low-density lipoprotein receptor-related protein 1), which are known to comigrate during trafficking, were dramatically reduced after metformin treatment as detected by biotinylation assays, whereas their total protein levels remained unchanged (Fig. 1D). However, the surface and the total BACE1 were markedly increased by metformin. Through further subfractionation, using sucrose gradients, we showed that metformin treatment caused changes in the compartmentalization of APP, as evidenced by increased distribution in trans-Golgi network (TGN) vesicles (fraction 2), including those trafficks en route to early endosomes and TGN (fraction 3), and decreased distribution in membranes (fraction 5) (Fig. S1 B and C). BACE1 protein levels were found to be elevated in all 3 fractions: 2, 3, and 5, with an 2-fold increase of the total protein. The increased distribution of both APP and BACE1 in fractions 2 and 3 are expected to favor A generation within TGN and/or endocytic compartments, the two compartments with mild acidic pH optimal for BACE1 activity (33, 34). Indeed, we detected increased immunofluorescent A40 signals after metformin treatment in TGN (Fig. 1E).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"CellStructure": "Endosomes", "Subgraph": "Insulin signal transduction"}, "source": 67, "target": 68, "key": 2}, {"relation": "increases", "evidence": "The surface levels of both APP and LRP1 (low-density lipoprotein receptor-related protein 1), which are known to comigrate during trafficking, were dramatically reduced after metformin treatment as detected by biotinylation assays, whereas their total protein levels remained unchanged (Fig. 1D). However, the surface and the total BACE1 were markedly increased by metformin. Through further subfractionation, using sucrose gradients, we showed that metformin treatment caused changes in the compartmentalization of APP, as evidenced by increased distribution in trans-Golgi network (TGN) vesicles (fraction 2), including those trafficks en route to early endosomes and TGN (fraction 3), and decreased distribution in membranes (fraction 5) (Fig. S1 B and C). BACE1 protein levels were found to be elevated in all 3 fractions: 2, 3, and 5, with an 2-fold increase of the total protein. The increased distribution of both APP and BACE1 in fractions 2 and 3 are expected to favor A generation within TGN and/or endocytic compartments, the two compartments with mild acidic pH optimal for BACE1 activity (33, 34). Indeed, we detected increased immunofluorescent A40 signals after metformin treatment in TGN (Fig. 1E).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"CellStructure": "Endosomes", "Subgraph": "Amyloidogenic subgraph"}, "source": 67, "target": 68, "key": 3}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 11, "key": 0}, {"relation": "increases", "evidence": "In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 68, "target": 0, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 68, "target": 1, "key": 0}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 1, "key": 1}, {"relation": "decreases", "evidence": "A can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of\\ superoxide anion radical. and decreased production of ATP.", "citation": {"type": "PubMed", "name": "Nature. 2004 Aug 5;430(7000):631-9", "reference": "15295589"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 68, "target": 1, "key": 2}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 1, "key": 3}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 2, "key": 0}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 68, "target": 2, "key": 1}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 3, "key": 0}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 4, "key": 0}, {"relation": "decreases", "evidence": "A large body of literature has suggested an important role for a number of factors including oxidative stress, mitochondrial DNA mutations, imbalance in calcium homeostasis and aging in the dysfunction of mitochondrial complexes (28-34, 40, 46, 47). In addition, recent studies have also implicated a role for targeting and accumulation of plasma membrane APP and cytosolic alpha synuclein to mitochondria in the pathogenesis of mitochondrial dysfunction in Alzheimers and Parkinsons diseases, respectively.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2010 Jan;1802(1):11-9. Epub 2009 Jul 18.", "reference": "19619643"}, "annotations": {"Disease": "Alzheimer's disease", "CellStructure": "Mitochondria", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 4, "key": 1}, {"relation": "increases", "evidence": "However, normal physiological functions of endogenous APP are not thoroughly understood but are thought to be involved in the stabilizing contact points between synapses and maintaining mitochondrial functions", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2010 Jan;1802(1):11-9. Epub 2009 Jul 18.", "reference": "19619643"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 68, "target": 4, "key": 2}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Apoptosis signaling subgraph"}, "source": 68, "target": 5, "key": 0}, {"relation": "decreases", "evidence": "APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins, such as components of the electron transport chain, impairing mitochondrial function. Intramitochondrial amyloid-beta is able to perturb mitochondrial function in several ways by directly influencing extracellular transport chain complex activities, impairing mitochondrial dynamics, or disturbing calcium storage, thus increasing apoptotic pathways. Moreover, amyloid-beta interacts with mitochondrial matrix components inducing an improper mitochondrial complex function leads to a decreased mitochondrial membrane potential of the organelle and impairing ATP formation.", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 5, "key": 1}, {"relation": "increases", "evidence": "Expression of familial Alzheimer's disease (FAD) mutants of APP in primary neurons causes both intracellular accumulation of the C-terminal beta-secretase cleavage product of APP and increased secretion of Abeta, and eventually results in apoptotic death of the cells.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2001", "reference": "11744168"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 68, "target": 5, "key": 2}, {"relation": "increases", "evidence": "Expression of familial Alzheimer's disease (FAD) mutants of APP in primary neurons causes both intracellular accumulation of the C-terminal beta-secretase cleavage product of APP and increased secretion of Abeta, and eventually results in apoptotic death of the cells.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2001", "reference": "11744168"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 5, "key": 3}, {"relation": "increases", "evidence": "In another study, the authors found that nonglycosylated full-length and C-terminal-truncated APP accumulates in the protein import channels of mitochondria of human AD brains but not in age-matched controls. The accumulation of APP across mitochondrial import channels inhibited the entry of nuclear-encoded cytochrome c-oxidase subunits IV and Vb proteins and was associated with decreased cytochrome oxidase and increased free radical production", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 6, "key": 0}, {"relation": "increases", "evidence": "In another study, the authors found that nonglycosylated full-length and C-terminal-truncated APP accumulates in the protein import channels of mitochondria of human AD brains but not in age-matched controls. The accumulation of APP across mitochondrial import channels inhibited the entry of nuclear-encoded cytochrome c-oxidase subunits IV and Vb proteins and was associated with decreased cytochrome oxidase and increased free radical production", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Electron transport chain"}, "source": 68, "target": 6, "key": 1}, {"relation": "increases", "evidence": "In another study, the authors found that nonglycosylated full-length and C-terminal-truncated APP accumulates in the protein import channels of mitochondria of human AD brains but not in age-matched controls. The accumulation of APP across mitochondrial import channels inhibited the entry of nuclear-encoded cytochrome c-oxidase subunits IV and Vb proteins and was associated with decreased cytochrome oxidase and increased free radical production", "citation": {"type": "PubMed", "name": "J Aging Res. 2012;2012:324968. Epub 2012 Mar 19", "reference": "22523685"}, "annotations": {"CellStructure": "Mitochondria", "Disease": "Alzheimer's disease", "Subgraph": "Reactive oxygen species subgraph"}, "source": 68, "target": 6, "key": 2}, {"relation": "increases", "evidence": "In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. ", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 7, "key": 0}, {"relation": "increases", "evidence": "In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. ", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Gamma secretase subgraph"}, "source": 68, "target": 7, "key": 1}, {"relation": "increases", "evidence": "Overexpression of wild-type APP significantly increased intracellular (45)Ca(2+) content prior to the activation of caspase-3 in NT2-derived neurons.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2002", "reference": "12425945"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 8, "key": 0}, {"relation": "increases", "evidence": "Several lines of evidence have revealed that APP may be involved in cell adhesion, cell migration, and neurite outgrowth ", "citation": {"type": "PubMed", "name": "J Neurosci. 2009 Jun 10;29(23):7459-73.", "reference": "19515914"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 9, "key": 0}, {"relation": "increases", "evidence": "Caille et al. provided evidence that APPsa and APLP2s act as cofactors for epidermal growth factor (EGF) to stimulate the proliferation of neurosphere cultures in vitro and neural stem cells in the subventricular zone of adult rodent brain in vivo (Caille et al. 2004). Gakhar-Koppole et al. (2008) and Rohe et al. (2008) also reported that APPs stimulated neurogenesis and neurite outgrowth, but suggested that it is mediated through enhanced ERK phosphorylation and may be dependent on membrane-bound APP. Han et al. (2005) offered yet a different mechanism that the growth promoting property is mediated by the ability of APPsa to down-regulate CDK5 and inhibit t hyperphosphorylation.", "citation": {"type": "PubMed", "name": "Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006288.", "reference": "22355794"}, "annotations": {"Subgraph": "Cyclin-CDK subgraph"}, "source": 68, "target": 9, "key": 1}, {"relation": "increases", "evidence": "However, normal physiological functions of endogenous APP are not thoroughly understood but are thought to be involved in the stabilizing contact points between synapses and maintaining mitochondrial functions", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2010 Jan;1802(1):11-9. Epub 2009 Jul 18.", "reference": "19619643"}, "annotations": {"Subgraph": "Cell adhesion subgraph"}, "source": 68, "target": 10, "key": 0}, {"relation": "increases", "evidence": "However, normal physiological functions of endogenous APP are not thoroughly understood but are thought to be involved in the stabilizing contact points between synapses and maintaining mitochondrial functions", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2010 Jan;1802(1):11-9. Epub 2009 Jul 18.", "reference": "19619643"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 68, "target": 10, "key": 1}, {"relation": "increases", "evidence": "Expression of familial Alzheimer's disease (FAD) mutants of APP in primary neurons causes both intracellular accumulation of the C-terminal beta-secretase cleavage product of APP and increased secretion of Abeta, and eventually results in apoptotic death of the cells.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2001", "reference": "11744168"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 68, "target": 141, "key": 0}, {"relation": "increases", "evidence": "Expression of familial Alzheimer's disease (FAD) mutants of APP in primary neurons causes both intracellular accumulation of the C-terminal beta-secretase cleavage product of APP and increased secretion of Abeta, and eventually results in apoptotic death of the cells.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2001", "reference": "11744168"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 141, "key": 1}, {"relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 68, "target": 141, "key": 2}, {"relation": "decreases", "evidence": "we observed that APP down regulates expression of four immediate early genes, Egr1, c-Fos, Bdnf and Arc. Down regulation of Egr1, c-Fos and Bdnf transcription resulted from a decreased enrichment of acetylated histone H4 on the corresponding gene promoter in APP-/- mice.", "citation": {"type": "PubMed", "name": "PLoS One. 2014 Jun 11;9(6):e99467. doi: 10.1371/journal.pone.0099467. eCollection 2014.", "reference": "24919190"}, "annotations": {"KnockoutMice": "App transgenic", "Encode_Feature_Types": "Promoter"}, "source": 68, "target": 142, "key": 0}, {"relation": "increases", "evidence": "We have previously reported that overexpression of wild-type amyloid precursor protein (APP) in postmitotic neurons induces cleavage-dependent activation of caspase-3 both in vivo and in vitro.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2002", "reference": "12425945"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Caspase subgraph"}, "source": 68, "target": 143, "key": 0}, {"relation": "increases", "evidence": "Furthermore, calpain, a Ca(2+)-dependent cysteine protease, was activated in neurons overexpressing APP as assessed by increased levels of calpain-cleaved alpha-fodrin and autolytic mu-calpain fragments. ", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2002", "reference": "12425945"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 144, "key": 0}, {"relation": "increases", "evidence": "Furthermore, calpain, a Ca(2+)-dependent cysteine protease, was activated in neurons overexpressing APP as assessed by increased levels of calpain-cleaved alpha-fodrin and autolytic mu-calpain fragments. ", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res2002", "reference": "12425945"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Calpastatin-calpain subgraph"}, "source": 68, "target": 144, "key": 1}, {"relation": "increases", "evidence": " Neurons overexpressing APP or APP(V642I) show increased APP-BP1 protein levels in lipid rafts. ", "citation": {"type": "PubMed", "name": "Journal of cell biology2003", "reference": "14557245"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 145, "key": 0}, {"relation": "increases", "evidence": "The receptor activation assays revealed that apoE as well as beta amyloid activated the CASR and that the level of activation appeared to be isoform dependent for apoE.", "citation": {"type": "PubMed", "name": "American journal of medical genetics. Part B, Neuropsychiatric genetics,2009", "reference": "19035514"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 68, "target": 146, "key": 0}, {"relation": "increases", "evidence": "The receptor activation assays revealed that apoE as well as beta amyloid activated the CASR and that the level of activation appeared to be isoform dependent for apoE.", "citation": {"type": "PubMed", "name": "American journal of medical genetics. Part B, Neuropsychiatric genetics,2009", "reference": "19035514"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 146, "key": 1}, {"relation": "increases", "evidence": "The receptor activation assays revealed that apoE as well as beta amyloid activated the CASR and that the level of activation appeared to be isoform dependent for apoE.", "citation": {"type": "PubMed", "name": "American journal of medical genetics. Part B, Neuropsychiatric genetics,2009", "reference": "19035514"}, "annotations": {"Subgraph": "Calcium-dependent signal transduction"}, "source": 68, "target": 146, "key": 2}, {"relation": "increases", "evidence": "integrins play important roles in neurite development, neuronal migration, and synapse functions. Several studies show that Reelin signaling has an important role in neuronal migration through its interaction with ApoE receptor 2 and the VLDL receptor, and the subsequent phosphorylation of Disabled-1. After removal of anyof these components (Reelin, receptors, or Disabled-1), cortical layer formation is severely disrupted, leading to the model that these interactions are important for laminar organization in development.In synapses, Reelin promotes tyrosine phosphorylation of NMDA receptor subunits (e.g., NR2A) and facilitates LTP. Reelin signaling has an important role in NMDA and AMPA receptor function, maturation of glutamatergic synapses.1 integrin facilitates reorganization of actin filaments and affects neuronal migration and neurite outgrowth. The Reelin-a31 integrin interaction regulates neuronal migration, perhaps by reorganizing the actin cytoskeleton, or by stabilizing the cytoskeleton through n-cofilin phosphorylation. Integrins also regulate synaptic glutamate receptor function, synaptic plasticity, working memory, and LTP. The APP-1 integrin interaction is also important in neurite outgrowth. We suggest that the functions of Reelin and 1 integrins on these processes may be modulated by APP (or other APP family members).", "citation": {"type": "PubMed", "name": "J Neurosci. 2009 Jun 10;29(23):7459-73.", "reference": "19515914"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Synapses", "Subgraph": "Reelin subgraph"}, "source": 68, "target": 147, "key": 0}, {"relation": "increases", "evidence": "integrins play important roles in neurite development, neuronal migration, and synapse functions. Several studies show that Reelin signaling has an important role in neuronal migration through its interaction with ApoE receptor 2 and the VLDL receptor, and the subsequent phosphorylation of Disabled-1. After removal of anyof these components (Reelin, receptors, or Disabled-1), cortical layer formation is severely disrupted, leading to the model that these interactions are important for laminar organization in development.In synapses, Reelin promotes tyrosine phosphorylation of NMDA receptor subunits (e.g., NR2A) and facilitates LTP. Reelin signaling has an important role in NMDA and AMPA receptor function, maturation of glutamatergic synapses.1 integrin facilitates reorganization of actin filaments and affects neuronal migration and neurite outgrowth. The Reelin-a31 integrin interaction regulates neuronal migration, perhaps by reorganizing the actin cytoskeleton, or by stabilizing the cytoskeleton through n-cofilin phosphorylation. Integrins also regulate synaptic glutamate receptor function, synaptic plasticity, working memory, and LTP. The APP-1 integrin interaction is also important in neurite outgrowth. We suggest that the functions of Reelin and 1 integrins on these processes may be modulated by APP (or other APP family members).", "citation": {"type": "PubMed", "name": "J Neurosci. 2009 Jun 10;29(23):7459-73.", "reference": "19515914"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Synapses", "Subgraph": "Glutamatergic subgraph"}, "source": 68, "target": 147, "key": 1}, {"relation": "increases", "evidence": "integrins play important roles in neurite development, neuronal migration, and synapse functions. Several studies show that Reelin signaling has an important role in neuronal migration through its interaction with ApoE receptor 2 and the VLDL receptor, and the subsequent phosphorylation of Disabled-1. After removal of anyof these components (Reelin, receptors, or Disabled-1), cortical layer formation is severely disrupted, leading to the model that these interactions are important for laminar organization in development.In synapses, Reelin promotes tyrosine phosphorylation of NMDA receptor subunits (e.g., NR2A) and facilitates LTP. Reelin signaling has an important role in NMDA and AMPA receptor function, maturation of glutamatergic synapses.1 integrin facilitates reorganization of actin filaments and affects neuronal migration and neurite outgrowth. The Reelin-a31 integrin interaction regulates neuronal migration, perhaps by reorganizing the actin cytoskeleton, or by stabilizing the cytoskeleton through n-cofilin phosphorylation. Integrins also regulate synaptic glutamate receptor function, synaptic plasticity, working memory, and LTP. The APP-1 integrin interaction is also important in neurite outgrowth. We suggest that the functions of Reelin and 1 integrins on these processes may be modulated by APP (or other APP family members).", "citation": {"type": "PubMed", "name": "J Neurosci. 2009 Jun 10;29(23):7459-73.", "reference": "19515914"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Synapses", "Subgraph": "Reelin subgraph"}, "source": 68, "target": 148, "key": 0}, {"relation": "increases", "evidence": "integrins play important roles in neurite development, neuronal migration, and synapse functions. Several studies show that Reelin signaling has an important role in neuronal migration through its interaction with ApoE receptor 2 and the VLDL receptor, and the subsequent phosphorylation of Disabled-1. After removal of anyof these components (Reelin, receptors, or Disabled-1), cortical layer formation is severely disrupted, leading to the model that these interactions are important for laminar organization in development.In synapses, Reelin promotes tyrosine phosphorylation of NMDA receptor subunits (e.g., NR2A) and facilitates LTP. Reelin signaling has an important role in NMDA and AMPA receptor function, maturation of glutamatergic synapses.1 integrin facilitates reorganization of actin filaments and affects neuronal migration and neurite outgrowth. The Reelin-a31 integrin interaction regulates neuronal migration, perhaps by reorganizing the actin cytoskeleton, or by stabilizing the cytoskeleton through n-cofilin phosphorylation. Integrins also regulate synaptic glutamate receptor function, synaptic plasticity, working memory, and LTP. The APP-1 integrin interaction is also important in neurite outgrowth. We suggest that the functions of Reelin and 1 integrins on these processes may be modulated by APP (or other APP family members).", "citation": {"type": "PubMed", "name": "J Neurosci. 2009 Jun 10;29(23):7459-73.", "reference": "19515914"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Synapses", "Subgraph": "Glutamatergic subgraph"}, "source": 68, "target": 148, "key": 1}, {"relation": "increases", "evidence": "Caille et al. provided evidence that APPsa and APLP2s act as cofactors for epidermal growth factor (EGF) to stimulate the proliferation of neurosphere cultures in vitro and neural stem cells in the subventricular zone of adult rodent brain in vivo (Caille et al. 2004). Gakhar-Koppole et al. (2008) and Rohe et al. (2008) also reported that APPs stimulated neurogenesis and neurite outgrowth, but suggested that it is mediated through enhanced ERK phosphorylation and may be dependent on membrane-bound APP. Han et al. (2005) offered yet a different mechanism that the growth promoting property is mediated by the ability of APPsa to down-regulate CDK5 and inhibit t hyperphosphorylation.", "citation": {"type": "PubMed", "name": "Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006288.", "reference": "22355794"}, "annotations": {"Subgraph": "Cyclin-CDK subgraph"}, "source": 68, "target": 149, "key": 0}, {"relation": "increases", "evidence": "Interestingly, we found that APP also affects excitatory synaptic transmission by altering AMPA receptor (AMPAR) and NMDA receptor (NMDAR) trafficking. Recently, we demonstrated that APP increases cell surface levels of the GluA2 (or GluR2) subunit of AMPA receptors (or GluAs), but does not alter levels of GluA1 (or GluR1), suggesting that APP regulates certain AMPAR subunits, specifically GluA2. Considering that alterations in AMPAR subunit expression (particularly in the synaptic content of GluA2-containing AMPARs) can impact synaptic transmission and plasticity, these changes may also potentially alter the function of excitatory synapses. The increase in GluA2 levels is expected to enhance excitatory synaptic transmission, especially because it occurred in the absence of a decrease in GluA1, suggesting an overall increase in AMPAR number at synapses.", "citation": {"type": "PubMed", "name": "CNS Neurosci Ther. 2012 Jan;18(1):47-56. doi: 10.1111/j.1755-5949.2010.00221.x. Epub 2010 Dec 27.", "reference": "21199446"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 68, "target": 150, "key": 0}, {"relation": "increases", "evidence": "These results indicate that the N-terminal domain of APP causes glial differentiation of neural progenitor cells through the activation of Notch signaling by a direct protein-protein interaction.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2011 Jan 10;650(1):18-27. Epub 2010 Sep 29.", "reference": "20883690"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Notch signaling subgraph"}, "source": 68, "target": 151, "key": 0}, {"relation": "increases", "evidence": "These results indicate that the N-terminal domain of APP causes glial differentiation of neural progenitor cells through the activation of Notch signaling by a direct protein-protein interaction.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2011 Jan 10;650(1):18-27. Epub 2010 Sep 29.", "reference": "20883690"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 151, "key": 1}, {"relation": "increases", "evidence": "These results indicate that the N-terminal domain of APP causes glial differentiation of neural progenitor cells through the activation of Notch signaling by a direct protein-protein interaction.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2011 Jan 10;650(1):18-27. Epub 2010 Sep 29.", "reference": "20883690"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Notch signaling subgraph"}, "source": 68, "target": 152, "key": 0}, {"relation": "increases", "evidence": "These results indicate that the N-terminal domain of APP causes glial differentiation of neural progenitor cells through the activation of Notch signaling by a direct protein-protein interaction.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2011 Jan 10;650(1):18-27. Epub 2010 Sep 29.", "reference": "20883690"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 68, "target": 152, "key": 1}, {"relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 68, "target": 153, "key": 0}, {"relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "GSK3 subgraph"}, "source": 68, "target": 154, "key": 0}, {"relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "object": {"modifier": "Activity"}, "annotations": {}, "source": 68, "target": 155, "key": 0}, {"relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "object": {"modifier": "Activity"}, "annotations": {}, "source": 68, "target": 156, "key": 0}, {"relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "object": {"modifier": "Activity"}, "annotations": {}, "source": 68, "target": 156, "key": 1}, {"relation": "decreases", "evidence": "we observed that APP down regulates expression of four immediate early genes, Egr1, c-Fos, Bdnf and Arc. Down regulation of Egr1, c-Fos and Bdnf transcription resulted from a decreased enrichment of acetylated histone H4 on the corresponding gene promoter in APP-/- mice.", "citation": {"type": "PubMed", "name": "PLoS One. 2014 Jun 11;9(6):e99467. doi: 10.1371/journal.pone.0099467. eCollection 2014.", "reference": "24919190"}, "annotations": {"KnockoutMice": "App transgenic", "Encode_Feature_Types": "Promoter"}, "source": 68, "target": 157, "key": 0}, {"relation": "decreases", "evidence": "we observed that APP down regulates expression of four immediate early genes, Egr1, c-Fos, Bdnf and Arc. Down regulation of Egr1, c-Fos and Bdnf transcription resulted from a decreased enrichment of acetylated histone H4 on the corresponding gene promoter in APP-/- mice.", "citation": {"type": "PubMed", "name": "PLoS One. 2014 Jun 11;9(6):e99467. doi: 10.1371/journal.pone.0099467. eCollection 2014.", "reference": "24919190"}, "annotations": {"KnockoutMice": "App transgenic", "Encode_Feature_Types": "Promoter"}, "source": 68, "target": 158, "key": 0}, {"relation": "decreases", "evidence": "MicroRNA-101 downregulates Alzheimer's amyloid- precursor protein levels in human cell cultures and is differentially expressed.Several bioinformatic algorithms predicted miR-101 target sites within the APP 3'-untranslated region (3'-UTR). Using reporter assays, we confirmed that, in human cell cultures, miR-101 significantly reduced the expression of a reporter under control of APP 3'-UTR. Mutation of predicted site 1, but not site 2, eliminated this reporter response. Delivery of miR-101 directly to human HeLa cells significantly reduced APP levels and this effect was eliminated by co-transfection with a miR-101 antisense inhibitor. Delivery of a specific target protector designed to blockade the interaction between miR-101 and its functional target site within APP 3'-UTR enhanced APP levels in HeLa. Therefore, endogenous miR-101 regulates expression of APP in human cells via a specific site located within its 3'-UTR. Finally, we demonstrate that, across a series of human cell lines, highest expression of miR-101 levels was observed in model NT2 neurons.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 2011 Jan 28;404(4):889-95. doi: 10.1016/j.bbrc.2010.12.053. Epub 2010 Dec 21.", "reference": "21172309"}, "annotations": {"Subgraph": "miRNA subgraph"}, "source": 69, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "MicroRNA-101 downregulates Alzheimer's amyloid- precursor protein levels in human cell cultures and is differentially expressed.Several bioinformatic algorithms predicted miR-101 target sites within the APP 3'-untranslated region (3'-UTR). Using reporter assays, we confirmed that, in human cell cultures, miR-101 significantly reduced the expression of a reporter under control of APP 3'-UTR. Mutation of predicted site 1, but not site 2, eliminated this reporter response. Delivery of miR-101 directly to human HeLa cells significantly reduced APP levels and this effect was eliminated by co-transfection with a miR-101 antisense inhibitor. Delivery of a specific target protector designed to blockade the interaction between miR-101 and its functional target site within APP 3'-UTR enhanced APP levels in HeLa. Therefore, endogenous miR-101 regulates expression of APP in human cells via a specific site located within its 3'-UTR. Finally, we demonstrate that, across a series of human cell lines, highest expression of miR-101 levels was observed in model NT2 neurons.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 2011 Jan 28;404(4):889-95. doi: 10.1016/j.bbrc.2010.12.053. Epub 2010 Dec 21.", "reference": "21172309"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 69, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "we observed that APP down regulates expression of four immediate early genes, Egr1, c-Fos, Bdnf and Arc. Down regulation of Egr1, c-Fos and Bdnf transcription resulted from a decreased enrichment of acetylated histone H4 on the corresponding gene promoter in APP-/- mice.", "citation": {"type": "PubMed", "name": "PLoS One. 2014 Jun 11;9(6):e99467. doi: 10.1371/journal.pone.0099467. eCollection 2014.", "reference": "24919190"}, "annotations": {"KnockoutMice": "App transgenic", "Encode_Feature_Types": "Promoter"}, "source": 69, "target": 68, "key": 2}, {"relation": "increases", "evidence": "We confirmed that higher initial disease severity (higher ADAS-Cog scores) and the increase in the con-centration of plasma Abeta(1-42) peptide following 2 weeks of treatment with an initial dose of rivastigmine", "citation": {"type": "PubMed", "name": "Neurol Neurochir Pol. 2009 Nov-Dec;43(6):507-16", "reference": "20054753"}, "annotations": {"Species": "10116", "FluidAndSecretion": "Plasma", "Subgraph": "Amyloidogenic subgraph"}, "source": 70, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Over the last several years a number of reports have emerged suggesting that at least some ChEI might take part in betaAPP metabolism, influencing its secretion and Abeta differential cleavage. Moreover, we (Sob6w and Kloszewska 2005) and others (Basun et al. 2002, Zimmermann et al. 2005) have shown that the treatment with ChEI might influence BAPP metabolism in AD patients as measured by changes in plasma (including platelet-derived) metabolites. In our previous pilot study we have demonstrated that short-term treatment with  ChEI  rivastigmine exhibits a significant effect on plasma concentrations of Abeta-42 (mean increase after treatment reached 7.8  8.4 pg/ml) with a negative correlation to patients age, while no changes  in  Abeta-40 levels  were  detected.", "citation": {"type": "PubMed", "name": "Acta Neurobiol Exp (Wars). 2007;67(2):131-9", "reference": "17691220"}, "annotations": {"Species": "10116", "Subgraph": "Amyloidogenic subgraph", "FluidAndSecretion": "Plasma"}, "source": 70, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Furthermore, Meserine (7.5 mg/kg) injected intraperitoneally once daily for 3 weeks lowered APP level by 28% and A42 level by 42% in APP/PS1 transgenic mouse cerebrum. And both APP and A42 lowering action of Meserine maintained longer than that of rivastigmin", "citation": {"type": "PubMed", "name": "CNS Neurosci Ther. 2014 Feb;20(2):165-71", "reference": "24279603"}, "annotations": {"Species": "10116", "NervousSystem": "Cerebrum", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 70, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Rivastigmine treatment induced an elevation in both metabolic activity and APP secretion, and differentially impacted two isoforms of sAPP. In our cultures, low molecular weight sAPP corresponded closely to neuronal viability, and high molecular weight sAPP corresponded with glial proliferation. Our results suggest that within the mixed culture system used, neurons are the primary source of sAPP, and rivastigmine's actions are mediated principally through neuronal, rather than glial, targets. Importantly, rivastigmine was found to increase the neurotrophic sAPP and decrease A secretion, suggesting a mechanism for the previously observed neuropreservation effects.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(7):e21954. doi: 10.1371/journal.pone.0021954. Epub 2011 Jul 22", "reference": "21799757"}, "annotations": {"Species": "10116", "NervousSystem": "Brain", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 70, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.", "citation": {"type": "Online Resource", "name": "AD_HBP", "reference": "DB00989"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 70, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.", "citation": {"type": "Online Resource", "name": "AD_HBP", "reference": "DB00989"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 70, "target": 34, "key": 0}, {"relation": "increases", "evidence": "Rivastigmine tartrate is a reversible cholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate dementia. Rivastigmine has been shown to improve or maintain patients' performance in 3 major domains: cognitive function, global function (ADLs), and behavior.", "citation": {"type": "PubMed", "name": "Clin Ther. 2003 Jun;25(6):1634-53", "reference": "12860489"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 70, "target": 44, "key": 0}, {"relation": "increases", "evidence": "Over the last several years a number of reports have emerged suggesting that at least some ChEI might take part in betaAPP metabolism, influencing its secretion and Abeta differential cleavage. Moreover, we (Sob6w and Kloszewska 2005) and others (Basun et al. 2002, Zimmermann et al. 2005) have shown that the treatment with ChEI might influence BAPP metabolism in AD patients as measured by changes in plasma (including platelet-derived) metabolites. In our previous pilot study we have demonstrated that short-term treatment with  ChEI  rivastigmine exhibits a significant effect on plasma concentrations of Abeta-42 (mean increase after treatment reached 7.8  8.4 pg/ml) with a negative correlation to patients age, while no changes  in  Abeta-40 levels  were  detected.", "citation": {"type": "PubMed", "name": "Acta Neurobiol Exp (Wars). 2007;67(2):131-9", "reference": "17691220"}, "annotations": {"Species": "10116", "Subgraph": "Amyloidogenic subgraph"}, "source": 70, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "Furthermore, Meserine (7.5 mg/kg) injected intraperitoneally once daily for 3 weeks lowered APP level by 28% and A42 level by 42% in APP/PS1 transgenic mouse cerebrum. And both APP and A42 lowering action of Meserine maintained longer than that of rivastigmin", "citation": {"type": "PubMed", "name": "CNS Neurosci Ther. 2014 Feb;20(2):165-71", "reference": "24279603"}, "annotations": {"Species": "10116", "NervousSystem": "Cerebrum", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 70, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Rivastigmine treatment induced an elevation in both metabolic activity and APP secretion, and differentially impacted two isoforms of sAPP. In our cultures, low molecular weight sAPP corresponded closely to neuronal viability, and high molecular weight sAPP corresponded with glial proliferation. Our results suggest that within the mixed culture system used, neurons are the primary source of sAPP, and rivastigmine's actions are mediated principally through neuronal, rather than glial, targets. Importantly, rivastigmine was found to increase the neurotrophic sAPP and decrease A secretion, suggesting a mechanism for the previously observed neuropreservation effects.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(7):e21954. doi: 10.1371/journal.pone.0021954. Epub 2011 Jul 22", "reference": "21799757"}, "annotations": {"Species": "10116", "NervousSystem": "Brain", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 70, "target": 68, "key": 2}, {"relation": "decreases", "evidence": "Rivastigmine decreased the reactivity of encephalitogenic T-cells and the production of pro-inflammatory cytokines (TNF-, IFN- and IL-17) without affecting IL-10 production.", "citation": {"type": "PubMed", "name": "J Neuroimmunol. 2008 Oct 15;203(1):12-22", "reference": "18692909"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 70, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "The moderating effect of rivastigmine on the endotoxin-induced suppression of GnRH/LH secretion may result from the inhibition of pro-inflammatory cytokines released through the cholinergic anti-inflammatory pathway. AChE inhibitors lead to an increase in the concentration of ACh and activate the cholinergic anti-inflammatory pathway (Borovikova et al., 2000). These inhibitors attenuate the cytokine release, including that of IL-1, IL-6 and TNF, which have been previously described both in vitro and in vivo ( Borovikova et al., 2000 and Pollak et al., 2005). The ability of rivastigmine to reduce the inflammatory action within the brain could have a profound effect on GnRH secretion, as numerous studies have reported that centrally acting pro-inflammatory cytokines, especially IL-1 but also IL-1 and TNF, may be primarily responsible for the inhibition of GnRH/LH secretion", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 70, "target": 140, "key": 1}, {"relation": "increases", "evidence": "These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.", "citation": {"type": "PubMed", "name": "Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.", "reference": "19394434"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Chemokine signaling subgraph"}, "source": 71, "target": 11, "key": 0}, {"relation": "increases", "evidence": "These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.", "citation": {"type": "PubMed", "name": "Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.", "reference": "19394434"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 71, "target": 11, "key": 1}, {"relation": "increases", "evidence": "-Amyloid (A) plays a central role in Alzheimer's disease (AD) pathogenesis. Neurons are major sources of A in the brain. However, astrocytes outnumber neurons by at least five-fold. Thus, even a small level of astrocytic A production could make a significant contribution to A burden in AD. Moreover, activated astrocytes may increase A generation. -Site APP cleaving enzyme 1 (BACE1) cleavage of amyloid precursor protein (APP) initiates A production.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2011 Nov 2;8:150.", "reference": "22047170"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Beta secretase subgraph"}, "source": 71, "target": 11, "key": 2}, {"relation": "increases", "evidence": "-Amyloid (A) plays a central role in Alzheimer's disease (AD) pathogenesis. Neurons are major sources of A in the brain. However, astrocytes outnumber neurons by at least five-fold. Thus, even a small level of astrocytic A production could make a significant contribution to A burden in AD. Moreover, activated astrocytes may increase A generation. -Site APP cleaving enzyme 1 (BACE1) cleavage of amyloid precursor protein (APP) initiates A production.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2011 Nov 2;8:150.", "reference": "22047170"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 71, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "We conclude that astrocytes: (i) strongly regulate neuronal APP expression in primary neurons, and (ii) promote the amyloidogenic pathway in an apoE4-dependent manner. Thus, apoE and astrocytic factor(s) may pmodulate the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Eur J Neurosci2001", "reference": "11553277"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 71, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Cholesterol may also be directly involved in -amyloid aggregation: abnormal oxidative metabolites such as cholesterol-derived aldehydes can modify -amyloid, firstly promoting Schiff bas formation, then accelerating the early stages of amyloidogenesis.", "citation": {"type": "PubMed", "name": "Curr Pharm Des. 2011;17(4):347-56.", "reference": "21352095"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 72, "target": 11, "key": 6}, {"relation": "increases", "evidence": "Cholesterol may also be directly involved in -amyloid aggregation: abnormal oxidative metabolites such as cholesterol-derived aldehydes can modify -amyloid, firstly promoting Schiff bas formation, then accelerating the early stages of amyloidogenesis.", "citation": {"type": "PubMed", "name": "Curr Pharm Des. 2011;17(4):347-56.", "reference": "21352095"}, "annotations": {"Subgraph": "Cholesterol metabolism subgraph"}, "source": 72, "target": 11, "key": 7}, {"relation": "increases", "evidence": "Cholesterol transport: High cholesterol levels have been linked to overproduction of A and are a risk factor for AD. One of the physiological functions of A has been suggested to control cholesterol transport [167]. Prevalence of AD is reduced among people treated with inhibitors of cholesterol biosynthesis, statins [168, 169] and animal studies support these results [170]. In vitro and in vivo studies have shown that cholesterol modulates APP processing and affects APP mRNA expression [171]. Another mechanism is the increased binding of A to ApoE4 over non-E4 alleles. ApoE is a lipid and cholesterol transport protein responsible for the efflux of cholesterol from neurons to form stable complexes both in vitro and in vivo [172]. Allele ApoE4 is a major risk factor in AD [173]. This relationship might promote synaptogenesis, since in vitro studies have demonstrated that cholesterol released by astroglia increases synaptogenesis [174, 175] with resulting modulation of spike rates [176]. Together, this evidence indicates that one of the physiological functions of APP might be to control cholesterol movement across neuronal membranes [167].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 72, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Cholesterol transport: High cholesterol levels have been linked to overproduction of A and are a risk factor for AD. One of the physiological functions of A has been suggested to control cholesterol transport [167]. Prevalence of AD is reduced among people treated with inhibitors of cholesterol biosynthesis, statins [168, 169] and animal studies support these results [170]. In vitro and in vivo studies have shown that cholesterol modulates APP processing and affects APP mRNA expression [171]. Another mechanism is the increased binding of A to ApoE4 over non-E4 alleles. ApoE is a lipid and cholesterol transport protein responsible for the efflux of cholesterol from neurons to form stable complexes both in vitro and in vivo [172]. Allele ApoE4 is a major risk factor in AD [173]. This relationship might promote synaptogenesis, since in vitro studies have demonstrated that cholesterol released by astroglia increases synaptogenesis [174, 175] with resulting modulation of spike rates [176]. Together, this evidence indicates that one of the physiological functions of APP might be to control cholesterol movement across neuronal membranes [167].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 72, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Cholesterol transport: High cholesterol levels have been linked to overproduction of A and are a risk factor for AD. One of the physiological functions of A has been suggested to control cholesterol transport [167]. Prevalence of AD is reduced among people treated with inhibitors of cholesterol biosynthesis, statins [168, 169] and animal studies support these results [170]. In vitro and in vivo studies have shown that cholesterol modulates APP processing and affects APP mRNA expression [171]. Another mechanism is the increased binding of A to ApoE4 over non-E4 alleles. ApoE is a lipid and cholesterol transport protein responsible for the efflux of cholesterol from neurons to form stable complexes both in vitro and in vivo [172]. Allele ApoE4 is a major risk factor in AD [173]. This relationship might promote synaptogenesis, since in vitro studies have demonstrated that cholesterol released by astroglia increases synaptogenesis [174, 175] with resulting modulation of spike rates [176]. Together, this evidence indicates that one of the physiological functions of APP might be to control cholesterol movement across neuronal membranes [167].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Cholesterol metabolism subgraph"}, "source": 72, "target": 68, "key": 2}, {"relation": "increases", "evidence": "Donepezil (Aricept), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimers disease where it is used to increase cortical acetylcholine. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function.Evidence suggests that the anticholinesterase activity of donepezil is relatively specific for acetylcholinesterase in the brain.", "citation": {"type": "Online Resource", "name": "AD_HBP", "reference": "DB00843"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 34, "key": 0}, {"relation": "increases", "evidence": "Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed short term trials (14 to 30 weeks) in 161 to 818 patients with mild to moderate Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Br J Clin Pharmacol. 2008 Apr;65(4):472-9", "reference": "18070217"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph", "Species": "9606"}, "source": 73, "target": 44, "key": 0}, {"relation": "increases", "evidence": "The donepezil group demonstrated a greater likelihood of increases in both non-declarative and declarative processes.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2007 Jul;4(3):273-6", "reference": "17627484"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph", "Species": "9606"}, "source": 73, "target": 46, "key": 0}, {"relation": "increases", "evidence": "donepezil results in increased abundance of APP protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18061284"}, "annotations": {}, "source": 73, "target": 68, "key": 0}, {"relation": "increases", "evidence": "donepezil results in increased abundance of APP protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18571635"}, "annotations": {}, "source": 73, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 238, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 239, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 240, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 241, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 242, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 243, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 244, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 245, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 246, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 247, "key": 0}, {"relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against A42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3 and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3 activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 73, "target": 248, "key": 0}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 74, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Chemokine signaling subgraph"}, "source": 74, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Interleukin signaling subgraph"}, "source": 74, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Cognitive decline in Alzheimer's disease (AD) occurs as a result of the buildup of pathological proteins and downstream events including an elevated and altered inflammatory response. Inflammation has previously been linked to increased abnormal phosphorylation of tau protein.To determine if endogenous amyloid-beta (Abeta)-induced neuroinflammation drives tau phosphorylation in vivo, we treated 8-month-old 3xTg-AD with minocycline, an anti-inflammatory agent, to assess how it influenced cognitive decline and development of pathology. 4 months of treatment restored cognition to non-transgenic performance. Inflammatory profiling revealed a marked decrease in GFAP, TNFalpha, and IL6 and an increase in the CXCL1 chemokines KC and MIP1a. Minocycline also reduced levels of insoluble Abeta and soluble fibrils. Despite reducing levels of the tau kinase cdk5 coactivator p25, minocycline did not have wide effects on tau pathology with only one phospho-epitope showing reduction with treatment (S212/S214). The sum of these findings shows that reduction of the inflammatory events in an AD mouse model prevents cognitive deficits associated with pathology, but that endogenous Abeta-derived neuroinflammation does not contribute significantly to the development of tau pathology.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;21(2):527-42", "reference": "20555131"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 74, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Minocycline inhibits the reaction [APP gene mutant form results in increased phosphorylation of EIF2S1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17406652"}, "annotations": {}, "source": 74, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "Minocycline inhibits the reaction [APP gene mutant form results in increased phosphorylation of EIF2S1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17406652"}, "annotations": {}, "source": 74, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19285099"}, "annotations": {}, "source": 74, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14588118"}, "annotations": {}, "source": 74, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15485488"}, "annotations": {}, "source": 74, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18836210"}, "annotations": {}, "source": 74, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22138609"}, "annotations": {}, "source": 75, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16162502"}, "annotations": {}, "source": 75, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16212921"}, "annotations": {}, "source": 75, "target": 68, "key": 2}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17597573"}, "annotations": {}, "source": 75, "target": 68, "key": 3}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20080969"}, "annotations": {}, "source": 75, "target": 68, "key": 4}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16162502"}, "annotations": {}, "source": 75, "target": 68, "key": 5}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20080969"}, "annotations": {}, "source": 75, "target": 68, "key": 6}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22118570"}, "annotations": {}, "source": 75, "target": 68, "key": 7}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15134381"}, "annotations": {}, "source": 75, "target": 68, "key": 8}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16183991"}, "annotations": {}, "source": 75, "target": 68, "key": 9}, {"relation": "decreases", "evidence": "(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16685418"}, "annotations": {}, "source": 75, "target": 68, "key": 10}, {"relation": "decreases", "evidence": "resveratrol results in decreased expression of PSEN2 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11606380"}, "annotations": {"Species": "9606"}, "source": 75, "target": 91, "key": 0}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10910059"}, "annotations": {}, "source": 75, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12716675"}, "annotations": {}, "source": 75, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15135313"}, "annotations": {}, "source": 75, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17988825"}, "annotations": {}, "source": 75, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18291098"}, "annotations": {}, "source": 75, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18549505"}, "annotations": {}, "source": 75, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19478208"}, "annotations": {}, "source": 75, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20418481"}, "annotations": {}, "source": 75, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20527891"}, "annotations": {}, "source": 75, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20943792"}, "annotations": {}, "source": 75, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21612158"}, "annotations": {}, "source": 75, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22197494"}, "annotations": {}, "source": 75, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22199285"}, "annotations": {}, "source": 75, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22447223"}, "annotations": {}, "source": 75, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16150460"}, "annotations": {}, "source": 75, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20978231"}, "annotations": {}, "source": 75, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10843709"}, "annotations": {}, "source": 75, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12208745"}, "annotations": {}, "source": 75, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12615669"}, "annotations": {}, "source": 75, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12716675"}, "annotations": {}, "source": 75, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12871381"}, "annotations": {}, "source": 75, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15135313"}, "annotations": {}, "source": 75, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15489888"}, "annotations": {}, "source": 75, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15779068"}, "annotations": {}, "source": 75, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16154495"}, "annotations": {}, "source": 75, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16317118"}, "annotations": {}, "source": 75, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16338976"}, "annotations": {}, "source": 75, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16614140"}, "annotations": {}, "source": 75, "target": 140, "key": 27}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16973825"}, "annotations": {}, "source": 75, "target": 140, "key": 28}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17055343"}, "annotations": {}, "source": 75, "target": 140, "key": 29}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17586618"}, "annotations": {}, "source": 75, "target": 140, "key": 30}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17929310"}, "annotations": {}, "source": 75, "target": 140, "key": 31}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17938187"}, "annotations": {}, "source": 75, "target": 140, "key": 32}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17984121"}, "annotations": {}, "source": 75, "target": 140, "key": 33}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18222423"}, "annotations": {}, "source": 75, "target": 140, "key": 34}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19284563"}, "annotations": {}, "source": 75, "target": 140, "key": 35}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19346296"}, "annotations": {}, "source": 75, "target": 140, "key": 36}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19416633"}, "annotations": {}, "source": 75, "target": 140, "key": 37}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549798"}, "annotations": {}, "source": 75, "target": 140, "key": 38}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20801891"}, "annotations": {}, "source": 75, "target": 140, "key": 39}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20844277"}, "annotations": {}, "source": 75, "target": 140, "key": 40}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20978007"}, "annotations": {}, "source": 75, "target": 140, "key": 41}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21211511"}, "annotations": {}, "source": 75, "target": 140, "key": 42}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21756928"}, "annotations": {}, "source": 75, "target": 140, "key": 43}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22254182"}, "annotations": {}, "source": 75, "target": 140, "key": 44}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22414048"}, "annotations": {}, "source": 75, "target": 140, "key": 45}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22493042"}, "annotations": {}, "source": 75, "target": 140, "key": 46}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9846848"}, "annotations": {}, "source": 75, "target": 140, "key": 47}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9974427"}, "annotations": {}, "source": 75, "target": 140, "key": 48}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10086329"}, "annotations": {}, "source": 75, "target": 140, "key": 49}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15589480"}, "annotations": {}, "source": 75, "target": 140, "key": 50}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15652768"}, "annotations": {}, "source": 75, "target": 140, "key": 51}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15985724"}, "annotations": {}, "source": 75, "target": 140, "key": 52}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17690738"}, "annotations": {}, "source": 75, "target": 140, "key": 53}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17872969"}, "annotations": {}, "source": 75, "target": 140, "key": 54}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17938187"}, "annotations": {}, "source": 75, "target": 140, "key": 55}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17967414"}, "annotations": {}, "source": 75, "target": 140, "key": 56}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18549505"}, "annotations": {}, "source": 75, "target": 140, "key": 57}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19014921"}, "annotations": {}, "source": 75, "target": 140, "key": 58}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19284563"}, "annotations": {}, "source": 75, "target": 140, "key": 59}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19346296"}, "annotations": {}, "source": 75, "target": 140, "key": 60}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19478208"}, "annotations": {}, "source": 75, "target": 140, "key": 61}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19689081"}, "annotations": {}, "source": 75, "target": 140, "key": 62}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19940103"}, "annotations": {}, "source": 75, "target": 140, "key": 63}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20132809"}, "annotations": {}, "source": 75, "target": 140, "key": 64}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20188786"}, "annotations": {}, "source": 75, "target": 140, "key": 65}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20675566"}, "annotations": {}, "source": 75, "target": 140, "key": 66}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20712904"}, "annotations": {}, "source": 75, "target": 140, "key": 67}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20730501"}, "annotations": {}, "source": 75, "target": 140, "key": 68}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21086752"}, "annotations": {}, "source": 75, "target": 140, "key": 69}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21530968"}, "annotations": {}, "source": 75, "target": 140, "key": 70}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21736731"}, "annotations": {}, "source": 75, "target": 140, "key": 71}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21807089"}, "annotations": {}, "source": 75, "target": 140, "key": 72}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22025971"}, "annotations": {}, "source": 75, "target": 140, "key": 73}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22069489"}, "annotations": {}, "source": 75, "target": 140, "key": 74}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22118570"}, "annotations": {}, "source": 75, "target": 140, "key": 75}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22363816"}, "annotations": {}, "source": 75, "target": 140, "key": 76}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22698256"}, "annotations": {}, "source": 75, "target": 140, "key": 77}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22952890"}, "annotations": {}, "source": 75, "target": 140, "key": 78}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11376495"}, "annotations": {}, "source": 75, "target": 140, "key": 79}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15589480"}, "annotations": {}, "source": 75, "target": 140, "key": 80}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15734790"}, "annotations": {}, "source": 75, "target": 140, "key": 81}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15971681"}, "annotations": {}, "source": 75, "target": 140, "key": 82}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16178859"}, "annotations": {}, "source": 75, "target": 140, "key": 83}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16366677"}, "annotations": {}, "source": 75, "target": 140, "key": 84}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16389574"}, "annotations": {}, "source": 75, "target": 140, "key": 85}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16474422"}, "annotations": {}, "source": 75, "target": 140, "key": 86}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16614140"}, "annotations": {}, "source": 75, "target": 140, "key": 87}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16971220"}, "annotations": {}, "source": 75, "target": 140, "key": 88}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17035056"}, "annotations": {}, "source": 75, "target": 140, "key": 89}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17041012"}, "annotations": {}, "source": 75, "target": 140, "key": 90}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17481685"}, "annotations": {}, "source": 75, "target": 140, "key": 91}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18424637"}, "annotations": {}, "source": 75, "target": 140, "key": 92}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18513711"}, "annotations": {}, "source": 75, "target": 140, "key": 93}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18940189"}, "annotations": {}, "source": 75, "target": 140, "key": 94}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20036306"}, "annotations": {}, "source": 75, "target": 140, "key": 95}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20211601"}, "annotations": {}, "source": 75, "target": 140, "key": 96}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20307516"}, "annotations": {}, "source": 75, "target": 140, "key": 97}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20422370"}, "annotations": {}, "source": 75, "target": 140, "key": 98}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20816014"}, "annotations": {}, "source": 75, "target": 140, "key": 99}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21111721"}, "annotations": {}, "source": 75, "target": 140, "key": 100}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21192278"}, "annotations": {}, "source": 75, "target": 140, "key": 101}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21439372"}, "annotations": {}, "source": 75, "target": 140, "key": 102}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21962734"}, "annotations": {}, "source": 75, "target": 140, "key": 103}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22213337"}, "annotations": {}, "source": 75, "target": 140, "key": 104}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22246136"}, "annotations": {}, "source": 75, "target": 140, "key": 105}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22713680"}, "annotations": {}, "source": 75, "target": 140, "key": 106}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9581680"}, "annotations": {}, "source": 75, "target": 140, "key": 107}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12690110"}, "annotations": {}, "source": 75, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15308739"}, "annotations": {}, "source": 75, "target": 195, "key": 1}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22197494"}, "annotations": {}, "source": 75, "target": 195, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12482581"}, "annotations": {}, "source": 75, "target": 195, "key": 3}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12690110"}, "annotations": {}, "source": 75, "target": 195, "key": 4}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12706485"}, "annotations": {}, "source": 75, "target": 195, "key": 5}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20878097"}, "annotations": {}, "source": 75, "target": 195, "key": 6}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21205742"}, "annotations": {}, "source": 75, "target": 195, "key": 7}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16081268"}, "annotations": {}, "source": 75, "target": 195, "key": 8}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21736731"}, "annotations": {}, "source": 75, "target": 195, "key": 9}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16280599"}, "annotations": {}, "source": 75, "target": 195, "key": 10}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21736731"}, "annotations": {}, "source": 75, "target": 195, "key": 11}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21852083"}, "annotations": {}, "source": 75, "target": 195, "key": 12}, {"relation": "increases", "evidence": "resveratrol results in increased expression of CHRNA4 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12569576"}, "annotations": {"Species": "9606"}, "source": 75, "target": 238, "key": 0}, {"relation": "increases", "evidence": "rosiglitazone promotes the reaction [LRP1 protein results in increased uptake of APP protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22040807"}, "annotations": {}, "source": 76, "target": 68, "key": 0}, {"relation": "increases", "evidence": "rosiglitazone promotes the reaction [LRP1 protein results in increased uptake of APP protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19621015"}, "annotations": {}, "source": 76, "target": 68, "key": 1}, {"relation": "increases", "evidence": "rosiglitazone promotes the reaction [LRP1 protein results in increased uptake of APP protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20336061"}, "annotations": {}, "source": 76, "target": 68, "key": 2}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12584205"}, "annotations": {}, "source": 76, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19201691"}, "annotations": {}, "source": 76, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19451898"}, "annotations": {}, "source": 76, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21484566"}, "annotations": {}, "source": 76, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21798687"}, "annotations": {}, "source": 76, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12670479"}, "annotations": {}, "source": 76, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17639046"}, "annotations": {}, "source": 76, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18093596"}, "annotations": {}, "source": 76, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18819888"}, "annotations": {}, "source": 76, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20003221"}, "annotations": {}, "source": 76, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22321707"}, "annotations": {}, "source": 76, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12566086"}, "annotations": {}, "source": 76, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15865214"}, "annotations": {}, "source": 76, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19139408"}, "annotations": {}, "source": 76, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19417127"}, "annotations": {}, "source": 76, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22173916"}, "annotations": {}, "source": 76, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15665514"}, "annotations": {}, "source": 76, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16539667"}, "annotations": {}, "source": 76, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16865780"}, "annotations": {}, "source": 76, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18455351"}, "annotations": {}, "source": 76, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19237016"}, "annotations": {}, "source": 76, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19356226"}, "annotations": {}, "source": 76, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19451898"}, "annotations": {}, "source": 76, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19464576"}, "annotations": {}, "source": 76, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19563079"}, "annotations": {}, "source": 76, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20965162"}, "annotations": {}, "source": 76, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21893696"}, "annotations": {}, "source": 76, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22842585"}, "annotations": {}, "source": 76, "target": 140, "key": 27}, {"relation": "decreases", "evidence": "2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [lipopolysaccharide, Escherichia coli 0111 B4 results in increased expression of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19474210"}, "annotations": {}, "source": 76, "target": 140, "key": 28}, {"relation": "decreases", "evidence": "rosiglitazone inhibits the reaction [Bleomycin results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19147827"}, "annotations": {}, "source": 76, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "rosiglitazone inhibits the reaction [Bleomycin results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17394460"}, "annotations": {}, "source": 76, "target": 195, "key": 1}, {"relation": "decreases", "evidence": "rosiglitazone inhibits the reaction [Bleomycin results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21515302"}, "annotations": {}, "source": 76, "target": 195, "key": 2}, {"relation": "decreases", "evidence": "2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [rosiglitazone results in decreased expression of CHRNA4 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19139119"}, "annotations": {"Species": "9606"}, "source": 76, "target": 238, "key": 0}, {"relation": "decreases", "evidence": "oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19944163"}, "annotations": {"Species": "9606"}, "source": 77, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17241114"}, "annotations": {"Species": "9606"}, "source": 77, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10946302"}, "annotations": {}, "source": 77, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12117737"}, "annotations": {}, "source": 77, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12615677"}, "annotations": {}, "source": 77, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12753293"}, "annotations": {}, "source": 77, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15234187"}, "annotations": {}, "source": 77, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15537504"}, "annotations": {}, "source": 77, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16321392"}, "annotations": {}, "source": 77, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16387846"}, "annotations": {}, "source": 77, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16443229"}, "annotations": {}, "source": 77, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16511915"}, "annotations": {}, "source": 77, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16740276"}, "annotations": {}, "source": 77, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17075836"}, "annotations": {}, "source": 77, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17277159"}, "annotations": {}, "source": 77, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17560598"}, "annotations": {}, "source": 77, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17901590"}, "annotations": {}, "source": 77, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20191585"}, "annotations": {}, "source": 77, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20863785"}, "annotations": {}, "source": 77, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21910007"}, "annotations": {}, "source": 77, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15187114"}, "annotations": {}, "source": 77, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17169357"}, "annotations": {}, "source": 77, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17178392"}, "annotations": {}, "source": 77, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17729120"}, "annotations": {}, "source": 77, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18310456"}, "annotations": {}, "source": 77, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18504409"}, "annotations": {}, "source": 77, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19080365"}, "annotations": {}, "source": 77, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21925249"}, "annotations": {}, "source": 77, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12829860"}, "annotations": {}, "source": 77, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12963647"}, "annotations": {}, "source": 77, "target": 140, "key": 27}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15705589"}, "annotations": {}, "source": 77, "target": 140, "key": 28}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15883752"}, "annotations": {}, "source": 77, "target": 140, "key": 29}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18047562"}, "annotations": {}, "source": 77, "target": 140, "key": 30}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19001041"}, "annotations": {}, "source": 77, "target": 140, "key": 31}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19024099"}, "annotations": {}, "source": 77, "target": 140, "key": 32}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19166837"}, "annotations": {}, "source": 77, "target": 140, "key": 33}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20126887"}, "annotations": {}, "source": 77, "target": 140, "key": 34}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20359552"}, "annotations": {}, "source": 77, "target": 140, "key": 35}, {"relation": "decreases", "evidence": "geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22305382"}, "annotations": {}, "source": 77, "target": 140, "key": 36}, {"relation": "increases", "evidence": "The present study examines the efficacy of Saxagliptin, a DPP-4 inhibitor in a streptozotocin (STZ) induced rat model of AD. Three months following induction of AD by intracerebral administration of streptozotocin, animals were orally administered Saxagliptin (0.25, 0.5 and 1 mg/kg) for 60 days. The effect of the DPP-4 inhibitor on hippocampal GLP-1 levels, A burden, tau phosphorylation, inflammatory markers and memory retention were evaluated. The results reveal an attenuation of A, tau phosphorylation and inflammatory markers and an improvement in hippocampal GLP-1 and memory retention following treatment.", "citation": {"type": "PubMed", "name": "Neuropharmacology. 2013 Sep;72:291-300. doi: 10.1016/j.neuropharm.2013.04.008. Epub 2013 Apr 17.", "reference": "23603201"}, "annotations": {"Species": "10116"}, "source": 78, "target": 33, "key": 0}, {"relation": "increases", "evidence": "The rat model of Alzheimer's disease used in the present study was induced by the intracerebroventricular (ICV) injection of streptozotocin (STZ) using a stereotaxic instrument.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2008 Oct 10;443(3):188-92", "reference": "18687381"}, "annotations": {}, "source": 78, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Streptozocin results in increased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21069392"}, "annotations": {}, "source": 78, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Streptozocin results in increased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21290839"}, "annotations": {}, "source": 78, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20446767"}, "annotations": {}, "source": 78, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11357882"}, "annotations": {}, "source": 78, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15862027"}, "annotations": {}, "source": 78, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15892581"}, "annotations": {}, "source": 78, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18789669"}, "annotations": {}, "source": 78, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20446767"}, "annotations": {}, "source": 78, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12123627"}, "annotations": {}, "source": 78, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15309289"}, "annotations": {}, "source": 78, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15862027"}, "annotations": {}, "source": 78, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15975818"}, "annotations": {}, "source": 78, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16129698"}, "annotations": {}, "source": 78, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16336586"}, "annotations": {}, "source": 78, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17167242"}, "annotations": {}, "source": 78, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17589825"}, "annotations": {}, "source": 78, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17854708"}, "annotations": {}, "source": 78, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18999900"}, "annotations": {}, "source": 78, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19133311"}, "annotations": {}, "source": 78, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19279317"}, "annotations": {}, "source": 78, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19682444"}, "annotations": {}, "source": 78, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20053369"}, "annotations": {}, "source": 78, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20223228"}, "annotations": {}, "source": 78, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20307516"}, "annotations": {}, "source": 78, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20643114"}, "annotations": {}, "source": 78, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20665664"}, "annotations": {}, "source": 78, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21439372"}, "annotations": {}, "source": 78, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21457706"}, "annotations": {}, "source": 78, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "PRDX4 protein inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21912612"}, "annotations": {}, "source": 78, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "Ethanol inhibits the reaction [Streptozocin results in increased expression of PRKCA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12198386"}, "annotations": {}, "source": 78, "target": 253, "key": 0}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223066"}, "annotations": {}, "source": 79, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19244175"}, "annotations": {}, "source": 79, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12039845"}, "annotations": {}, "source": 79, "target": 68, "key": 2}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12117551"}, "annotations": {}, "source": 79, "target": 68, "key": 3}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of APP mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223066"}, "annotations": {}, "source": 79, "target": 68, "key": 4}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223066"}, "annotations": {}, "source": 79, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22841563"}, "annotations": {}, "source": 79, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "23348005"}, "annotations": {}, "source": 79, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10921504"}, "annotations": {}, "source": 79, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19735175"}, "annotations": {}, "source": 79, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21086752"}, "annotations": {}, "source": 79, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15223066"}, "annotations": {}, "source": 79, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15862027"}, "annotations": {}, "source": 79, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "Vitamin E inhibits the reaction [Ethanol results in increased secretion of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16545059"}, "annotations": {}, "source": 79, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of EGR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19244175"}, "annotations": {}, "source": 79, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "Vitamin E results in decreased expression of EGR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11444866"}, "annotations": {}, "source": 79, "target": 195, "key": 1}, {"relation": "increases", "evidence": "gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.", "citation": {"type": "PubMed", "name": "CNS Drugs. 2006;20(5):351-72.", "reference": "16696577"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Notch signaling subgraph"}, "source": 80, "target": 11, "key": 0}, {"relation": "increases", "evidence": "gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.", "citation": {"type": "PubMed", "name": "CNS Drugs. 2006;20(5):351-72.", "reference": "16696577"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 80, "target": 11, "key": 1}, {"relation": "increases", "evidence": "gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.", "citation": {"type": "PubMed", "name": "CNS Drugs. 2006;20(5):351-72.", "reference": "16696577"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 80, "target": 11, "key": 2}, {"relation": "increases", "evidence": " In this issue of Nature Medicine, Thathiah et al.4 now provide provocative evidence that the adaptor protein  mediates the A-altering effects of these GPCRs by promoting A generation. This newly uncovered function of -arrestin 2 suggests it could be targeted to decrease amyloid pathology in patients with Alzheimer's disease. Production of the amyloid- peptide in Alzheimer's disease by the -secretase complex can be regulated by certain G proteincoupled receptors. This regulation seems to be mediated by -arrestin-2, whose expression was found to be elevated in Alzheimer's disease brains.Recruitment of -arrestin 2 to a GPCR leads to interaction with the -secretase complex via the Aph-1 subunit. Other members of the complex include presenilin-1 (PS-1), nicastrin (Nct) and Pen-2. The complex then moves laterally into lipid rafts, where -secretase activation is enhanced. Internalization may also occur to localize -secretase to late endosomes, where its activation is also increased. Cleavage of APP by -secretase (BACE1) to release soluble APP (sAPPb) followed by -secretase produces A and APP intracellular domain (AICD). Increased production and secretion of A from cells can lead to extracellular A aggregation in the form of plaques. Mutagenesis of GPR3 in regions of the protein that specifically interact with either G protein or -arrestin 2 further showed that -arrestin 2, not G protein, mediates the ability of GPR3 to increase A levels.", "citation": {"type": "PubMed", "name": "Nat Med. 2013 Jan;19(1):22-4. doi: 10.1038/nm.3053.", "reference": "23296004"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "G-protein-mediated signaling"}, "source": 80, "target": 11, "key": 3}, {"relation": "increases", "evidence": " In this issue of Nature Medicine, Thathiah et al.4 now provide provocative evidence that the adaptor protein  mediates the A-altering effects of these GPCRs by promoting A generation. This newly uncovered function of -arrestin 2 suggests it could be targeted to decrease amyloid pathology in patients with Alzheimer's disease. Production of the amyloid- peptide in Alzheimer's disease by the -secretase complex can be regulated by certain G proteincoupled receptors. This regulation seems to be mediated by -arrestin-2, whose expression was found to be elevated in Alzheimer's disease brains.Recruitment of -arrestin 2 to a GPCR leads to interaction with the -secretase complex via the Aph-1 subunit. Other members of the complex include presenilin-1 (PS-1), nicastrin (Nct) and Pen-2. The complex then moves laterally into lipid rafts, where -secretase activation is enhanced. Internalization may also occur to localize -secretase to late endosomes, where its activation is also increased. Cleavage of APP by -secretase (BACE1) to release soluble APP (sAPPb) followed by -secretase produces A and APP intracellular domain (AICD). Increased production and secretion of A from cells can lead to extracellular A aggregation in the form of plaques. Mutagenesis of GPR3 in regions of the protein that specifically interact with either G protein or -arrestin 2 further showed that -arrestin 2, not G protein, mediates the ability of GPR3 to increase A levels.", "citation": {"type": "PubMed", "name": "Nat Med. 2013 Jan;19(1):22-4. doi: 10.1038/nm.3053.", "reference": "23296004"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 80, "target": 11, "key": 4}, {"relation": "increases", "evidence": " In this issue of Nature Medicine, Thathiah et al.4 now provide provocative evidence that the adaptor protein  mediates the A-altering effects of these GPCRs by promoting A generation. This newly uncovered function of -arrestin 2 suggests it could be targeted to decrease amyloid pathology in patients with Alzheimer's disease. Production of the amyloid- peptide in Alzheimer's disease by the -secretase complex can be regulated by certain G proteincoupled receptors. This regulation seems to be mediated by -arrestin-2, whose expression was found to be elevated in Alzheimer's disease brains.Recruitment of -arrestin 2 to a GPCR leads to interaction with the -secretase complex via the Aph-1 subunit. Other members of the complex include presenilin-1 (PS-1), nicastrin (Nct) and Pen-2. The complex then moves laterally into lipid rafts, where -secretase activation is enhanced. Internalization may also occur to localize -secretase to late endosomes, where its activation is also increased. Cleavage of APP by -secretase (BACE1) to release soluble APP (sAPPb) followed by -secretase produces A and APP intracellular domain (AICD). Increased production and secretion of A from cells can lead to extracellular A aggregation in the form of plaques. Mutagenesis of GPR3 in regions of the protein that specifically interact with either G protein or -arrestin 2 further showed that -arrestin 2, not G protein, mediates the ability of GPR3 to increase A levels.", "citation": {"type": "PubMed", "name": "Nat Med. 2013 Jan;19(1):22-4. doi: 10.1038/nm.3053.", "reference": "23296004"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 80, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Moreover, we find that PLD1 also regulates PS1 trafficking and that PLD1 overexpression promotes cell surface accumulation of PS1 in an APP-independent manner. Our results clearly elucidate a physiological function of APP in regulating protein trafficking and suggest that intracellular trafficking of PS1/gamma-secretase is regulated by multiple factors, including APP and PLD1.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2009 May 1;284(18):12145-52. doi: 10.1074/jbc.M808497200. Epub 2009 Mar 10.", "reference": "19276086"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 80, "target": 11, "key": 6}, {"relation": "increases", "evidence": "Moreover, we find that PLD1 also regulates PS1 trafficking and that PLD1 overexpression promotes cell surface accumulation of PS1 in an APP-independent manner. Our results clearly elucidate a physiological function of APP in regulating protein trafficking and suggest that intracellular trafficking of PS1/gamma-secretase is regulated by multiple factors, including APP and PLD1.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2009 May 1;284(18):12145-52. doi: 10.1074/jbc.M808497200. Epub 2009 Mar 10.", "reference": "19276086"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 80, "target": 11, "key": 7}, {"relation": "increases", "evidence": "Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.", "reference": "18650430"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Beta secretase subgraph"}, "source": 80, "target": 11, "key": 8}, {"relation": "increases", "evidence": "Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.", "reference": "18650430"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 80, "target": 11, "key": 9}, {"relation": "increases", "evidence": "Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.", "reference": "18650430"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 80, "target": 11, "key": 10}, {"relation": "increases", "evidence": "In this study, we demonstrate that ER stress induces presenilin-1 expression through activating transcription factor 4 (ATF4), resulting in increased amyloid- (A) secretion by -secretase activity, which is suppressed by quercetin by modifying UPR signaling.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):362-6. doi: 10.1016/j.bbrc.2011.11.042. Epub 2011 Nov 16.", "reference": "22115781"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"FluidAndSecretion": "Bodily Secretions", "Subgraph": "Unfolded protein response subgraph"}, "source": 80, "target": 11, "key": 11}, {"relation": "increases", "evidence": "In this study, we demonstrate that ER stress induces presenilin-1 expression through activating transcription factor 4 (ATF4), resulting in increased amyloid- (A) secretion by -secretase activity, which is suppressed by quercetin by modifying UPR signaling.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):362-6. doi: 10.1016/j.bbrc.2011.11.042. Epub 2011 Nov 16.", "reference": "22115781"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"FluidAndSecretion": "Bodily Secretions", "Subgraph": "Amyloidogenic subgraph"}, "source": 80, "target": 11, "key": 12}, {"relation": "increases", "evidence": "In this study, we demonstrate that ER stress induces presenilin-1 expression through activating transcription factor 4 (ATF4), resulting in increased amyloid- (A) secretion by -secretase activity, which is suppressed by quercetin by modifying UPR signaling.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):362-6. doi: 10.1016/j.bbrc.2011.11.042. Epub 2011 Nov 16.", "reference": "22115781"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"FluidAndSecretion": "Bodily Secretions", "Subgraph": "Gamma secretase subgraph"}, "source": 80, "target": 11, "key": 13}, {"relation": "increases", "evidence": "The main factors responsible for Abeta formation are mutation of APP or PS1 and PS2 genes or ApoE gene. All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specifically the more amyloidogenic form, Abeta42.", "citation": {"type": "PubMed", "name": "J Clin Neurosci. 2004 Jun;11(5):456-67", "reference": "15177383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 81, "target": 11, "key": 0}, {"relation": "increases", "evidence": "The main factors responsible for Abeta formation are mutation of APP or PS1 and PS2 genes or ApoE gene. All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specifically the more amyloidogenic form, Abeta42.", "citation": {"type": "PubMed", "name": "J Clin Neurosci. 2004 Jun;11(5):456-67", "reference": "15177383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 81, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The ApoE gene responsible for the Alzheimer's disease has been examined to identify functional consequences of single-nucleotide polymorphisms (SNPs). Eighty-eight SNPs have been identified in the ApoE gene in which 31 are found to be nonsynonymous, 8 of them are coding synonymous, 33 are found to be in intron, and 3 are in untranslated region. The SNPs found in the untranslated region consisted of two SNPs from 5' and one SNP from the 3'. Twenty-nine percent of the identified nsSNPs have been reported as damaging. In the analysis of SNPs in the UTR regions, it has been recognized that rs72654467 from 5' and rs71673244 from 5' and 3' are responsible for the alteration in levels of expression. Both native and mutant protein structures were analyzed along with the stabilization residues. It has been concluded that among all SNPs of ApoE, the mutation in rs11542041 (R132S) has the most significant effect on functional variation.", "citation": {"type": "PubMed", "name": "Funct Integr Genomics. 2011 Dec;11(4):519-22. Epub 2011 Jul 19.", "reference": "21769591"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 81, "target": 33, "key": 0}, {"relation": "increases", "evidence": "The ApoE gene responsible for the Alzheimer's disease has been examined to identify functional consequences of single-nucleotide polymorphisms (SNPs). Eighty-eight SNPs have been identified in the ApoE gene in which 31 are found to be nonsynonymous, 8 of them are coding synonymous, 33 are found to be in intron, and 3 are in untranslated region. The SNPs found in the untranslated region consisted of two SNPs from 5' and one SNP from the 3'. Twenty-nine percent of the identified nsSNPs have been reported as damaging. In the analysis of SNPs in the UTR regions, it has been recognized that rs72654467 from 5' and rs71673244 from 5' and 3' are responsible for the alteration in levels of expression. Both native and mutant protein structures were analyzed along with the stabilization residues. It has been concluded that among all SNPs of ApoE, the mutation in rs11542041 (R132S) has the most significant effect on functional variation.", "citation": {"type": "PubMed", "name": "Funct Integr Genomics. 2011 Dec;11(4):519-22. Epub 2011 Jul 19.", "reference": "21769591"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 81, "target": 33, "key": 1}, {"relation": "increases", "evidence": "polymorphisms in three other genes (among others), apolipoprotein E (apoE), alpha2-macroglobulin (alpham), and the low density lipoprotein receptor-related protein (LRP), are implicated to contribute to AD pathogenesis", "citation": {"type": "PubMed", "name": "Microsc Res Tech. 2000 Aug 15;50(4):268-72.", "reference": "10936878"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 81, "target": 33, "key": 2}, {"relation": "directlyIncreases", "evidence": "An alternative pathway is shown on the right side of the figure whereby superoxide (O2) or hydrogen peroxide (H2O2) oxidize lipids such as prostaglandins forming F2a-isoprostanes. Both H2O2 and F2a-isoprostanes are known to accelerate A aggregation", "citation": {"type": "PubMed", "name": "J Clin Invest. 2005 May;115(5):1121-9", "reference": "15864339"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 82, "target": 11, "key": 0}, {"relation": "directlyIncreases", "evidence": "An alternative pathway is shown on the right side of the figure whereby superoxide (O2) or hydrogen peroxide (H2O2) oxidize lipids such as prostaglandins forming F2a-isoprostanes. Both H2O2 and F2a-isoprostanes are known to accelerate A aggregation", "citation": {"type": "PubMed", "name": "J Clin Invest. 2005 May;115(5):1121-9", "reference": "15864339"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 82, "target": 11, "key": 1}, {"relation": "directlyIncreases", "evidence": "An alternative pathway is shown on the right side of the figure whereby superoxide (O2) or hydrogen peroxide (H2O2) oxidize lipids such as prostaglandins forming F2a-isoprostanes. Both H2O2 and F2a-isoprostanes are known to accelerate A aggregation", "citation": {"type": "PubMed", "name": "J Clin Invest. 2005 May;115(5):1121-9", "reference": "15864339"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Hydrogen peroxide subgraph"}, "source": 82, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16863996"}, "annotations": {}, "source": 82, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16910777"}, "annotations": {}, "source": 82, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "7534305"}, "annotations": {}, "source": 82, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20978231"}, "annotations": {}, "source": 82, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10802230"}, "annotations": {}, "source": 82, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11034997"}, "annotations": {}, "source": 82, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11726202"}, "annotations": {}, "source": 82, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12723939"}, "annotations": {}, "source": 82, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15550384"}, "annotations": {}, "source": 82, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16531283"}, "annotations": {}, "source": 82, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16794257"}, "annotations": {}, "source": 82, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18951874"}, "annotations": {}, "source": 82, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19608869"}, "annotations": {}, "source": 82, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19926933"}, "annotations": {}, "source": 82, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20351055"}, "annotations": {}, "source": 82, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21347231"}, "annotations": {}, "source": 82, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12791701"}, "annotations": {}, "source": 82, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15723204"}, "annotations": {}, "source": 82, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640975"}, "annotations": {}, "source": 82, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19900513"}, "annotations": {}, "source": 82, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15035594"}, "annotations": {}, "source": 82, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22081883"}, "annotations": {}, "source": 82, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "resveratrol inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9374527"}, "annotations": {}, "source": 82, "target": 140, "key": 22}, {"relation": "directlyIncreases", "evidence": "An alternative pathway is shown on the right side of the figure whereby superoxide (O2) or hydrogen peroxide (H2O2) oxidize lipids such as prostaglandins forming F2a-isoprostanes. Both H2O2 and F2a-isoprostanes are known to accelerate A aggregation", "citation": {"type": "PubMed", "name": "J Clin Invest. 2005 May;115(5):1121-9", "reference": "15864339"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 83, "target": 11, "key": 0}, {"relation": "directlyIncreases", "evidence": "An alternative pathway is shown on the right side of the figure whereby superoxide (O2) or hydrogen peroxide (H2O2) oxidize lipids such as prostaglandins forming F2a-isoprostanes. Both H2O2 and F2a-isoprostanes are known to accelerate A aggregation", "citation": {"type": "PubMed", "name": "J Clin Invest. 2005 May;115(5):1121-9", "reference": "15864339"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Free radical formation subgraph"}, "source": 83, "target": 11, "key": 1}, {"relation": "directlyIncreases", "evidence": "An alternative pathway is shown on the right side of the figure whereby superoxide (O2) or hydrogen peroxide (H2O2) oxidize lipids such as prostaglandins forming F2a-isoprostanes. Both H2O2 and F2a-isoprostanes are known to accelerate A aggregation", "citation": {"type": "PubMed", "name": "J Clin Invest. 2005 May;115(5):1121-9", "reference": "15864339"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Hydrogen peroxide subgraph"}, "source": 83, "target": 11, "key": 2}, {"relation": "increases", "evidence": "NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift from the signal transducing actions to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide. We identified amyloid  (A) as an NO target, which is nitrated at tyrosine 10 (3NTyr(10)-A). Nitration of A accelerated its aggregation and was detected in the core of A plaques of APP/PS1 mice and AD brains.", "citation": {"type": "PubMed", "name": "Neuron. 2011 Sep 8;71(5):833-44.", "reference": "21903077"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Nitric oxide subgraph"}, "source": 84, "target": 11, "key": 0}, {"relation": "increases", "evidence": "NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift from the signal transducing actions to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide. We identified amyloid  (A) as an NO target, which is nitrated at tyrosine 10 (3NTyr(10)-A). Nitration of A accelerated its aggregation and was detected in the core of A plaques of APP/PS1 mice and AD brains.", "citation": {"type": "PubMed", "name": "Neuron. 2011 Sep 8;71(5):833-44.", "reference": "21903077"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 84, "target": 11, "key": 1}, {"relation": "increases", "evidence": "NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift from the signal transducing actions to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide. We identified amyloid  (A) as an NO target, which is nitrated at tyrosine 10 (3NTyr(10)-A). Nitration of A accelerated its aggregation and was detected in the core of A plaques of APP/PS1 mice and AD brains.", "citation": {"type": "PubMed", "name": "Neuron. 2011 Sep 8;71(5):833-44.", "reference": "21903077"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Nitric oxide subgraph"}, "source": 84, "target": 33, "key": 0}, {"relation": "increases", "evidence": "NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift from the signal transducing actions to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide. We identified amyloid  (A) as an NO target, which is nitrated at tyrosine 10 (3NTyr(10)-A). Nitration of A accelerated its aggregation and was detected in the core of A plaques of APP/PS1 mice and AD brains.", "citation": {"type": "PubMed", "name": "Neuron. 2011 Sep 8;71(5):833-44.", "reference": "21903077"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 84, "target": 33, "key": 1}, {"relation": "decreases", "evidence": "In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low throughput-screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol lowering drug, in mild to moderate sporadic AD led to significant increases in CSF apoE levels and a decrease of CSF beta amyloid 1-42 without significant modifications of CSF tau concentration or CSF lipid peroxides levels. These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2005 Mar;26(3):355-61", "reference": "15639314"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ApoE subgraph"}, "source": 85, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low throughput-screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol lowering drug, in mild to moderate sporadic AD led to significant increases in CSF apoE levels and a decrease of CSF beta amyloid 1-42 without significant modifications of CSF tau concentration or CSF lipid peroxides levels. These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2005 Mar;26(3):355-61", "reference": "15639314"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 85, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low throughput-screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol lowering drug, in mild to moderate sporadic AD led to significant increases in CSF apoE levels and a decrease of CSF beta amyloid 1-42 without significant modifications of CSF tau concentration or CSF lipid peroxides levels. These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2005 Mar;26(3):355-61", "reference": "15639314"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Cholesterol metabolism subgraph"}, "source": 85, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low throughput-screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol lowering drug, in mild to moderate sporadic AD led to significant increases in CSF apoE levels and a decrease of CSF beta amyloid 1-42 without significant modifications of CSF tau concentration or CSF lipid peroxides levels. These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2005 Mar;26(3):355-61", "reference": "15639314"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 85, "target": 33, "key": 0}, {"relation": "decreases", "evidence": "In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low throughput-screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol lowering drug, in mild to moderate sporadic AD led to significant increases in CSF apoE levels and a decrease of CSF beta amyloid 1-42 without significant modifications of CSF tau concentration or CSF lipid peroxides levels. These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2005 Mar;26(3):355-61", "reference": "15639314"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 85, "target": 33, "key": 1}, {"relation": "decreases", "evidence": "In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low throughput-screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol lowering drug, in mild to moderate sporadic AD led to significant increases in CSF apoE levels and a decrease of CSF beta amyloid 1-42 without significant modifications of CSF tau concentration or CSF lipid peroxides levels. These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2005 Mar;26(3):355-61", "reference": "15639314"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Cholesterol metabolism subgraph"}, "source": 85, "target": 33, "key": 2}, {"relation": "increases", "evidence": "The finding that acetylcholinesterase (AChE) colocalizes with -amyloid (A) and promotes and accelerates A aggregation has renewed an intense interest in developing new multifunctional AChE inhibitors as potential disease-modifying drugs for Alzheimer's therapy.", "citation": {"type": "PubMed", "name": "ACS Chem Neurosci. 2010 Nov 17;1(11):737-46", "reference": "22778810"}, "annotations": {"Species": "10116", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 86, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The finding that acetylcholinesterase (AChE) colocalizes with -amyloid (A) and promotes and accelerates A aggregation has renewed an intense interest in developing new multifunctional AChE inhibitors as potential disease-modifying drugs for Alzheimer's therapy.", "citation": {"type": "PubMed", "name": "ACS Chem Neurosci. 2010 Nov 17;1(11):737-46", "reference": "22778810"}, "annotations": {"Species": "10116", "Subgraph": "Amyloidogenic subgraph"}, "source": 86, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "name": "J Mol Biol. 1997 Sep 26;272(3):348-61.", "reference": "9325095"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 86, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "name": "J Mol Biol. 1997 Sep 26;272(3):348-61.", "reference": "9325095"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 86, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "name": "J Mol Biol1997", "reference": "9325095"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 86, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "name": "J Mol Biol1997", "reference": "9325095"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 86, "target": 11, "key": 6}, {"relation": "increases", "evidence": " The ER calcium pump SERCA was also found to form a protein complex with endogenous PSs, an interaction that influences SERCA function by controlling ER calcium sequestration and InsP3-mediated calcium liberation. Several of these studies have also proposed that increased ER calcium release via InsP3Rs or RyRs or via modulation of SERCA may modulate APP processing and facilitate A accumulation", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Calcium-dependent signal transduction"}, "source": 87, "target": 11, "key": 0}, {"relation": "increases", "evidence": " The ER calcium pump SERCA was also found to form a protein complex with endogenous PSs, an interaction that influences SERCA function by controlling ER calcium sequestration and InsP3-mediated calcium liberation. Several of these studies have also proposed that increased ER calcium release via InsP3Rs or RyRs or via modulation of SERCA may modulate APP processing and facilitate A accumulation", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "G-protein-mediated signaling"}, "source": 87, "target": 11, "key": 1}, {"relation": "increases", "evidence": " The ER calcium pump SERCA was also found to form a protein complex with endogenous PSs, an interaction that influences SERCA function by controlling ER calcium sequestration and InsP3-mediated calcium liberation. Several of these studies have also proposed that increased ER calcium release via InsP3Rs or RyRs or via modulation of SERCA may modulate APP processing and facilitate A accumulation", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 87, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Neuronal Fe65 is a central adapter for the intracellular protein network of Alzheimer's disease related amyloid precursor protein (APP). It contains a unique tandem array of phosphotyrosine-binding (PTB) domains that recognize NPXY internalization motifs present in the intracellular domains of APP (AICD) and the low-density lipoprotein receptor-related protein LRP1 (LICD). The ternary APP/Fe65/LRP1 complex is an important mediator of APP processing and affects -amyloid peptide production. Here we dissect by biochemical and biophysical methods the direct interactions within the ternary complex and reveal a phosphorylation-dependent insulin receptor substrate (IRS-) like interaction of the distal NPVY(4507) motif of LICD with Fe65-PTB1.", "citation": {"type": "PubMed", "name": "FEBS Lett. 2011 Oct 20;585(20):3229-35. Epub 2011 Sep 29.", "reference": "21968187"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 88, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Neuronal Fe65 is a central adapter for the intracellular protein network of Alzheimer's disease related amyloid precursor protein (APP). It contains a unique tandem array of phosphotyrosine-binding (PTB) domains that recognize NPXY internalization motifs present in the intracellular domains of APP (AICD) and the low-density lipoprotein receptor-related protein LRP1 (LICD). The ternary APP/Fe65/LRP1 complex is an important mediator of APP processing and affects -amyloid peptide production. Here we dissect by biochemical and biophysical methods the direct interactions within the ternary complex and reveal a phosphorylation-dependent insulin receptor substrate (IRS-) like interaction of the distal NPVY(4507) motif of LICD with Fe65-PTB1.", "citation": {"type": "PubMed", "name": "FEBS Lett. 2011 Oct 20;585(20):3229-35. Epub 2011 Sep 29.", "reference": "21968187"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Low density lipoprotein subgraph"}, "source": 88, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Alzheimer's disease is associated with impaired clearance of -amyloid from the brain, a process normally facilitated by apolipoprotein E (ApoE)", "citation": {"type": "PubMed", "name": "Science. 2012 Feb 9. [Epub ahead of print]", "reference": "22323736"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Alzheimer's disease is associated with impaired clearance of -amyloid from the brain, a process normally facilitated by apolipoprotein E (ApoE)", "citation": {"type": "PubMed", "name": "Science. 2012 Feb 9. [Epub ahead of print]", "reference": "22323736"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Alzheimer's disease is associated with impaired clearance of -amyloid from the brain, a process normally facilitated by apolipoprotein E (ApoE)", "citation": {"type": "PubMed", "name": "Science. 2012 Feb 9. [Epub ahead of print]", "reference": "22323736"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Alzheimer's disease is associated with impaired clearance of -amyloid from the brain, a process normally facilitated by apolipoprotein E (ApoE)", "citation": {"type": "PubMed", "name": "Science. 2012 Feb 9. [Epub ahead of print]", "reference": "22323736"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 3}, {"relation": "increases", "evidence": " Recently, many amyloid PET-positive and cognitively normal subjects were found in PiB-PET studies. PiB-PET studies on healthy subjects have also shown that apolipoprotein (APO) E4 boosts the accumulation of amyloid-beta and may consequently accelerate the pathogenesis of AD", "citation": {"type": "PubMed", "name": "Brain Nerve. 2010 Jul;62(7):757-67.", "reference": "20675880"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 4}, {"relation": "increases", "evidence": " Recently, many amyloid PET-positive and cognitively normal subjects were found in PiB-PET studies. PiB-PET studies on healthy subjects have also shown that apolipoprotein (APO) E4 boosts the accumulation of amyloid-beta and may consequently accelerate the pathogenesis of AD", "citation": {"type": "PubMed", "name": "Brain Nerve. 2010 Jul;62(7):757-67.", "reference": "20675880"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Apolipoprotein E is the main lipid carrier in the brain and the best-established risk factor for late-onset Alzheimer's disease. Intracellular cholesterol levels influence the generation of amyloid-beta peptides, the toxic species thought to be a primary cause of Alzheimer's disease. Finally, compounds that modulate cholesterol metabolism affect amyloid-beta generation.", "citation": {"type": "PubMed", "name": "Curr Opin Lipidol. 2007 Jun;18(3):325-32.", "reference": "17495608"}, "annotations": {"NervousSystem": "Brain", "Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 6}, {"relation": "increases", "evidence": "Apolipoprotein E is the main lipid carrier in the brain and the best-established risk factor for late-onset Alzheimer's disease. Intracellular cholesterol levels influence the generation of amyloid-beta peptides, the toxic species thought to be a primary cause of Alzheimer's disease. Finally, compounds that modulate cholesterol metabolism affect amyloid-beta generation.", "citation": {"type": "PubMed", "name": "Curr Opin Lipidol. 2007 Jun;18(3):325-32.", "reference": "17495608"}, "annotations": {"NervousSystem": "Brain", "Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 7}, {"relation": "increases", "evidence": " ApoE was not protective, but was injurious, as deletion of ApoE delayed the neurodegeneration caused by alpha-synuclein and suppressed the accumulation of Abeta. ", "citation": {"type": "PubMed", "name": "Nat Neurosci2008", "reference": "18297066"}, "annotations": {"Subgraph": "Synuclein subgraph"}, "source": 89, "target": 11, "key": 8}, {"relation": "increases", "evidence": " ApoE was not protective, but was injurious, as deletion of ApoE delayed the neurodegeneration caused by alpha-synuclein and suppressed the accumulation of Abeta. ", "citation": {"type": "PubMed", "name": "Nat Neurosci2008", "reference": "18297066"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 9}, {"relation": "increases", "evidence": " ApoE was not protective, but was injurious, as deletion of ApoE delayed the neurodegeneration caused by alpha-synuclein and suppressed the accumulation of Abeta. ", "citation": {"type": "PubMed", "name": "Nat Neurosci2008", "reference": "18297066"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 10}, {"relation": "decreases", "evidence": "We report that ApoE plays a role in facilitating the proteolytic clearance of soluble Abeta from the brain. ", "citation": {"type": "PubMed", "name": "Neuron2008", "reference": "18549781"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 11}, {"relation": "decreases", "evidence": "We report that ApoE plays a role in facilitating the proteolytic clearance of soluble Abeta from the brain. ", "citation": {"type": "PubMed", "name": "Neuron2008", "reference": "18549781"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 12}, {"relation": "decreases", "evidence": " We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta(29-42) via a direct interaction. ", "citation": {"type": "PubMed", "name": "J Neurochem1999", "reference": "10428074"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 89, "target": 11, "key": 13}, {"relation": "decreases", "evidence": " We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta(29-42) via a direct interaction. ", "citation": {"type": "PubMed", "name": "J Neurochem1999", "reference": "10428074"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 89, "target": 11, "key": 14}, {"relation": "increases", "evidence": "In AD, an increased ApoE mRNA was reported in the hippocampus. The risk for AD has been reported to correlate with transcriptional activity of the ApoE gene. Binding sites for putative transcriptional factors (TF), such\\ as AP-1, AP-2 and NF-kappaB, are present in the ApoE promoter. The promoter also contains sites for the inflammatory response transcription factors IL-6 RE-BP, MED1, STAT1 and STAT2. A functional peroxisome-proliferator-activated receptor gamma (PPARgamma) has been detected in the ApoE/ApoCI intergenic region.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2004;23(3):225-33.", "reference": "15181251"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 89, "target": 33, "key": 10}, {"relation": "increases", "evidence": "It has been suggested that the C-->T (224Ala-->Val) transition within exon 2 of the cathepsin D gene (CTSD) might represent a risk factor for late onset AD.Possession of the CTSD T allele does not increase the risk of developing AD per se, but has a modulating effect on the pathogenesis of the disorder by increasing, in concert with the APOE e4 allele, the amount of Abeta deposited as senile plaques in the brain in the form of Abeta40.", "citation": {"type": "PubMed", "name": "J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7", "reference": "16543533"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 89, "target": 33, "key": 1}, {"relation": "increases", "evidence": "The implication that cholesterol plays an essential role in the pathogenesis of Alzheimer's disease (AD) is based on the 1993 finding that the presence of apolipoprotein E (apoE) allele epsilon;4 is a strong risk factor for developing AD. Since apoE is a regulator of lipid metabolism, it is reasonable to assume that lipids such as cholesterol are involved in the pathogenesis of AD", "citation": {"type": "PubMed", "name": "Mol Neurobiol. 2003 Feb;27(1):1-12.", "reference": "12668899"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ApoE subgraph"}, "source": 89, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The PSEN1 AD mutations giving rise to CWP produce unusually high levels of the amyloid beta peptide (Abeta) ending at position 42 or 43, and the main component of CWP is amino-terminally truncated forms of amyloid beta peptide starting after the alternative beta-secretase cleavage site at position 11.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "17995932"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 90, "target": 11, "key": 2}, {"relation": "increases", "evidence": "The PSEN1 AD mutations giving rise to CWP produce unusually high levels of the amyloid beta peptide (Abeta) ending at position 42 or 43, and the main component of CWP is amino-terminally truncated forms of amyloid beta peptide starting after the alternative beta-secretase cleavage site at position 11.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "17995932"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 3}, {"relation": "increases", "evidence": "This cleavage is similar to the PS-dependent gamma-secretase cleavage of the beta-amyloid precursor protein (betaAPP). ", "citation": {"type": "PubMed", "name": "EMBO journal2002", "reference": "12374741"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 4}, {"relation": "increases", "evidence": "This cleavage is similar to the PS-dependent gamma-secretase cleavage of the beta-amyloid precursor protein (betaAPP). ", "citation": {"type": "PubMed", "name": "EMBO journal2002", "reference": "12374741"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Presenilin-1 (PS1) is intimately involved in cleavage of amyloid precursor protein to form beta-amyloid peptides, certain forms of which aggregate in the brains of patients with Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Neurosci Lett2002", "reference": "11814648"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 6}, {"relation": "increases", "evidence": "Presenilin-1 (PS1) is intimately involved in cleavage of amyloid precursor protein to form beta-amyloid peptides, certain forms of which aggregate in the brains of patients with Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Neurosci Lett2002", "reference": "11814648"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 7}, {"relation": "increases", "evidence": "It was hypothesized that PS1 might directly cleave APP.", "citation": {"type": "PubMed", "name": "Prog Neurobiol2000", "reference": "10670705"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 8}, {"relation": "increases", "evidence": "It was hypothesized that PS1 might directly cleave APP.", "citation": {"type": "PubMed", "name": "Prog Neurobiol2000", "reference": "10670705"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 9}, {"relation": "increases", "evidence": "Therefore, our results show that PS1 binds to APP directly and suggest that the PS1 protein itself is involved in the metabolism of beta-amyloid peptide.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun1997", "reference": "9344855"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 10}, {"relation": "increases", "evidence": "Therefore, our results show that PS1 binds to APP directly and suggest that the PS1 protein itself is involved in the metabolism of beta-amyloid peptide.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun1997", "reference": "9344855"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 11}, {"relation": "increases", "evidence": "Our results indicate PS1 and APP can interact in the ER and Golgi, where PS1 is required for proper gamma-secretase processing of APP CTFs, and that PS1 mutations augment Abeta42 levels principally in Golgi-like vesicles.", "citation": {"type": "PubMed", "name": "Biochemistry1998", "reference": "9843412"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 12}, {"relation": "increases", "evidence": "Our results indicate PS1 and APP can interact in the ER and Golgi, where PS1 is required for proper gamma-secretase processing of APP CTFs, and that PS1 mutations augment Abeta42 levels principally in Golgi-like vesicles.", "citation": {"type": "PubMed", "name": "Biochemistry1998", "reference": "9843412"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 13}, {"relation": "increases", "evidence": "Missense substitutions in the presenilin 1 (PS1) and presenilin 2 (PS2) proteins are associated with early-onset familial Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem1999", "reference": "10037471"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 14}, {"relation": "increases", "evidence": "Missense substitutions in the presenilin 1 (PS1) and presenilin 2 (PS2) proteins are associated with early-onset familial Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem1999", "reference": "10037471"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 15}, {"relation": "increases", "evidence": "Amyloid beta-peptide (Abeta) is generated by the consecutive cleavages of beta- and gamma-secretase.", "citation": {"type": "PubMed", "name": "J Cell Biol2002", "reference": "12147673"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 16}, {"relation": "increases", "evidence": "Amyloid beta-peptide (Abeta) is generated by the consecutive cleavages of beta- and gamma-secretase.", "citation": {"type": "PubMed", "name": "J Cell Biol2002", "reference": "12147673"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 17}, {"relation": "increases", "evidence": "Abundant biochemical and genetic evidence suggests that presenilins are catalytic components of gamma-secretase, the protease responsible for generating the Alzheimer amyloid beta-protein.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2003", "reference": "12603837"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 11, "key": 18}, {"relation": "increases", "evidence": "Abundant biochemical and genetic evidence suggests that presenilins are catalytic components of gamma-secretase, the protease responsible for generating the Alzheimer amyloid beta-protein.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2003", "reference": "12603837"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 11, "key": 19}, {"relation": "increases", "evidence": "hypomethylation of the promoter of the presenilin 1 (PS1) gene, which will lead to overexpression of presenilin 1 and, consequently, to increased Abeta(1-42) (Abeta42) formation ", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2005 Sep 30;386(2):69-71.", "reference": "16040194"}, "annotations": {"Encode_Feature_Types": "Promoter"}, "source": 90, "target": 11, "key": 20}, {"relation": "increases", "evidence": "Presenilin-1 (PS1) is the catalytic subunit of gamma-secretase and mutations in this protein cause familial Alzheimer Disease (FAD). ", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 29. [Epub ahead of print]", "reference": "22461631"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Among the different APP-interacting proteins, we focused our interest on the GRB2 adaptor protein, which connects cell surface receptors to intracellular signaling pathways. In this study we provide evidence by co-immunoprecipitation experiments, confocal and electron microscopy, and by fluorescence resonance energy transfer experiments that both APP and presenilin1 interact with GRB2 in vesicular structures at the centrosome of the cell. The final target for these interactions is ERK1,2, which is activated in mitotic centrosomes in a PS1- and APP-dependent manner. These data suggest that both APP and presenilin1 can be part of a common signaling pathway that regulates ERK1,2 and the cell cycle.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2007 May 4;282(18):13833-44. Epub 2007 Feb 21.", "reference": "17314098"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 90, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Among the different APP-interacting proteins, we focused our interest on the GRB2 adaptor protein, which connects cell surface receptors to intracellular signaling pathways. In this study we provide evidence by co-immunoprecipitation experiments, confocal and electron microscopy, and by fluorescence resonance energy transfer experiments that both APP and presenilin1 interact with GRB2 in vesicular structures at the centrosome of the cell. The final target for these interactions is ERK1,2, which is activated in mitotic centrosomes in a PS1- and APP-dependent manner. These data suggest that both APP and presenilin1 can be part of a common signaling pathway that regulates ERK1,2 and the cell cycle.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2007 May 4;282(18):13833-44. Epub 2007 Feb 21.", "reference": "17314098"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 33, "key": 2}, {"relation": "increases", "evidence": "In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. ", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 90, "target": 68, "key": 0}, {"relation": "increases", "evidence": "In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. ", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Gamma secretase subgraph"}, "source": 90, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 91, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.", "citation": {"type": "Online Resource", "name": "Alzheimer's disease - Homo sapiens (human)", "reference": "hsa05010"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Mutations in presenilin2 (PS2), a homolog of PS1, are also associated with FAD. While the precise mechanism on how these mutations cause AD is unknown, multiple theories have arisen to explain the role of PS1 and PS2 mutations on AD pathogenesis. These mutations lead to abnormal function of gamma- secretase, the -catenin pathway, calcium homoeostasis and the lysosomal/autophagy pathway as well as chaperones. Among these hypotheses, the effect of PS mutations on gamma-secretase has been extensively investigated. gamma-Secretase is composed of at least four subunits: PS, Nicastrin, Aph1 and Pen2; with a total of 19 putative transmembrane domains.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 29. [Epub ahead of print]", "reference": "22461631"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Mechanistic studies have shown that FAD mutants of presenilin can affect the intracellular calcium levels by affecting the ER calcium stores. A function for presenilins as ER calcium leak channels has been established and studies show that presenilins affect ER calcium load through an effect on IP(3) receptors, ryanodine receptors, or SERCA pumps. Even in the absence of an active gamma-secretase complex, presenilins seem to affect calcium homeostasis suggesting that these two functions of presenilins are independent of each other.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Endoplasmic Reticulum"}, "toLoc": {"namespace": "MESHCS", "name": "Cytoplasm"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 8, "key": 0}, {"relation": "increases", "evidence": "Studies of the presenilins (PS) have implicated ER Ca2+ mishandling in AD. PS functions as an ER Ca2+ leak channel and FAD PS mutations impair this Ca2+ leak channel function resulting in excessive accumulation of Ca2+ in the ER and, as a consequence, enhances Ca2+ release through ryanodine receptor (RyR) and IP3 receptor (IP3R) channels", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Endoplasmic Reticulum"}, "toLoc": {"namespace": "MESHCS", "name": "Cytoplasm"}}}, "annotations": {"Subgraph": "Gamma secretase subgraph", "Disease": "Alzheimer's disease", "CellStructure": "Endoplasmic Reticulum"}, "source": 91, "target": 8, "key": 1}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Calcium-dependent signal transduction"}, "source": 91, "target": 12, "key": 0}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 12, "key": 1}, {"relation": "decreases", "evidence": " Both A and presenilins seem to affect calcium homeostasis at very early stages of disease development affecting the synaptic transmission and function prior to neuritic plaque development. Altered calcium signaling differentially regulates genes such as calcineurin, calmodulin kinase II, MAP kinase etc and induces protein modifications and neurite degeneration. Since functional synapses and synaptic transmission are fundamental processes in memory formation, alterations in these processes can lead to neuronal dysfunction and memory deficit as seen in Alzheimer's disease. This chapter gives an overview of calcium signaling in different systems, specifically neurons, the functioning of pre- and post-synaptic signaling, and how their deregulation influences pathology development in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Adv Exp Med Biol. 2012;740:1193-217.", "reference": "22453989"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 18, "key": 0}, {"relation": "increases", "evidence": "In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. ", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 91, "target": 7, "key": 0}, {"relation": "increases", "evidence": "In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. ", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 7, "key": 1}, {"relation": "increases", "evidence": "The death of cholinergic neurons in the cerebral cortex and certain subcortical regions is linked to irreversible dementia relevant to AD (Alzheimer's disease). Although multiple studies have shown that expression of a FAD (familial AD)-linked APP (amyloid  precursor protein) or a PS (presenilin) mutant, but not that of wild-type APP or PS, induced neuronal death by activating intracellular death signals, it remains to be addressed how these signals are interrelated and what the key molecule involved in this process is. In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. MOCA (modifier of cell adhesion), which was originally identified as being a PS- and Rac1-binding protein, is a common downstream constituent of these neuronal death signals. Detailed molecular analysis indicates that MOCA is a key molecule of the AD-relevant neuronal death signals that links the PS-mediated death signal with the APP-mediated death signal at a point between Rac1 [or Cdc42 (cell division cycle 42)] and ASK1 (apoptosis signal-regulating kinase 1).", "citation": {"type": "PubMed", "name": "Biochem J. 2012 Mar 1;442(2):413-22.", "reference": "22115042"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 7, "key": 2}, {"relation": "decreases", "evidence": "When PS and calpain were separately expressed in COS cells by cDNA transfection and then combined in vitro, or both were co-transfected to be co-expressed in vivo in COS cells, PS1 and PS2 reduced the casein proteolysis activity of m-calpain but not that of mu-calpain. ", "citation": {"type": "PubMed", "name": "International journal of molecular medicine2000", "reference": "10677567"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Calpastatin-calpain subgraph"}, "source": 91, "target": 144, "key": 0}, {"relation": "decreases", "evidence": "When PS and calpain were separately expressed in COS cells by cDNA transfection and then combined in vitro, or both were co-transfected to be co-expressed in vivo in COS cells, PS1 and PS2 reduced the casein proteolysis activity of m-calpain but not that of mu-calpain. ", "citation": {"type": "PubMed", "name": "International journal of molecular medicine2000", "reference": "10677567"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 144, "key": 1}, {"relation": "decreases", "evidence": "gene mutation of presenilin, which is a component of the gamma-secretase complex and is associated with familial AD, results in an attenuation of ER chaperone expression during ER stress. Mutations in presenilin inhibit activation of IRE1, ATF6, and PERK, all of which act as signal transducers of ER stress in the ER membrane (for details, see the article by Hosoi and Ozawa in this Forum Minireview series: Ref. 14), thereby making neurons vulnerable to ER stress. In addition, nitric oxideinduced S-nitrosylation of ER chaperone protein disulfide isomerase (PDI) inhibits its enzymatic activity, leading to ER stressinduced neuronal death. Interestingly, S-nitrosylation of PDI has been observed in the brain of sporadic AD and PD patients. ER stress can also cause AD onset. For example, eIF2a phosphorylation, which is induced by eIF2a kinase PERK, elevates BACE1 (-secretase) levels and causes increased A production (17). Furthermore, A has been reported to induce ER stress, leading to activation of ER stressspecific initiator caspases, including mouse caspase- 12 and human caspase-4. In conclusion, because postmortem AD patient brain samples exhibit activated UPR markers, including phosphorylated PERK, eIF2a, and IRE1, ER stress probably plays a key role in AD pathogenesis as a cause or consequence", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Unfolded protein response subgraph"}, "source": 91, "target": 215, "key": 0}, {"relation": "decreases", "evidence": "gene mutation of presenilin, which is a component of the gamma-secretase complex and is associated with familial AD, results in an attenuation of ER chaperone expression during ER stress. Mutations in presenilin inhibit activation of IRE1, ATF6, and PERK, all of which act as signal transducers of ER stress in the ER membrane (for details, see the article by Hosoi and Ozawa in this Forum Minireview series: Ref. 14), thereby making neurons vulnerable to ER stress. In addition, nitric oxideinduced S-nitrosylation of ER chaperone protein disulfide isomerase (PDI) inhibits its enzymatic activity, leading to ER stressinduced neuronal death. Interestingly, S-nitrosylation of PDI has been observed in the brain of sporadic AD and PD patients. ER stress can also cause AD onset. For example, eIF2a phosphorylation, which is induced by eIF2a kinase PERK, elevates BACE1 (-secretase) levels and causes increased A production (17). Furthermore, A has been reported to induce ER stress, leading to activation of ER stressspecific initiator caspases, including mouse caspase- 12 and human caspase-4. In conclusion, because postmortem AD patient brain samples exhibit activated UPR markers, including phosphorylated PERK, eIF2a, and IRE1, ER stress probably plays a key role in AD pathogenesis as a cause or consequence", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2012;118(3):325-30. Epub 2012 Mar 2.", "reference": "22382662"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Gamma secretase subgraph"}, "source": 91, "target": 215, "key": 1}, {"relation": "decreases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Subgraph": "Ubiquitin degradation subgraph"}, "source": 92, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 92, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"UserdefinedCellLine": "App transgenic", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"UserdefinedCellLine": "App transgenic", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 92, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (A) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.", "reference": "19660836"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (A) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.", "reference": "19660836"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 92, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.", "citation": {"type": "PubMed", "name": "Medical Hypotheses2006", "reference": "16828233"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.", "citation": {"type": "PubMed", "name": "Medical Hypotheses2006", "reference": "16828233"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 92, "target": 11, "key": 8}, {"relation": "decreases", "evidence": "The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (A) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.", "reference": "19660836"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 11, "key": 9}, {"relation": "decreases", "evidence": "The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (A) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.", "reference": "19660836"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 92, "target": 11, "key": 10}, {"relation": "decreases", "evidence": "PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.", "citation": {"type": "PubMed", "name": "Medical Hypotheses2006", "reference": "16828233"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 11, "key": 11}, {"relation": "decreases", "evidence": "PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.", "citation": {"type": "PubMed", "name": "Medical Hypotheses2006", "reference": "16828233"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 92, "target": 11, "key": 12}, {"relation": "increases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph", "MeSHDisease": "Diabetes Mellitus, Type 2"}, "source": 92, "target": 46, "key": 0}, {"relation": "increases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPAR leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against A neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in -catenin and inhibition of GSK-3 is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPAR by a potent ligand leads to -catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPAR activation in neuroprotection, PPAR agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPAR activation . A recent report demonstrates that overexpression of PPAR in cultured cells leads to a dramatic decrease in the production of A, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing A secretion, PPAR protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "subject": {"modifier": "Activity"}, "annotations": {"UserdefinedCellLine": "App transgenic", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 46, "key": 1}, {"relation": "increases", "evidence": "As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 140, "key": 0}, {"relation": "increases", "evidence": "As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 92, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Peroxisome proliferator activated receptor subgraph"}, "source": 92, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 92, "target": 140, "key": 3}, {"relation": "increases", "evidence": "To some extent vascular complications of type 2 diabetes or glucose  intolerance might  be leading  to neurodegeneration due to  insufficient neuronal nutrient supply as well  as  im paired -amyloid (A) clearance from  the  brain  [12] .  Furthermore,   disturbed  cerebral   perfusion  due   to  endothelial dysfunction and  alteration of  the  blood  brain  barrier  results in upregulation of  amyloid  precursor protein  (APP)  expres sion  and  Adeposition [13].  Also, hyperinsulinemia as  it is present  in type 2 diabetes may  play an  important role  in for mation of senile  plaques  (14].", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 93, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Experiments  in  Caenoi-habditis elegans  revealed    new insights into the role oflR/IGF-IR signaling in A1  -42  toxic ity,  and  Ametabolism. Cohen   and coworkers could  show that   knocking  down    the   DAF-2  pathway   in   C. elegans, which   is orthologous to  the  mammalian insulin   and  IGF-l signaling cascade, reduces Al31-42  toxicity [35]. Furthermore, this  effect   was  mediated  by  the  two  downstream transcrip tion  factors, DAF-16 and  HSF-l  (heat  shock   transcription factor-!) [132}.   DAF-\\6  encodes a  forkhead transcription factor  [133,   134],  which  translocates into  the  nucleus [135], and  modulates transcription when  DAF-2 signaling is abro gated . The  mammalian DAF-16 orthologs are  Foxol, 3, and 4  [136). In  the  mammalian  system   the  IR/IGF-1 R  induces phosphorylation of  Foxo I   and triggers its translocation from the  nucleus. The  DAF-2 pathway reduces A ,_42  toxicity  by two possible mechanisms of detoxification [35]: The  first detoxification route  leads  to disaggregation of  the toxic  oli gomer  that  is positively regulated by HSF-1 and degradation of the  amyloidogenic peptides. The  second  mechanism mediates  the formation of low toxic, high  molecular weight aggregates from  high toxic  low molecular weight aggregates, which   is  positively  regulated  by  DAF-!6. Both  detoxifica tion mechanisms are  negatively regulated by  DAF-2 signal ing.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "object": {"modifier": "Activity"}, "annotations": {"UserdefinedSpecies": "C elegans", "Subgraph": "Insulin signal transduction"}, "source": 94, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Experiments  in  Caenoi-habditis elegans  revealed    new insights into the role oflR/IGF-IR signaling in A1  -42  toxic ity,  and  Ametabolism. Cohen   and coworkers could  show that   knocking  down    the   DAF-2  pathway   in   C. elegans, which   is orthologous to  the  mammalian insulin   and  IGF-l signaling cascade, reduces Al31-42  toxicity [35]. Furthermore, this  effect   was  mediated  by  the  two  downstream transcrip tion  factors, DAF-16 and  HSF-l  (heat  shock   transcription factor-!) [132}.   DAF-\\6  encodes a  forkhead transcription factor  [133,   134],  which  translocates into  the  nucleus [135], and  modulates transcription when  DAF-2 signaling is abro gated . The  mammalian DAF-16 orthologs are  Foxol, 3, and 4  [136). In  the  mammalian  system   the  IR/IGF-1 R  induces phosphorylation of  Foxo I   and triggers its translocation from the  nucleus. The  DAF-2 pathway reduces A ,_42  toxicity  by two possible mechanisms of detoxification [35]: The  first detoxification route  leads  to disaggregation of  the toxic  oli gomer  that  is positively regulated by HSF-1 and degradation of the  amyloidogenic peptides. The  second  mechanism mediates  the formation of low toxic, high  molecular weight aggregates from  high toxic  low molecular weight aggregates, which   is  positively  regulated  by  DAF-!6. Both  detoxifica tion mechanisms are  negatively regulated by  DAF-2 signal ing.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "object": {"modifier": "Activity"}, "annotations": {"UserdefinedSpecies": "C elegans", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 94, "target": 11, "key": 1}, {"relation": "increases", "evidence": "As far as the metabolism of amyloid precursor protein (APP) in late-onset sporadic Alzheimer disease is concerned, neuronal insulin receptor dysfunction may result in the intracellular accumulation of Abeta and in subsequent cellular damage.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2004 Apr 19;490(1-3):115-25.", "reference": "15094078"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Insulin signal transduction"}, "source": 95, "target": 11, "key": 2}, {"relation": "increases", "evidence": "As far as the metabolism of amyloid precursor protein (APP) in late-onset sporadic Alzheimer disease is concerned, neuronal insulin receptor dysfunction may result in the intracellular accumulation of Abeta and in subsequent cellular damage.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2004 Apr 19;490(1-3):115-25.", "reference": "15094078"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 95, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "Glutamatergic subgraph"}, "source": 96, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "NMDA receptor"}, "source": 96, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 96, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "NervousSystem": "Hippocampus", "Subgraph": "Glutamatergic subgraph"}, "source": 96, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "NervousSystem": "Hippocampus", "Subgraph": "NMDA receptor"}, "source": 96, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "NervousSystem": "Hippocampus", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 96, "target": 11, "key": 5}, {"relation": "decreases", "evidence": " The over-expressions of A(1-42) and amyloid precursor protein (APP) were also decreased in the brains of APP/PS1 mice. Interestingly, MEM treatment improved the decreased NGF levels in APP/PS1 mice. Furthermore, NGF/TrkA signaling was activated by increasing the phosphorylation levels of tyrosine kinase (TrkA), proto-oncogene serine/threonine-protein kinase, Raf1 (c-Raf), extracellular regulated protein kinases (ERK)1/2 and cAMP-response element binding protein (CREB) after MEM treatment. Simultaneously, MEM also inhibited NGF/p75(NTR) signaling via decreasing the cleavage substrate of p75(NTR), increasing the JNK2 phosphorylation and decreasing the levels of p53 and cleaved-caspase 3.", "citation": {"type": "PubMed", "name": "Neuroscience. 2014 Jul 25;273:141-51", "reference": "24846616"}, "annotations": {"Species": "10090", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 96, "target": 11, "key": 6}, {"relation": "increases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "Glutamatergic subgraph"}, "source": 96, "target": 44, "key": 0}, {"relation": "increases", "evidence": "After the treatment, memantine-treated mice had restored cognition and significantly reduced the levels of insoluble amyloid-beta (Abeta), Abeta dodecamers (Abeta*56), prefibrillar soluble oligomers, and fibrillar oligomers. The effects on pathology were stronger in older, more impaired animals. Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau. Finally, memantine pre-incubation prevented Abeta-induced inhibition of long-term potentiation in hippocampal slices of cognitively normal mice.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "NMDA receptor"}, "source": 96, "target": 44, "key": 1}, {"relation": "increases", "evidence": "Currently available treatments for Alzheimer's disease (EC 3.1.1.7 (acetylcholinesterase) inhibitors and memantine) improve cognitive function, but do not slow the long-term progression of this disorder.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2010 Mar;9(3):235-7", "reference": "20170836"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 96, "target": 44, "key": 2}, {"relation": "increases", "evidence": "In this study, we found that memantine improved both hippocampus- and amygdala-dependent memory impairments in 3xTg-AD mice of three different ages and degrees of pathology.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "Glutamatergic subgraph"}, "source": 96, "target": 46, "key": 0}, {"relation": "increases", "evidence": "In this study, we found that memantine improved both hippocampus- and amygdala-dependent memory impairments in 3xTg-AD mice of three different ages and degrees of pathology.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):870-80", "reference": "20042680"}, "annotations": {"Species": "10090", "Subgraph": "NMDA receptor"}, "source": 96, "target": 46, "key": 1}, {"relation": "decreases", "evidence": "Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT3) receptor with a potency that is similar to that at the NMDA receptor", "citation": {"type": "Online Resource", "name": "AD_HBP", "reference": "DB01043"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 96, "target": 48, "key": 0}, {"relation": "decreases", "evidence": "Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT3) receptor with a potency that is similar to that at the NMDA receptor", "citation": {"type": "Online Resource", "name": "AD_HBP", "reference": "DB01043"}, "annotations": {"Subgraph": "NMDA receptor"}, "source": 96, "target": 48, "key": 1}, {"relation": "decreases", "evidence": "In addition to blocking the NMDA receptor, memantine also decreases the basal level of intracellular Ca(2+) and increases the sensitivity of cells to extracellular stimuli. All these effects may be of benefit in the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Cell Physiol Biochem. 2008;22(1-4):205-14", "reference": "18769047"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 96, "target": 235, "key": 0}, {"relation": "decreases", "evidence": "In addition to blocking the NMDA receptor, memantine also decreases the basal level of intracellular Ca(2+) and increases the sensitivity of cells to extracellular stimuli. All these effects may be of benefit in the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Cell Physiol Biochem. 2008;22(1-4):205-14", "reference": "18769047"}, "annotations": {"Subgraph": "NMDA receptor"}, "source": 96, "target": 235, "key": 1}, {"relation": "decreases", "evidence": "Paroxetine treatment ameliorated the spatial navigation deficit in 3xTgAD male and female mice, without affecting swim speed or distance traveled, suggesting a preservation of cognitive function. Levels of amyloid beta-peptide (A) and numbers of A immunoreactive neurons were significantly reduced in the hippocampus of male and female paroxetine-treated 3xTgAD mice compared to saline-treated 3xTgAD mice.", "citation": {"type": "PubMed", "name": "Exp Neurol. 2007 May;205(1):166-76. Epub 2007 Feb 13", "reference": "17368447"}, "annotations": {"Species": "10090", "Subgraph": "Serotonergic subgraph"}, "source": 97, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Paroxetine treatment ameliorated the spatial navigation deficit in 3xTgAD male and female mice, without affecting swim speed or distance traveled, suggesting a preservation of cognitive function. Levels of amyloid beta-peptide (A) and numbers of A immunoreactive neurons were significantly reduced in the hippocampus of male and female paroxetine-treated 3xTgAD mice compared to saline-treated 3xTgAD mice.", "citation": {"type": "PubMed", "name": "Exp Neurol. 2007 May;205(1):166-76. Epub 2007 Feb 13", "reference": "17368447"}, "annotations": {"Species": "10090", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 97, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Since APP holoprotein levels are proportionate to Abeta peptide output in many systems we tested the efficacy of paroxetine and dimercaptopropanol to limit Abeta secretion as measured by ELISA assays. Paroxetine and dimercaptopropanol limited Abeta peptide secretion from lens epithelial cells (B3 cells). Interestingly, paroxetine changed the steady-state levels of transferrin receptor mRNAs. These data suggested that this serotonin reuptake inhibitor (SSRI) provided extra pharmacological action to chelate interacellular iron or change the intracellular iron distribution. An altered iron distribution would be predicted to indirectly limit APP holoprotein expression and Abeta peptide secretion.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2004;24(1):129-36", "reference": "15314261"}, "annotations": {"Subgraph": "Serotonergic subgraph"}, "source": 97, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Since APP holoprotein levels are proportionate to Abeta peptide output in many systems we tested the efficacy of paroxetine and dimercaptopropanol to limit Abeta secretion as measured by ELISA assays. Paroxetine and dimercaptopropanol limited Abeta peptide secretion from lens epithelial cells (B3 cells). Interestingly, paroxetine changed the steady-state levels of transferrin receptor mRNAs. These data suggested that this serotonin reuptake inhibitor (SSRI) provided extra pharmacological action to chelate interacellular iron or change the intracellular iron distribution. An altered iron distribution would be predicted to indirectly limit APP holoprotein expression and Abeta peptide secretion.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2004;24(1):129-36", "reference": "15314261"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 97, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Administration of paroxetine, a SSRI, to 3 transgenic mice for 5 months reversed the memory impairment as assessed by the spatial version of the Morris water maze as well as decreased the AD-like neuropathology characteristic of these transgenic mice (Nelson et al., this issue).", "citation": {"type": "PubMed", "name": "Exp Neurol. 2007 Sep;207(1):1-3. Epub 2007 Jun 23", "reference": "17662278"}, "annotations": {"Subgraph": "Serotonergic subgraph", "Species": "10090"}, "source": 97, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Paroxetine treatment ameliorated the spatial navigation deficit in 3xTgAD male and female mice, without affecting swim speed or distance traveled, suggesting a preservation of cognitive function. Levels of amyloid beta-peptide (A) and numbers of A immunoreactive neurons were significantly reduced in the hippocampus of male and female paroxetine-treated 3xTgAD mice compared to saline-treated 3xTgAD mice.", "citation": {"type": "PubMed", "name": "Exp Neurol. 2007 May;205(1):166-76. Epub 2007 Feb 13", "reference": "17368447"}, "annotations": {"Species": "10090", "Subgraph": "Serotonergic subgraph"}, "source": 97, "target": 44, "key": 0}, {"relation": "increases", "evidence": "Paroxetine treatment ameliorated the spatial navigation deficit in 3xTgAD male and female mice, without affecting swim speed or distance traveled, suggesting a preservation of cognitive function. Levels of amyloid beta-peptide (A) and numbers of A immunoreactive neurons were significantly reduced in the hippocampus of male and female paroxetine-treated 3xTgAD mice compared to saline-treated 3xTgAD mice.", "citation": {"type": "PubMed", "name": "Exp Neurol. 2007 May;205(1):166-76. Epub 2007 Feb 13", "reference": "17368447"}, "annotations": {"Species": "10090", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 97, "target": 44, "key": 1}, {"relation": "decreases", "evidence": "Paroxetine results in decreased secretion of TNF protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17499975"}, "annotations": {"Species": "9606"}, "source": 97, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Flurbiprofen, the NSAID of which tarenflurbil is the R-enantiomer, has substantial amyloid-reducing activity. Because the R-enantiomer retains this anti-amyloid effect but does not have the cyclo-oxygenase inhibitory effect of flurbiprofen, it can be given at relatively high doses to elderly patients. It is thus a promising candidate for treatment of AD.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2008 Jun;7(6):468-9", "reference": "18450518"}, "annotations": {"FDASTATUS": "Phase 2", "DiseaseState": "Mild AD", "Subgraph": "Inflammatory response subgraph"}, "source": 98, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Results from a phase 2 study of tarenflurbil, a compound that inhibits gamma-secretase and has positive effects on cognition in animals, seemed promising in slowing decline in Alzheimer's disease assessment scale-cognitive (ADAS-cog) scores in patients with mild Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2010 Mar;9(3):235-7", "reference": "20170836"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Inflammatory response subgraph"}, "source": 98, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Results from a phase 2 study of tarenflurbil, a compound that inhibits gamma-secretase and has positive effects on cognition in animals, seemed promising in slowing decline in Alzheimer's disease assessment scale-cognitive (ADAS-cog) scores in patients with mild Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2010 Mar;9(3):235-7", "reference": "20170836"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Gamma secretase subgraph"}, "source": 98, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Results from a phase 2 study of tarenflurbil, a compound that inhibits gamma-secretase and has positive effects on cognition in animals, seemed promising in slowing decline in Alzheimer's disease assessment scale-cognitive (ADAS-cog) scores in patients with mild Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2010 Mar;9(3):235-7", "reference": "20170836"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 98, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "There has been a lot of disappointment surrounding the recent failure of the largest ever study in patients with Alzheimer's disease (AD) with tarenflurbil. A straightforward explanation of this failure is that the gamma-secretase is not the right target for therapy or that, in general, blocking A beta does not produce clinical benefits in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2009;17(4):757-60", "reference": "19542625"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Inflammatory response subgraph"}, "source": 98, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "There has been a lot of disappointment surrounding the recent failure of the largest ever study in patients with Alzheimer's disease (AD) with tarenflurbil. A straightforward explanation of this failure is that the gamma-secretase is not the right target for therapy or that, in general, blocking A beta does not produce clinical benefits in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2009;17(4):757-60", "reference": "19542625"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Gamma secretase subgraph"}, "source": 98, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "There has been a lot of disappointment surrounding the recent failure of the largest ever study in patients with Alzheimer's disease (AD) with tarenflurbil. A straightforward explanation of this failure is that the gamma-secretase is not the right target for therapy or that, in general, blocking A beta does not produce clinical benefits in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2009;17(4):757-60", "reference": "19542625"}, "annotations": {"FDASTATUS": "Phase 3", "DiseaseState": "Mild AD", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 98, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "The present investigation reports that clinically relevant concentrations of tarenflurbil (i.e., 1-5 microM) protect both cultured human neuroblastoma cell lines and primary neurons from cytotoxicity associated with exposure to Abeta_{42} or H_{2}O_{2}. In concert with this protection, there is an upregulation of neurotrophins [i.e., nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)]. Furthermore, blocking exogenous NGF or BDNF by binding it to antibody prevents tarenflurbil from protecting human neuronal cells from Abeta_{42} and H_{2}O_{2} cytotoxicity. These findings suggest that up-regulation of neurotrophins might represent an underlying mechanism contributing to the beneficial effects seen with tarenflurbil in AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Nov;15(3):397-407", "reference": "18997293"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 98, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "The present investigation reports that clinically relevant concentrations of tarenflurbil (i.e., 1-5 microM) protect both cultured human neuroblastoma cell lines and primary neurons from cytotoxicity associated with exposure to Abeta_{42} or H_{2}O_{2}. In concert with this protection, there is an upregulation of neurotrophins [i.e., nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)]. Furthermore, blocking exogenous NGF or BDNF by binding it to antibody prevents tarenflurbil from protecting human neuronal cells from Abeta_{42} and H_{2}O_{2} cytotoxicity. These findings suggest that up-regulation of neurotrophins might represent an underlying mechanism contributing to the beneficial effects seen with tarenflurbil in AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2008 Nov;15(3):397-407", "reference": "18997293"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 98, "target": 11, "key": 8}, {"relation": "decreases", "evidence": "Tarenflurbil binds to a gamma-secretase site other than the active/catalytic center of relevance to production of Abeta42, thereby altering the conformation of gamma-secretase and shifting production away from Abeta42, while avoiding interference with other physiologically essential gamma-secretase substrates. Tarenflurbil, which is the pure, R-enantiomer of flurbiprofen, shifts cleavage of APP away from Abeta42, thereby producing shorter, nontoxic fragments (e.g., Abeta38).", "citation": {"type": "PubMed", "name": "Prim Care Companion J Clin Psychiatry. 2007; 9(1): 3241", "reference": "17599166"}, "annotations": {"FDASTATUS": "Phase 2", "DiseaseState": "Mild AD", "Subgraph": "Inflammatory response subgraph"}, "source": 98, "target": 11, "key": 9}, {"relation": "decreases", "evidence": "Tarenflurbil binds to a gamma-secretase site other than the active/catalytic center of relevance to production of Abeta42, thereby altering the conformation of gamma-secretase and shifting production away from Abeta42, while avoiding interference with other physiologically essential gamma-secretase substrates. Tarenflurbil, which is the pure, R-enantiomer of flurbiprofen, shifts cleavage of APP away from Abeta42, thereby producing shorter, nontoxic fragments (e.g., Abeta38).", "citation": {"type": "PubMed", "name": "Prim Care Companion J Clin Psychiatry. 2007; 9(1): 3241", "reference": "17599166"}, "annotations": {"FDASTATUS": "Phase 2", "DiseaseState": "Mild AD", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 98, "target": 11, "key": 10}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 99, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 99, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 99, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 99, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 99, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 99, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 99, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 99, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "To explore the molecular mechanism underlying AD, HTN, and CAA, we hypothesize a feedback signaling loop consisted of Pin1, eNOS, and A. Pin1 and eNOS mainly inhibit A deposition in cerebral vessels, cerebral microbleeds, and elevation of blood pressure, preventing the development of AD, HTN, and CAA, however, A plays an opposite role and aggravates these diseases.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 99, "target": 33, "key": 0}, {"relation": "decreases", "evidence": "To explore the molecular mechanism underlying AD, HTN, and CAA, we hypothesize a feedback signaling loop consisted of Pin1, eNOS, and A. Pin1 and eNOS mainly inhibit A deposition in cerebral vessels, cerebral microbleeds, and elevation of blood pressure, preventing the development of AD, HTN, and CAA, however, A plays an opposite role and aggravates these diseases.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 99, "target": 33, "key": 1}, {"relation": "decreases", "evidence": "Pioglitazone decreased hippocampal -amyloid accumulation and Fas ligand, but did not ameliorate the neurobehavioural deficits induced by MSG. MSG treatment enhances -amyloid accumulation in the rat hippocampus.", "citation": {"type": "PubMed", "name": "Neurotoxicology. 2014 May;42:76-82", "reference": "24769037"}, "annotations": {"NervousSystem": "Hippocampus", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 100, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Pioglitazone decreased hippocampal -amyloid accumulation and Fas ligand, but did not ameliorate the neurobehavioural deficits induced by MSG. MSG treatment enhances -amyloid accumulation in the rat hippocampus.", "citation": {"type": "PubMed", "name": "Neurotoxicology. 2014 May;42:76-82", "reference": "24769037"}, "annotations": {"NervousSystem": "Hippocampus", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 100, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid (DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces A beta peptide release from aging human brain cells and is severely depleted in Alzheimer's disease (AD) brain.", "citation": {"type": "PubMed", "name": "PLoS One. 2011 Jan 5;6(1):e15816. doi: 10.1371/journal.pone.0015816.", "reference": "21246057"}, "annotations": {"Subgraph": "Neuroprotection subgraph"}, "source": 101, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid (DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces A beta peptide release from aging human brain cells and is severely depleted in Alzheimer's disease (AD) brain.", "citation": {"type": "PubMed", "name": "PLoS One. 2011 Jan 5;6(1):e15816. doi: 10.1371/journal.pone.0015816.", "reference": "21246057"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 101, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 101, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Neuroprotection subgraph"}, "source": 101, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 101, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 101, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid (DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces Abeta42 peptide release from aging human brain cells and is severely depleted in Alzheimer's disease (AD) brain.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 101, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid (DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces Abeta42 peptide release from aging human brain cells and is severely depleted in Alzheimer's disease (AD) brain.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Neuroprotection subgraph"}, "source": 101, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid (DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces Abeta42 peptide release from aging human brain cells and is severely depleted in Alzheimer's disease (AD) brain.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 101, "target": 11, "key": 8}, {"relation": "decreases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "Neuroprotection subgraph"}, "source": 101, "target": 11, "key": 9}, {"relation": "decreases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 101, "target": 11, "key": 10}, {"relation": "decreases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 101, "target": 11, "key": 11}, {"relation": "decreases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 101, "target": 11, "key": 12}, {"relation": "decreases", "evidence": "Acrolein inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15650393"}, "annotations": {}, "source": 102, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Acrolein inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17491020"}, "annotations": {}, "source": 102, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Acrolein inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18951912"}, "annotations": {}, "source": 102, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Acrolein inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19464576"}, "annotations": {}, "source": 102, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Acrolein inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20359552"}, "annotations": {}, "source": 102, "target": 140, "key": 4}, {"relation": "increases", "evidence": "Acrolein results in increased expression of EGR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20015449"}, "annotations": {}, "source": 102, "target": 195, "key": 0}, {"relation": "increases", "evidence": "Acrolein results in increased expression of EGR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18515264"}, "annotations": {}, "source": 102, "target": 195, "key": 1}, {"relation": "increases", "evidence": "Clioquinol results in increased expression of EGR1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19502547"}, "annotations": {"Species": "9606"}, "source": 103, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18549505"}, "annotations": {}, "source": 104, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19243473"}, "annotations": {}, "source": 104, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14555224"}, "annotations": {}, "source": 104, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15489888"}, "annotations": {}, "source": 104, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16023083"}, "annotations": {}, "source": 104, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16219905"}, "annotations": {}, "source": 104, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16819191"}, "annotations": {}, "source": 104, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17151092"}, "annotations": {}, "source": 104, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17198877"}, "annotations": {}, "source": 104, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17273796"}, "annotations": {}, "source": 104, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17291458"}, "annotations": {}, "source": 104, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17640567"}, "annotations": {}, "source": 104, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17666914"}, "annotations": {}, "source": 104, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17927689"}, "annotations": {}, "source": 104, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17973899"}, "annotations": {}, "source": 104, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18357586"}, "annotations": {}, "source": 104, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20599780"}, "annotations": {}, "source": 104, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21256849"}, "annotations": {}, "source": 104, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15489888"}, "annotations": {}, "source": 104, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16584726"}, "annotations": {}, "source": 104, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16751071"}, "annotations": {}, "source": 104, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18200517"}, "annotations": {}, "source": 104, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18403477"}, "annotations": {}, "source": 104, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18549505"}, "annotations": {}, "source": 104, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18752423"}, "annotations": {}, "source": 104, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19188055"}, "annotations": {}, "source": 104, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20712904"}, "annotations": {}, "source": 104, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21782934"}, "annotations": {}, "source": 104, "target": 140, "key": 27}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16782535"}, "annotations": {}, "source": 104, "target": 140, "key": 28}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16867261"}, "annotations": {}, "source": 104, "target": 140, "key": 29}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17276891"}, "annotations": {}, "source": 104, "target": 140, "key": 30}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17355460"}, "annotations": {}, "source": 104, "target": 140, "key": 31}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17383825"}, "annotations": {}, "source": 104, "target": 140, "key": 32}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17887948"}, "annotations": {}, "source": 104, "target": 140, "key": 33}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18001810"}, "annotations": {}, "source": 104, "target": 140, "key": 34}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18006644"}, "annotations": {}, "source": 104, "target": 140, "key": 35}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18368483"}, "annotations": {}, "source": 104, "target": 140, "key": 36}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18379247"}, "annotations": {}, "source": 104, "target": 140, "key": 37}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18565277"}, "annotations": {}, "source": 104, "target": 140, "key": 38}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18838107"}, "annotations": {}, "source": 104, "target": 140, "key": 39}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19225048"}, "annotations": {}, "source": 104, "target": 140, "key": 40}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19413659"}, "annotations": {}, "source": 104, "target": 140, "key": 41}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22465177"}, "annotations": {}, "source": 104, "target": 140, "key": 42}, {"relation": "decreases", "evidence": "chromium mesoporphyrin inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22683883"}, "annotations": {}, "source": 104, "target": 140, "key": 43}, {"relation": "decreases", "evidence": "anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Curcumin results in increased expression of EGR1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18462866"}, "annotations": {}, "source": 104, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Curcumin results in increased expression of EGR1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17198877"}, "annotations": {}, "source": 104, "target": 195, "key": 1}, {"relation": "decreases", "evidence": "anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Curcumin results in increased expression of EGR1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17999991"}, "annotations": {}, "source": 104, "target": 195, "key": 2}, {"relation": "decreases", "evidence": "anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Curcumin results in increased expression of EGR1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18316600"}, "annotations": {}, "source": 104, "target": 195, "key": 3}, {"relation": "decreases", "evidence": "anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Curcumin results in increased expression of EGR1 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18316600"}, "annotations": {}, "source": 104, "target": 195, "key": 4}, {"relation": "increases", "evidence": "[PRKCA protein results in increased phosphorylation of CFTR protein] promotes the reaction [Curcumin results in increased activity of CFTR protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17178710"}, "annotations": {}, "source": 104, "target": 253, "key": 0}, {"relation": "decreases", "evidence": "Indomethacin inhibits the reaction [VEGFA protein results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11595463"}, "annotations": {"Species": "9606"}, "source": 105, "target": 195, "key": 0}, {"relation": "decreases", "evidence": "Indomethacin inhibits the reaction [VEGFA protein results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15509713"}, "annotations": {"Species": "9606"}, "source": 105, "target": 195, "key": 1}, {"relation": "decreases", "evidence": "Indomethacin inhibits the reaction [VEGFA protein results in increased expression of EGR1 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16227405"}, "annotations": {"Species": "9606"}, "source": 105, "target": 195, "key": 2}, {"relation": "increases", "evidence": "polymorphisms in three other genes (among others), apolipoprotein E (apoE), alpha2-macroglobulin (alpham), and the low density lipoprotein receptor-related protein (LRP), are implicated to contribute to AD pathogenesis", "citation": {"type": "PubMed", "name": "Microsc Res Tech. 2000 Aug 15;50(4):268-72.", "reference": "10936878"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Alpha 2 macroglobulin subgraph"}, "source": 106, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Recently genome-wide association studies have identified significant association between Alzheimer's disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and ABCA7", "citation": {"type": "PubMed", "name": "G3 (Bethesda). 2012 Jan;2(1):71-8. Epub 2012 Jan 1", "reference": "22384383"}, "annotations": {"Disease": "Alzheimer's disease"}, "source": 107, "target": 33, "key": 3}, {"relation": "directlyIncreases", "evidence": "These studies combined include data from over 43000 independent individuals and provide compelling evidence that variants in four novel susceptibility genes (CLU, PICALM, CR1, BIN1) are associated with disease risk.", "citation": {"type": "PubMed", "name": "Int J Geriatr Psychiatry. 2011 Aug;26(8):793-802. doi: 10.1002/gps.2628. Epub 2010 Oct 19", "reference": "20957767"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Synaptic vesicle endocytosis subgraph"}, "source": 107, "target": 33, "key": 4}, {"relation": "increases", "evidence": "Recently genome-wide association studies have identified significant association between Alzheimer's disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and ABCA7", "citation": {"type": "PubMed", "name": "G3 (Bethesda). 2012 Jan;2(1):71-8. Epub 2012 Jan 1", "reference": "22384383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 108, "target": 33, "key": 1}, {"relation": "directlyIncreases", "evidence": "These studies combined include data from over 43000 independent individuals and provide compelling evidence that variants in four novel susceptibility genes (CLU, PICALM, CR1, BIN1) are associated with disease risk.", "citation": {"type": "PubMed", "name": "Int J Geriatr Psychiatry. 2011 Aug;26(8):793-802. doi: 10.1002/gps.2628. Epub 2010 Oct 19", "reference": "20957767"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 108, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Recently genome-wide association studies have identified significant association between Alzheimer's disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and ABCA7", "citation": {"type": "PubMed", "name": "G3 (Bethesda). 2012 Jan;2(1):71-8. Epub 2012 Jan 1", "reference": "22384383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 109, "target": 33, "key": 0}, {"relation": "directlyIncreases", "evidence": "These studies combined include data from over 43000 independent individuals and provide compelling evidence that variants in four novel susceptibility genes (CLU, PICALM, CR1, BIN1) are associated with disease risk.", "citation": {"type": "PubMed", "name": "Int J Geriatr Psychiatry. 2011 Aug;26(8):793-802. doi: 10.1002/gps.2628. Epub 2010 Oct 19", "reference": "20957767"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 109, "target": 33, "key": 1}, {"relation": "increases", "evidence": "CLU expression has been shown to be elevated in AD brains and is detected in amyloid Clusterin directly interacts with Ab and modifies fibril formation in vitro. rs11136000 associated with higher brain levels of clusterin . May modify microglial activation via regulation of complement. Alteration of fibril formation may affect Ab clearance", "citation": {"type": "PubMed", "name": "Curr Opin Neurobiol. 2016 Feb;36:74-81. doi: 10.1016/j.conb.2015.10.004. Epub 2015 Oct 24.", "reference": "  26517285 "}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 109, "target": 33, "key": 7}, {"relation": "increases", "evidence": "These results suggest a biological mechanism for the genetic association of CLU with AD risk and indicate rs9331888 is one of the functional DNA variants underlying this association.", "citation": {"type": "PubMed", "name": "Transl Psychiatry. 2011 Jul 1;1(7). pii: e18", "reference": "21892414"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 109, "target": 33, "key": 3}, {"relation": "increases", "evidence": "Recently genome-wide association studies have identified significant association between Alzheimer's disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and ABCA7", "citation": {"type": "PubMed", "name": "G3 (Bethesda). 2012 Jan;2(1):71-8. Epub 2012 Jan 1", "reference": "22384383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 110, "target": 33, "key": 0}, {"relation": "directlyIncreases", "evidence": "These studies combined include data from over 43000 independent individuals and provide compelling evidence that variants in four novel susceptibility genes (CLU, PICALM, CR1, BIN1) are associated with disease risk.", "citation": {"type": "PubMed", "name": "Int J Geriatr Psychiatry. 2011 Aug;26(8):793-802. doi: 10.1002/gps.2628. Epub 2010 Oct 19", "reference": "20957767"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 110, "target": 33, "key": 1}, {"relation": "increases", "evidence": "These data indicate that PICALM, an adaptor protein involved in clathrin-mediated endocytosis, regulates APP internalization and subsequent A generation. PICALM contributes to amyloid plaque load in brain likely via its effect on A metabolism.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Apr 26. [Epub ahead of print]", "reference": "22539346"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 110, "target": 11, "key": 0}, {"relation": "increases", "evidence": "These data indicate that PICALM, an adaptor protein involved in clathrin-mediated endocytosis, regulates APP internalization and subsequent A generation. PICALM contributes to amyloid plaque load in brain likely via its effect on A metabolism.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Apr 26. [Epub ahead of print]", "reference": "22539346"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 110, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Recently genome-wide association studies have identified significant association between Alzheimer's disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and ABCA7", "citation": {"type": "PubMed", "name": "G3 (Bethesda). 2012 Jan;2(1):71-8. Epub 2012 Jan 1", "reference": "22384383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Immunoglobulin subgraph"}, "source": 111, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Our data revealed the allele (T) of the rs3865444 polymorphism of the CD33 gene and the allele (C) of the rs610932 polymorphism of the MS4A6A gene may contribute to AD risk in the Chinese Han population.", "citation": {"type": "PubMed", "name": "Hum Genet. 2012 Mar 1. [Epub ahead of print]", "reference": "22382309"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Immunoglobulin subgraph"}, "source": 111, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Our results support the view that rs10868366 and rs7019241 in GOLPH2 and rs3826656 in near gene 5' region of CD33 are significantly associated with SAD in the north Chinese Han population.", "citation": {"type": "PubMed", "name": "Neurol Sci. 2011 Dec 14. [Epub ahead of print]", "reference": "22167654"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Immunoglobulin subgraph"}, "source": 111, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Recently genome-wide association studies have identified significant association between Alzheimer's disease (AD) and variations in CLU, PICALM, BIN1, CR1, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, and ABCA7", "citation": {"type": "PubMed", "name": "G3 (Bethesda). 2012 Jan;2(1):71-8. Epub 2012 Jan 1", "reference": "22384383"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Regulation of cytoskeleton subgraph"}, "source": 112, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Overall, this large, independent follow-up study for 15 of the top LOAD candidate genes provides support for GAB2 and LOC651924 (6q24.1) as risk modifiers of LOAD and novel associations between PGBD1 and EBF3 with age-at-onset.", "citation": {"type": "PubMed", "name": "Hum Genet. 2011 Mar;129(3):273-82. Epub 2010 Dec 4", "reference": "21132329"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Phosphatidylinositol 3 subgraph"}, "source": 113, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Overall, this large, independent follow-up study for 15 of the top LOAD candidate genes provides support for GAB2 and LOC651924 (6q24.1) as risk modifiers of LOAD and novel associations between PGBD1 and EBF3 with age-at-onset.", "citation": {"type": "PubMed", "name": "Hum Genet. 2011 Mar;129(3):273-82. Epub 2010 Dec 4", "reference": "21132329"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Akt subgraph"}, "source": 113, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2001 Oct;17(2):147-55.", "reference": "11816788"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 114, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy.", "citation": {"type": "PubMed", "name": "J Mol Neurosci. 2001 Oct;17(2):147-55.", "reference": "11816788"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 114, "target": 33, "key": 3}, {"relation": "increases", "evidence": "Our data revealed the allele (T) of the rs3865444 polymorphism of the CD33 gene and the allele (C) of the rs610932 polymorphism of the MS4A6A gene may contribute to AD risk in the Chinese Han population.", "citation": {"type": "PubMed", "name": "Hum Genet. 2012 Mar 1. [Epub ahead of print]", "reference": "22382309"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Immunoglobulin subgraph"}, "source": 115, "target": 33, "key": 0}, {"relation": "increases", "evidence": " 8-oxo-dG is widely used as biomarker of oxidative DNA damage due to demethylation. 8-dihydro-2 '-deoxyguanosine (8-oxo-dG), a general marker of oxidative stress", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.", "reference": "19245828"}, "annotations": {"Species": "10090"}, "source": 116, "target": 33, "key": 3}, {"relation": "decreases", "evidence": "Recently, we have reported that intracerebroventricular (ICV) administration of okadaic acid (OKA) in rats induces memory impairment that was associated with increased oxidative stress. Besides memory deficit, OKA caused impairment in mitochondrial function as revealed by alterations in calcium ion, reactive oxygen species (ROS) generation, mitochondrial membrane potential (MMP), SDH activity and ATP level in the brain regions. Further, in histopathological study it was observed that donepezil and memantine reduced the cell loss and neurodegeneration in hippocampus and periventricular cortex regions in OKA treated rats.", "citation": {"type": "PubMed", "name": "Pharmacol Biochem Behav. 2011 Dec;100(2):311-9", "reference": "21893081"}, "annotations": {"Species": "10116", "Subgraph": "Reactive oxygen species subgraph", "NervousSystem": "Cerebral Cortex"}, "source": 116, "target": 46, "key": 0}, {"relation": "decreases", "evidence": "Recently, we have reported that intracerebroventricular (ICV) administration of okadaic acid (OKA) in rats induces memory impairment that was associated with increased oxidative stress. Besides memory deficit, OKA caused impairment in mitochondrial function as revealed by alterations in calcium ion, reactive oxygen species (ROS) generation, mitochondrial membrane potential (MMP), SDH activity and ATP level in the brain regions. Further, in histopathological study it was observed that donepezil and memantine reduced the cell loss and neurodegeneration in hippocampus and periventricular cortex regions in OKA treated rats.", "citation": {"type": "PubMed", "name": "Pharmacol Biochem Behav. 2011 Dec;100(2):311-9", "reference": "21893081"}, "annotations": {"Species": "10116", "Subgraph": "Reactive oxygen species subgraph", "NervousSystem": "Hippocampus"}, "source": 116, "target": 46, "key": 1}, {"relation": "decreases", "evidence": "Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.", "citation": {"type": "PubMed", "name": "J Pharm Sci. 1991 Aug;80(8):750-1", "reference": "1791534"}, "annotations": {"Species": "10116", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 117, "target": 33, "key": 0}, {"relation": "decreases", "evidence": "In addition, studies in animals have demonstrated that androgens can play a protective role against Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2013 Nov 15;720(1-3):107-14", "reference": "24177288"}, "annotations": {"Subgraph": "Androgen subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 118, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Hypertension"}, "source": 119, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Hypercholesterolemia"}, "source": 119, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 119, "target": 33, "key": 2}, {"relation": "decreases", "evidence": "Therapeutic trials with melatonin have been effective in slowing the progression of Alzheimer's disease but not of Parkinson's disease.", "citation": {"type": "PubMed", "name": "Neurotox Res. 2005;7(4):293-318", "reference": "16179266"}, "annotations": {"Species": "9606", "MeSHDisease": "Parkinson Disease"}, "source": 120, "target": 33, "key": 2}, {"relation": "decreases", "evidence": "Therapeutic trials with melatonin have been effective in slowing the progression of Alzheimer's disease but not of Parkinson's disease.", "citation": {"type": "PubMed", "name": "Neurotox Res. 2005;7(4):293-318", "reference": "16179266"}, "annotations": {"Species": "9606", "MeSHDisease": "Alzheimer Disease"}, "source": 120, "target": 33, "key": 3}, {"relation": "increases", "evidence": "We will continue to investigate the effect of apoE isoform and Abeta conformation on the structural and functional interactions between these two proteins in relation to the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2004", "reference": "15181252"}, "annotations": {"Subgraph": "ApoE subgraph"}, "source": 121, "target": 33, "key": 0}, {"relation": "increases", "evidence": "We will continue to investigate the effect of apoE isoform and Abeta conformation on the structural and functional interactions between these two proteins in relation to the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2004", "reference": "15181252"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 121, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD) Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process.These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC) BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Aug;20(0):5-36", "reference": "18715507"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 122, "target": 140, "key": 0}, {"relation": "increases", "evidence": "Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD) Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process.These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC) BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Aug;20(0):5-36", "reference": "18715507"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Chemokine signaling subgraph"}, "source": 122, "target": 140, "key": 1}, {"relation": "increases", "evidence": "Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD) Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process.These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC) BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Aug;20(0):5-36", "reference": "18715507"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Interleukin signaling subgraph"}, "source": 122, "target": 140, "key": 2}, {"relation": "increases", "evidence": "Mechanistically, the increased risk of dementia in T2DM and obesity could be linked to chronic hyperglycemia, peripheral insulin resistance, oxidative stress, accumulation of advanced glycation end products, increased production of pro-inflammatory cytokines, and/orcerebral microvascular disease.", "citation": {"type": "PubMed", "name": "J Diabetes Sci Technol. Nov 2008; 2(6): 11011113.", "reference": "19885299"}, "annotations": {"MeSHDisease": "Diabetes Mellitus, Type 2", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 123, "target": 140, "key": 0}, {"relation": "increases", "evidence": "Mechanistically, the increased risk of dementia in T2DM and obesity could be linked to chronic hyperglycemia, peripheral insulin resistance, oxidative stress, accumulation of advanced glycation end products, increased production of pro-inflammatory cytokines, and/orcerebral microvascular disease.", "citation": {"type": "PubMed", "name": "J Diabetes Sci Technol. Nov 2008; 2(6): 11011113.", "reference": "19885299"}, "annotations": {"MeSHDisease": "Diabetes Mellitus, Type 2", "Subgraph": "Insulin signal transduction"}, "source": 123, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "AD risk may be attenuated by antipsychotics and lithium (down-regulate TNF), atypical antipsychotics (down-regulate TF), risperidone (down-regulates IL1B), olanzapine (up-regulates TFAM, down-regulates PRNP), fluoxetine (up-regulates CLU, SORCS1, NEDD9, GRN, and ECE1), and lithium coadministered with antipsychotics (down-regulates IL1B). ", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):1-7", "reference": "21399480"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 124, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "AD risk may be attenuated by antipsychotics and lithium (down-regulate TNF), atypical antipsychotics (down-regulate TF), risperidone (down-regulates IL1B), olanzapine (up-regulates TFAM, down-regulates PRNP), fluoxetine (up-regulates CLU, SORCS1, NEDD9, GRN, and ECE1), and lithium coadministered with antipsychotics (down-regulates IL1B). ", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):1-7", "reference": "21399480"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 124, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "AD risk may be attenuated by antipsychotics and lithium (down-regulate TNF), atypical antipsychotics (down-regulate TF), risperidone (down-regulates IL1B), olanzapine (up-regulates TFAM, down-regulates PRNP), fluoxetine (up-regulates CLU, SORCS1, NEDD9, GRN, and ECE1), and lithium coadministered with antipsychotics (down-regulates IL1B). ", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):1-7", "reference": "21399480"}, "annotations": {"Subgraph": "NMDA receptor"}, "source": 124, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15229385"}, "annotations": {}, "source": 125, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17964422"}, "annotations": {}, "source": 125, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16310260"}, "annotations": {}, "source": 125, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20017808"}, "annotations": {}, "source": 125, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22413959"}, "annotations": {}, "source": 125, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15489888"}, "annotations": {}, "source": 126, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16702388"}, "annotations": {}, "source": 126, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16230411"}, "annotations": {}, "source": 126, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20844471"}, "annotations": {}, "source": 126, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17908994"}, "annotations": {}, "source": 126, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19247274"}, "annotations": {}, "source": 126, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20039930"}, "annotations": {}, "source": 126, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "celecoxib inhibits the reaction [TNF protein results in increased activity of CHUK protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21893697"}, "annotations": {}, "source": 126, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "Folic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16595132"}, "annotations": {}, "source": 127, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Folic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {}, "source": 127, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Folic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21528358"}, "annotations": {}, "source": 127, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Folic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16214333"}, "annotations": {}, "source": 127, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Glucocorticoids results in decreased expression of [TNF protein results in increased expression of CCL20 protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16306769"}, "annotations": {"Species": "9606"}, "source": 128, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10336562"}, "annotations": {}, "source": 129, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10328874"}, "annotations": {}, "source": 129, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10602496"}, "annotations": {}, "source": 129, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11753679"}, "annotations": {}, "source": 129, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14586007"}, "annotations": {}, "source": 129, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15263833"}, "annotations": {}, "source": 129, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15489888"}, "annotations": {}, "source": 129, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16769766"}, "annotations": {}, "source": 129, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9890559"}, "annotations": {}, "source": 129, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10903797"}, "annotations": {}, "source": 129, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15060681"}, "annotations": {}, "source": 129, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16407166"}, "annotations": {}, "source": 129, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17630191"}, "annotations": {}, "source": 129, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9281604"}, "annotations": {}, "source": 129, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11545620"}, "annotations": {}, "source": 129, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "Ibuprofen inhibits the reaction [TNF protein results in increased expression of MMP3 mRNA]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21121909"}, "annotations": {}, "source": 129, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15866594"}, "annotations": {}, "source": 130, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16045524"}, "annotations": {}, "source": 130, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20363256"}, "annotations": {}, "source": 130, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19439560"}, "annotations": {}, "source": 130, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12504806"}, "annotations": {}, "source": 130, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "21501669"}, "annotations": {}, "source": 130, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "22157104"}, "annotations": {}, "source": 130, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12843254"}, "annotations": {}, "source": 130, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16916501"}, "annotations": {}, "source": 131, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17516992"}, "annotations": {}, "source": 131, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18550065"}, "annotations": {}, "source": 131, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19159436"}, "annotations": {}, "source": 131, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20167660"}, "annotations": {}, "source": 131, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20975550"}, "annotations": {}, "source": 131, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15140182"}, "annotations": {}, "source": 132, "target": 140, "key": 0}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "17013434"}, "annotations": {}, "source": 132, "target": 140, "key": 1}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10496904"}, "annotations": {}, "source": 132, "target": 140, "key": 2}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11367517"}, "annotations": {}, "source": 132, "target": 140, "key": 3}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11592764"}, "annotations": {}, "source": 132, "target": 140, "key": 4}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11788559"}, "annotations": {}, "source": 132, "target": 140, "key": 5}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12411981"}, "annotations": {}, "source": 132, "target": 140, "key": 6}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "12422154"}, "annotations": {}, "source": 132, "target": 140, "key": 7}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14687169"}, "annotations": {}, "source": 132, "target": 140, "key": 8}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15687330"}, "annotations": {}, "source": 132, "target": 140, "key": 9}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15863203"}, "annotations": {}, "source": 132, "target": 140, "key": 10}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15982930"}, "annotations": {}, "source": 132, "target": 140, "key": 11}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16454849"}, "annotations": {}, "source": 132, "target": 140, "key": 12}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9068814"}, "annotations": {}, "source": 132, "target": 140, "key": 13}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9623511"}, "annotations": {}, "source": 132, "target": 140, "key": 14}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "10720640"}, "annotations": {}, "source": 132, "target": 140, "key": 15}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "14617101"}, "annotations": {}, "source": 132, "target": 140, "key": 16}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15060740"}, "annotations": {}, "source": 132, "target": 140, "key": 17}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16510725"}, "annotations": {}, "source": 132, "target": 140, "key": 18}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16680017"}, "annotations": {}, "source": 132, "target": 140, "key": 19}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "15464241"}, "annotations": {}, "source": 132, "target": 140, "key": 20}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16078585"}, "annotations": {}, "source": 132, "target": 140, "key": 21}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16549389"}, "annotations": {}, "source": 132, "target": 140, "key": 22}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16597438"}, "annotations": {}, "source": 132, "target": 140, "key": 23}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16604421"}, "annotations": {}, "source": 132, "target": 140, "key": 24}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16815871"}, "annotations": {}, "source": 132, "target": 140, "key": 25}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "16943688"}, "annotations": {}, "source": 132, "target": 140, "key": 26}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18291259"}, "annotations": {}, "source": 132, "target": 140, "key": 27}, {"relation": "decreases", "evidence": "Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19050852"}, "annotations": {}, "source": 132, "target": 140, "key": 28}, {"relation": "decreases", "evidence": "Clinical tr ials in health y hum ans under  hyper insulin emic euglycemic  clamp   conditions  showed  a  n egative  shi ft  in transcortica l direct  current potentials, indicati ng that circ ulat ing insulin can  rapidly  act on  brain activity independent from its systemic effects [91 ]. Longitudinal studies revealed   th at insulin resistance  with   persisting   hyperi nsu linem i a  comes along  w ith an elevated risk  for disturbed cognition, impa ired memory and  A D (10, 92,  93].  In AD  patients as  well  as  i n h ealthy subjects  hyperinsulinemic eug lycemic clamp studies revea led an i mproving effect  of.insu li n on cognitive functio n (94,  95].  Intranasa l  app l ication  of  insu lin in healthy  hum ans directly  entered th e CSF  and  improved memory  function and cogn it ive capacity especi a lly in women  with out  in fluencing per i phera l  blood  gl ucose  levels  (96-98]. These  gender spe cific findings  suggest an influence of sex  hormon es. Accord  ingly, Cl egg el a!. d emonstrated th a t i nsul in sensitiv i ty in ra t brains differ,  dependin g on estrogen  levels (99].", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Hyperinsulinism"}, "source": 133, "target": 44, "key": 0}, {"relation": "decreases", "evidence": "Clinical tr ials in health y hum ans under  hyper insulin emic euglycemic  clamp   conditions  showed  a  n egative  shi ft  in transcortica l direct  current potentials, indicati ng that circ ulat ing insulin can  rapidly  act on  brain activity independent from its systemic effects [91 ]. Longitudinal studies revealed   th at insulin resistance  with   persisting   hyperi nsu linem i a  comes along  w ith an elevated risk  for disturbed cognition, impa ired memory and  A D (10, 92,  93].  In AD  patients as  well  as  i n h ealthy subjects  hyperinsulinemic eug lycemic clamp studies revea led an i mproving effect  of.insu li n on cognitive functio n (94,  95].  Intranasa l  app l ication  of  insu lin in healthy  hum ans directly  entered th e CSF  and  improved memory  function and cogn it ive capacity especi a lly in women  with out  in fluencing per i phera l  blood  gl ucose  levels  (96-98]. These  gender spe cific findings  suggest an influence of sex  hormon es. Accord  ingly, Cl egg el a!. d emonstrated th a t i nsul in sensitiv i ty in ra t brains differ,  dependin g on estrogen  levels (99].", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Hyperinsulinism"}, "source": 133, "target": 46, "key": 0}, {"relation": "increases", "evidence": "Phosphorylation of ERK leads to the activation of a number of transcription factors, important in controlling differentiation, neuronal survival, learning and memory plasticity.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 134, "target": 44, "key": 0}, {"relation": "increases", "evidence": "Phosphorylation of ERK leads to the activation of a number of transcription factors, important in controlling differentiation, neuronal survival, learning and memory plasticity.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 134, "target": 46, "key": 0}, {"relation": "decreases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Phosphatidylinositol 3 subgraph"}, "source": 135, "target": 253, "key": 0}, {"relation": "decreases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 135, "target": 253, "key": 1}, {"relation": "decreases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro. We examined which PKC isoforms were activated by VEGF by immunoprecipitating isoforms using specific antibodies and then performing immunoblotting using an anti-phospho-PKC antibody.We found that VEGF increased the level of phospho-PKC II, but had minimal effect on the phosphorylation of PKC , PKC I, or PKC  (Fig. 2D). Riluzole inhibits the reaction [VEGFA protein results in increased phosphorylation of PRKCB protein]", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Phosphatidylinositol 3 subgraph"}, "source": 135, "target": 253, "key": 2}, {"relation": "increases", "evidence": "As far as the metabolism of amyloid precursor protein (APP) in late-onset sporadic Alzheimer disease is concerned, neuronal insulin receptor dysfunction may result in the intracellular accumulation of Abeta and in subsequent cellular damage.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2004 Apr 19;490(1-3):115-25", "reference": "15094078"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 136, "target": 11, "key": 0}, {"relation": "increases", "evidence": "As far as the metabolism of amyloid precursor protein (APP) in late-onset sporadic Alzheimer disease is concerned, neuronal insulin receptor dysfunction may result in the intracellular accumulation of Abeta and in subsequent cellular damage.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2004 Apr 19;490(1-3):115-25", "reference": "15094078"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 136, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 20, "key": 0}, {"relation": "increases", "evidence": "The extracellular amyloid deposits in senile plaques also trigger reactive glial changes and neuroinflammation that can also contribute to neuronal loss through production of reactive oxygen species (ROS), NO, and proinflammatory cytokines such as TNF-a and IL-1.", "citation": {"type": "PubMed", "name": "J Clin Invest. 2004 Jul;114(1):23-7", "reference": "15232608"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 140, "target": 20, "key": 1}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 20, "key": 2}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 140, "target": 20, "key": 3}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 42, "key": 0}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 140, "target": 42, "key": 1}, {"relation": "increases", "evidence": "As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 42, "key": 2}, {"relation": "increases", "evidence": "An important factor in the onset of inflammatory process is the overexpression of interleukin (IL)-1, which produces many reactions in a vicious circle that cause dysfunction and neuronal death. Other important cytokines in neuroinflammation are IL-6 and tumor necrosis factor (TNF)-. By contrast, other cytokines such as IL-1 receptor antagonist (IL-1ra), IL-4, IL-10, and transforming growth factor (TGF)- can suppress both proinflammatory cytokine production and their action, subsequently protecting the brain. ", "citation": {"type": "PubMed", "name": "ScientificWorldJournal. 2012;2012:756357. doi: 10.1100/2012/756357. Epub 2012 Apr 1.", "reference": "22566778"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 42, "key": 3}, {"relation": "increases", "evidence": "An important factor in the onset of inflammatory process is the overexpression of interleukin (IL)-1, which produces many reactions in a vicious circle that cause dysfunction and neuronal death. Other important cytokines in neuroinflammation are IL-6 and tumor necrosis factor (TNF)-. By contrast, other cytokines such as IL-1 receptor antagonist (IL-1ra), IL-4, IL-10, and transforming growth factor (TGF)- can suppress both proinflammatory cytokine production and their action, subsequently protecting the brain. ", "citation": {"type": "PubMed", "name": "ScientificWorldJournal. 2012;2012:756357. doi: 10.1100/2012/756357. Epub 2012 Apr 1.", "reference": "22566778"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 140, "target": 42, "key": 4}, {"relation": "increases", "evidence": "As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 42, "key": 5}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 43, "key": 0}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 140, "target": 43, "key": 1}, {"relation": "increases", "evidence": "A significant role of a pathological glial cell activation in the pathogenesis of Alzheimer's disease is supported by the growing evidence that inflammatory proteins, which are produced by reactive astrocytes, promote the transformation of diffuse beta-amyloid deposits into the filamentous, neurotoxic form. A number of vicious circles, driven by the release of TNF-a and free oxygen radicals from microglial cells, may cause an upregulated microglial activation and their production of interleukin-1 which triggers, secondarily, the crucial activation of astrocytes.", "citation": {"type": "PubMed", "name": "J Neural Transm Suppl. 1998;54:167-74.", "reference": "9850925"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 43, "key": 2}, {"relation": "increases", "evidence": "A significant role of a pathological glial cell activation in the pathogenesis of Alzheimer's disease is supported by the growing evidence that inflammatory proteins, which are produced by reactive astrocytes, promote the transformation of diffuse beta-amyloid deposits into the filamentous, neurotoxic form. A number of vicious circles, driven by the release of TNF-a and free oxygen radicals from microglial cells, may cause an upregulated microglial activation and their production of interleukin-1 which triggers, secondarily, the crucial activation of astrocytes.", "citation": {"type": "PubMed", "name": "J Neural Transm Suppl. 1998;54:167-74.", "reference": "9850925"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 140, "target": 43, "key": 3}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 14, "key": 0}, {"relation": "increases", "evidence": "Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-a are key mediators of neuroinflammation and may contribute to neuronal dysfunction", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2012 Jan 25;9:23", "reference": "22277195"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Inflammatory response subgraph"}, "source": 140, "target": 14, "key": 1}, {"relation": "increases", "evidence": "Cytokines, particularly tumor necrosis factor  (TNF-) and interleukin 1 (IL-1), can induce chronic inflammation that may promote the loss of synapses, cognitive dysfunction, and eventually neuronal death [19] and [20].", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2014 Jun 21. pii: S0891-5849(14)00265-2", "reference": "24960578"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 26, "key": 0}, {"relation": "increases", "evidence": "TNF- and IL-1 play vital roles in joint inflammation and bone destruction.", "citation": {"type": "PubMed", "name": "Clin Med Circ Respirat Pulm Med. 2008 Apr 29;2:35-44", "reference": "21157520"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 26, "key": 1}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 137, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 138, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 139, "key": 0}, {"relation": "increases", "evidence": "Further, TNF-alpha upregulated the production of TSP1 and CD47 by myoblasts.", "citation": {"type": "PubMed", "name": "J Neuroimmunol. 2007 Jul;187(1-2):166-74. Epub 2007 Jun 18", "reference": "17572512"}, "annotations": {"Subgraph": "Cell adhesion subgraph"}, "source": 140, "target": 179, "key": 0}, {"relation": "increases", "evidence": "Further, TNF-alpha upregulated the production of TSP1 and CD47 by myoblasts.", "citation": {"type": "PubMed", "name": "J Neuroimmunol. 2007 Jul;187(1-2):166-74. Epub 2007 Jun 18", "reference": "17572512"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 179, "key": 1}, {"relation": "increases", "evidence": "Both IL-1 and TNF are known to trigger a classical IB kinase (IKK)-dependent activation of NF-B,", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 192, "key": 0}, {"relation": "increases", "evidence": "Both IL-1 and TNF are known to trigger a classical IB kinase (IKK)-dependent activation of NF-B,", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 140, "target": 192, "key": 1}, {"relation": "decreases", "evidence": "There is a physiological decline of the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis with ageing and the possibility that the GH/ IGF-I axis is involved in cognitive deficits has been recognized for several years. The IGF-I is a potent neurotrophic as well neuroprotective factor found in the brain with a wide range of actions in both central and peripheral nervous system. IGF-I is a critical promoter of brain development and neuronal survival and plays a role in neuronal rescue during degenerative diseases.When a cholinesterase inhibitor as rivastigmine, a drug for AD, is acutely administered the area under the curve of the GH response to GHRH doubled, showing that rivastigmine is a powerful drug to enhance GH release. TNF production may promote neurodegeneration not through direct killing of neurons but rather through inhibition of IGF-I survival signalling", "citation": {"type": "PubMed", "name": "Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):274-86", "reference": "22524398"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 204, "key": 0}, {"relation": "decreases", "evidence": "There is a physiological decline of the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis with ageing and the possibility that the GH/ IGF-I axis is involved in cognitive deficits has been recognized for several years. The IGF-I is a potent neurotrophic as well neuroprotective factor found in the brain with a wide range of actions in both central and peripheral nervous system. IGF-I is a critical promoter of brain development and neuronal survival and plays a role in neuronal rescue during degenerative diseases.When a cholinesterase inhibitor as rivastigmine, a drug for AD, is acutely administered the area under the curve of the GH response to GHRH doubled, showing that rivastigmine is a powerful drug to enhance GH release. TNF production may promote neurodegeneration not through direct killing of neurons but rather through inhibition of IGF-I survival signalling", "citation": {"type": "PubMed", "name": "Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):274-86", "reference": "22524398"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Insulin signal transduction"}, "source": 140, "target": 204, "key": 1}, {"relation": "decreases", "evidence": "The effect of IGF-I in  amyloid clearance is mediated by enhancing the transport of the  amyloid carrier proteins, albumin and transthyretin into the brain through the choroid plexus, with increased levels of  amyloid in the cerebrospinal fluid and this process is blocked by TNF", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Albumin subgraph"}, "source": 140, "target": 204, "key": 2}, {"relation": "decreases", "evidence": "The effect of IGF-I in  amyloid clearance is mediated by enhancing the transport of the  amyloid carrier proteins, albumin and transthyretin into the brain through the choroid plexus, with increased levels of  amyloid in the cerebrospinal fluid and this process is blocked by TNF", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 204, "key": 3}, {"relation": "decreases", "evidence": "The effect of IGF-I in  amyloid clearance is mediated by enhancing the transport of the  amyloid carrier proteins, albumin and transthyretin into the brain through the choroid plexus, with increased levels of  amyloid in the cerebrospinal fluid and this process is blocked by TNF", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Insulin signal transduction"}, "source": 140, "target": 204, "key": 4}, {"relation": "decreases", "evidence": "The effect of IGF-I in  amyloid clearance is mediated by enhancing the transport of the  amyloid carrier proteins, albumin and transthyretin into the brain through the choroid plexus, with increased levels of  amyloid in the cerebrospinal fluid and this process is blocked by TNF", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Albumin subgraph"}, "source": 140, "target": 204, "key": 5}, {"relation": "decreases", "evidence": "The effect of IGF-I in  amyloid clearance is mediated by enhancing the transport of the  amyloid carrier proteins, albumin and transthyretin into the brain through the choroid plexus, with increased levels of  amyloid in the cerebrospinal fluid and this process is blocked by TNF", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 204, "key": 6}, {"relation": "decreases", "evidence": "The effect of IGF-I in  amyloid clearance is mediated by enhancing the transport of the  amyloid carrier proteins, albumin and transthyretin into the brain through the choroid plexus, with increased levels of  amyloid in the cerebrospinal fluid and this process is blocked by TNF", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Insulin signal transduction"}, "source": 140, "target": 204, "key": 7}, {"relation": "decreases", "evidence": "Activated microglia release a combination of bioactive agents including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), and insulin-like growth factor 1 (IGF-1). These bioactive agents have both protective and detrimental consequences for the surrounding brain tissue. We found that, while mitochondrial toxins did not affect LPS-induced activation, as measured by release of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta), they did inhibit part of the IL-4-induced alternative activation, as measured by arginase activity and expression, induction of insulin-like growth factor 1 (IGF-1) and the counteraction of the LPS induced cytokine release.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2010 Aug 11;7:45", "reference": "20701773"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 204, "key": 8}, {"relation": "decreases", "evidence": "Activated microglia release a combination of bioactive agents including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), and insulin-like growth factor 1 (IGF-1). These bioactive agents have both protective and detrimental consequences for the surrounding brain tissue. We found that, while mitochondrial toxins did not affect LPS-induced activation, as measured by release of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta), they did inhibit part of the IL-4-induced alternative activation, as measured by arginase activity and expression, induction of insulin-like growth factor 1 (IGF-1) and the counteraction of the LPS induced cytokine release.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2010 Aug 11;7:45", "reference": "20701773"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 140, "target": 204, "key": 9}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 216, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 217, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 218, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 219, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 220, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 221, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 222, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 223, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 224, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 225, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 226, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 227, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 228, "key": 0}, {"relation": "decreases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 140, "target": 229, "key": 0}, {"relation": "increases", "evidence": "In addition, pericytes respond to the pro-inflammatory cytokines tumor necrosis factor- and Interferon- by inducing the expression of the CYP27B1 gene which is involved in 1,25D synthesis.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2014 Jun 16", "reference": "24934545"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 230, "key": 0}, {"relation": "increases", "evidence": "In addition, pericytes respond to the pro-inflammatory cytokines tumor necrosis factor- and Interferon- by inducing the expression of the CYP27B1 gene which is involved in 1,25D synthesis.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2014 Jun 16", "reference": "24934545"}, "annotations": {"Subgraph": "Vitamin subgraph"}, "source": 140, "target": 230, "key": 1}, {"relation": "increases", "evidence": "In addition, pericytes respond to the pro-inflammatory cytokines tumor necrosis factor- and Interferon- by inducing the expression of the CYP27B1 gene which is involved in 1,25D synthesis.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2014 Jun 16", "reference": "24934545"}, "annotations": {"Subgraph": "Metabolism of steroid hormones subgraph"}, "source": 140, "target": 230, "key": 2}, {"relation": "increases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 140, "target": 231, "key": 0}, {"relation": "increases", "evidence": "In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.", "citation": {"type": "PubMed", "name": "Mediators Inflamm. 2014;2014:861231", "reference": "24966471"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 231, "key": 1}, {"relation": "decreases", "evidence": "The moderating effect of rivastigmine on the endotoxin-induced suppression of GnRH/LH secretion may result from the inhibition of pro-inflammatory cytokines released through the cholinergic anti-inflammatory pathway. AChE inhibitors lead to an increase in the concentration of ACh and activate the cholinergic anti-inflammatory pathway (Borovikova et al., 2000). These inhibitors attenuate the cytokine release, including that of IL-1, IL-6 and TNF, which have been previously described both in vitro and in vivo ( Borovikova et al., 2000 and Pollak et al., 2005). The ability of rivastigmine to reduce the inflammatory action within the brain could have a profound effect on GnRH secretion, as numerous studies have reported that centrally acting pro-inflammatory cytokines, especially IL-1 but also IL-1 and TNF, may be primarily responsible for the inhibition of GnRH/LH secretion", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 232, "key": 0}, {"relation": "decreases", "evidence": "Activated microglia release a combination of bioactive agents including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), and insulin-like growth factor 1 (IGF-1). These bioactive agents have both protective and detrimental consequences for the surrounding brain tissue. We found that, while mitochondrial toxins did not affect LPS-induced activation, as measured by release of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta), they did inhibit part of the IL-4-induced alternative activation, as measured by arginase activity and expression, induction of insulin-like growth factor 1 (IGF-1) and the counteraction of the LPS induced cytokine release.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2010 Aug 11;7:45", "reference": "20701773"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 233, "key": 0}, {"relation": "decreases", "evidence": "Activated microglia release a combination of bioactive agents including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), and insulin-like growth factor 1 (IGF-1). These bioactive agents have both protective and detrimental consequences for the surrounding brain tissue. We found that, while mitochondrial toxins did not affect LPS-induced activation, as measured by release of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta), they did inhibit part of the IL-4-induced alternative activation, as measured by arginase activity and expression, induction of insulin-like growth factor 1 (IGF-1) and the counteraction of the LPS induced cytokine release.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2010 Aug 11;7:45", "reference": "20701773"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 140, "target": 233, "key": 1}, {"relation": "increases", "evidence": "Both IL-1 and TNF are known to trigger a classical IB kinase (IKK)-dependent activation of NF-B,", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 140, "target": 234, "key": 0}, {"relation": "increases", "evidence": "Both IL-1 and TNF are known to trigger a classical IB kinase (IKK)-dependent activation of NF-B,", "citation": {"type": "PubMed", "name": "J Immunol. 2015 Mar 15;194(6):2862-70. doi: 10.4049/jimmunol.1400874. Epub 2015 Feb 13.", "reference": "25681350"}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 140, "target": 234, "key": 1}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 0}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 1}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Response to oxidative stress"}, "source": 141, "target": 11, "key": 2}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Ex vivo studies show that the levels of BACE1 are tightly regulated by the ATases. Specifically, up-regulation of ATase1 and ATase2 increases the levels of BACE1 and the generation of A while siRNA-mediated down-regulation of either transferase achieves the opposite effects.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 9;287(11):8424-33. Epub 2012 Jan 20", "reference": "22267734"}, "annotations": {"Condition": "Normal Healthy State", "NervousSystem": "Neurons", "Cell": "microglial cell", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Ex vivo studies show that the levels of BACE1 are tightly regulated by the ATases. Specifically, up-regulation of ATase1 and ATase2 increases the levels of BACE1 and the generation of A while siRNA-mediated down-regulation of either transferase achieves the opposite effects.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 9;287(11):8424-33. Epub 2012 Jan 20", "reference": "22267734"}, "annotations": {"Condition": "Normal Healthy State", "NervousSystem": "Neurons", "Cell": "microglial cell", "Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.", "reference": "18650430"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 6}, {"relation": "increases", "evidence": "Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.", "reference": "18650430"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 7}, {"relation": "increases", "evidence": "Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.", "reference": "18650430"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Gamma secretase subgraph"}, "source": 141, "target": 11, "key": 8}, {"relation": "increases", "evidence": " Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.", "citation": {"type": "PubMed", "name": "J Neurosci. 2007 Apr 11;27(15):4052-60.", "reference": "17428983"}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 9}, {"relation": "increases", "evidence": " Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.", "citation": {"type": "PubMed", "name": "J Neurosci. 2007 Apr 11;27(15):4052-60.", "reference": "17428983"}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 10}, {"relation": "increases", "evidence": " Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.", "citation": {"type": "PubMed", "name": "J Neurosci. 2007 Apr 11;27(15):4052-60.", "reference": "17428983"}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 141, "target": 11, "key": 11}, {"relation": "increases", "evidence": "The level of -site APP-cleaving enzyme 1 (BACE1) has been documented to increase in the brains of patients with Alzheimer's disease, which has resulted in elevation of -amyloid (A) peptides.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2012 Jan 30;675(1-3):15-21. Epub 2011 Dec 7.", "reference": "22166376"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 12}, {"relation": "increases", "evidence": "The level of -site APP-cleaving enzyme 1 (BACE1) has been documented to increase in the brains of patients with Alzheimer's disease, which has resulted in elevation of -amyloid (A) peptides.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2012 Jan 30;675(1-3):15-21. Epub 2011 Dec 7.", "reference": "22166376"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 13}, {"relation": "increases", "evidence": "CerebraiiR/IGF-1 signaling in APP  metabolism. Binding of insulin and IGF-1  to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3and  the tau phosphatase  PP2A. Inter estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK  cascade regulate different transcription  factors involved in transcriptional  regulation of metabolism and clearance of   amyloid. APP is cleaved by a.-,  -secretase (BACE-1) and y-secretase (presenilin).  - and subsequent  y-cleavage of APP leads to generation of  -amyloid 1 -4o/ t-42  IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest  that not only BACE-1 is int1uenced  by IRIIGF- IR mediated signals but also a. secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 14}, {"relation": "increases", "evidence": "CerebraiiR/IGF-1 signaling in APP  metabolism. Binding of insulin and IGF-1  to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3and  the tau phosphatase  PP2A. Inter estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK  cascade regulate different transcription  factors involved in transcriptional  regulation of metabolism and clearance of   amyloid. APP is cleaved by a.-,  -secretase (BACE-1) and y-secretase (presenilin).  - and subsequent  y-cleavage of APP leads to generation of  -amyloid 1 -4o/ t-42  IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest  that not only BACE-1 is int1uenced  by IRIIGF- IR mediated signals but also a. secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 15}, {"relation": "increases", "evidence": "CerebraiiR/IGF-1 signaling in APP  metabolism. Binding of insulin and IGF-1  to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3and  the tau phosphatase  PP2A. Inter estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK  cascade regulate different transcription  factors involved in transcriptional  regulation of metabolism and clearance of   amyloid. APP is cleaved by a.-,  -secretase (BACE-1) and y-secretase (presenilin).  - and subsequent  y-cleavage of APP leads to generation of  -amyloid 1 -4o/ t-42  IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest  that not only BACE-1 is int1uenced  by IRIIGF- IR mediated signals but also a. secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Nerve growth factor subgraph"}, "source": 141, "target": 11, "key": 16}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 17}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 18}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Response to oxidative stress"}, "source": 141, "target": 11, "key": 19}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 141, "target": 11, "key": 20}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Response to oxidative stress"}, "source": 141, "target": 11, "key": 21}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 141, "target": 11, "key": 22}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 23}, {"relation": "increases", "evidence": "oxidative stress-mediated ERK activation contributes to increases in -secretase and, thus, an increase of A generation in neuronal cells expressing mutant PS2", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9", "reference": "22249458"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 24}, {"relation": "decreases", "evidence": "In this study, we aimed to investigate the possibility of P-gp as a potential therapeutic target for Alzheimer's disease by examining the impact of P-gp up-regulation on the clearance of A, a neuropathological hallmark of Alzheimer's disease.Uptake studies for-radiolabelled A Approximately 10-35% decrease in A intracellular accumulation was observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, -estradiol and pentylenetetrazole compared with control.", "citation": {"type": "PubMed", "name": "J Pharm Pharmacol. 2011 Aug;63(8):1111-8", "reference": "21718295"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 25}, {"relation": "decreases", "evidence": "In this study, we aimed to investigate the possibility of P-gp as a potential therapeutic target for Alzheimer's disease by examining the impact of P-gp up-regulation on the clearance of A, a neuropathological hallmark of Alzheimer's disease.Uptake studies for-radiolabelled A Approximately 10-35% decrease in A intracellular accumulation was observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, -estradiol and pentylenetetrazole compared with control.", "citation": {"type": "PubMed", "name": "J Pharm Pharmacol. 2011 Aug;63(8):1111-8", "reference": "21718295"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 26}, {"relation": "increases", "evidence": "RAGE stimulates functional BACE1 expression through NFAT1 activation, resulting in more Abeta production and deposition in the brain.", "citation": {"type": "PubMed", "name": "FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.", "reference": "19332646"}, "annotations": {"Subgraph": "Immunoglobulin subgraph"}, "source": 141, "target": 11, "key": 27}, {"relation": "increases", "evidence": "RAGE stimulates functional BACE1 expression through NFAT1 activation, resulting in more Abeta production and deposition in the brain.", "citation": {"type": "PubMed", "name": "FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.", "reference": "19332646"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 28}, {"relation": "increases", "evidence": "RAGE stimulates functional BACE1 expression through NFAT1 activation, resulting in more Abeta production and deposition in the brain.", "citation": {"type": "PubMed", "name": "FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.", "reference": "19332646"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 29}, {"relation": "increases", "evidence": "RAGE stimulates functional BACE1 expression through NFAT1 activation, resulting in more Abeta production and deposition in the brain.", "citation": {"type": "PubMed", "name": "FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.", "reference": "19332646"}, "annotations": {"Subgraph": "T cells signaling"}, "source": 141, "target": 11, "key": 30}, {"relation": "increases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 31}, {"relation": "increases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Neuroprotection subgraph"}, "source": 141, "target": 11, "key": 32}, {"relation": "increases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 33}, {"relation": "increases", "evidence": "Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.", "citation": {"type": "PubMed", "name": "PLoS One2011", "reference": "21246057"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 141, "target": 11, "key": 34}, {"relation": "increases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "Neuroprotection subgraph"}, "source": 141, "target": 11, "key": 35}, {"relation": "increases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 36}, {"relation": "increases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 141, "target": 11, "key": 37}, {"relation": "increases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 38}, {"relation": "increases", "evidence": "A pathogenic mutation at codons 670/671 in APP (APP Swedish) leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A1999", "reference": "10500121"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 39}, {"relation": "increases", "evidence": "A pathogenic mutation at codons 670/671 in APP (APP Swedish) leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A1999", "reference": "10500121"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 40}, {"relation": "increases", "evidence": "The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta-secretase that cleaves amyloid precursor protein to initiate beta-amyloid formation.", "citation": {"type": "PubMed", "name": "J Biol Chem2000", "reference": "10956649"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 41}, {"relation": "increases", "evidence": "The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta-secretase that cleaves amyloid precursor protein to initiate beta-amyloid formation.", "citation": {"type": "PubMed", "name": "J Biol Chem2000", "reference": "10956649"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 42}, {"relation": "increases", "evidence": "A beta is generated by the sequential intracellular cleavage of APP by beta-secretase to generate the N-terminal end of A beta, and intramembranous cleavage by gamma-secretase to generate the C-terminal end.", "citation": {"type": "PubMed", "name": "Histol Histopathol2002", "reference": "11813874"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 43}, {"relation": "increases", "evidence": "A beta is generated by the sequential intracellular cleavage of APP by beta-secretase to generate the N-terminal end of A beta, and intramembranous cleavage by gamma-secretase to generate the C-terminal end.", "citation": {"type": "PubMed", "name": "Histol Histopathol2002", "reference": "11813874"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 44}, {"relation": "increases", "evidence": "beta-Secretase, a beta-site amyloid precursor protein (APP) cleaving enzyme (BACE), participates in the secretion of beta-amyloid peptides (Abeta), the major components of the toxic amyloid plaques found in the brains of patients with Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Acta Biochim Pol2004", "reference": "15218540"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 45}, {"relation": "increases", "evidence": "beta-Secretase, a beta-site amyloid precursor protein (APP) cleaving enzyme (BACE), participates in the secretion of beta-amyloid peptides (Abeta), the major components of the toxic amyloid plaques found in the brains of patients with Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Acta Biochim Pol2004", "reference": "15218540"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 46}, {"relation": "increases", "evidence": "Amyloid-beta (Abeta) the primary component of the senile plaques found in Alzheimer's disease (AD) is generated by the rate-limiting cleavage of amyloid precursor protein (APP) by beta-secretase followed by gamma-secretase cleavage.", "citation": {"type": "PubMed", "name": "J Biol Chem2004", "reference": "15452128"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 47}, {"relation": "increases", "evidence": "Amyloid-beta (Abeta) the primary component of the senile plaques found in Alzheimer's disease (AD) is generated by the rate-limiting cleavage of amyloid precursor protein (APP) by beta-secretase followed by gamma-secretase cleavage.", "citation": {"type": "PubMed", "name": "J Biol Chem2004", "reference": "15452128"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 48}, {"relation": "increases", "evidence": "The generation of beta-amyloid peptides requires the enzymatic activity of the beta-site APP-cleaving enzyme 1 (BACE1).", "citation": {"type": "PubMed", "name": "Int J Dev Neurosci2004", "reference": "15465276"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 49}, {"relation": "increases", "evidence": "The generation of beta-amyloid peptides requires the enzymatic activity of the beta-site APP-cleaving enzyme 1 (BACE1).", "citation": {"type": "PubMed", "name": "Int J Dev Neurosci2004", "reference": "15465276"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 50}, {"relation": "increases", "evidence": "The generation of beta-amyloid peptides by proteolytical processing of the amyloid precursor protein (APP) requires the enzymatic activity of the beta-site APP cleaving enzyme 1 (BACE1).", "citation": {"type": "PubMed", "name": "J Neurochem2005", "reference": "15663471"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 51}, {"relation": "increases", "evidence": "The generation of beta-amyloid peptides by proteolytical processing of the amyloid precursor protein (APP) requires the enzymatic activity of the beta-site APP cleaving enzyme 1 (BACE1).", "citation": {"type": "PubMed", "name": "J Neurochem2005", "reference": "15663471"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 52}, {"relation": "increases", "evidence": "Using an assay that incorporates full-length recombinant APP as a substrate for beta-secretase (BACE), we have identified a series of compounds that inhibit APP processing, but do not affect the cleavage of peptide substrates by BACE1.", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "15737955"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 53}, {"relation": "increases", "evidence": "Sequential processing of amyloid precursor protein (APP) by membrane-bound proteases, BACE1 and gamma-secretase, plays a crucial role in the pathogenesis of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "15824102"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 54}, {"relation": "increases", "evidence": "Sequential processing of amyloid precursor protein (APP) by membrane-bound proteases, BACE1 and gamma-secretase, plays a crucial role in the pathogenesis of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "15824102"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 55}, {"relation": "increases", "evidence": "gamma-Secretase is a membrane protein complex that cleaves the beta-amyloid precursor protein (APP) within the transmembrane region, after prior processing by beta-secretase, producing amyloid beta peptides Abeta(40) and Abeta(42).", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2005", "reference": "15890777"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 56}, {"relation": "increases", "evidence": "Release of Abeta from the amyloid precursor protein (APP) requires proteolysis by the beta-site APP-cleaving enzyme (BACE1).", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "16027115"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 57}, {"relation": "increases", "evidence": "Release of Abeta from the amyloid precursor protein (APP) requires proteolysis by the beta-site APP-cleaving enzyme (BACE1).", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "16027115"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 58}, {"relation": "increases", "evidence": "Abeta is produced from beta-amyloid precursor protein (APP) by beta-secretase and gamma-secretase. beta-Secretase has been identified as beta-site APP cleaving enzyme1 (BACE1).", "citation": {"type": "PubMed", "name": "Neurosci Res2006", "reference": "16290302"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 59}, {"relation": "increases", "evidence": "Abeta is produced from beta-amyloid precursor protein (APP) by beta-secretase and gamma-secretase. beta-Secretase has been identified as beta-site APP cleaving enzyme1 (BACE1).", "citation": {"type": "PubMed", "name": "Neurosci Res2006", "reference": "16290302"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 60}, {"relation": "increases", "evidence": "The beta-amyloid peptide (Abeta) is a major component of the Alzheimer's disease (AD)-associated senile plaques and is generated by sequential cleavage of the beta-amyloid precursor protein (APP) by beta-secretase and gamma-secretase.", "citation": {"type": "PubMed", "name": "RNA2006", "reference": "16888322"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 61}, {"relation": "increases", "evidence": "The beta-amyloid peptide (Abeta) is a major component of the Alzheimer's disease (AD)-associated senile plaques and is generated by sequential cleavage of the beta-amyloid precursor protein (APP) by beta-secretase and gamma-secretase.", "citation": {"type": "PubMed", "name": "RNA2006", "reference": "16888322"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 62}, {"relation": "increases", "evidence": "Amyloid beta-peptide (Abeta), which is a product of the proteolytic effect of beta-secretase (BACE) on an amyloid precursor protein, is closely associated with Alzheimer's disease (AD) pathogenesis.", "citation": {"type": "PubMed", "name": "J Microbiol2006", "reference": "17205046"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 63}, {"relation": "increases", "evidence": "Amyloid beta-peptide (Abeta), which is a product of the proteolytic effect of beta-secretase (BACE) on an amyloid precursor protein, is closely associated with Alzheimer's disease (AD) pathogenesis.", "citation": {"type": "PubMed", "name": "J Microbiol2006", "reference": "17205046"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 64}, {"relation": "increases", "evidence": "TNF-alpha directly stimulated beta-site APP-cleaving enzyme (BACE1) expression and enhanced beta-processing of APP in astrocytes.", "citation": {"type": "PubMed", "name": "Am J Pathol2007", "reference": "17255335"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 65}, {"relation": "increases", "evidence": "TNF-alpha directly stimulated beta-site APP-cleaving enzyme (BACE1) expression and enhanced beta-processing of APP in astrocytes.", "citation": {"type": "PubMed", "name": "Am J Pathol2007", "reference": "17255335"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 66}, {"relation": "increases", "evidence": "The peptides not only inhibited the formation of APPbeta (a soluble N-terminal fragment of APP cleaved by beta-secretase), but also significantly reduced Abeta40 production.", "citation": {"type": "PubMed", "name": "Peptides2007", "reference": "17293005"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 67}, {"relation": "increases", "evidence": "The peptides not only inhibited the formation of APPbeta (a soluble N-terminal fragment of APP cleaved by beta-secretase), but also significantly reduced Abeta40 production.", "citation": {"type": "PubMed", "name": "Peptides2007", "reference": "17293005"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 68}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is associated with accumulation of the neurotoxic peptide amyloid-beta (Abeta), which is produced by sequential cleavage of amyloid precursor protein (APP) by the aspartyl protease beta-secretase and the presenilin-dependent protease gamma-secretase.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360493"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 69}, {"relation": "increases", "evidence": "Alzheimer's disease (AD) is associated with accumulation of the neurotoxic peptide amyloid-beta (Abeta), which is produced by sequential cleavage of amyloid precursor protein (APP) by the aspartyl protease beta-secretase and the presenilin-dependent protease gamma-secretase.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360493"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 70}, {"relation": "increases", "evidence": "Such an approach limits APP processing by beta-secretase, mainly through the endocytic pathway, and overcomes some of the limitations of BACE inhibition.", "citation": {"type": "PubMed", "name": "Neurodegener Dis2007", "reference": "17536186"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 71}, {"relation": "increases", "evidence": "Such an approach limits APP processing by beta-secretase, mainly through the endocytic pathway, and overcomes some of the limitations of BACE inhibition.", "citation": {"type": "PubMed", "name": "Neurodegener Dis2007", "reference": "17536186"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 72}, {"relation": "increases", "evidence": "Proteolytic processing of the amyloid precursor protein (APP) by beta-secretase, beta-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid beta (Abeta) peptide, which is involved in the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17573534"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 73}, {"relation": "increases", "evidence": "Proteolytic processing of the amyloid precursor protein (APP) by beta-secretase, beta-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid beta (Abeta) peptide, which is involved in the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17573534"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 74}, {"relation": "increases", "evidence": "To address this issue, temporal neocortex of 27 AD and 21 non-demented control brains was examined to assess mRNA levels of APP isoforms (total APP, APP containing the Kunitz protease inhibitor domain [APP-KPI] and APP770) and APP metabolic enzymatic partners (the APP cleaving enzymes beta-secretase [BACE] and presenilin-1 [PS-1], and putative clearance molecules, low-density lipoprotein receptor protein [LRP] and apolipoprotein E [apoE]).", "citation": {"type": "PubMed", "name": "Brain Res2007", "reference": "17586478"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 75}, {"relation": "increases", "evidence": "To address this issue, temporal neocortex of 27 AD and 21 non-demented control brains was examined to assess mRNA levels of APP isoforms (total APP, APP containing the Kunitz protease inhibitor domain [APP-KPI] and APP770) and APP metabolic enzymatic partners (the APP cleaving enzymes beta-secretase [BACE] and presenilin-1 [PS-1], and putative clearance molecules, low-density lipoprotein receptor protein [LRP] and apolipoprotein E [apoE]).", "citation": {"type": "PubMed", "name": "Brain Res2007", "reference": "17586478"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 76}, {"relation": "increases", "evidence": "Pathologically, AD is characterized by the deposition in the brain of amyloid-beta peptides derived from proteolysis of amyloid precursor protein (APP) by beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase.", "citation": {"type": "PubMed", "name": "Nat Clin Pract Neurol2007", "reference": "17611486"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 77}, {"relation": "increases", "evidence": "Pathologically, AD is characterized by the deposition in the brain of amyloid-beta peptides derived from proteolysis of amyloid precursor protein (APP) by beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase.", "citation": {"type": "PubMed", "name": "Nat Clin Pract Neurol2007", "reference": "17611486"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 78}, {"relation": "increases", "evidence": "Abeta is generated by proteolytic processing of amyloid precursor protein (APP) via beta and gamma-secretases.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res2007", "reference": "17908048"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 79}, {"relation": "increases", "evidence": "Abeta is generated by proteolytic processing of amyloid precursor protein (APP) via beta and gamma-secretases.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res2007", "reference": "17908048"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 80}, {"relation": "increases", "evidence": "The PSEN1 AD mutations giving rise to CWP produce unusually high levels of the amyloid beta peptide (Abeta) ending at position 42 or 43, and the main component of CWP is amino-terminally truncated forms of amyloid beta peptide starting after the alternative beta-secretase cleavage site at position 11.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "17995932"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 81}, {"relation": "increases", "evidence": "The PSEN1 AD mutations giving rise to CWP produce unusually high levels of the amyloid beta peptide (Abeta) ending at position 42 or 43, and the main component of CWP is amino-terminally truncated forms of amyloid beta peptide starting after the alternative beta-secretase cleavage site at position 11.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "17995932"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 82}, {"relation": "increases", "evidence": "Quetiapine also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by beta-secretase) in the transgenic mice.", "citation": {"type": "PubMed", "name": "Neurobiol Aging2009", "reference": "18079026"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 83}, {"relation": "increases", "evidence": "Quetiapine also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by beta-secretase) in the transgenic mice.", "citation": {"type": "PubMed", "name": "Neurobiol Aging2009", "reference": "18079026"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 84}, {"relation": "increases", "evidence": "Proteolytic cleavage of amyloid precursor protein by beta-secretase (BACE-1) and gamma-secretase leads to formation of beta-amyloid (A beta) a key component of amyloid plaques, which are considered the hallmark of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Bioorg Med Chem Lett2008", "reference": "18162398"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 85}, {"relation": "increases", "evidence": "Proteolytic cleavage of amyloid precursor protein by beta-secretase (BACE-1) and gamma-secretase leads to formation of beta-amyloid (A beta) a key component of amyloid plaques, which are considered the hallmark of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Bioorg Med Chem Lett2008", "reference": "18162398"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 86}, {"relation": "increases", "evidence": "Here we describe that the two enzymatic activities responsible for Abeta production, beta-secretase and gamma-secretase, are inhibited in parallel by cholesterol reduction.", "citation": {"type": "PubMed", "name": "J Biol Chem2008", "reference": "18308724"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 87}, {"relation": "increases", "evidence": "Here we describe that the two enzymatic activities responsible for Abeta production, beta-secretase and gamma-secretase, are inhibited in parallel by cholesterol reduction.", "citation": {"type": "PubMed", "name": "J Biol Chem2008", "reference": "18308724"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 88}, {"relation": "increases", "evidence": "There was also an induced expression of the key APP processing enzyme i.e. beta-site APP cleaving enzyme 1 in both high fat/cholesterol-fed C57BL/6 and LDLR-/- mice accompanied by an increased generation of C-terminal fragments of APP.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "18410513"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 89}, {"relation": "increases", "evidence": "There was also an induced expression of the key APP processing enzyme i.e. beta-site APP cleaving enzyme 1 in both high fat/cholesterol-fed C57BL/6 and LDLR-/- mice accompanied by an increased generation of C-terminal fragments of APP.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "18410513"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 90}, {"relation": "increases", "evidence": "The study provides new cell-based assays for the profiling of small molecule inhibitors of QC and points to conspicuous differences in processing of APP depending on sequence at the beta-secretase cleavage site.", "citation": {"type": "PubMed", "name": "Biochemistry2008", "reference": "18570439"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 91}, {"relation": "increases", "evidence": "The study provides new cell-based assays for the profiling of small molecule inhibitors of QC and points to conspicuous differences in processing of APP depending on sequence at the beta-secretase cleavage site.", "citation": {"type": "PubMed", "name": "Biochemistry2008", "reference": "18570439"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 92}, {"relation": "increases", "evidence": "The Abeta peptide results from cleavage of APP initially by BACE1 to produce the C99 fragment and releases soluble APPbeta (sAPPbeta); C99 is then further cleaved by gamma-secretase leading to the Abeta peptide.", "citation": {"type": "PubMed", "name": "Scand J Clin Lab Invest2009", "reference": "18609117"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 93}, {"relation": "increases", "evidence": "Here, we show that lysines 587 and 595 of APP, which are immediately adjacent to the site of beta-secretase cleavage, are covalently pmodified by SUMO proteins in vivo.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun2008", "reference": "18675254"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 94}, {"relation": "increases", "evidence": "Here, we show that lysines 587 and 595 of APP, which are immediately adjacent to the site of beta-secretase cleavage, are covalently pmodified by SUMO proteins in vivo.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun2008", "reference": "18675254"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 95}, {"relation": "increases", "evidence": "Specifically, hypoxia significantly increases beta-site APP cleaving enzyme (BACE1) gene transcription through the over-expression of hypoxia inducible factor 1alpha, resulting in increased BACE1 secretase activity and amyloid-beta production.", "citation": {"type": "PubMed", "name": "J Neurochem2009", "reference": "19196431"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 96}, {"relation": "increases", "evidence": "Specifically, hypoxia significantly increases beta-site APP cleaving enzyme (BACE1) gene transcription through the over-expression of hypoxia inducible factor 1alpha, resulting in increased BACE1 secretase activity and amyloid-beta production.", "citation": {"type": "PubMed", "name": "J Neurochem2009", "reference": "19196431"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 97}, {"relation": "increases", "evidence": "Specifically, hypoxia significantly increases beta-site APP cleaving enzyme (BACE1) gene transcription through the over-expression of hypoxia inducible factor 1alpha, resulting in increased BACE1 secretase activity and amyloid-beta production.", "citation": {"type": "PubMed", "name": "J Neurochem2009", "reference": "19196431"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Hypoxia response subgraph"}, "source": 141, "target": 11, "key": 98}, {"relation": "increases", "evidence": "It is produced from amyloid precursor protein (APP) by proteolytic processing dependent on the beta-site APP-cleaving enzyme 1 (BACE1) and gamma-secretase, and is degraded by a broad range of proteases.", "citation": {"type": "PubMed", "name": "Scand J Clin Lab Invest2009", "reference": "19199126"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 99}, {"relation": "increases", "evidence": "It is produced from amyloid precursor protein (APP) by proteolytic processing dependent on the beta-site APP-cleaving enzyme 1 (BACE1) and gamma-secretase, and is degraded by a broad range of proteases.", "citation": {"type": "PubMed", "name": "Scand J Clin Lab Invest2009", "reference": "19199126"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 100}, {"relation": "increases", "evidence": "Three-dimensional quantitative structure-activity relationship (3D-QSAR) pmodels were developed based on comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), on a series of 43 hydroxyethylamine derivatives, acting as potent inhibitors of beta-site amyloid precursor protein (APP) cleavage enzyme (BACE-1).", "citation": {"type": "PubMed", "name": "Mol Divers2010", "reference": "19330459"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 101}, {"relation": "increases", "evidence": "Three-dimensional quantitative structure-activity relationship (3D-QSAR) pmodels were developed based on comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), on a series of 43 hydroxyethylamine derivatives, acting as potent inhibitors of beta-site amyloid precursor protein (APP) cleavage enzyme (BACE-1).", "citation": {"type": "PubMed", "name": "Mol Divers2010", "reference": "19330459"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 102}, {"relation": "increases", "evidence": "beta-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is a membrane-bound protease that is essential for the production of beta-amyloid protein (Abeta).", "citation": {"type": "PubMed", "name": "J Neurosci Res2009", "reference": "19405102"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 103}, {"relation": "increases", "evidence": "beta-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is a membrane-bound protease that is essential for the production of beta-amyloid protein (Abeta).", "citation": {"type": "PubMed", "name": "J Neurosci Res2009", "reference": "19405102"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 104}, {"relation": "increases", "evidence": "Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.", "citation": {"type": "PubMed", "name": "Hum Mutat2009", "reference": "19462468"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 105}, {"relation": "increases", "evidence": "Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.", "citation": {"type": "PubMed", "name": "Hum Mutat2009", "reference": "19462468"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 106}, {"relation": "increases", "evidence": " The effect of nicotine (2 mg/(kg day)) on Abeta-induced spatial learning and memory impairments was assessed by evaluation of performance in the radial arm water maze (RAWM), in vivo electrophysiological recordings of early-phase long-term potentiation (E-LTP) in urethane-anesthetized rats, and immunoblot analysis to determine changes in the levels of beta-site amyloid precursor protein (APP)-cleaving enzyme (BACE), Abeta and memory-related protei", "citation": {"type": "PubMed", "name": "Neurobiol Aging2011", "reference": "19464074"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 107}, {"relation": "increases", "evidence": " The effect of nicotine (2 mg/(kg day)) on Abeta-induced spatial learning and memory impairments was assessed by evaluation of performance in the radial arm water maze (RAWM), in vivo electrophysiological recordings of early-phase long-term potentiation (E-LTP) in urethane-anesthetized rats, and immunoblot analysis to determine changes in the levels of beta-site amyloid precursor protein (APP)-cleaving enzyme (BACE), Abeta and memory-related protei", "citation": {"type": "PubMed", "name": "Neurobiol Aging2011", "reference": "19464074"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 108}, {"relation": "increases", "evidence": "Beta-site amyloid precursor protein cleaving enzyme (BACE1) is the rate-limiting enzyme for production of beta-amyloid peptides (Abeta), which are proposed to drive the pathological changes found in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Neuromolecular Med2009", "reference": "19669607"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 109}, {"relation": "increases", "evidence": "Beta-site amyloid precursor protein cleaving enzyme (BACE1) is the rate-limiting enzyme for production of beta-amyloid peptides (Abeta), which are proposed to drive the pathological changes found in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Neuromolecular Med2009", "reference": "19669607"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 110}, {"relation": "increases", "evidence": "Core CSF biomarkers include secreted Abeta and amyloid precursor protein (APP) isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1).", "citation": {"type": "PubMed", "name": "Exp Gerontol2010", "reference": "19698775"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 111}, {"relation": "increases", "evidence": "Core CSF biomarkers include secreted Abeta and amyloid precursor protein (APP) isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1).", "citation": {"type": "PubMed", "name": "Exp Gerontol2010", "reference": "19698775"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 112}, {"relation": "increases", "evidence": " In the amyloidogenic pathway, a small proportion of APP is cleaved by beta- and gamma-secretases, known as beta-site APP-cleaving enzyme 1 (BACE1) and presenilin, respectively, leading to the secretion of Abeta peptides.", "citation": {"type": "PubMed", "name": "FASEB J2010", "reference": "19729516"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 113}, {"relation": "increases", "evidence": " In the amyloidogenic pathway, a small proportion of APP is cleaved by beta- and gamma-secretases, known as beta-site APP-cleaving enzyme 1 (BACE1) and presenilin, respectively, leading to the secretion of Abeta peptides.", "citation": {"type": "PubMed", "name": "FASEB J2010", "reference": "19729516"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 114}, {"relation": "increases", "evidence": "We have recently demonstrated that bis(7)-Cognitin, a promising multifunctional anti-Alzheimer's dimer, can remarkably reduce the generation of amyloid beta peptide (Abeta) by inhibiting beta-secretase (BACE-1) and activating alpha-secretase activity.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol2009", "reference": "19765582"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 115}, {"relation": "increases", "evidence": "We have recently demonstrated that bis(7)-Cognitin, a promising multifunctional anti-Alzheimer's dimer, can remarkably reduce the generation of amyloid beta peptide (Abeta) by inhibiting beta-secretase (BACE-1) and activating alpha-secretase activity.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol2009", "reference": "19765582"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 116}, {"relation": "increases", "evidence": "A beta is generated upon the sequential proteolytic cleavage of transmembrane amyloid precursor protein (APP) by two membrane-bound proteases, beta-secretase (BACE1) and the gamma-secretase complex comprising presenilin 1 (PS1), nicastrin, APH-1 and PEN-2.", "citation": {"type": "PubMed", "name": "J Neurosci Res2010", "reference": "19885829"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 117}, {"relation": "increases", "evidence": "A beta is generated upon the sequential proteolytic cleavage of transmembrane amyloid precursor protein (APP) by two membrane-bound proteases, beta-secretase (BACE1) and the gamma-secretase complex comprising presenilin 1 (PS1), nicastrin, APH-1 and PEN-2.", "citation": {"type": "PubMed", "name": "J Neurosci Res2010", "reference": "19885829"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 118}, {"relation": "increases", "evidence": "In Alzheimer disease, this feedback loop is disrupted, and the increased level of Abeta oligomers bind to PrP(C) and prevent it from regulating BACE1 activity. PrP(C) interacts with and inhibits the beta-secretase BACE1, the rate-limiting enzyme in the production of Abeta.", "citation": {"type": "PubMed", "name": "Prion2009", "reference": "19887909"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 119}, {"relation": "increases", "evidence": "In Alzheimer disease, this feedback loop is disrupted, and the increased level of Abeta oligomers bind to PrP(C) and prevent it from regulating BACE1 activity. PrP(C) interacts with and inhibits the beta-secretase BACE1, the rate-limiting enzyme in the production of Abeta.", "citation": {"type": "PubMed", "name": "Prion2009", "reference": "19887909"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 120}, {"relation": "increases", "evidence": "The beta-site APP cleaving enzyme (BACE1) is responsible for the first step in the production of the beta-amyloid protein of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem2010", "reference": "20067575"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 121}, {"relation": "increases", "evidence": "The beta-site APP cleaving enzyme (BACE1) is responsible for the first step in the production of the beta-amyloid protein of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem2010", "reference": "20067575"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 122}, {"relation": "increases", "evidence": "beta-Site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates amyloid-beta (Abeta) generation that is central to the pathophysiology of Alzheimer's disease (AD). Therefore, lowering Abeta levels by BACE1 manipulations represents a key therapeutic strategy, but it remains unclear whether partial inhibition of BACE1, as expected for AD treatments, can improve memory deficits.", "citation": {"type": "PubMed", "name": "J Neurochem2010", "reference": "20089133"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 123}, {"relation": "increases", "evidence": "beta-Site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates amyloid-beta (Abeta) generation that is central to the pathophysiology of Alzheimer's disease (AD). Therefore, lowering Abeta levels by BACE1 manipulations represents a key therapeutic strategy, but it remains unclear whether partial inhibition of BACE1, as expected for AD treatments, can improve memory deficits.", "citation": {"type": "PubMed", "name": "J Neurochem2010", "reference": "20089133"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 124}, {"relation": "increases", "evidence": "Abeta is generated from AbetaPP through an initial cleavage by the beta-secretase, BACE-1, which results in the generation of the soluble AbetaPPbeta fragment (sAbetaPPbeta) and the membrane bound C-terminal fragment beta (CTFbeta or C99). ", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2010", "reference": "20157255"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 125}, {"relation": "increases", "evidence": "Abeta is generated from AbetaPP through an initial cleavage by the beta-secretase, BACE-1, which results in the generation of the soluble AbetaPPbeta fragment (sAbetaPPbeta) and the membrane bound C-terminal fragment beta (CTFbeta or C99). ", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2010", "reference": "20157255"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 126}, {"relation": "increases", "evidence": "We previously indicated that amyloid beta (Abeta) augments protein levels of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) through oxidative stress.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun2010", "reference": "20171164"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 127}, {"relation": "increases", "evidence": "We previously indicated that amyloid beta (Abeta) augments protein levels of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) through oxidative stress.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun2010", "reference": "20171164"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 128}, {"relation": "increases", "evidence": "Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res2010", "reference": "20205669"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 129}, {"relation": "increases", "evidence": "Abeta is derived from a type I transmembrane protein, amyloid precursor protein (APP), by the sequential proteolytic events mediated by beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2010", "reference": "20303415"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 130}, {"relation": "increases", "evidence": "Abeta is derived from a type I transmembrane protein, amyloid precursor protein (APP), by the sequential proteolytic events mediated by beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2010", "reference": "20303415"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 131}, {"relation": "increases", "evidence": "BACKGROUND: A central feature of Alzheimer's disease is the cleavage of the amyloid precursor protein (APP) to form beta-amyloid peptide (Abeta) by the beta-secretase and gamma-secretase enzymes.", "citation": {"type": "PubMed", "name": "Mol Brain2010", "reference": "20409323"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 132}, {"relation": "increases", "evidence": "BACKGROUND: A central feature of Alzheimer's disease is the cleavage of the amyloid precursor protein (APP) to form beta-amyloid peptide (Abeta) by the beta-secretase and gamma-secretase enzymes.", "citation": {"type": "PubMed", "name": "Mol Brain2010", "reference": "20409323"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 133}, {"relation": "increases", "evidence": "Basic understanding of the activities of the amyloid beta peptide (Abeta) and associated proteins such as beta-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD.", "citation": {"type": "PubMed", "name": "Exp Neurol2010", "reference": "20451519"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 134}, {"relation": "increases", "evidence": "Basic understanding of the activities of the amyloid beta peptide (Abeta) and associated proteins such as beta-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD.", "citation": {"type": "PubMed", "name": "Exp Neurol2010", "reference": "20451519"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 135}, {"relation": "increases", "evidence": "Cleavage of APP by BACE1 is the first proteolytic step in the production of amyloid-beta (Abeta), which accumulates in senile plaques in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Exp Neurol2010", "reference": "20685197"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 136}, {"relation": "increases", "evidence": "Cleavage of APP by BACE1 is the first proteolytic step in the production of amyloid-beta (Abeta), which accumulates in senile plaques in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Exp Neurol2010", "reference": "20685197"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 137}, {"relation": "increases", "evidence": "Abeta is generated from the beta-amyloid precursor protein (APP) through the proteolysis of beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase. ", "citation": {"type": "PubMed", "name": "Neurosci Lett2010", "reference": "20727383"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 138}, {"relation": "increases", "evidence": "Abeta is generated from the beta-amyloid precursor protein (APP) through the proteolysis of beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase. ", "citation": {"type": "PubMed", "name": "Neurosci Lett2010", "reference": "20727383"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 139}, {"relation": "increases", "evidence": "The Swedish mutation (K595N/M596L) of amyloid precursor protein (APP-swe) has been known to increase abnormal cleavage of cellular APP by Beta-secretase (BACE), which causes tau protein hyperphosphorylation and early-onset Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "BMB Rep2010", "reference": "21034535"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 140}, {"relation": "increases", "evidence": "The Swedish mutation (K595N/M596L) of amyloid precursor protein (APP-swe) has been known to increase abnormal cleavage of cellular APP by Beta-secretase (BACE), which causes tau protein hyperphosphorylation and early-onset Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "BMB Rep2010", "reference": "21034535"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 141}, {"relation": "increases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the betaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway. ", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 142}, {"relation": "increases", "evidence": " In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the betaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway. ", "citation": {"type": "PubMed", "name": "Mol Neurobiol2011", "reference": "21431475"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 143}, {"relation": "increases", "evidence": "Amyloid-beta peptide (Abeta) is generated by sequential cleavage of the amyloid precursor protein (APP) by beta-site amyloid precursor protein cleaving enzyme 1 (beta-secretase, or BACE1) and gamma-secretase. ", "citation": {"type": "PubMed", "name": "J Neurosci Res2011", "reference": "21433051"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 144}, {"relation": "increases", "evidence": "Amyloid-beta peptide (Abeta) is generated by sequential cleavage of the amyloid precursor protein (APP) by beta-site amyloid precursor protein cleaving enzyme 1 (beta-secretase, or BACE1) and gamma-secretase. ", "citation": {"type": "PubMed", "name": "J Neurosci Res2011", "reference": "21433051"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 145}, {"relation": "increases", "evidence": "To release the amyloidogenic peptide A beta from the Alzheimer amyloid precursor protein (APP), two secretases act sequentially: first, beta-secretase cleaves close to the membrane within the ectodomain and then gamma-secretase cuts within the transmembrane domain.", "citation": {"type": "PubMed", "name": "Nat Med1998", "reference": "9623986"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 146}, {"relation": "increases", "evidence": "To release the amyloidogenic peptide A beta from the Alzheimer amyloid precursor protein (APP), two secretases act sequentially: first, beta-secretase cleaves close to the membrane within the ectodomain and then gamma-secretase cuts within the transmembrane domain.", "citation": {"type": "PubMed", "name": "Nat Med1998", "reference": "9623986"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 147}, {"relation": "increases", "evidence": "Proteolytic processing of APP by beta-secretase, on the other hand, exposes the N-terminus of beta-amyloid, which is liberated after gamma-secretase cleavage at the variable amyloid C-terminus.", "citation": {"type": "PubMed", "name": "Prog Neurobiol1998", "reference": "9775403"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 148}, {"relation": "increases", "evidence": "Proteolytic processing of APP by beta-secretase, on the other hand, exposes the N-terminus of beta-amyloid, which is liberated after gamma-secretase cleavage at the variable amyloid C-terminus.", "citation": {"type": "PubMed", "name": "Prog Neurobiol1998", "reference": "9775403"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 149}, {"relation": "increases", "evidence": "Pulse-chase experiments revealed beta-secretase cleavage from immature full-length amyloid precursor protein harboring the Swedish mutation.", "citation": {"type": "PubMed", "name": "J Mol Neurosci1998", "reference": "10096041"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 150}, {"relation": "increases", "evidence": "Pulse-chase experiments revealed beta-secretase cleavage from immature full-length amyloid precursor protein harboring the Swedish mutation.", "citation": {"type": "PubMed", "name": "J Mol Neurosci1998", "reference": "10096041"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 151}, {"relation": "increases", "evidence": "Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the beta-secretase site, and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer's disease in Sweden.", "citation": {"type": "PubMed", "name": "Nature1999", "reference": "10591213"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 152}, {"relation": "increases", "evidence": "Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the beta-secretase site, and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer's disease in Sweden.", "citation": {"type": "PubMed", "name": "Nature1999", "reference": "10591213"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 153}, {"relation": "increases", "evidence": "Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-associated C-terminal beta-secretase APP fragment.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci1999", "reference": "10656250"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 154}, {"relation": "increases", "evidence": "Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-associated C-terminal beta-secretase APP fragment.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci1999", "reference": "10656250"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 155}, {"relation": "increases", "evidence": "Recombinant memapsin 2 specifically hydrolyzed peptides derived from the beta-secretase site of both the wild-type and Swedish mutant beta-amyloid precursor protein (APP) with over 60-fold increase of catalytic efficiency for the latter. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2000", "reference": "10677483"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 156}, {"relation": "increases", "evidence": "Recombinant memapsin 2 specifically hydrolyzed peptides derived from the beta-secretase site of both the wild-type and Swedish mutant beta-amyloid precursor protein (APP) with over 60-fold increase of catalytic efficiency for the latter. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2000", "reference": "10677483"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 157}, {"relation": "increases", "evidence": "IFNgamma in combination with TNFalpha or IL-1beta seems to trigger Abeta production by supporting beta-secretase cleavage of the immature APP molecule.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2000", "reference": "11114266"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 158}, {"relation": "increases", "evidence": "IFNgamma in combination with TNFalpha or IL-1beta seems to trigger Abeta production by supporting beta-secretase cleavage of the immature APP molecule.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2000", "reference": "11114266"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 159}, {"relation": "increases", "evidence": "Amyloid precursor protein/P-selectin, which is sorted from early to late endosomes, undergoes significantly less alpha-secretase cleavage, and more beta-secretase cleavage, than amyloid precursor protein/P-selectin768A, a mutant that recycles more efficiently to the cell surface.", "citation": {"type": "PubMed", "name": "Traffic2001", "reference": "11737828"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 160}, {"relation": "increases", "evidence": "Amyloid precursor protein/P-selectin, which is sorted from early to late endosomes, undergoes significantly less alpha-secretase cleavage, and more beta-secretase cleavage, than amyloid precursor protein/P-selectin768A, a mutant that recycles more efficiently to the cell surface.", "citation": {"type": "PubMed", "name": "Traffic2001", "reference": "11737828"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 161}, {"relation": "increases", "evidence": "Homeostatic APPsbetaswe levels with aging suggest that progressive amyloid deposition in brain results not from increased beta-secretase cleavage of APP but from impaired Abeta/amyloid clearance mechanisms.", "citation": {"type": "PubMed", "name": "Am J Pathol2002", "reference": "11839594"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 162}, {"relation": "increases", "evidence": "Homeostatic APPsbetaswe levels with aging suggest that progressive amyloid deposition in brain results not from increased beta-secretase cleavage of APP but from impaired Abeta/amyloid clearance mechanisms.", "citation": {"type": "PubMed", "name": "Am J Pathol2002", "reference": "11839594"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 163}, {"relation": "increases", "evidence": "ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways.", "citation": {"type": "PubMed", "name": "J Neurochem2002", "reference": "11953452"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 164}, {"relation": "increases", "evidence": "ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways.", "citation": {"type": "PubMed", "name": "J Neurochem2002", "reference": "11953452"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 165}, {"relation": "increases", "evidence": "beta-Site APP-cleaving enzyme (BACE) initiates the processing of the amyloid precursor protein (APP) leading to the generation of beta-amyloid, the main component of Alzheimer's disease senile plaques.", "citation": {"type": "PubMed", "name": "J Neurochem2002", "reference": "11953458"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 166}, {"relation": "increases", "evidence": "beta-Site APP-cleaving enzyme (BACE) initiates the processing of the amyloid precursor protein (APP) leading to the generation of beta-amyloid, the main component of Alzheimer's disease senile plaques.", "citation": {"type": "PubMed", "name": "J Neurochem2002", "reference": "11953458"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 167}, {"relation": "increases", "evidence": "Beta-secretase cleavage represents the first step in the generation of Abeta polypeptides and initiates the amyloid cascade that leads to neurodegeneration in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Ann Neurol2002", "reference": "12112088"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 168}, {"relation": "increases", "evidence": "Beta-secretase cleavage represents the first step in the generation of Abeta polypeptides and initiates the amyloid cascade that leads to neurodegeneration in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Ann Neurol2002", "reference": "12112088"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 169}, {"relation": "increases", "evidence": "We show that, in Sf9 cells, BACE performs the expected beta-secretase cleavage of APP, generating C99.", "citation": {"type": "PubMed", "name": "J Neurochem2002", "reference": "12423249"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 170}, {"relation": "increases", "evidence": "We show that, in Sf9 cells, BACE performs the expected beta-secretase cleavage of APP, generating C99.", "citation": {"type": "PubMed", "name": "J Neurochem2002", "reference": "12423249"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 171}, {"relation": "increases", "evidence": "Our recent knockout studies show that BACE1 is critical for Abeta generation, but the knockout mice show an otherwise normal phenotype, raising the possibility that therapeutic BACE1 inhibition could be accomplished without major mechanism based toxicity.", "citation": {"type": "PubMed", "name": "Neurobiol Aging2002", "reference": "12470797"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 172}, {"relation": "increases", "evidence": "Our recent knockout studies show that BACE1 is critical for Abeta generation, but the knockout mice show an otherwise normal phenotype, raising the possibility that therapeutic BACE1 inhibition could be accomplished without major mechanism based toxicity.", "citation": {"type": "PubMed", "name": "Neurobiol Aging2002", "reference": "12470797"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 173}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis.", "citation": {"type": "PubMed", "name": "J Biol Chem2003", "reference": "12473667"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 174}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis.", "citation": {"type": "PubMed", "name": "J Biol Chem2003", "reference": "12473667"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 175}, {"relation": "increases", "evidence": "APP is cleaved either by beta-secretase or by alpha-secretase to initiate amyloidogenic (release of A beta) or nonamyloidogenic processing of APP, respectively.", "citation": {"type": "PubMed", "name": "J Cell Biol2003", "reference": "12515826"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 176}, {"relation": "increases", "evidence": "APP is cleaved either by beta-secretase or by alpha-secretase to initiate amyloidogenic (release of A beta) or nonamyloidogenic processing of APP, respectively.", "citation": {"type": "PubMed", "name": "J Cell Biol2003", "reference": "12515826"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 177}, {"relation": "increases", "evidence": "Employing a superior BACE1 cleavage sequence to probe cellular APP processing.", "citation": {"type": "PubMed", "name": "J Neurochem2003", "reference": "12603825"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 178}, {"relation": "increases", "evidence": "Employing a superior BACE1 cleavage sequence to probe cellular APP processing.", "citation": {"type": "PubMed", "name": "J Neurochem2003", "reference": "12603825"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 179}, {"relation": "increases", "evidence": "An integral membrane aspartyl protease, BACE, is responsible for beta-secretase processing of the beta-amyloid precursor protein (APP) to the large secreted sAPPbeta and membrane-bound CTFbeta of 99 residues.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2003", "reference": "14501002"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 180}, {"relation": "increases", "evidence": "An integral membrane aspartyl protease, BACE, is responsible for beta-secretase processing of the beta-amyloid precursor protein (APP) to the large secreted sAPPbeta and membrane-bound CTFbeta of 99 residues.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2003", "reference": "14501002"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 181}, {"relation": "increases", "evidence": "Here we report evidence that heparan sulfate (HS) interacts with beta-site APP-cleaving enzyme (BACE) 1 and regulates its cleavage of APP.", "citation": {"type": "PubMed", "name": "J Cell Biol2003", "reference": "14530380"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 182}, {"relation": "increases", "evidence": "Here we report evidence that heparan sulfate (HS) interacts with beta-site APP-cleaving enzyme (BACE) 1 and regulates its cleavage of APP.", "citation": {"type": "PubMed", "name": "J Cell Biol2003", "reference": "14530380"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 183}, {"relation": "increases", "evidence": "Together, these results suggest that T668 phosphorylation may facilitate the BACE1 cleavage of APP to increase Abeta generation.", "citation": {"type": "PubMed", "name": "J Cell Biol2003", "reference": "14557249"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 184}, {"relation": "increases", "evidence": "Together, these results suggest that T668 phosphorylation may facilitate the BACE1 cleavage of APP to increase Abeta generation.", "citation": {"type": "PubMed", "name": "J Cell Biol2003", "reference": "14557249"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 185}, {"relation": "increases", "evidence": "Our results indicate that BACE1 siRNA specifically impacts on beta-cleavage of APP and may be a potential therapeutic approach for treating AD.", "citation": {"type": "PubMed", "name": "J Biol Chem2004", "reference": "14600149"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 186}, {"relation": "increases", "evidence": "Our results indicate that BACE1 siRNA specifically impacts on beta-cleavage of APP and may be a potential therapeutic approach for treating AD.", "citation": {"type": "PubMed", "name": "J Biol Chem2004", "reference": "14600149"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 187}, {"relation": "increases", "evidence": "The cerebral deposition of amyloid beta-peptide (Abeta) is a major factor in the etiology of Alzheimer's disease. beta-Secretase (BACE) initiates the generation of Abeta by cleaving the amyloid precursor protein at the beta-site and is therefore a prime target for therapeutic intervention.", "citation": {"type": "PubMed", "name": "Anal Biochem2003", "reference": "14622952"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 188}, {"relation": "increases", "evidence": "The cerebral deposition of amyloid beta-peptide (Abeta) is a major factor in the etiology of Alzheimer's disease. beta-Secretase (BACE) initiates the generation of Abeta by cleaving the amyloid precursor protein at the beta-site and is therefore a prime target for therapeutic intervention.", "citation": {"type": "PubMed", "name": "Anal Biochem2003", "reference": "14622952"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 189}, {"relation": "increases", "evidence": "BACE1, the major beta-secretase involved in cleaving APP, has been identified as a type 1 membrane-associated aspartyl protease.", "citation": {"type": "PubMed", "name": "Mol Cell Biol2004", "reference": "14701757"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 190}, {"relation": "increases", "evidence": "beta-site APP cleaving enzyme 1 (BACE1) is the beta-secretase enzyme required for generating pathogenic beta-amyloid (Abeta) peptides in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Neuron2004", "reference": "14715132"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 191}, {"relation": "increases", "evidence": "beta-site APP cleaving enzyme 1 (BACE1) is the beta-secretase enzyme required for generating pathogenic beta-amyloid (Abeta) peptides in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Neuron2004", "reference": "14715132"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 192}, {"relation": "increases", "evidence": "Alzheimer's beta-secretase (BACE1) is a membrane-bound protease that cleaves the amyloid precursor protein (APP) in the trans-Golgi network, an initial step in the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Glycoconj J2004", "reference": "14973371"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 193}, {"relation": "increases", "evidence": "Alzheimer's beta-secretase (BACE1) is a membrane-bound protease that cleaves the amyloid precursor protein (APP) in the trans-Golgi network, an initial step in the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Glycoconj J2004", "reference": "14973371"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 194}, {"relation": "increases", "evidence": "The activity of BACE-1 as measured by the formation of the cleavage product of amyloid beta precursor protein, transiently increased up to 48 h after injury, but returned to basal level 7 days post injury.", "citation": {"type": "PubMed", "name": "J Neural Transm2004", "reference": "15057522"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 195}, {"relation": "increases", "evidence": "The activity of BACE-1 as measured by the formation of the cleavage product of amyloid beta precursor protein, transiently increased up to 48 h after injury, but returned to basal level 7 days post injury.", "citation": {"type": "PubMed", "name": "J Neural Transm2004", "reference": "15057522"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 196}, {"relation": "increases", "evidence": "BACE is an aspartyl protease that cleaves the amyloid precursor protein (APP) at the beta-secretase cleavage site and is involved in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci2004", "reference": "15080893"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 197}, {"relation": "increases", "evidence": "BACE is an aspartyl protease that cleaves the amyloid precursor protein (APP) at the beta-secretase cleavage site and is involved in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci2004", "reference": "15080893"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 198}, {"relation": "increases", "evidence": "The beta-site APP-cleaving enzyme (BACE1) has been identified as the key enzyme leading to beta-amyloid formation, and cholinergic mechanisms have been shown to control APP processing.", "citation": {"type": "PubMed", "name": "J Neurosci Res2004", "reference": "15211591"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 199}, {"relation": "increases", "evidence": "The beta-site APP-cleaving enzyme (BACE1) has been identified as the key enzyme leading to beta-amyloid formation, and cholinergic mechanisms have been shown to control APP processing.", "citation": {"type": "PubMed", "name": "J Neurosci Res2004", "reference": "15211591"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 200}, {"relation": "increases", "evidence": "Because alpha-secretase and BACE-1 cleave APP within the secretory pathway, it is likely that the two enzymes compete for the APP substrate.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2004", "reference": "15314262"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 201}, {"relation": "increases", "evidence": "Because alpha-secretase and BACE-1 cleave APP within the secretory pathway, it is likely that the two enzymes compete for the APP substrate.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2004", "reference": "15314262"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 202}, {"relation": "increases", "evidence": "Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Glycoconj J2004", "reference": "15467394"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 203}, {"relation": "increases", "evidence": "Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Glycoconj J2004", "reference": "15467394"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 204}, {"relation": "increases", "evidence": "Mapping to the Down syndrome critical region (chromosome 21) and identified as a homologue of BACE1, BACE2 also cleaves amyloid precursor protein at the beta-site.", "citation": {"type": "PubMed", "name": "J Proteome Res2004", "reference": "15473697"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 205}, {"relation": "increases", "evidence": "Mapping to the Down syndrome critical region (chromosome 21) and identified as a homologue of BACE1, BACE2 also cleaves amyloid precursor protein at the beta-site.", "citation": {"type": "PubMed", "name": "J Proteome Res2004", "reference": "15473697"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 206}, {"relation": "increases", "evidence": "Preventing Abeta42 production with an M596I mutation (beta-), which blocks beta-secretase cleavage of APP, or by treatment with a gamma-secretase inhibitor increased the resistance of APP(FAD)-expressing cells to apoptosis.", "citation": {"type": "PubMed", "name": "J Neurochem2004", "reference": "15584903"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 207}, {"relation": "increases", "evidence": "Preventing Abeta42 production with an M596I mutation (beta-), which blocks beta-secretase cleavage of APP, or by treatment with a gamma-secretase inhibitor increased the resistance of APP(FAD)-expressing cells to apoptosis.", "citation": {"type": "PubMed", "name": "J Neurochem2004", "reference": "15584903"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 208}, {"relation": "increases", "evidence": "Although pmodest overexpression enhanced amyloid deposition, high BACE overexpression inhibited amyloid formation despite increased beta-cleavage of APP. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo.", "citation": {"type": "PubMed", "name": "J Cell Biol2005", "reference": "15642747"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 209}, {"relation": "increases", "evidence": "Although pmodest overexpression enhanced amyloid deposition, high BACE overexpression inhibited amyloid formation despite increased beta-cleavage of APP. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo.", "citation": {"type": "PubMed", "name": "J Cell Biol2005", "reference": "15642747"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 210}, {"relation": "increases", "evidence": "Here, we established a novel approach to regulate production of Abeta based on intracellular expression of single chain antibodies (intrabodies) raised to an epitope adjacent to the beta-secretase cleavage site of human APP.", "citation": {"type": "PubMed", "name": "J Cell Biol2005", "reference": "15767460"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 211}, {"relation": "increases", "evidence": "Here, we established a novel approach to regulate production of Abeta based on intracellular expression of single chain antibodies (intrabodies) raised to an epitope adjacent to the beta-secretase cleavage site of human APP.", "citation": {"type": "PubMed", "name": "J Cell Biol2005", "reference": "15767460"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 212}, {"relation": "increases", "evidence": "BACE1 increased APP cleavage at the beta-site and Abeta production whereas BACE2 did not.", "citation": {"type": "PubMed", "name": "FASEB J2005", "reference": "15857888"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 213}, {"relation": "increases", "evidence": "BACE1 increased APP cleavage at the beta-site and Abeta production whereas BACE2 did not.", "citation": {"type": "PubMed", "name": "FASEB J2005", "reference": "15857888"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 214}, {"relation": "increases", "evidence": "The aspartic protease beta-secretase (BACE) cleaves the amyloid precursor protein into a 42 residue beta-peptide, which is the principal biochemical marker of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Structure2005", "reference": "16216580"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 215}, {"relation": "increases", "evidence": "The aspartic protease beta-secretase (BACE) cleaves the amyloid precursor protein into a 42 residue beta-peptide, which is the principal biochemical marker of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Structure2005", "reference": "16216580"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 216}, {"relation": "increases", "evidence": "Beta-secretase [beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the beta-amyloid (Abeta) peptide involved in the pathogenesis of Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "J Neurosci2005", "reference": "16306400"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 217}, {"relation": "increases", "evidence": "Beta-secretase [beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the beta-amyloid (Abeta) peptide involved in the pathogenesis of Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "J Neurosci2005", "reference": "16306400"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 218}, {"relation": "increases", "evidence": "This was associated with inefficient plasminogen binding and plasmin activation, the displacement of beta-secretase (BACE) from DRMs to APP-containing membrane fractions, increased beta-cleavage of APP and high levels of Abeta peptides.", "citation": {"type": "PubMed", "name": "EMBO J2006", "reference": "16407971"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 219}, {"relation": "increases", "evidence": "Heparin can promote beta-secretase cleavage of APP in neuroblastoma cells.", "citation": {"type": "PubMed", "name": "Biochemistry2006", "reference": "16716081"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 220}, {"relation": "increases", "evidence": "Heparin can promote beta-secretase cleavage of APP in neuroblastoma cells.", "citation": {"type": "PubMed", "name": "Biochemistry2006", "reference": "16716081"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 221}, {"relation": "increases", "evidence": "In AD, the specific inhibition of beta- or beta-secretase activities would decrease the production of Abeta from its precursor, in such a way that its relative concentration could be low enough to avoid the formation of aggregates.", "citation": {"type": "PubMed", "name": "Bull Mem Acad R Med Belg2005", "reference": "16768248"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 222}, {"relation": "increases", "evidence": "In AD, the specific inhibition of beta- or beta-secretase activities would decrease the production of Abeta from its precursor, in such a way that its relative concentration could be low enough to avoid the formation of aggregates.", "citation": {"type": "PubMed", "name": "Bull Mem Acad R Med Belg2005", "reference": "16768248"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 223}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartyl protease that specifically cleaves amyloid precursor protein (APP) at the beta-secretase site.", "citation": {"type": "PubMed", "name": "J Mol Biol2006", "reference": "16979658"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 224}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartyl protease that specifically cleaves amyloid precursor protein (APP) at the beta-secretase site.", "citation": {"type": "PubMed", "name": "J Mol Biol2006", "reference": "16979658"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 225}, {"relation": "increases", "evidence": "Using high-throughput siRNA screening technology, we assessed 15,200 genes for their role in Abeta42 secretion and identified leucine-rich repeat transmembrane 3 (LRRTM3) as a neuronal gene that promotes APP processing by BACE1. siRNAs targeting LRRTM3 inhibit the secretion of Abeta40, Abeta42, and sAPPbeta, the N-terminal APP fragment produced by BACE1 cleavage, from cultured cells and primary neurons by up to 60%, whereas overexpression increases Abeta secretion.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2006", "reference": "17098871"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 226}, {"relation": "increases", "evidence": "Using high-throughput siRNA screening technology, we assessed 15,200 genes for their role in Abeta42 secretion and identified leucine-rich repeat transmembrane 3 (LRRTM3) as a neuronal gene that promotes APP processing by BACE1. siRNAs targeting LRRTM3 inhibit the secretion of Abeta40, Abeta42, and sAPPbeta, the N-terminal APP fragment produced by BACE1 cleavage, from cultured cells and primary neurons by up to 60%, whereas overexpression increases Abeta secretion.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2006", "reference": "17098871"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 227}, {"relation": "increases", "evidence": "Hypoxia up-regulated beta-secretase cleavage of APP and amyloid-beta protein (Abeta) production by increasing BACE1 gene transcription and expression both in vitro and in vivo.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2006", "reference": "17121991"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 228}, {"relation": "increases", "evidence": "Hypoxia up-regulated beta-secretase cleavage of APP and amyloid-beta protein (Abeta) production by increasing BACE1 gene transcription and expression both in vitro and in vivo.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2006", "reference": "17121991"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 229}, {"relation": "increases", "evidence": "Hypoxia up-regulated beta-secretase cleavage of APP and amyloid-beta protein (Abeta) production by increasing BACE1 gene transcription and expression both in vitro and in vivo.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2006", "reference": "17121991"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Hypoxia response subgraph"}, "source": 141, "target": 11, "key": 230}, {"relation": "increases", "evidence": "Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem2007", "reference": "17156133"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 231}, {"relation": "increases", "evidence": "Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem2007", "reference": "17156133"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 232}, {"relation": "increases", "evidence": "In addition, we show that some NF-kappaB inhibitors decrease sAPPbeta and APP-CTFbeta suggesting that they reduce the beta-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "Neurosci Lett2007", "reference": "17223266"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 233}, {"relation": "increases", "evidence": "In addition, we show that some NF-kappaB inhibitors decrease sAPPbeta and APP-CTFbeta suggesting that they reduce the beta-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "Neurosci Lett2007", "reference": "17223266"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 234}, {"relation": "increases", "evidence": "Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) (beta-secretase) initiates generation of beta-amyloid (Abeta), which plays an early role in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "J Neurosci2007", "reference": "17409228"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 235}, {"relation": "increases", "evidence": "Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) (beta-secretase) initiates generation of beta-amyloid (Abeta), which plays an early role in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "J Neurosci2007", "reference": "17409228"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 236}, {"relation": "increases", "evidence": "Beta-secretase is a potential target for inhibitory drugs against Alzheimer's disease as it cleaves amyloid precursor protein (APP) to form insoluble amyloid plaques and vascular deposits in the brain.", "citation": {"type": "PubMed", "name": "Comput Biol Chem2007", "reference": "17500040"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 237}, {"relation": "increases", "evidence": "Beta-secretase is a potential target for inhibitory drugs against Alzheimer's disease as it cleaves amyloid precursor protein (APP) to form insoluble amyloid plaques and vascular deposits in the brain.", "citation": {"type": "PubMed", "name": "Comput Biol Chem2007", "reference": "17500040"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 238}, {"relation": "increases", "evidence": "Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach to the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Anal Bioanal Chem2007", "reference": "17541560"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 239}, {"relation": "increases", "evidence": "Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach to the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Anal Bioanal Chem2007", "reference": "17541560"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 240}, {"relation": "increases", "evidence": "Beta-site APP-cleaving enzyme (BACE) is required for production of the Alzheimer's disease (AD)-associated Abeta protein.", "citation": {"type": "PubMed", "name": "Neuron2007", "reference": "17553422"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 241}, {"relation": "increases", "evidence": "Beta-site APP-cleaving enzyme (BACE) is required for production of the Alzheimer's disease (AD)-associated Abeta protein.", "citation": {"type": "PubMed", "name": "Neuron2007", "reference": "17553422"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 242}, {"relation": "increases", "evidence": "The aspartyl protease beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates processing of amyloid precursor protein (APP) into amyloid beta (Abeta) peptide, the major component of Alzheimer disease (AD) plaques.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17616527"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 243}, {"relation": "increases", "evidence": "The aspartyl protease beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates processing of amyloid precursor protein (APP) into amyloid beta (Abeta) peptide, the major component of Alzheimer disease (AD) plaques.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17616527"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 244}, {"relation": "increases", "evidence": "The proteolytic enzyme beta-secretase (BACE-1) produces amyloid beta (Abeta) peptide, the primary constituent of neurofibrillary plaques, implicated in Alzheimer's disease, by cleavage of the amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Bioorg Med Chem Lett2008", "reference": "18068983"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 245}, {"relation": "increases", "evidence": "The proteolytic enzyme beta-secretase (BACE-1) produces amyloid beta (Abeta) peptide, the primary constituent of neurofibrillary plaques, implicated in Alzheimer's disease, by cleavage of the amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Bioorg Med Chem Lett2008", "reference": "18068983"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 246}, {"relation": "increases", "evidence": "After inhibitor treatment, the improved memory function was accompanied by reduced amyloid plaque load, decreased Abeta40 and Abeta42, and reduced C-terminal beta-secretase fragment derived from APP by beta-secretase.", "citation": {"type": "PubMed", "name": "J Biol Chem2008", "reference": "18184658"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 247}, {"relation": "increases", "evidence": "Beta-amyloid (Abeta) peptides that accumulate in Alzheimer disease are generated from the beta-amyloid precursor protein (betaAPP) by cleavages by beta-secretase BACE1 and by presenilin-dependent gamma-secretase activities.", "citation": {"type": "PubMed", "name": "J Biol Chem2008", "reference": "18263584"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 248}, {"relation": "increases", "evidence": "Beta-amyloid (Abeta) peptides that accumulate in Alzheimer disease are generated from the beta-amyloid precursor protein (betaAPP) by cleavages by beta-secretase BACE1 and by presenilin-dependent gamma-secretase activities.", "citation": {"type": "PubMed", "name": "J Biol Chem2008", "reference": "18263584"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 249}, {"relation": "increases", "evidence": "Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of AD.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2008", "reference": "18295609"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 250}, {"relation": "increases", "evidence": "Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of AD.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta2008", "reference": "18295609"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 251}, {"relation": "increases", "evidence": "In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.", "citation": {"type": "PubMed", "name": "Expert Opin Ther Targets2008", "reference": "18479216"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 252}, {"relation": "increases", "evidence": "In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.", "citation": {"type": "PubMed", "name": "Expert Opin Ther Targets2008", "reference": "18479216"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 253}, {"relation": "increases", "evidence": "BACE-1 cleavage is limiting for the production of Abeta, making it a particularly good drug target for the generation of inhibitors that lower Abeta.", "citation": {"type": "PubMed", "name": "CNS Neurol Disord Drug Targets2008", "reference": "18673212"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 254}, {"relation": "increases", "evidence": "One group described the poor kinetics of BACE 1 for cleaving the wild-type (WT) beta-secretase site of APP found in most AD patients.", "citation": {"type": "PubMed", "name": "Biol Chem2008", "reference": "18979625"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 255}, {"relation": "increases", "evidence": "One group described the poor kinetics of BACE 1 for cleaving the wild-type (WT) beta-secretase site of APP found in most AD patients.", "citation": {"type": "PubMed", "name": "Biol Chem2008", "reference": "18979625"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 256}, {"relation": "increases", "evidence": "These results indicate that post-translational S-palmitoylation of BACE1 is not required for APP processing, and that BACE1 can efficiently cleave APP in both raft and non-raft microdomains.", "citation": {"type": "PubMed", "name": "J Biol Chem2009", "reference": "19074428"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 257}, {"relation": "increases", "evidence": "Because beta-site APP-cleaving enzyme 1 (BACE1), an essential protease for Abeta production, is up-regulated in cells overexpressing RAGE and in RAGE-injected brains of Tg2576 mice, the molecular mechanisms underlying RAGE, BACE1 expression, and Abeta production were examined.", "citation": {"type": "PubMed", "name": "FASEB J2009", "reference": "19332646"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 258}, {"relation": "increases", "evidence": "Because beta-site APP-cleaving enzyme 1 (BACE1), an essential protease for Abeta production, is up-regulated in cells overexpressing RAGE and in RAGE-injected brains of Tg2576 mice, the molecular mechanisms underlying RAGE, BACE1 expression, and Abeta production were examined.", "citation": {"type": "PubMed", "name": "FASEB J2009", "reference": "19332646"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 259}, {"relation": "increases", "evidence": "However, unlike BRI2, the binding of BRI3 to the beta-secretase cleaved APP C-terminal fragment is negligible and BRI3 does not cause the massive accumulation of this APP fragment, suggesting that, unlike BRI2, BRI3 is a poor gamma-cleavage inhibitor.", "citation": {"type": "PubMed", "name": "J Biol Chem2009", "reference": "19366692"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 260}, {"relation": "increases", "evidence": "However, unlike BRI2, the binding of BRI3 to the beta-secretase cleaved APP C-terminal fragment is negligible and BRI3 does not cause the massive accumulation of this APP fragment, suggesting that, unlike BRI2, BRI3 is a poor gamma-cleavage inhibitor.", "citation": {"type": "PubMed", "name": "J Biol Chem2009", "reference": "19366692"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 261}, {"relation": "increases", "evidence": "BACE 1 (beta-site APP-cleaving enzyme 1 or beta-secretase), the key enzyme required for generating Abeta from the beta-amyloid precursor protein (APP), is regarded as an ideal target for AD therapeutic drug design.", "citation": {"type": "PubMed", "name": "Curr Med Chem2009", "reference": "19442147"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 262}, {"relation": "increases", "evidence": "BACE 1 (beta-site APP-cleaving enzyme 1 or beta-secretase), the key enzyme required for generating Abeta from the beta-amyloid precursor protein (APP), is regarded as an ideal target for AD therapeutic drug design.", "citation": {"type": "PubMed", "name": "Curr Med Chem2009", "reference": "19442147"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 263}, {"relation": "increases", "evidence": "The beta-secretase, beta-site amyloid precursor protein cleaving enzyme (BACE1; also called Asp2, memapsin 2), is the enzyme responsible for initiating Abeta generation.", "citation": {"type": "PubMed", "name": "J Neurosci2009", "reference": "19828790"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 264}, {"relation": "increases", "evidence": "The beta-secretase, beta-site amyloid precursor protein cleaving enzyme (BACE1; also called Asp2, memapsin 2), is the enzyme responsible for initiating Abeta generation.", "citation": {"type": "PubMed", "name": "J Neurosci2009", "reference": "19828790"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 265}, {"relation": "increases", "evidence": "BACE1 initiates the amyloidogenic processing of APP; therefore, early or active amyloidogenic loci might exhibit site-specific BACE1 and Abeta elevation.", "citation": {"type": "PubMed", "name": "Eur J Neurosci2009", "reference": "20092570"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 266}, {"relation": "increases", "evidence": "BACE1 initiates the amyloidogenic processing of APP; therefore, early or active amyloidogenic loci might exhibit site-specific BACE1 and Abeta elevation.", "citation": {"type": "PubMed", "name": "Eur J Neurosci2009", "reference": "20092570"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 267}, {"relation": "increases", "evidence": "Taken together, ATXN1 functions as a genetic risk pmodifier that contributes to AD pathogenesis through a loss-of-function mechanism by regulating beta-secretase cleavage of APP and Abeta levels.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20097758"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 268}, {"relation": "increases", "evidence": "Taken together, ATXN1 functions as a genetic risk pmodifier that contributes to AD pathogenesis through a loss-of-function mechanism by regulating beta-secretase cleavage of APP and Abeta levels.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20097758"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 269}, {"relation": "increases", "evidence": "Three proteases that are involved in the processing of amyloid precursor protein-alpha-secretase, beta-secretase and gamma-secretase-are of particular interest as they are central to the generation and pmodulation of amyloid-beta peptide and can be targeted by small compounds in vitro and in vivo.", "citation": {"type": "PubMed", "name": "Nat Rev Neurol2010", "reference": "20139999"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 270}, {"relation": "increases", "evidence": "Three proteases that are involved in the processing of amyloid precursor protein-alpha-secretase, beta-secretase and gamma-secretase-are of particular interest as they are central to the generation and pmodulation of amyloid-beta peptide and can be targeted by small compounds in vitro and in vivo.", "citation": {"type": "PubMed", "name": "Nat Rev Neurol2010", "reference": "20139999"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 271}, {"relation": "increases", "evidence": "Although pmoderate decreases of either gamma-secretase or BACE1 are not associated with mechanism-based toxicities, they provide only pmodest benefits in reducing Abeta in the brains of APPswe/PS1DeltaE9 mice.", "citation": {"type": "PubMed", "name": "Sci Transl Med2010", "reference": "20371462"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 272}, {"relation": "increases", "evidence": "Although pmoderate decreases of either gamma-secretase or BACE1 are not associated with mechanism-based toxicities, they provide only pmodest benefits in reducing Abeta in the brains of APPswe/PS1DeltaE9 mice.", "citation": {"type": "PubMed", "name": "Sci Transl Med2010", "reference": "20371462"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 273}, {"relation": "increases", "evidence": "Reticulons are a group of membrane-bound proteins involved in diverse cellular functions, and are suggested to act as inhibitors of beta-secretase enzyme 1 (BACE1) activity that cleaves amyloid precursor protein. ", "citation": {"type": "PubMed", "name": "Neuropathology2010", "reference": "20374499"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 274}, {"relation": "increases", "evidence": "Here we tested the possibility of targeting the cellular environment of beta-secretase cleavage instead of the beta-secretase enzyme itself. beta-Secretase has an acidic pH optimum and cleaves the amyloid precursor protein in the acidic endosomes.", "citation": {"type": "PubMed", "name": "J Neurosci2010", "reference": "20592218"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 275}, {"relation": "increases", "evidence": "ABCA2 expression promoted b-secretase (BACE1) cleavage of APP not at the common Asp1 amino acid site (beta-site) of Abeta in APP but at the Glu11 site (beta'-site) to increase C89 carboxyl-terminal fragment levels (beta'-CTF/C89). ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res2010", "reference": "20704561"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 276}, {"relation": "increases", "evidence": "We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner.", "citation": {"type": "PubMed", "name": "J Neurosci2010", "reference": "20720123"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 277}, {"relation": "increases", "evidence": "We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner.", "citation": {"type": "PubMed", "name": "J Neurosci2010", "reference": "20720123"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 278}, {"relation": "increases", "evidence": "Western blot analyses detected increased levels of BACE1 protein and beta-site-cleavage amyloid precursor protein C-terminal fragments in plaque-bearing human and monkey cortex relative to controls. ", "citation": {"type": "PubMed", "name": "Eur J Neurosci2010", "reference": "20726888"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 279}, {"relation": "increases", "evidence": "beta-Site APP-cleaving enzyme 1 (BACE1) initiates amyloid-beta (Abeta) generation and thus represents a prime therapeutic target in treating Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "PLoS One2010", "reference": "20886088"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 280}, {"relation": "increases", "evidence": "Importantly, recent evidence reveals that expression and activity levels of the beta-site APP cleaving enzyme 1 (BACE1), which initiates amyloid-beta (Abeta) production, are elevated in AD brains.", "citation": {"type": "PubMed", "name": "Mol Brain2010", "reference": "21059265"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 281}, {"relation": "increases", "evidence": "Importantly, recent evidence reveals that expression and activity levels of the beta-site APP cleaving enzyme 1 (BACE1), which initiates amyloid-beta (Abeta) production, are elevated in AD brains.", "citation": {"type": "PubMed", "name": "Mol Brain2010", "reference": "21059265"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 282}, {"relation": "increases", "evidence": "BACE1 (beta-site beta-amyloid precursor protein (APP)-cleaving enzyme 1) mediates the first proteolytic cleavage of APP, leading to amyloid beta-peptide (Abeta) production.", "citation": {"type": "PubMed", "name": "J Biol Chem2011", "reference": "21245145"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 283}, {"relation": "increases", "evidence": "Increased beta-secretase cleavage of APP after introduction of the Swedish double mutation causes apical missorting of about 20% of beta-secretase-cleaved APP.", "citation": {"type": "PubMed", "name": "J Biol Chem1995", "reference": "7876155"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 284}, {"relation": "increases", "evidence": "Taken together, the data suggest that the processing pathway for betaPP is similar for both betaPP-wt and betaPP-sw cells and that increased Abeta production by betaPP-sw cells arises from enhanced cleavage of mutant betaPP by beta-secretase, the as-yet unidentified enzyme(s) that cleaves at the NH2 terminus of Abeta.", "citation": {"type": "PubMed", "name": "J Biol Chem1996", "reference": "8621560"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 285}, {"relation": "increases", "evidence": "Taken together, the data suggest that the processing pathway for betaPP is similar for both betaPP-wt and betaPP-sw cells and that increased Abeta production by betaPP-sw cells arises from enhanced cleavage of mutant betaPP by beta-secretase, the as-yet unidentified enzyme(s) that cleaves at the NH2 terminus of Abeta.", "citation": {"type": "PubMed", "name": "J Biol Chem1996", "reference": "8621560"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 286}, {"relation": "increases", "evidence": "Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Neurochem Int1997", "reference": "9152995"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 287}, {"relation": "increases", "evidence": "Sequential proteolytic cleavage of APP by beta-secretase and gamma-secretase liberates Abeta from APP.", "citation": {"type": "PubMed", "name": "Biol Chem2010", "reference": "20731541"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 288}, {"relation": "increases", "evidence": "Sequential proteolytic cleavage of APP by beta-secretase and gamma-secretase liberates Abeta from APP.", "citation": {"type": "PubMed", "name": "Biol Chem2010", "reference": "20731541"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 289}, {"relation": "increases", "evidence": "Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Nat Med1997", "reference": "9055862"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 290}, {"relation": "increases", "evidence": "Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Nat Med1997", "reference": "9055862"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 291}, {"relation": "increases", "evidence": "The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta-secretase that cleaves amyloid precursor protein to initiate beta-amyloid formation. As such, BACE is a prime therapeutic target for the treatment of Alzheimer's disease. ", "citation": {"type": "PubMed", "name": "J Biol Chem2000", "reference": "10956649"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {}, "source": 141, "target": 11, "key": 292}, {"relation": "increases", "evidence": "beta-Secretase (BACE) carries out the first of two proteolysis steps to generate the amyloid-beta peptides that accumulate in the senile plaques in Alzheimer's disease (AD). ", "citation": {"type": "PubMed", "name": "J Cell Sci2004", "reference": "15466887"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 293}, {"relation": "increases", "evidence": "beta-Secretase (BACE) carries out the first of two proteolysis steps to generate the amyloid-beta peptides that accumulate in the senile plaques in Alzheimer's disease (AD). ", "citation": {"type": "PubMed", "name": "J Cell Sci2004", "reference": "15466887"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 294}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartyl protease that specifically cleaves amyloid precursor protein (APP) at the beta-secretase site.", "citation": {"type": "PubMed", "name": "J Mol Biol2006", "reference": "16979658"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 295}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartyl protease that specifically cleaves amyloid precursor protein (APP) at the beta-secretase site.", "citation": {"type": "PubMed", "name": "J Mol Biol2006", "reference": "16979658"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 296}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis. ", "citation": {"type": "PubMed", "name": "J Biol Chem2003", "reference": "12473667"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 297}, {"relation": "increases", "evidence": "BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis. ", "citation": {"type": "PubMed", "name": "J Biol Chem2003", "reference": "12473667"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 298}, {"relation": "increases", "evidence": "LRRTM3 promotes processing of amyloid-precursor protein by BACE1 ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2006", "reference": "17098871"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 299}, {"relation": "increases", "evidence": "The complex mediates the intramembraneous proteolysis of beta-secretase cleaved beta-amyloid precursor protein (APP) leading to the secretion of the Alzheimer's disease-associated amyloid beta-peptide (Abeta).", "citation": {"type": "PubMed", "name": "J Neurochem2004", "reference": "15189355"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 300}, {"relation": "increases", "evidence": "The complex mediates the intramembraneous proteolysis of beta-secretase cleaved beta-amyloid precursor protein (APP) leading to the secretion of the Alzheimer's disease-associated amyloid beta-peptide (Abeta).", "citation": {"type": "PubMed", "name": "J Neurochem2004", "reference": "15189355"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 301}, {"relation": "increases", "evidence": "The familial Alzheimer's disease gene product amyloid beta precursor protein (APP) is sequentially processed by beta- and gamma-secretases to generate the Abeta peptide.", "citation": {"type": "PubMed", "name": "J Biol Chem2002", "reference": "11724784"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 302}, {"relation": "increases", "evidence": "The familial Alzheimer's disease gene product amyloid beta precursor protein (APP) is sequentially processed by beta- and gamma-secretases to generate the Abeta peptide.", "citation": {"type": "PubMed", "name": "J Biol Chem2002", "reference": "11724784"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 303}, {"relation": "increases", "evidence": "The level of -site APP-cleaving enzyme 1 (BACE1) has been documented to increase in the brains of patients with Alzheimer's disease, which has resulted in elevation of -amyloid (A) peptides.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2012 Jan 30;675(1-3):15-21. Epub 2011 Dec 7.", "reference": "22166376"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 11, "key": 304}, {"relation": "increases", "evidence": "The level of -site APP-cleaving enzyme 1 (BACE1) has been documented to increase in the brains of patients with Alzheimer's disease, which has resulted in elevation of -amyloid (A) peptides.", "citation": {"type": "PubMed", "name": "Eur J Pharmacol. 2012 Jan 30;675(1-3):15-21. Epub 2011 Dec 7.", "reference": "22166376"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 11, "key": 305}, {"relation": "increases", "evidence": "Down regulation of DNMT results in hypomethylation of BACE1 and APP which are involved in Abeta production and causes upregulation of their protein expression; in turn SP1 transcription factor increases which finally results in Abeta production.", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.", "reference": "19245828"}, "annotations": {"Species": "10090"}, "source": 141, "target": 11, "key": 306}, {"relation": "increases", "evidence": "Taken together, these findings suggest that those neurons that survive in AD brains might generate more BACE1 than normal neurons in control brains, indicating that increased BACE1 activity could be one of the causes of AD. ", "citation": {"type": "PubMed", "name": "Neurosci Res2006", "reference": "16290302"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Glycoconj J2004", "reference": "15467394"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 141, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Glycoconj J2004", "reference": "15467394"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 141, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Consistently, overexpression of calpain in heterologous APP expressing cells up-regulated the level of BACE1 and increased Abeta production. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 144, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Consistently, overexpression of calpain in heterologous APP expressing cells up-regulated the level of BACE1 and increased Abeta production. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 144, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "subject": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "Reelin subgraph"}, "source": 147, "target": 0, "key": 0}, {"relation": "increases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "subject": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "NMDA receptor"}, "source": 147, "target": 0, "key": 1}, {"relation": "increases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "subject": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 147, "target": 0, "key": 2}, {"relation": "decreases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "subject": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "Reelin subgraph"}, "source": 147, "target": 33, "key": 0}, {"relation": "decreases", "evidence": "Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and APP was discovered, leading to increase in the cell surface levels of APP and affecting APP processing and A production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A peptides, reelin can no longer overcome the A-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686"}, "subject": {"modifier": "Activity"}, "annotations": {"CellStructure": "Centrosome", "Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 147, "target": 33, "key": 1}, {"relation": "increases", "evidence": " Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.", "citation": {"type": "PubMed", "name": "J Neurosci. 2007 Apr 11;27(15):4052-60.", "reference": "17428983"}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Beta secretase subgraph"}, "source": 153, "target": 11, "key": 0}, {"relation": "increases", "evidence": " Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.", "citation": {"type": "PubMed", "name": "J Neurosci. 2007 Apr 11;27(15):4052-60.", "reference": "17428983"}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 153, "target": 11, "key": 1}, {"relation": "increases", "evidence": " Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.", "citation": {"type": "PubMed", "name": "J Neurosci. 2007 Apr 11;27(15):4052-60.", "reference": "17428983"}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Endosomal lysosomal subgraph"}, "source": 153, "target": 11, "key": 2}, {"relation": "increases", "evidence": "These data suggest that BACE2 contributes to Abeta production in individuals bearing the Flemish mutation, and that selective inhibition of these highly similar proteases may be feasible and therapeutically advantageous.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2000", "reference": "10931940"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 153, "target": 11, "key": 3}, {"relation": "increases", "evidence": "These data suggest that BACE2 contributes to Abeta production in individuals bearing the Flemish mutation, and that selective inhibition of these highly similar proteases may be feasible and therapeutically advantageous.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2000", "reference": "10931940"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 153, "target": 11, "key": 4}, {"relation": "increases", "evidence": "BACE2 cleaves the amyloid precursor protein at the beta-secretase site and is thought to contribute to amyloid beta protein production.", "citation": {"type": "PubMed", "name": "Neurosci Lett2002", "reference": "12052539"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 153, "target": 11, "key": 5}, {"relation": "increases", "evidence": "BACE2 cleaves the amyloid precursor protein at the beta-secretase site and is thought to contribute to amyloid beta protein production.", "citation": {"type": "PubMed", "name": "Neurosci Lett2002", "reference": "12052539"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 153, "target": 11, "key": 6}, {"relation": "increases", "evidence": "Mapping to the Down syndrome critical region (chromosome 21) and identified as a homologue of BACE1, BACE2 also cleaves amyloid precursor protein at the beta-site.", "citation": {"type": "PubMed", "name": "J Proteome Res2004", "reference": "15473697"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 153, "target": 11, "key": 7}, {"relation": "increases", "evidence": "Mapping to the Down syndrome critical region (chromosome 21) and identified as a homologue of BACE1, BACE2 also cleaves amyloid precursor protein at the beta-site.", "citation": {"type": "PubMed", "name": "J Proteome Res2004", "reference": "15473697"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 153, "target": 11, "key": 8}, {"relation": "decreases", "evidence": "The inhibition of this kinase can prevent the aggregation of -amyloid (A) and hyperphosphorylation of tau protein.", "citation": {"type": "PubMed", "name": "Rev Neurosci. 2011 Dec 21;23(1):1-11. doi: 10.1515/rns.2011.061.", "reference": "22718609"}, "subject": {"modifier": "Degradation"}, "annotations": {"Subgraph": "GSK3 subgraph"}, "source": 154, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "The inhibition of this kinase can prevent the aggregation of -amyloid (A) and hyperphosphorylation of tau protein.", "citation": {"type": "PubMed", "name": "Rev Neurosci. 2011 Dec 21;23(1):1-11. doi: 10.1515/rns.2011.061.", "reference": "22718609"}, "subject": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 154, "target": 11, "key": 1}, {"relation": "directlyDecreases", "evidence": "Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia", "citation": {"type": "PubMed", "name": "J Neurosci. 2006 May 10;26(19):5167-79", "reference": "16687508"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Response to oxidative stress"}, "source": 155, "target": 33, "key": 0}, {"relation": "directlyDecreases", "evidence": "Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia", "citation": {"type": "PubMed", "name": "J Neurosci. 2006 May 10;26(19):5167-79", "reference": "16687508"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 155, "target": 33, "key": 1}, {"relation": "increases", "evidence": "In CAA, and probably in AD, corticosteroid treatment suppresses the secondarily induced vascular inflammation (Chang et al., 2012, Kloppenborg et al., 2010 and Machida et al., 2012) and the activation of S100A9/Mrp14 (Gebhardt et al., 2002 and Kametani and Ikeda, 2013). Recently, it has been reported that anti-A autoantibodies were progressively reduced in the cerebrospinal fluid of a patient with CAA-related inflammation, following intravenous steroid administration (Piazza et al., 2013). Reduction of S100A9/Mrp14 might induce suppression of amyloid fibril formation (Zhang et al., 2012) and increase phagocytosis of fibrillar A in microglia cells (Kummer et al., 2012), resulting in reduced A amyloid fibril deposition.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2014 Apr;35(4):e11-2", "reference": "24262203"}, "annotations": {"Subgraph": "Inflammatory response subgraph"}, "source": 156, "target": 11, "key": 0}, {"relation": "increases", "evidence": "In CAA, and probably in AD, corticosteroid treatment suppresses the secondarily induced vascular inflammation (Chang et al., 2012, Kloppenborg et al., 2010 and Machida et al., 2012) and the activation of S100A9/Mrp14 (Gebhardt et al., 2002 and Kametani and Ikeda, 2013). Recently, it has been reported that anti-A autoantibodies were progressively reduced in the cerebrospinal fluid of a patient with CAA-related inflammation, following intravenous steroid administration (Piazza et al., 2013). Reduction of S100A9/Mrp14 might induce suppression of amyloid fibril formation (Zhang et al., 2012) and increase phagocytosis of fibrillar A in microglia cells (Kummer et al., 2012), resulting in reduced A amyloid fibril deposition.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2014 Apr;35(4):e11-2", "reference": "24262203"}, "annotations": {"Subgraph": "Metabolism of steroid hormones subgraph"}, "source": 156, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with A.", "citation": {"type": "PubMed", "name": "Acta Neuropathol. 2014 Apr;127(4):507-22", "reference": "24240735"}, "annotations": {"Subgraph": "Toll like receptor subgraph"}, "source": 156, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with A.", "citation": {"type": "PubMed", "name": "Acta Neuropathol. 2014 Apr;127(4):507-22", "reference": "24240735"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 156, "target": 11, "key": 3}, {"relation": "increases", "evidence": "We therefore conclude that Mrp14 promotes APP processing and A accumulation under neuroinflammatory conditions.", "citation": {"type": "PubMed", "name": "J Neurosci. 2012 Dec 5;32(49):17824-9.", "reference": "23223301"}, "annotations": {"Subgraph": "Toll like receptor subgraph"}, "source": 156, "target": 11, "key": 4}, {"relation": "increases", "evidence": "We therefore conclude that Mrp14 promotes APP processing and A accumulation under neuroinflammatory conditions.", "citation": {"type": "PubMed", "name": "J Neurosci. 2012 Dec 5;32(49):17824-9.", "reference": "23223301"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 156, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Evidence indicates that S100A9 contributes to Alzheimer's disease (AD) pathology, although the precise mechanisms are not clear.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2013 May 30;10:68. doi: 10.1186/1742-2094-10-68", "reference": "23721320"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 156, "target": 33, "key": 0}, {"relation": "decreases", "evidence": " Inhibition of HDAC2 activity by trichostatin A substantially recovered the histone H3 acetylation in the promoter region of Bdnf exon VI and BDNF expression, thus mitigating the synaptic dysfunction and memory deficiency induced by amyloid fibrils.", "citation": {"type": "PubMed", "name": "Pharmacol Biochem Behav. 2014 Nov;126:83-9. doi: 10.1016/j.pbb.2014.09.009. Epub 2014 Sep 19.", "reference": "25242807"}, "annotations": {"Encode_Feature_Types": "Promoter"}, "source": 157, "target": 46, "key": 0}, {"relation": "increases", "evidence": "Utilizing a novel microfluidic culture chamber, we demonstrate that A oligomers compromise BDNF-mediated retrograde transport by impairing endosomal vesicle velocities, resulting in impaired downstream signaling driven by BDNF/TrkB, including ERK5 activation, and CREB-dependent gene regulation. Our data suggest that a key mechanism mediating the deficit involves ubiquitin C-terminal hydrolase L1 (UCH-L1), a deubiquitinating enzyme that functions to regulate cellular ubiquitin. A-induced deficits in BDNF trafficking and signaling are mimicked by LDN (an inhibitor of UCH-L1) and can be reversed by increasing cellular UCH-L1 levels, demonstrated here using a transducible TAT-UCH-L1 strategy. Finally, our data reveal that UCH-L1 mRNA levels are decreased in the hippocampi of AD brains. Taken together, our data implicate that UCH-L1 is important for regulating neurotrophin receptor sorting to signaling endosomes and supporting retrograde transport. Further, our results support the idea that in AD, A may down-regulate UCH-L1 in the AD brain, which in turn impairs BDNF/TrkB-mediated retrograde signaling, compromising synaptic plasticity and neuronal survival.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2013 Jun 7;288(23):16937-48. doi: 10.1074/jbc.M113.463711. Epub 2013 Apr 18.", "reference": "23599427"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "Neurotrophic subgraph"}, "source": 157, "target": 61, "key": 0}, {"relation": "increases", "evidence": "Assemblies of -amyloid (A) peptides are pathological mediators of Alzheimer's Disease (AD) and are produced by the sequential cleavages of amyloid precursor protein (APP) by -secretase (BACE1) and gamma-secretase. The generation of A is coupled to neuronal activity, but the molecular basis is unknown. Here, we report that the immediate early gene Arc is required for activity-dependent generation of A. Arc is a postsynaptic protein that recruits endophilin2/3 and dynamin to early/recycling endosomes that traffic AMPA receptors to reduce synaptic strength in both hebbian and non-hebbian forms of plasticity. The Arc-endosome also traffics APP and BACE1, and Arc physically associates with presenilin1 (PS1) to regulate gamma-secretase trafficking and confer activity dependence.", "citation": {"type": "PubMed", "name": "Cell. 2011 Oct 28;147(3):615-28.", "reference": "22036569"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Glutamatergic subgraph"}, "source": 158, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Assemblies of -amyloid (A) peptides are pathological mediators of Alzheimer's Disease (AD) and are produced by the sequential cleavages of amyloid precursor protein (APP) by -secretase (BACE1) and gamma-secretase. The generation of A is coupled to neuronal activity, but the molecular basis is unknown. Here, we report that the immediate early gene Arc is required for activity-dependent generation of A. Arc is a postsynaptic protein that recruits endophilin2/3 and dynamin to early/recycling endosomes that traffic AMPA receptors to reduce synaptic strength in both hebbian and non-hebbian forms of plasticity. The Arc-endosome also traffics APP and BACE1, and Arc physically associates with presenilin1 (PS1) to regulate gamma-secretase trafficking and confer activity dependence.", "citation": {"type": "PubMed", "name": "Cell. 2011 Oct 28;147(3):615-28.", "reference": "22036569"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 158, "target": 68, "key": 1}, {"relation": "increases", "evidence": " IL-1 levels are elevated in Alzheimer brain, and overexpression of IL-1 is associated with beta-amyloid plaque progression.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol2000", "reference": "10850859"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 160, "target": 11, "key": 0}, {"relation": "increases", "evidence": " IL-1 levels are elevated in Alzheimer brain, and overexpression of IL-1 is associated with beta-amyloid plaque progression.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol2000", "reference": "10850859"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 160, "target": 11, "key": 1}, {"relation": "increases", "evidence": " IL-1 levels are elevated in Alzheimer brain, and overexpression of IL-1 is associated with beta-amyloid plaque progression.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2000 Jun;59(6):471-6.", "reference": "10850859"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 160, "target": 11, "key": 2}, {"relation": "increases", "evidence": " IL-1 levels are elevated in Alzheimer brain, and overexpression of IL-1 is associated with beta-amyloid plaque progression.", "citation": {"type": "PubMed", "name": "J Neuropathol Exp Neurol. 2000 Jun;59(6):471-6.", "reference": "10850859"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 160, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Mar;104(5):1387-93. Epub 2007 Nov 16.", "reference": "18021299"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 160, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Mar;104(5):1387-93. Epub 2007 Nov 16.", "reference": "18021299"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 160, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Mar;104(5):1387-93. Epub 2007 Nov 16.", "reference": "18021299"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 160, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "18021299"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 160, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "18021299"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 160, "target": 11, "key": 8}, {"relation": "decreases", "evidence": "we unexpectedly found that IL-1beta significantly enhanced alpha-cleavage, indicated by increases in sAPPalpha and C83, but reduced beta-cleavage, indicated by decreases in sAPPbeta and Abeta40/42, in human neuroblastoma SK-N-SH cells. IL-1beta did not significantly alter the mRNA levels of BACE1, ADAM-9, and ADAM-10, but up-regulated that of TACE by threefold.", "citation": {"type": "PubMed", "name": "J Neurochem2008", "reference": "18021299"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 160, "target": 11, "key": 9}, {"relation": "decreases", "evidence": " IL-1Ra, a physiological antagonist for the IL-1 receptor, reversed the effects of IL-1beta, suggesting that the IL-1beta-dependent up-regulation of alpha-cleavage is mediated by the IL-1 receptor. IL-1beta also induced this concomitant increase in alpha-cleavage and decrease in beta-cleavage in mouse primary cultured neurons. Taken together we conclude that IL-1beta is an anti-amyloidogenic factor, and that enhancement of its signaling or inhibition of IL-1Ra activity could represent potential therapeutic strategies against Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurochem. 2008 Mar;104(5):1387-93. Epub 2007 Nov 16.", "reference": "18021299"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 160, "target": 33, "key": 0}, {"relation": "increases", "evidence": "The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-1 (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1alpha and IL-1beta increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5'-untranslated region (5'-UTR) conferred translational regulation by IL-1alpha and IL-1beta to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5'-UTR)/CAT mRNAs were unchanged, whereas both base-line and IL-1-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5'-cap site and is homologous to related translational control elements in the 5'-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "J Biol Chem. 1999 Mar 5;274(10):6421-31.", "reference": "10037734"}, "annotations": {"NervousSystem": "Astrocytes", "Subgraph": "Amyloidogenic subgraph"}, "source": 160, "target": 68, "key": 0}, {"relation": "increases", "evidence": "The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-1 (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1alpha and IL-1beta increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5'-untranslated region (5'-UTR) conferred translational regulation by IL-1alpha and IL-1beta to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5'-UTR)/CAT mRNAs were unchanged, whereas both base-line and IL-1-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5'-cap site and is homologous to related translational control elements in the 5'-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "J Biol Chem. 1999 Mar 5;274(10):6421-31.", "reference": "10037734"}, "annotations": {"NervousSystem": "Astrocytes", "Subgraph": "Interleukin signaling subgraph"}, "source": 160, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Abeta-dependent inactivation of the JAK2/STAT3 axis causes memory loss through cholinergic dysfunction.", "citation": {"type": "PubMed", "name": "Mol Psychiatry. 2009 Feb;14(2):206-22. Epub 2008 Sep 23", "reference": "18813209"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "JAK-STAT signaling subgraph", "Disease": "Alzheimer's disease"}, "source": 163, "target": 46, "key": 0}, {"relation": "increases", "evidence": "These results reveal a potential regulatory link between Dyrk1A and PS1 in the Abeta pathway of DS and AD brains, suggesting that up-regulated Dyrk1A may accelerate AD pathogenesis through PS1 phosphorylation.", "citation": {"type": "PubMed", "name": "J Neurochem2010", "reference": "20456003"}, "annotations": {"Subgraph": "DYRK1A subgraph"}, "source": 168, "target": 33, "key": 0}, {"relation": "increases", "evidence": "These results reveal a potential regulatory link between Dyrk1A and PS1 in the Abeta pathway of DS and AD brains, suggesting that up-regulated Dyrk1A may accelerate AD pathogenesis through PS1 phosphorylation.", "citation": {"type": "PubMed", "name": "J Neurochem2010", "reference": "20456003"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 168, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Diverse types of proteins have been identified as the substrates of Dyrk1A, including transcription factors, including NF-AT and Forkhead , several\\ endocytosis and synaptic vesicle recycling proteins, such as dynamin 1 and amphiphysin 1\\ , and cytosolic proteins, such as APP and tau\\ , implying that Dyrk1A participates in various biological responses.", "citation": {"type": "PubMed", "name": "Exp Neurobiol. 2011 Mar;20(1):35-44. Epub 2011 Mar 31.", "reference": "22110360"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "DYRK1A subgraph"}, "source": 168, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Diverse types of proteins have been identified as the substrates of Dyrk1A, including transcription factors, including NF-AT and Forkhead , several\\ endocytosis and synaptic vesicle recycling proteins, such as dynamin 1 and amphiphysin 1\\ , and cytosolic proteins, such as APP and tau\\ , implying that Dyrk1A participates in various biological responses.", "citation": {"type": "PubMed", "name": "Exp Neurobiol. 2011 Mar;20(1):35-44. Epub 2011 Mar 31.", "reference": "22110360"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 168, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 169, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 169, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Our laboratory has previously shown that EGCG can increase non-amyloidogenic processing of APP through promotion of the beta-secretase ADAM10, which consequently reduced Abeta deposition and improved cognition in AD mice", "citation": {"type": "PubMed", "name": "FEBS Lett2010", "reference": "20849853"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 169, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Our laboratory has previously shown that EGCG can increase non-amyloidogenic processing of APP through promotion of the beta-secretase ADAM10, which consequently reduced Abeta deposition and improved cognition in AD mice", "citation": {"type": "PubMed", "name": "FEBS Lett2010", "reference": "20849853"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 169, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Our laboratory has previously shown that EGCG can increase non-amyloidogenic processing of APP through promotion of the beta-secretase ADAM10, which consequently reduced Abeta deposition and improved cognition in AD mice", "citation": {"type": "PubMed", "name": "FEBS Lett2010", "reference": "20849853"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 169, "target": 44, "key": 0}, {"relation": "increases", "evidence": "Our laboratory has previously shown that EGCG can increase non-amyloidogenic processing of APP through promotion of the beta-secretase ADAM10, which consequently reduced Abeta deposition and improved cognition in AD mice", "citation": {"type": "PubMed", "name": "FEBS Lett2010", "reference": "20849853"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 169, "target": 44, "key": 1}, {"relation": "increases", "evidence": "Amyloidogenic APP processing may prevent a-secretase (a) cleavage of APP which would otherwise generate a secreted form of APP (sAPPa).", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "object": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 169, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Amyloidogenic APP processing may prevent a-secretase (a) cleavage of APP which would otherwise generate a secreted form of APP (sAPPa).", "citation": {"type": "PubMed", "name": "Trends Neurosci. 2008 Sep;31(9):454-63. Epub 2008 Jul 31", "reference": "18675468"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "object": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 169, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 169, "target": 68, "key": 2}, {"relation": "increases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 169, "target": 68, "key": 3}, {"relation": "increases", "evidence": "Our laboratory has previously shown that EGCG can increase non-amyloidogenic processing of APP through promotion of the beta-secretase ADAM10, which consequently reduced Abeta deposition and improved cognition in AD mice", "citation": {"type": "PubMed", "name": "FEBS Lett2010", "reference": "20849853"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 169, "target": 68, "key": 4}, {"relation": "increases", "evidence": "Our laboratory has previously shown that EGCG can increase non-amyloidogenic processing of APP through promotion of the beta-secretase ADAM10, which consequently reduced Abeta deposition and improved cognition in AD mice", "citation": {"type": "PubMed", "name": "FEBS Lett2010", "reference": "20849853"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 169, "target": 68, "key": 5}, {"relation": "increases", "evidence": "Glutamate is the most abundant excitatory neurotransmitter of the mammalian nervous system. At the neuronal membrane, glutamate binds to ionotropic and metabotropic receptors. Ionotropic receptors include NMDA, kainate, and AMPA receptors", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Glutamatergic subgraph"}, "source": 170, "target": 63, "key": 0}, {"relation": "increases", "evidence": "Glutamate is the most abundant excitatory neurotransmitter of the mammalian nervous system. At the neuronal membrane, glutamate binds to ionotropic and metabotropic receptors. Ionotropic receptors include NMDA, kainate, and AMPA receptors", "citation": {"type": "PubMed", "name": "Mol Neurodegener. 2009 May 6;4:20.", "reference": "19419557"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "NMDA receptor"}, "source": 170, "target": 63, "key": 1}, {"relation": "increases", "evidence": "Background and Objective: Could a normal - but persistent - stress response to impeded axonal transport lead to late-onset Alzheimer's disease (AD)? Our results offer an affirmative answer, suggesting a mechanism for the abnormal production of amyloid- (A), triggered by the slowed axonal transport at old age. We hypothesize that A precursor protein (APP) is a sensor at the endoplasmic reticulum (ER) that detects, and signals to the nucleus, abnormalities in axonal transport. When persistently activated, due to chronically slowed-down transport, this signaling pathway leads to accumulation of A within the ER. Methods and Results: We tested this hypothesis with the neuronal cell line CAD. We show that, normally, a fraction of APP is transported into neurites by recruiting kinesin-1 via the adaptor protein, Fe65. Under conditions that block kinesin-1-dependent transport, APP, Fe65 and kinesin-1 accumulate in the soma, and form a complex at the ER. This complex recruits active c-Jun N-terminal kinase (JNK), which phosphorylates APP at Thr(668). This phosphorylation increases the cleavage of APP by the amyloidogenic pathway, which generates A within the ER lumen, and releases Fe65 into the cytoplasm. Part of the released Fe65 translocates into the nucleus, likely to initiate a gene transcription response to arrested transport. Prolonged arrest of kinesin-1-dependent transport could thus lead to accumulation and oligomerization of A in the ER. Conclusion: These results support a model where the APP:Fe65 complex is a sensor at the ER for detecting the increased level of kinesin-1 caused by halted transport, which signals to the nucleus, while concomitantly generating an oligomerization-prone pool of A in the ER. Our hypothesis could thus explain a pathogenic mechanism in AD.", "citation": {"type": "PubMed", "name": "Neurodegener Dis. 2012;10(1-4):60-3. Epub 2011 Dec 7.", "reference": "22156573"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "MAPK-JNK subgraph"}, "source": 171, "target": 11, "key": 0}, {"relation": "increases", "evidence": "These findings raise the possibility that the JNK pathway may also contribute to Abeta-dependent death in AD patients.", "citation": {"type": "PubMed", "name": "J Neurosci. 2001 Oct 1;21(19):7551-60", "reference": "11567045"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Species": "9606", "Subgraph": "MAPK-JNK subgraph"}, "source": 171, "target": 11, "key": 1}, {"relation": "increases", "evidence": "These findings raise the possibility that the JNK pathway may also contribute to Abeta-dependent death in AD patients.", "citation": {"type": "PubMed", "name": "J Neurosci. 2001 Oct 1;21(19):7551-60", "reference": "11567045"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Species": "9606", "Subgraph": "Amyloidogenic subgraph"}, "source": 171, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Soluble Abeta oligomers can rapidly disrupt synaptic memory mechanisms at extremely low concentrations via stress-activated kinases and oxidative/nitrosative stress mediators.", "citation": {"type": "PubMed", "name": "Biochem Soc Trans. 2007 Nov;35(Pt 5):1219-23.", "reference": "17956317"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "Disease": "Alzheimer's disease"}, "source": 171, "target": 46, "key": 0}, {"relation": "increases", "evidence": "VEGF genetic variability is associated with increased risk of developing Alzheimer's disease.", "citation": {"type": "PubMed", "name": "J Neurol Sci. 2009 Aug 15;283(1-2):66-8", "reference": "19272614"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Vascular endothelial growth factor subgraph"}, "source": 173, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Our aim was to test if this enzyme could also degrade the insoluble 40-42 residues long A beta peptides purified from Alzheimer Disease brain. Our results indicate that MMP2 hydrolyzes A beta 1-40 and A beta 1-42 peptides at Lys 16-Leu 17, at Leu 34-Met 35, and Met 35-Val 36 peptide bonds.These results suggest that MMP2 has the ability of degrading A beta of AD in vitro.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 1994 Dec 30;205(3):1755-61", "reference": "7811262"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "object": {"modifier": "Degradation"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Brain", "Subgraph": "Matrix metalloproteinase subgraph"}, "source": 174, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Our aim was to test if this enzyme could also degrade the insoluble 40-42 residues long A beta peptides purified from Alzheimer Disease brain. Our results indicate that MMP2 hydrolyzes A beta 1-40 and A beta 1-42 peptides at Lys 16-Leu 17, at Leu 34-Met 35, and Met 35-Val 36 peptide bonds.These results suggest that MMP2 has the ability of degrading A beta of AD in vitro.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun. 1994 Dec 30;205(3):1755-61", "reference": "7811262"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "object": {"modifier": "Degradation"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Brain", "Subgraph": "Amyloidogenic subgraph"}, "source": 174, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci. 2012 Apr;49(4):423-9", "reference": "22402435"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 174, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci. 2012 Apr;49(4):423-9", "reference": "22402435"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 174, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Cells overexpressing Bcl-xL were significantly protected from beta-amyloid neurotoxicity and staurosporine-induced apoptosis compared to vector-transfected controls.", "citation": {"type": "PubMed", "name": "Neuroscience. 2001;102(1):139-50", "reference": "11226677"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "Subgraph": "Amyloidogenic subgraph"}, "source": 175, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Cells overexpressing Bcl-xL were significantly protected from beta-amyloid neurotoxicity and staurosporine-induced apoptosis compared to vector-transfected controls.", "citation": {"type": "PubMed", "name": "Neuroscience. 2001;102(1):139-50", "reference": "11226677"}, "annotations": {"MeSHDisease": "Wounds and Injuries", "Subgraph": "Bcl-2 subgraph"}, "source": 175, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 176, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 176, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "To explore the molecular mechanism underlying AD, HTN, and CAA, we hypothesize a feedback signaling loop consisted of Pin1, eNOS, and A. Pin1 and eNOS mainly inhibit A deposition in cerebral vessels, cerebral microbleeds, and elevation of blood pressure, preventing the development of AD, HTN, and CAA, however, A plays an opposite role and aggravates these diseases.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 176, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "To explore the molecular mechanism underlying AD, HTN, and CAA, we hypothesize a feedback signaling loop consisted of Pin1, eNOS, and A. Pin1 and eNOS mainly inhibit A deposition in cerebral vessels, cerebral microbleeds, and elevation of blood pressure, preventing the development of AD, HTN, and CAA, however, A plays an opposite role and aggravates these diseases.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 176, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Data from recent observational studies have revealed a potential role for statins in prevention of AD.", "citation": {"type": "PubMed", "name": "Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131-6", "reference": "12218642"}, "annotations": {"Subgraph": "Nitric oxide subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 176, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Thus, endogenous tPA, preferentially its aggregate form, could degrade A molecules and maintain low levels of brain A, resulting in the delay of AD pathogenesis.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2014 Mar;35(3):511-9", "reference": "24126163"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 178, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Thus, endogenous tPA, preferentially its aggregate form, could degrade A molecules and maintain low levels of brain A, resulting in the delay of AD pathogenesis.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2014 Mar;35(3):511-9", "reference": "24126163"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Plasminogen activator subgraph"}, "source": 178, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Subsequent studies showed that it was plasmin, the product of tPA activation of plasminogen, that specifically cleaved A beta 1-40 in the amino terminal region between Arg5 and His6.", "citation": {"type": "PubMed", "name": "Biochemistry. 1999 Aug 31;38(35):11570-6", "reference": "10471309"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 178, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Subsequent studies showed that it was plasmin, the product of tPA activation of plasminogen, that specifically cleaved A beta 1-40 in the amino terminal region between Arg5 and His6.", "citation": {"type": "PubMed", "name": "Biochemistry. 1999 Aug 31;38(35):11570-6", "reference": "10471309"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Plasminogen activator subgraph"}, "source": 178, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Additionally, plasmin (activated by tPA) attenuates Abeta neurotoxicity by degrading the peptide and rendering it inactive.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2003", "reference": "14501010"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Plasminogen activator subgraph"}, "source": 178, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Additionally, plasmin (activated by tPA) attenuates Abeta neurotoxicity by degrading the peptide and rendering it inactive.", "citation": {"type": "PubMed", "name": "J Mol Neurosci2003", "reference": "14501010"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 178, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "Tissue plasminogen activator arrests Alzheimer's disease pathogenesis.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2014 Mar;35(3):511-9", "reference": "24126163"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Plasminogen activator subgraph"}, "source": 178, "target": 33, "key": 0}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Endothelin subgraph"}, "source": 180, "target": 11, "key": 0}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 180, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 180, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Activated gadd153 can generate oxidative damage and reactive oxygen species (ROS), increase -amyloid (A) levels, disturb iron homeostasis and induce inflammation as well as cell death, which are all pathological hallmarks of AD.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(10):e26420", "reference": "22046282"}, "annotations": {"Subgraph": "Unfolded protein response subgraph", "MeSHDisease": "Inflammation"}, "source": 182, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Activated gadd153 can generate oxidative damage and reactive oxygen species (ROS), increase -amyloid (A) levels, disturb iron homeostasis and induce inflammation as well as cell death, which are all pathological hallmarks of AD.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(10):e26420", "reference": "22046282"}, "annotations": {"Subgraph": "Unfolded protein response subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 182, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Activated gadd153 can generate oxidative damage and reactive oxygen species (ROS), increase -amyloid (A) levels, disturb iron homeostasis and induce inflammation as well as cell death, which are all pathological hallmarks of AD.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(10):e26420", "reference": "22046282"}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "MeSHDisease": "Inflammation"}, "source": 182, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Activated gadd153 can generate oxidative damage and reactive oxygen species (ROS), increase -amyloid (A) levels, disturb iron homeostasis and induce inflammation as well as cell death, which are all pathological hallmarks of AD.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(10):e26420", "reference": "22046282"}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 182, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus.", "citation": {"type": "PubMed", "name": "PLoS One. 2011;6(10):e26420", "reference": "22046282"}, "subject": {"modifier": "Degradation"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "NervousSystem": "Hippocampus", "Subgraph": "Unfolded protein response subgraph"}, "source": 182, "target": 33, "key": 0}, {"relation": "increases", "evidence": "This suggests that increased expression of uPA may initially serve as a protective mechanism leading to localized degradation and clearance of the pathogenic stimulus A beta.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2003 May 23;278(21):19054-61", "reference": "12754271"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 185, "target": 11, "key": 0}, {"relation": "increases", "evidence": "This suggests that increased expression of uPA may initially serve as a protective mechanism leading to localized degradation and clearance of the pathogenic stimulus A beta.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2003 May 23;278(21):19054-61", "reference": "12754271"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Plasminogen activator subgraph"}, "source": 185, "target": 11, "key": 1}, {"relation": "increases", "evidence": "It is believed that amyloid-beta peptide (Abeta) plays a central role in the pathogenesis of Alzheimer's disease (AD). Thus, the process of amyloid precursor protein (APP) cleavage is a key event and has raised much attention in the field of AD research. It is proposed that APP, beta- and gamma-secretases are all located on the lipid raft, and the meeting of them is an indispensable step for Abeta generation. Endocytosis can lead to clustering of APP, beta- and gamma-secretases from separate smaller lipid rafts into a larger one. On the other hand, for myristoylated alanine-rich C kinase substrate (MARCKS), phosphorylation by protein kinase C (PKC) or interaction with Ca(2+) can lead to its release from membrane into cytoplasm. This process induces the release of actins and phosphatidylinositol 4, 5-bisphosphate (PIP2), which are important factors for endocytosis. Thus, the present review proposes that MARCKS may be implicated in Abeta generation, by modulating free PIP2 level and actin movement, causing endocytosis", "citation": {"type": "PubMed", "name": "Neurosci Bull. 2010 Aug;26(4):338-44.", "reference": "20651816"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Phosphatidylinositol 3 subgraph"}, "source": 186, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Our data suggest that microvascular RAGE levels increase in conjunction with the onset of AD, and continue to increase linearly as a function of AD pathologic severity", "citation": {"type": "PubMed", "name": "Brain Res2008", "reference": "18657529"}, "annotations": {"Subgraph": "Immunoglobulin subgraph"}, "source": 188, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Our data suggest that microvascular RAGE levels increase in conjunction with the onset of AD, and continue to increase linearly as a function of AD pathologic severity", "citation": {"type": "PubMed", "name": "Brain Res2008", "reference": "18657529"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 188, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Clinical studies have recently shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery disease, hypertension, the metabolic syndrome, arthritis and Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Curr Med Chem2006", "reference": "16842191"}, "annotations": {"Subgraph": "Immunoglobulin subgraph"}, "source": 188, "target": 33, "key": 2}, {"relation": "increases", "evidence": "Aggregated Abeta induced IFN-gamma production from co-culture of astrocytes and microglia, and IFN-gamma elicited tumor necrosis factor (TNF)-alpha secretion in wild type (WT) but not GRKO microglia co-cultured with astrocytes. ", "citation": {"type": "PubMed", "name": "Am J Pathol2007", "reference": "17255335"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 190, "target": 140, "key": 0}, {"relation": "increases", "evidence": "Aggregated Abeta induced IFN-gamma production from co-culture of astrocytes and microglia, and IFN-gamma elicited tumor necrosis factor (TNF)-alpha secretion in wild type (WT) but not GRKO microglia co-cultured with astrocytes. ", "citation": {"type": "PubMed", "name": "Am J Pathol2007", "reference": "17255335"}, "annotations": {"Subgraph": "Interferon signaling"}, "source": 190, "target": 140, "key": 1}, {"relation": "increases", "evidence": "In addition, we show that some NF-kappaB inhibitors decrease sAPPbeta and APP-CTFbeta suggesting that they reduce the beta-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "Neurosci Lett2007", "reference": "17223266"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 192, "target": 11, "key": 0}, {"relation": "increases", "evidence": "In addition, we show that some NF-kappaB inhibitors decrease sAPPbeta and APP-CTFbeta suggesting that they reduce the beta-secretase cleavage of APP.", "citation": {"type": "PubMed", "name": "Neurosci Lett2007", "reference": "17223266"}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 192, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 192, "target": 68, "key": 0}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 192, "target": 68, "key": 1}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 192, "target": 68, "key": 2}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 192, "target": 68, "key": 3}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 192, "target": 91, "key": 0}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 192, "target": 91, "key": 1}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 192, "target": 91, "key": 2}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 192, "target": 91, "key": 3}, {"relation": "increases", "evidence": "Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46", "reference": "21969301"}, "annotations": {"Subgraph": "GABA subgraph", "MeSHDisease": "Glaucoma"}, "source": 195, "target": 32, "key": 0}, {"relation": "increases", "evidence": "Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46", "reference": "21969301"}, "annotations": {"Subgraph": "GABA subgraph", "MeSHDisease": "Alzheimer Disease"}, "source": 195, "target": 32, "key": 1}, {"relation": "increases", "evidence": "In this study, we found that lentivirus-mediated overexpression of Egr-1 in rat brain hippocampus and primary neurons in culture activates proline-directed kinase Cdk5, inactivates PP1, promotes tau phosphorylation at both proline-directed Sep(396/404) and non-proline-directed Sep(262) sites, and destabilizes microtubules.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2011 Jun 10;286(23):20569-81", "reference": "21489990"}, "annotations": {"Species": "10116", "Subgraph": "Tau protein subgraph", "NervousSystem": "Neurons"}, "source": 195, "target": 17, "key": 0}, {"relation": "increases", "evidence": "In this study, we found that lentivirus-mediated overexpression of Egr-1 in rat brain hippocampus and primary neurons in culture activates proline-directed kinase Cdk5, inactivates PP1, promotes tau phosphorylation at both proline-directed Sep(396/404) and non-proline-directed Sep(262) sites, and destabilizes microtubules.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2011 Jun 10;286(23):20569-81", "reference": "21489990"}, "annotations": {"Species": "10116", "Subgraph": "Tau protein subgraph", "NervousSystem": "Brain"}, "source": 195, "target": 17, "key": 1}, {"relation": "increases", "evidence": "In this study, we found that lentivirus-mediated overexpression of Egr-1 in rat brain hippocampus and primary neurons in culture activates proline-directed kinase Cdk5, inactivates PP1, promotes tau phosphorylation at both proline-directed Sep(396/404) and non-proline-directed Sep(262) sites, and destabilizes microtubules.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2011 Jun 10;286(23):20569-81", "reference": "21489990"}, "annotations": {"Species": "10116", "Subgraph": "Tau protein subgraph", "NervousSystem": "Hippocampus"}, "source": 195, "target": 17, "key": 2}, {"relation": "increases", "evidence": "Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.", "citation": {"type": "PubMed", "name": "Gene. 2003 Oct 30;318:113-24", "reference": "14585504"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "GABA subgraph"}, "source": 195, "target": 91, "key": 0}, {"relation": "increases", "evidence": "In this study, we found that lentivirus-mediated overexpression of Egr-1 in rat brain hippocampus and primary neurons in culture activates proline-directed kinase Cdk5, inactivates PP1, promotes tau phosphorylation at both proline-directed Sep(396/404) and non-proline-directed Sep(262) sites, and destabilizes microtubules.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2011 Jun 10;286(23):20569-81", "reference": "21489990"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10116", "Subgraph": "Cyclin-CDK subgraph", "NervousSystem": "Neurons"}, "source": 195, "target": 196, "key": 0}, {"relation": "increases", "evidence": "In this study, we found that lentivirus-mediated overexpression of Egr-1 in rat brain hippocampus and primary neurons in culture activates proline-directed kinase Cdk5, inactivates PP1, promotes tau phosphorylation at both proline-directed Sep(396/404) and non-proline-directed Sep(262) sites, and destabilizes microtubules.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2011 Jun 10;286(23):20569-81", "reference": "21489990"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10116", "Subgraph": "Cyclin-CDK subgraph", "NervousSystem": "Brain"}, "source": 195, "target": 196, "key": 1}, {"relation": "increases", "evidence": "In this study, we found that lentivirus-mediated overexpression of Egr-1 in rat brain hippocampus and primary neurons in culture activates proline-directed kinase Cdk5, inactivates PP1, promotes tau phosphorylation at both proline-directed Sep(396/404) and non-proline-directed Sep(262) sites, and destabilizes microtubules.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2011 Jun 10;286(23):20569-81", "reference": "21489990"}, "object": {"modifier": "Activity"}, "annotations": {"Species": "10116", "Subgraph": "Cyclin-CDK subgraph", "NervousSystem": "Hippocampus"}, "source": 195, "target": 196, "key": 2}, {"relation": "decreases", "evidence": "Redox and phosphorylative energetic exhaustion: A-induced mitochondrial and synaptic dysfunction:Increasing evidence indicates that the mitochondrial dysfunction is an important early factor in the development of AD-like pathology. Mitochondria are known to accumulate in synapses and mitochondrial trafficking to synapses is dynamic and regulated by synaptic activity. However, increasing evidence indicates that accumulation of A in mitochondria occurs before extracellular amyloid deposition and increases with age. APP and its derivatives, monomeric and oligomeric forms of A, interact with mitochondrial membranes or mitochondrial matrix protein ABAD leading to mitochondrial dysfunction.Substantial evidence indicates that mitochondria serve as direct targets for A protein mediated neuronal toxicity. Lower levels of ROS are required for synaptic signaling with ROS acting as messenger molecules in the process of LTP. However, high levels of ROS have been implicated as damaging toxic molecules in the age-related impairments of LTP. Our previous work shows that ROS levels increase with age of neurons in parallel with an age-related decline in transmembrane potential. As mitochondrial transmembrane potential is a driving force for cellular production of ATP, its decline in neurons will have a long term effect in many important energy driven reactions. Increased oxidative stress, coupled with dysregulation of calcium homeostasis and resulting apoptosis of vulnerable neuronal populations, are proposed to underlie the loss of synaptic activity and associated cognitive decline. From these deficiencies emerges the concept of synaptic energy exhaustion in AD, both phosphorylative (ATP) and redox (NAD[P]H) energies. Our previous work shows that hippocampal NAD(P)H and glutathione (GSH) decline with age in association with increased susceptibility to glutamate toxicity in neurons of old-age. Thus, an age-related decline in neuronal reducing currency (NAD[P]H) and reducing buffer (GSH) will surely promote oxidative stress and excess ROS. It is noteworthy that in the early stages of AD, there is already a reduction in the number of mitochondria and the activities of tricarboxylic acid cycle enzymes and cytochrome C oxidase. However, how ROS are produced at the synapse in response to A oligomers is not fully known. Excessive ROS are locally generated in response to synaptic A oligomer binding. This ROS formation can be totally blocked by the mitochondrial uncoupler, 2,4-dinitrophenol which suggests a central role of mitochondria in A-induced oxidative stress. Many studies suggest the possible involvement of oxidative stress and calcium dysfunction in A toxicity.The question as to why brain synaptic ROS levels increase with age is uncertain, but may involve lack of use followed by acute overstimulation of excitatory NMDARs that leads to excessive ROS, related to excess Ca2+ entry into mitochondria. Dysregulation of NMDAR function induced by A binding to neuronal synapses may lead to synaptic mitochondrial dysfunction and excessive ROS formation. Memory mechanisms might be directly compromised by elevated ROS, which could explain the connection between AD and oxidative stress. The increase in oxidative damage exhibited by synaptic mitochondria will damage synapses, affect neurotransmission and might be ultimately responsible for cognitive decline in AD patients. Taken together these studies provide convincing evidence for the concept that mitochondria have a pivotal role in A-induced synaptic dysfunction and neuronal stress. Improved function of mitochondria is an effective way of reducing effects of aging and may inhibit neuronal cell death in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Glutathione reductase subgraph"}, "source": 198, "target": 48, "key": 0}, {"relation": "decreases", "evidence": "Redox and phosphorylative energetic exhaustion: A-induced mitochondrial and synaptic dysfunction:Increasing evidence indicates that the mitochondrial dysfunction is an important early factor in the development of AD-like pathology. Mitochondria are known to accumulate in synapses and mitochondrial trafficking to synapses is dynamic and regulated by synaptic activity. However, increasing evidence indicates that accumulation of A in mitochondria occurs before extracellular amyloid deposition and increases with age. APP and its derivatives, monomeric and oligomeric forms of A, interact with mitochondrial membranes or mitochondrial matrix protein ABAD leading to mitochondrial dysfunction.Substantial evidence indicates that mitochondria serve as direct targets for A protein mediated neuronal toxicity. Lower levels of ROS are required for synaptic signaling with ROS acting as messenger molecules in the process of LTP. However, high levels of ROS have been implicated as damaging toxic molecules in the age-related impairments of LTP. Our previous work shows that ROS levels increase with age of neurons in parallel with an age-related decline in transmembrane potential. As mitochondrial transmembrane potential is a driving force for cellular production of ATP, its decline in neurons will have a long term effect in many important energy driven reactions. Increased oxidative stress, coupled with dysregulation of calcium homeostasis and resulting apoptosis of vulnerable neuronal populations, are proposed to underlie the loss of synaptic activity and associated cognitive decline. From these deficiencies emerges the concept of synaptic energy exhaustion in AD, both phosphorylative (ATP) and redox (NAD[P]H) energies. Our previous work shows that hippocampal NAD(P)H and glutathione (GSH) decline with age in association with increased susceptibility to glutamate toxicity in neurons of old-age. Thus, an age-related decline in neuronal reducing currency (NAD[P]H) and reducing buffer (GSH) will surely promote oxidative stress and excess ROS. It is noteworthy that in the early stages of AD, there is already a reduction in the number of mitochondria and the activities of tricarboxylic acid cycle enzymes and cytochrome C oxidase. However, how ROS are produced at the synapse in response to A oligomers is not fully known. Excessive ROS are locally generated in response to synaptic A oligomer binding. This ROS formation can be totally blocked by the mitochondrial uncoupler, 2,4-dinitrophenol which suggests a central role of mitochondria in A-induced oxidative stress. Many studies suggest the possible involvement of oxidative stress and calcium dysfunction in A toxicity.The question as to why brain synaptic ROS levels increase with age is uncertain, but may involve lack of use followed by acute overstimulation of excitatory NMDARs that leads to excessive ROS, related to excess Ca2+ entry into mitochondria. Dysregulation of NMDAR function induced by A binding to neuronal synapses may lead to synaptic mitochondrial dysfunction and excessive ROS formation. Memory mechanisms might be directly compromised by elevated ROS, which could explain the connection between AD and oxidative stress. The increase in oxidative damage exhibited by synaptic mitochondria will damage synapses, affect neurotransmission and might be ultimately responsible for cognitive decline in AD patients. Taken together these studies provide convincing evidence for the concept that mitochondria have a pivotal role in A-induced synaptic dysfunction and neuronal stress. Improved function of mitochondria is an effective way of reducing effects of aging and may inhibit neuronal cell death in AD", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Reactive oxygen species subgraph"}, "source": 198, "target": 48, "key": 1}, {"relation": "increases", "evidence": "AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include -amyloid protein (A) generation and tau phosphorylation. In particular, AMPK may regulate A generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating A generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph", "Disease": "Alzheimer's disease"}, "source": 199, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 199, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "mTOR signaling subgraph"}, "source": 199, "target": 11, "key": 2}, {"relation": "increases", "evidence": "AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include -amyloid protein (A) generation and tau phosphorylation. In particular, AMPK may regulate A generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating A generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Membrane Structures"}}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Akt subgraph"}, "source": 199, "target": 68, "key": 0}, {"relation": "increases", "evidence": "AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include -amyloid protein (A) generation and tau phosphorylation. In particular, AMPK may regulate A generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating A generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Membrane Structures"}}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Sphingolipid metabolic subgraph"}, "source": 199, "target": 68, "key": 1}, {"relation": "increases", "evidence": "AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include -amyloid protein (A) generation and tau phosphorylation. In particular, AMPK may regulate A generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating A generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of A. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including A generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.", "citation": {"type": "PubMed", "name": "Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.", "reference": "22367557"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Membrane Structures"}}}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Cholesterol metabolism subgraph"}, "source": 199, "target": 68, "key": 2}, {"relation": "decreases", "evidence": "Insulin modulates metabolism of -amyloid precursor protein (APP) in neurons, decreasing the intracellular accumulation of -amyloid (A) peptides, which are pivotal in AD pathogenesis. The present study investigates whether the widely prescribed insulin-sensitizing drug, metformin (GlucophageR), affects APP metabolism and A generation in various cell models. We demonstrate that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular A species", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Insulin signal transduction"}, "source": 203, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Insulin modulates metabolism of -amyloid precursor protein (APP) in neurons, decreasing the intracellular accumulation of -amyloid (A) peptides, which are pivotal in AD pathogenesis. The present study investigates whether the widely prescribed insulin-sensitizing drug, metformin (GlucophageR), affects APP metabolism and A generation in various cell models. We demonstrate that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular A species", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.", "reference": "19237574"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 203, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Insulin and insulin receptors were shown to decrease in a normal brain with aging, but increase in AD brains [29]. Several basic science studies have explored and shown the relationship between the increased insulin and AD pathology in the aspects other than A degradation alone. For example, insulin increases the secretion of A into extracellular space [31], stimulates tau phosphorylation to form neurofibrillary tangles, and impairs insulin signal transduction [32] and [40] (reviewed by Gasparini and Hoyer). Insulin also affected APP processing in vivo, a critical molecular step in generating A, to secrete sAPP [13], [16] and [81]. In addition, A reduces insulin binding to insulin receptors [95].", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2006 Feb;27(2):190-8. Epub 2005 Feb 17.", "reference": "16399206"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Insulin signal transduction"}, "source": 203, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Insulin and insulin receptors were shown to decrease in a normal brain with aging, but increase in AD brains [29]. Several basic science studies have explored and shown the relationship between the increased insulin and AD pathology in the aspects other than A degradation alone. For example, insulin increases the secretion of A into extracellular space [31], stimulates tau phosphorylation to form neurofibrillary tangles, and impairs insulin signal transduction [32] and [40] (reviewed by Gasparini and Hoyer). Insulin also affected APP processing in vivo, a critical molecular step in generating A, to secrete sAPP [13], [16] and [81]. In addition, A reduces insulin binding to insulin receptors [95].", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2006 Feb;27(2):190-8. Epub 2005 Feb 17.", "reference": "16399206"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "extracellular space"}}}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 203, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Glucose transport within the brain is mostly insulin independent, suggesting that the primary role of brain insulin might be in signal transduction pathways involved in cognitive processes [Schulingkamp et al., 2000]. Indeed, studies have shown that insulin and insulin receptors are abundantly but selectively distributed in brain areas that are important for learning and memory [Schulingkamp et al., 2000], and treatment of both normal healthy individuals and patients with mild AD with insulin has been shown to improve cognition [Watson and Craft, 2004].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Subgraph": "Insulin signal transduction", "NervousSystem": "Brain"}, "source": 203, "target": 44, "key": 0}, {"relation": "increases", "evidence": "Glucose transport within the brain is mostly insulin independent, suggesting that the primary role of brain insulin might be in signal transduction pathways involved in cognitive processes [Schulingkamp et al., 2000]. Indeed, studies have shown that insulin and insulin receptors are abundantly but selectively distributed in brain areas that are important for learning and memory [Schulingkamp et al., 2000], and treatment of both normal healthy individuals and patients with mild AD with insulin has been shown to improve cognition [Watson and Craft, 2004].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Subgraph": "Insulin signal transduction", "MeSHDisease": "Alzheimer Disease"}, "source": 203, "target": 44, "key": 1}, {"relation": "increases", "evidence": "Clinical tr ials in health y hum ans under  hyper insulin emic euglycemic  clamp   conditions  showed  a  n egative  shi ft  in transcortica l direct  current potentials, indicati ng that circ ulat ing insulin can  rapidly  act on  brain activity independent from its systemic effects [91 ]. Longitudinal studies revealed   th at insulin resistance  with   persisting   hyperi nsu linem i a  comes along  w ith an elevated risk  for disturbed cognition, impa ired memory and  A D (10, 92,  93].  In AD  patients as  well  as  i n h ealthy subjects  hyperinsulinemic eug lycemic clamp studies revea led an i mproving effect  of.insu li n on cognitive functio n (94,  95].  Intranasa l  app l ication  of  insu lin in healthy  hum ans directly  entered th e CSF  and  improved memory  function and cogn it ive capacity especi a lly in women  with out  in fluencing per i phera l  blood  gl ucose  levels  (96-98]. These  gender spe cific findings  suggest an influence of sex  hormon es. Accord  ingly, Cl egg el a!. d emonstrated th a t i nsul in sensitiv i ty in ra t brains differ,  dependin g on estrogen  levels (99].", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "annotations": {"Subgraph": "Insulin signal transduction", "UserdefinedGender": "Female"}, "source": 203, "target": 44, "key": 2}, {"relation": "increases", "evidence": "Patients without an APOE 4 allele require higher amounts of insulin to improve memory [Craft and Watson, 2004], consistent with the observation of insulin resistance and hyperinsulinemia in some studies of APOE 4 allele negative individuals [Kuusisto et al., 1997]. Furthermore, the association between diabetes and dementia is particularly strong in APOE 4 carriers [Peila et al., 2002].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Patient": "APOE e4 -ve", "Subgraph": "ApoE subgraph"}, "source": 203, "target": 46, "key": 0}, {"relation": "increases", "evidence": "Patients without an APOE 4 allele require higher amounts of insulin to improve memory [Craft and Watson, 2004], consistent with the observation of insulin resistance and hyperinsulinemia in some studies of APOE 4 allele negative individuals [Kuusisto et al., 1997]. Furthermore, the association between diabetes and dementia is particularly strong in APOE 4 carriers [Peila et al., 2002].", "citation": {"type": "PubMed", "name": "Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.", "reference": "19885299"}, "annotations": {"Patient": "APOE e4 -ve", "Subgraph": "Insulin signal transduction"}, "source": 203, "target": 46, "key": 1}, {"relation": "increases", "evidence": "Clinical tr ials in health y hum ans under  hyper insulin emic euglycemic  clamp   conditions  showed  a  n egative  shi ft  in transcortica l direct  current potentials, indicati ng that circ ulat ing insulin can  rapidly  act on  brain activity independent from its systemic effects [91 ]. Longitudinal studies revealed   th at insulin resistance  with   persisting   hyperi nsu linem i a  comes along  w ith an elevated risk  for disturbed cognition, impa ired memory and  A D (10, 92,  93].  In AD  patients as  well  as  i n h ealthy subjects  hyperinsulinemic eug lycemic clamp studies revea led an i mproving effect  of.insu li n on cognitive functio n (94,  95].  Intranasa l  app l ication  of  insu lin in healthy  hum ans directly  entered th e CSF  and  improved memory  function and cogn it ive capacity especi a lly in women  with out  in fluencing per i phera l  blood  gl ucose  levels  (96-98]. These  gender spe cific findings  suggest an influence of sex  hormon es. Accord  ingly, Cl egg el a!. d emonstrated th a t i nsul in sensitiv i ty in ra t brains differ,  dependin g on estrogen  levels (99].", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "annotations": {"Subgraph": "Insulin signal transduction", "UserdefinedGender": "Female"}, "source": 203, "target": 46, "key": 2}, {"relation": "decreases", "evidence": "We found that insulin administration reduced plasma APP for patients with Alzheimers disease with an APOE 4 allele but raised APP for patients without an 4 allele", "citation": {"type": "PubMed", "name": "CNS Drugs. 2003;17(1):27-45.", "reference": "19383491"}, "annotations": {"Subgraph": "Insulin signal transduction", "FluidAndSecretion": "Plasma", "MeSHDisease": "Alzheimer Disease", "Patient": "APOE e4 +ve"}, "source": 203, "target": 68, "key": 0}, {"relation": "increases", "evidence": "We found that insulin administration reduced plasma APP for patients with Alzheimers disease with an APOE 4 allele but raised APP for patients without an 4 allele", "citation": {"type": "PubMed", "name": "CNS Drugs. 2003;17(1):27-45.", "reference": "19383491"}, "annotations": {"Subgraph": "Insulin signal transduction", "FluidAndSecretion": "Plasma", "MeSHDisease": "Alzheimer Disease", "Patient": "APOE e4 -ve"}, "source": 203, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Insulin and IGF-I may pmodulate brain levels of insulin degrading enzyme, which would also lead to an accumulation of Abeta amyloid.", "citation": {"type": "PubMed", "name": "Neural Plast2005", "reference": "16444902"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 204, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Insulin and IGF-I may pmodulate brain levels of insulin degrading enzyme, which would also lead to an accumulation of Abeta amyloid.", "citation": {"type": "PubMed", "name": "Neural Plast2005", "reference": "16444902"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 204, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Thus, neuroserpin inhibition of tissue plasminogen activator activity leads to reduced plasmin and may be responsible for reduced clearance of amyloid-beta in the Alzheimer disease brain.", "citation": {"type": "PubMed", "name": "J Neurochem. 2009 Apr;109(2):303-15", "reference": "19222708"}, "annotations": {"Species": "9606", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 208, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Thus, neuroserpin inhibition of tissue plasminogen activator activity leads to reduced plasmin and may be responsible for reduced clearance of amyloid-beta in the Alzheimer disease brain.", "citation": {"type": "PubMed", "name": "J Neurochem. 2009 Apr;109(2):303-15", "reference": "19222708"}, "annotations": {"Species": "9606", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Plasminogen activator subgraph"}, "source": 208, "target": 11, "key": 1}, {"relation": "decreases", "evidence": " Tau toxicity has been implicated in the emergence of synaptic dysfunction in Alzheimer's disease (AD), but the mechanism by which tau alters synapse physiology and leads to cognitive decline is unclear. Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains, promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein, a memory-associated protein.acetylated tau reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion. The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression. In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA. These findings suggest a novel mechanism by which pathogenic tau causes synaptic dysfunction and cognitive decline in AD pathogenesis.", "citation": {"type": "PubMed", "name": "Neuron. 2016 Apr 20;90(2):245-60. doi: 10.1016/j.neuron.2016.03.005. Epub 2016 Mar 31.", "reference": "27041503 "}, "annotations": {"Subgraph": "KANSL1 subgraph"}, "source": 231, "target": 54, "key": 0}, {"relation": "increases", "evidence": "NEP and IDE also contributed to IL-4-induced degradation of Abeta(1-42), b ecause their inhibitors, thiorphan and insulin, respectively, significantly suppressed this activity.", "citation": {"type": "PubMed", "name": "J Immunol2008", "reference": "18941241"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 233, "target": 11, "key": 0}, {"relation": "increases", "evidence": "NEP and IDE also contributed to IL-4-induced degradation of Abeta(1-42), b ecause their inhibitors, thiorphan and insulin, respectively, significantly suppressed this activity.", "citation": {"type": "PubMed", "name": "J Immunol2008", "reference": "18941241"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 233, "target": 11, "key": 1}, {"relation": "increases", "evidence": "NEP and IDE also contributed to IL-4-induced degradation of Abeta(1-42), b ecause their inhibitors, thiorphan and insulin, respectively, significantly suppressed this activity.", "citation": {"type": "PubMed", "name": "J Immunol2008", "reference": "18941241"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 233, "target": 11, "key": 2}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 234, "target": 68, "key": 0}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 234, "target": 68, "key": 1}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 234, "target": 68, "key": 2}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 234, "target": 68, "key": 3}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 234, "target": 91, "key": 0}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 234, "target": 91, "key": 1}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 234, "target": 91, "key": 2}, {"relation": "increases", "evidence": "The effect of NFB on BACE1 promoter could be direct or through changes in PPAR, because PPAR agonists can antagonize the activity of transcription factors such as NFB.NFB sites are present in the promoters of APP [86], presenilin and BACE1 [87]. In neurons exposed to soluble A peptides and in TNF-activated glial cells the mutation of the BACE1 promoter NFB site led to significant decreases in promoter activity, indicating an activating role for NFB in BACE1 expression in A.", "citation": {"type": "PubMed", "name": "J Neuroinflammation. 2008 Jun 18;5:25", "reference": "18564425"}, "subject": {"modifier": "Activity", "effect": {"name": "tscript", "namespace": "bel"}}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 234, "target": 91, "key": 3}, {"relation": "increases", "evidence": "During differentiation of macrophages primarily the promoter 3 and to a certain extent promoter 1 is activated. Consequently macrophages mainly express PPAR1 (10). In macrophages PPAR represses inducible nitric-oxide (NO) synthase induction as well as concomitant NO production (11) and attenuates the oxidative burst (13, 14). Moreover, inhibiting nuclear factor B (NFB) decreases expression of inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor  (TNF) or IL-6 (12). Thus, PPAR is important to shape an anti-inflammatory macrophage phenotype and appears crucial for dampening inflammation", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Tumor necrosis factor subgraph"}, "source": 234, "target": 140, "key": 0}, {"relation": "increases", "evidence": "During differentiation of macrophages primarily the promoter 3 and to a certain extent promoter 1 is activated. Consequently macrophages mainly express PPAR1 (10). In macrophages PPAR represses inducible nitric-oxide (NO) synthase induction as well as concomitant NO production (11) and attenuates the oxidative burst (13, 14). Moreover, inhibiting nuclear factor B (NFB) decreases expression of inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor  (TNF) or IL-6 (12). Thus, PPAR is important to shape an anti-inflammatory macrophage phenotype and appears crucial for dampening inflammation", "citation": {"type": "PubMed", "name": "J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.", "reference": "20164187"}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 234, "target": 140, "key": 1}, {"relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 235, "target": 44, "key": 0}, {"relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 235, "target": 45, "key": 0}, {"relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "name": "J Pharmacol Sci. 2011;117(1):6-11", "reference": "21821968"}, "annotations": {"Species": "10116", "Subgraph": "GABA subgraph"}, "source": 235, "target": 46, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Glutamatergic subgraph"}, "source": 235, "target": 169, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "NMDA receptor"}, "source": 235, "target": 169, "key": 1}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 235, "target": 169, "key": 2}, {"relation": "decreases", "evidence": "In animal models as well as in humans, the activation of muscarinic M1 acetylcholine receptors increases a-secretase cleavage of APP and consequently reduces A levels [63, 64] whereas activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 235, "target": 169, "key": 3}, {"relation": "decreases", "evidence": "In animal models as well as in humans, the activation of muscarinic M1 acetylcholine receptors increases a-secretase cleavage of APP and consequently reduces A levels [63, 64] whereas activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 235, "target": 169, "key": 4}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Glutamatergic subgraph"}, "source": 235, "target": 236, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "NMDA receptor"}, "source": 235, "target": 236, "key": 1}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 235, "target": 236, "key": 2}, {"relation": "decreases", "evidence": "In animal models as well as in humans, the activation of muscarinic M1 acetylcholine receptors increases a-secretase cleavage of APP and consequently reduces A levels [63, 64] whereas activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 235, "target": 236, "key": 3}, {"relation": "decreases", "evidence": "In animal models as well as in humans, the activation of muscarinic M1 acetylcholine receptors increases a-secretase cleavage of APP and consequently reduces A levels [63, 64] whereas activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 235, "target": 236, "key": 4}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Glutamatergic subgraph"}, "source": 235, "target": 237, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "NMDA receptor"}, "source": 235, "target": 237, "key": 1}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 235, "target": 237, "key": 2}, {"relation": "decreases", "evidence": "In animal models as well as in humans, the activation of muscarinic M1 acetylcholine receptors increases a-secretase cleavage of APP and consequently reduces A levels [63, 64] whereas activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 235, "target": 237, "key": 3}, {"relation": "decreases", "evidence": "In animal models as well as in humans, the activation of muscarinic M1 acetylcholine receptors increases a-secretase cleavage of APP and consequently reduces A levels [63, 64] whereas activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Glutamatergic subgraph"}, "source": 235, "target": 237, "key": 4}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 236, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 236, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 236, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 236, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 237, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 237, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 237, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Activation of NMDARs decreases a-secretase cleavage, consequently increasing A levels [65]. Stimulation with muscarinic agonists or\\ activators of protein kinase C (PKC), such as phorbol esters causes the up-regulation of the a-secretase cleavage\\ of APP", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "ADAM Metallopeptidase subgraph"}, "source": 237, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 238, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 238, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 238, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 239, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 239, "target": 48, "key": 1}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 239, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 240, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 240, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 240, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 241, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 241, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 242, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 242, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 242, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 243, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 243, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 243, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 244, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 244, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 244, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 245, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 245, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 245, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 246, "target": 47, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 246, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 247, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 247, "target": 48, "key": 1}, {"relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by A requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the A-induced increase of synaptic plasticity and memory under normal conditions, A may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of A42 on nAChRs are conflicting. Some studies have reported that A42 activates nAChRs [243, 244], while others indicate that A42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of A42 were effective in activating nAChRs while higher levels of A produced inhibitory action. The disparity may depend on the nanomolar A142 inhibition of nicotine-induced Ca2+ responses while picomolar A42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. A42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that A42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the A peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that A42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that A could be tightly associated with nAChR [247]. Alternatively, A might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher A42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 247, "target": 49, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 248, "target": 48, "key": 0}, {"relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "subject": {"modifier": "Activity"}, "annotations": {"Species": "10090", "Subgraph": "GABA subgraph"}, "source": 248, "target": 48, "key": 1}, {"relation": "increases", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "name": "J Mol Biol. 1997 Sep 26;272(3):348-61.", "reference": "9325095"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 249, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "name": "J Mol Biol. 1997 Sep 26;272(3):348-61.", "reference": "9325095"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 249, "target": 11, "key": 1}, {"relation": "increases", "evidence": " The fact that acetylcholinesterase accelerates amyloid formation and the effect is sensitive to peripherical anionic site blockers of the enzyme, suggests that specific and new EC 3.1.1.7 (acetylcholinesterase) inhibitors may well provide an attractive possibility for treating Alzheimer's disease. ", "citation": {"type": "PubMed", "name": "FEBS J2008", "reference": "18205831"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 249, "target": 11, "key": 2}, {"relation": "increases", "evidence": " The fact that acetylcholinesterase accelerates amyloid formation and the effect is sensitive to peripherical anionic site blockers of the enzyme, suggests that specific and new EC 3.1.1.7 (acetylcholinesterase) inhibitors may well provide an attractive possibility for treating Alzheimer's disease. ", "citation": {"type": "PubMed", "name": "FEBS J2008", "reference": "18205831"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 249, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "name": "J Mol Biol1997", "reference": "9325095"}, "annotations": {"Subgraph": "Acetylcholine signaling subgraph"}, "source": 249, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "name": "J Mol Biol1997", "reference": "9325095"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 249, "target": 11, "key": 5}, {"relation": "directlyIncreases", "evidence": "Acetylcholinesterase (AChE) enzyme inhibition is an important target for the management of Alzheimer disease (AD) and AChE inhibitors are the main stay drugs for its management. Coumarins are the phytochemicals with wide range of biological activities including AChE inhibition", "citation": {"type": "PubMed", "name": "Bioorg Med Chem. 2012 Feb 1;20(3):1175-80. Epub 2011 Dec 30", "reference": "22257528"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Acetylcholine signaling subgraph"}, "source": 249, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Some cholinesterase inhibitors (tacrine, donepezil, galantamine) are metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2007 Sep;4(4):479-500", "reference": "17908053"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Cholesterol metabolism subgraph"}, "source": 251, "target": 50, "key": 0}, {"relation": "increases", "evidence": "In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid  peptide (A) and the A x-42/ x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.", "reference": "20888417"}, "annotations": {"Subgraph": "GABA subgraph"}, "source": 252, "target": 52, "key": 0}, {"relation": "increases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "annotations": {"Subgraph": "Phosphatidylinositol 3 subgraph"}, "source": 253, "target": 5, "key": 0}, {"relation": "increases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro.", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 253, "target": 5, "key": 1}, {"relation": "increases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro. We examined which PKC isoforms were activated by VEGF by immunoprecipitating isoforms using specific antibodies and then performing immunoblotting using an anti-phospho-PKC antibody.We found that VEGF increased the level of phospho-PKC II, but had minimal effect on the phosphorylation of PKC , PKC I, or PKC  (Fig. 2D). Riluzole inhibits the reaction [VEGFA protein results in increased phosphorylation of PRKCB protein]", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "annotations": {"Subgraph": "Phosphatidylinositol 3 subgraph"}, "source": 253, "target": 5, "key": 2}, {"relation": "increases", "evidence": "Of the signaling molecules downstream of VEGF receptors, PKC has been demonstrated to be critical in mediating endothelial cell proliferation.17 18 19 Although inhibition of PKC may seem a reasonable approach to curtail endothelial cell proliferation in proliferative retinopathies,20 21 PKC serves diverse essential normal roles in intracellular signaling, indicating broad-spectrum inhibition of all PKCs may have harmful side effects, including cell apoptosis. Riluzole inhibited PKC activity in cortical cell cultures, and also inhibited the activity of purified PKC in vitro. We examined which PKC isoforms were activated by VEGF by immunoprecipitating isoforms using specific antibodies and then performing immunoblotting using an anti-phospho-PKC antibody.We found that VEGF increased the level of phospho-PKC II, but had minimal effect on the phosphorylation of PKC , PKC I, or PKC  (Fig. 2D). Riluzole inhibits the reaction [VEGFA protein results in increased phosphorylation of PRKCB protein]", "citation": {"type": "PubMed", "name": "Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7", "reference": "16303979"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 253, "target": 5, "key": 3}, {"relation": "increases", "evidence": "Similar effects of BACE1 up-regulation were observed when protein kinase C was directly activated by phorbol esters.", "citation": {"type": "PubMed", "name": "J Neurosci Res2004", "reference": "15211591"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 253, "target": 141, "key": 0}, {"relation": "increases", "evidence": "Protein kinase C: PKC is part of a multigene family of serine-threonine kinases central to many signal transduction pathways [138] with a prominent role in memory [139]. It is likely that A-induced increases in cytosolic Ca2+ signals are transmitted to PKC for PKC-mediated transcriptional activation. In addition, PKC activates ERK by interacting with Ras or Raf-1 [140] to initiate CREB phosphorylation. While PKC levels decline in AD [141], their activation restores K+ channel function in cells from AD patients [142]. In addition, activation of PKC directly or indirectly enhances the a-processing cleavage of APP [143].", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 253, "target": 169, "key": 0}, {"relation": "decreases", "evidence": "alpha(2)M) is an abundant plasma/extracellular space protein implicated in clearance of amyloid beta (Abeta)", "citation": {"type": "PubMed", "name": "Neurobiol Dis2003", "reference": "14678766"}, "annotations": {"Subgraph": "Alpha 2 macroglobulin subgraph"}, "source": 254, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "alpha(2)M) is an abundant plasma/extracellular space protein implicated in clearance of amyloid beta (Abeta)", "citation": {"type": "PubMed", "name": "Neurobiol Dis2003", "reference": "14678766"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 254, "target": 11, "key": 1}, {"relation": "increases", "evidence": "In the present study, we investigated whether alpha2-macroglobulin (alpha2M), a protein present in neuritic plaques and elevated in Alzheimer's disease brain, is a potential regulatory factor for A beta fibril formation", "citation": {"type": "PubMed", "name": "J Neurochem1998", "reference": "9489740"}, "annotations": {"Subgraph": "Alpha 2 macroglobulin subgraph"}, "source": 254, "target": 11, "key": 2}, {"relation": "increases", "evidence": "In the present study, we investigated whether alpha2-macroglobulin (alpha2M), a protein present in neuritic plaques and elevated in Alzheimer's disease brain, is a potential regulatory factor for A beta fibril formation", "citation": {"type": "PubMed", "name": "J Neurochem1998", "reference": "9489740"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 254, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "alpha(2)-Macroglobulin (alpha(2)M) is an abundant plasma/extracellular space protein implicated in clearance of amyloid beta (Abeta)", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Dec;14(3):504-12.", "reference": "14678766"}, "annotations": {"Subgraph": "Alpha 2 macroglobulin subgraph"}, "source": 254, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "alpha(2)-Macroglobulin (alpha(2)M) is an abundant plasma/extracellular space protein implicated in clearance of amyloid beta (Abeta)", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2003 Dec;14(3):504-12.", "reference": "14678766"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 254, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "Deletion of Abca1 increases Abeta deposition", "citation": {"type": "PubMed", "name": "J Biol Chem. 2005 Dec 30;280(52):43236-42. Epub 2005 Oct 5.", "reference": "16207708"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 256, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Deletion of Abca1 increases Abeta deposition", "citation": {"type": "PubMed", "name": "J Biol Chem. 2005 Dec 30;280(52):43236-42. Epub 2005 Oct 5.", "reference": "16207708"}, "annotations": {"Subgraph": "ATP binding cassette transport subgraph"}, "source": 256, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Human serum albumin (HSA) binds 95% of A in blood plasma and is thought to inhibit plaque formation in peripheral tissue. However, the role of albumin in binding A in the cerebrospinal fluid has been largely overlooked. Here we investigate the effect of HSA on both A(1-40) and A(1-42) fibril growth. We show that at micromolar cerebrospinal fluid levels, HSA inhibits the kinetics of A fibrillization, significantly increasing the lag time and decreasing the total amount of fibrils produced", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Aug 10;287(33):28163-8. doi: 10.1074/jbc.C112.360800. Epub 2012 Jun 20.", "reference": "22718756"}, "subject": {"modifier": "Activity"}, "annotations": {"FluidAndSecretion": "Cerebrospinal Fluid", "Subgraph": "Albumin subgraph"}, "source": 270, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Human serum albumin (HSA) binds 95% of A in blood plasma and is thought to inhibit plaque formation in peripheral tissue. However, the role of albumin in binding A in the cerebrospinal fluid has been largely overlooked. Here we investigate the effect of HSA on both A(1-40) and A(1-42) fibril growth. We show that at micromolar cerebrospinal fluid levels, HSA inhibits the kinetics of A fibrillization, significantly increasing the lag time and decreasing the total amount of fibrils produced", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Aug 10;287(33):28163-8. doi: 10.1074/jbc.C112.360800. Epub 2012 Jun 20.", "reference": "22718756"}, "subject": {"modifier": "Activity"}, "annotations": {"FluidAndSecretion": "Cerebrospinal Fluid", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 270, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Human serum albumin (HSA) is a potent inhibitor of A self-association and this novel, to our knowledge, function of HSA is of potential therapeutic interest for the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Biophys J. 2013 Oct 1;105(7):1700-9", "reference": "24094411"}, "annotations": {"FluidAndSecretion": "Serum", "Species": "9606", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Albumin subgraph"}, "source": 270, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Human serum albumin (HSA) is a potent inhibitor of A self-association and this novel, to our knowledge, function of HSA is of potential therapeutic interest for the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Biophys J. 2013 Oct 1;105(7):1700-9", "reference": "24094411"}, "annotations": {"FluidAndSecretion": "Serum", "Species": "9606", "MeSHDisease": "Alzheimer Disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 270, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "We show that knock-down of ATXN1 significantly increases the levels of both Abeta40 and Abeta42. This effect could be rescued with concurrent overexpression of ATXN1. Moreover, overexpression of ATXN1 decreased Abeta levels. ", "citation": {"type": "PubMed", "name": "Nat Rev Neurol2010", "reference": "20139999"}, "annotations": {"Subgraph": "Akt subgraph"}, "source": 275, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "We show that knock-down of ATXN1 significantly increases the levels of both Abeta40 and Abeta42. This effect could be rescued with concurrent overexpression of ATXN1. Moreover, overexpression of ATXN1 decreased Abeta levels. ", "citation": {"type": "PubMed", "name": "Nat Rev Neurol2010", "reference": "20139999"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 275, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Cathepsin B cleaves the wild-type beta-secretase site sequence in AbetaPP to produce Abeta, and cathepsin B inhibitors administered to animal pmodels expressing AbetaPP containing the wild-type beta-secretase site sequence reduce brain Abeta in a manner consistent with beta-secretase inhibition. ", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2011", "reference": "21613740"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 299, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Some cholinesterase inhibitors (tacrine, donepezil, galantamine) are metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2007 Sep;4(4):479-500", "reference": "17908053"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Cholesterol metabolism subgraph"}, "source": 304, "target": 50, "key": 0}, {"relation": "decreases", "evidence": "Seladin-1 was considered a novel neuroprotective factor, because of its anti-apoptotic activity. Subsequently, it was demonstrated that seladin-1 has also enzymatic activity [3--hydroxysterol delta-24-reductase, (DHCR24)], which catalyzes the synthesis of cholesterol from desmosterol. The amount of membrane cholesterol may play an important role both in protecting neuronal cells against toxic insults and in inhibiting the production of -amyloid. We demonstrated that seladin-1 overexpression increases the amount of membrane cholesterol and induces resistance against -amyloid aggregates in neuroblastoma cells, whereas a specific inhibitor of DHCR24 increased cell vulnerability. We also hypothesized that seladin-1 might be a mediator of the neuroprotective effects of estrogens. We first demonstrated that, in human fetal neuroepithelial cells (FNC), 17-estradiol, raloxifene, and tamoxifen exert protective effects against -amyloid toxicity and oxidative stress. In addition, these molecules significantly increased the expression of seladin-1 and the amount of cell cholesterol. Then, we showed that, upon seladin-1 silencing, the protective effects of estrogens were abolished, thus indicating this factor as a fundamental mediator of estrogen-mediated neuroprotection, at least in FNC cells. Furthermore, we detected the presence of functionally active half-palindromic estrogen responsive elements upstream the coding region of the seladin-1 gene. Overall, our results indicate that seladin-1 may be viewed as a multi-faceted protein, which conjugates both the neuroprotective properties of estrogens and the important functions of cholesterol in maintaining brain homeostasis", "citation": {"type": "PubMed", "name": "Neuroscience. 2011 Sep 15;191:107-17. doi: 10.1016/j.neuroscience.2011.03.011. Epub 2011 Mar 22.", "reference": "21396986"}, "annotations": {"UserdefinedCellLine": "Neuroblastoma cell", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 307, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Seladin-1 was considered a novel neuroprotective factor, because of its anti-apoptotic activity. Subsequently, it was demonstrated that seladin-1 has also enzymatic activity [3--hydroxysterol delta-24-reductase, (DHCR24)], which catalyzes the synthesis of cholesterol from desmosterol. The amount of membrane cholesterol may play an important role both in protecting neuronal cells against toxic insults and in inhibiting the production of -amyloid. We demonstrated that seladin-1 overexpression increases the amount of membrane cholesterol and induces resistance against -amyloid aggregates in neuroblastoma cells, whereas a specific inhibitor of DHCR24 increased cell vulnerability. We also hypothesized that seladin-1 might be a mediator of the neuroprotective effects of estrogens. We first demonstrated that, in human fetal neuroepithelial cells (FNC), 17-estradiol, raloxifene, and tamoxifen exert protective effects against -amyloid toxicity and oxidative stress. In addition, these molecules significantly increased the expression of seladin-1 and the amount of cell cholesterol. Then, we showed that, upon seladin-1 silencing, the protective effects of estrogens were abolished, thus indicating this factor as a fundamental mediator of estrogen-mediated neuroprotection, at least in FNC cells. Furthermore, we detected the presence of functionally active half-palindromic estrogen responsive elements upstream the coding region of the seladin-1 gene. Overall, our results indicate that seladin-1 may be viewed as a multi-faceted protein, which conjugates both the neuroprotective properties of estrogens and the important functions of cholesterol in maintaining brain homeostasis", "citation": {"type": "PubMed", "name": "Neuroscience. 2011 Sep 15;191:107-17. doi: 10.1016/j.neuroscience.2011.03.011. Epub 2011 Mar 22.", "reference": "21396986"}, "annotations": {"UserdefinedCellLine": "Neuroblastoma cell", "Subgraph": "Cholesterol metabolism subgraph"}, "source": 307, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Akt substrates such as mammalian target of rapamycin (mTOR; Ser2448) and decreased levels of cell-cycle inhibitors (p27kip1) are found in AD temporal cortex when compared to controls . GSK-3a has been implicated in the production of A peptide while increased GSK-3 activity has been implicated in tau hyperphosphorylation and neuronal cell death", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "GSK3 subgraph"}, "source": 326, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Akt substrates such as mammalian target of rapamycin (mTOR; Ser2448) and decreased levels of cell-cycle inhibitors (p27kip1) are found in AD temporal cortex when compared to controls . GSK-3a has been implicated in the production of A peptide while increased GSK-3 activity has been implicated in tau hyperphosphorylation and neuronal cell death", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 326, "target": 11, "key": 1}, {"relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Subgraph": "GSK3 subgraph"}, "source": 326, "target": 11, "key": 2}, {"relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 326, "target": 11, "key": 3}, {"relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 326, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Our in vivo studies using transgenic mice have shown that overexpression of LRP in central nervous system (CNS) neurons increases soluble brain Abeta and this increase correlates with deficits in memory.", "citation": {"type": "PubMed", "name": "Ann N Y Acad Sci2006", "reference": "17185504"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 348, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Our in vivo studies using transgenic mice have shown that overexpression of LRP in central nervous system (CNS) neurons increases soluble brain Abeta and this increase correlates with deficits in memory.", "citation": {"type": "PubMed", "name": "Ann N Y Acad Sci2006", "reference": "17185504"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 348, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Furthermore, LDLR overexpression dramatically reduced A beta aggregation and enhanced A beta clearance from the brain extracellular space. ", "citation": {"type": "PubMed", "name": "Neuron2009", "reference": "20005821"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 348, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Furthermore, LDLR overexpression dramatically reduced A beta aggregation and enhanced A beta clearance from the brain extracellular space. ", "citation": {"type": "PubMed", "name": "Neuron2009", "reference": "20005821"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 348, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Furthermore, LDLR overexpression dramatically reduced A beta aggregation and enhanced A beta clearance from the brain extracellular space. ", "citation": {"type": "PubMed", "name": "Neuron2009", "reference": "20005821"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 348, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Furthermore, LDLR overexpression dramatically reduced A beta aggregation and enhanced A beta clearance from the brain extracellular space. ", "citation": {"type": "PubMed", "name": "Neuron2009", "reference": "20005821"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 348, "target": 11, "key": 5}, {"relation": "increases", "evidence": "APP (amyloid precursor protein) and LRP1 (low-density lipoprotein receptor-related protein 1) have been implicated in the pathogenesis of AD (Alzheimer's disease). They are functionally linked by Fe65, a PTB (phosphotyrosine-binding)-domain-containing adaptor protein that binds to intracellular NPxY-motifs of APP and LRP1, thereby influencing expression levels, cellular trafficking and processing. Additionally, Fe65 has been reported to mediate nuclear signalling in combination with intracellular domains of APP and LRP1. We have previously identified another adaptor protein, GULP1 (engulfment adaptor PTB-domain-containing 1). In the present study we characterize and compare nuclear trafficking and transactivation of GULP1 and Fe65 together with APP and LRP1 and report differential nuclear trafficking of adaptors when APP or LRP1 are co-expressed. The observed effects were additionally supported by a reporter-plasmid-based transactivation assay. The results from the present study indicate that Fe65 might have signalling properties together with APP and LRP1, whereas GULP1 only mediates LRP1 transactivation.", "citation": {"type": "PubMed", "name": "Biochem J. 2013 Mar 1;450(2):333-43. doi: 10.1042/BJ20121100.", "reference": "23167255"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 350, "target": 33, "key": 0}, {"relation": "increases", "evidence": "APP (amyloid precursor protein) and LRP1 (low-density lipoprotein receptor-related protein 1) have been implicated in the pathogenesis of AD (Alzheimer's disease). They are functionally linked by Fe65, a PTB (phosphotyrosine-binding)-domain-containing adaptor protein that binds to intracellular NPxY-motifs of APP and LRP1, thereby influencing expression levels, cellular trafficking and processing. Additionally, Fe65 has been reported to mediate nuclear signalling in combination with intracellular domains of APP and LRP1. We have previously identified another adaptor protein, GULP1 (engulfment adaptor PTB-domain-containing 1). In the present study we characterize and compare nuclear trafficking and transactivation of GULP1 and Fe65 together with APP and LRP1 and report differential nuclear trafficking of adaptors when APP or LRP1 are co-expressed. The observed effects were additionally supported by a reporter-plasmid-based transactivation assay. The results from the present study indicate that Fe65 might have signalling properties together with APP and LRP1, whereas GULP1 only mediates LRP1 transactivation.", "citation": {"type": "PubMed", "name": "Biochem J. 2013 Mar 1;450(2):333-43. doi: 10.1042/BJ20121100.", "reference": "23167255"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 350, "target": 33, "key": 1}, {"relation": "increases", "evidence": "Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16505-10", "reference": "19805328"}, "annotations": {"Species": "10090", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Hippocampus", "Subgraph": "Inflammatory response subgraph"}, "source": 359, "target": 45, "key": 0}, {"relation": "increases", "evidence": "Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16505-10", "reference": "19805328"}, "annotations": {"Species": "10090", "MeSHDisease": "Alzheimer Disease", "NervousSystem": "Hippocampus", "Subgraph": "Free radical formation subgraph"}, "source": 359, "target": 45, "key": 1}, {"relation": "decreases", "evidence": "Cellular overexpression of PrP(C) inhibited the beta-secretase cleavage of APP and reduced Abeta formation. ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17573534"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 371, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.", "citation": {"type": "PubMed", "name": "Expert Opin Ther Targets2008", "reference": "18479216"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 371, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.", "citation": {"type": "PubMed", "name": "Expert Opin Ther Targets2008", "reference": "18479216"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 371, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17573534"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 371, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17573534"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 371, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "PrP(C) decreases amyloid-beta (Abeta) production, which is involved in AD pathogenesis, by inhibiting beta-secretase (BACE1) activity.", "citation": {"type": "PubMed", "name": "PLoS One2013", "reference": "23577068"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 371, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "PrP(C) decreases amyloid-beta (Abeta) production, which is involved in AD pathogenesis, by inhibiting beta-secretase (BACE1) activity.", "citation": {"type": "PubMed", "name": "PLoS One2013", "reference": "23577068"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 371, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "PrP(C) decreases amyloid-beta (Abeta) production, which is involved in AD pathogenesis, by inhibiting beta-secretase (BACE1) activity.", "citation": {"type": "PubMed", "name": "PLoS One2013", "reference": "23577068"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 371, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "PrP(C) decreases amyloid-beta (Abeta) production, which is involved in AD pathogenesis, by inhibiting beta-secretase (BACE1) activity.", "citation": {"type": "PubMed", "name": "PLoS One2013", "reference": "23577068"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 371, "target": 11, "key": 8}, {"relation": "increases", "evidence": "overexpression of PrP results in increased cleavage of APP in contrast to previous suggestion suggesting a reduction. Our findings suggest that any relation between PrP and BACE-1 is indirect. Altered expression of PrP causes changes in the expression of many other proteins which may be as a result of altered copper metabolism.", "citation": {"type": "PubMed", "name": "Neurochem Int. 2012 Jul 10. [Epub ahead of print]", "reference": "22796214"}, "object": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Beta secretase subgraph"}, "source": 371, "target": 68, "key": 0}, {"relation": "increases", "evidence": "SORL1 regulates and traps APP in the Golgi apparatus and reduces the production of the amyloid-beta peptide (Abeta), the main component of senile plaques in AD4. Cell biology experiments have indicated that SORL1 underexperssion leads to overproduction of Abeta3 , whereas SORL1 overexpression considerably reduces cellular APP and extracellular Abeta5. Although the underlying mechanisms of SORL1 in AD and neurodegenerative processes remain unclear, a recent comprehensive review on multiple functional domains of SORL1 suggested that SORL1 can assume various characters in AD pathogenesis", "citation": {"type": "PubMed", "name": "Sci Rep. 2016 Mar 21;6:23362. doi: 10.1038/srep23362.", "reference": "26996954"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 394, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "SORLA is proposed to act as a retention factor for APP in the TGN, preventing the release of precursor molecules into the processing pathways. Consequently, over-expression of SORLA in neurons prevents the targeting of APP from TGN to the cell surface and to endosomes and reduces the production of A peptides [9-11]. The importance of SORLA for AD is further supported by low levels of receptor expression seen in patients suffering from the disease", "citation": {"type": "PubMed", "name": "BMC Syst Biol. 2012 Jun 22;6(1):74. [Epub ahead of print]", "reference": "22727043"}, "subject": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "trans-Golgi Network"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}}}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 394, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "SORLA is proposed to act as a retention factor for APP in the TGN, preventing the release of precursor molecules into the processing pathways. Consequently, over-expression of SORLA in neurons prevents the targeting of APP from TGN to the cell surface and to endosomes and reduces the production of A peptides [9-11]. The importance of SORLA for AD is further supported by low levels of receptor expression seen in patients suffering from the disease", "citation": {"type": "PubMed", "name": "BMC Syst Biol. 2012 Jun 22;6(1):74. [Epub ahead of print]", "reference": "22727043"}, "subject": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "trans-Golgi Network"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}}}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 394, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "SORLA is proposed to act as a retention factor for APP in the TGN, preventing the release of precursor molecules into the processing pathways. Consequently, over-expression of SORLA in neurons prevents the targeting of APP from TGN to the cell surface and to endosomes and reduces the production of A peptides [9-11]. The importance of SORLA for AD is further supported by low levels of receptor expression seen in patients suffering from the disease", "citation": {"type": "PubMed", "name": "BMC Syst Biol. 2012 Jun 22;6(1):74. [Epub ahead of print]", "reference": "22727043"}, "subject": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 394, "target": 68, "key": 2}, {"relation": "decreases", "evidence": "SORLA is proposed to act as a retention factor for APP in the TGN, preventing the release of precursor molecules into the processing pathways. Consequently, over-expression of SORLA in neurons prevents the targeting of APP from TGN to the cell surface and to endosomes and reduces the production of A peptides [9-11]. The importance of SORLA for AD is further supported by low levels of receptor expression seen in patients suffering from the disease", "citation": {"type": "PubMed", "name": "BMC Syst Biol. 2012 Jun 22;6(1):74. [Epub ahead of print]", "reference": "22727043"}, "subject": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Membrane"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 394, "target": 68, "key": 3}, {"relation": "decreases", "evidence": "SORL1 regulates and traps APP in the Golgi apparatus and reduces the production of the amyloid-beta peptide (Abeta), the main component of senile plaques in AD4. Cell biology experiments have indicated that SORL1 underexperssion leads to overproduction of Abeta3 , whereas SORL1 overexpression considerably reduces cellular APP and extracellular Abeta5. Although the underlying mechanisms of SORL1 in AD and neurodegenerative processes remain unclear, a recent comprehensive review on multiple functional domains of SORL1 suggested that SORL1 can assume various characters in AD pathogenesis", "citation": {"type": "PubMed", "name": "Sci Rep. 2016 Mar 21;6:23362. doi: 10.1038/srep23362.", "reference": "26996954"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph", "CellStructure": "Golgi Apparatus"}, "source": 394, "target": 68, "key": 4}, {"relation": "decreases", "evidence": "SORL1 regulates and traps APP in the Golgi apparatus and reduces the production of the amyloid-beta peptide (Abeta), the main component of senile plaques in AD4. Cell biology experiments have indicated that SORL1 underexperssion leads to overproduction of Abeta3 , whereas SORL1 overexpression considerably reduces cellular APP and extracellular Abeta5. Although the underlying mechanisms of SORL1 in AD and neurodegenerative processes remain unclear, a recent comprehensive review on multiple functional domains of SORL1 suggested that SORL1 can assume various characters in AD pathogenesis", "citation": {"type": "PubMed", "name": "Sci Rep. 2016 Mar 21;6:23362. doi: 10.1038/srep23362.", "reference": "26996954"}, "annotations": {"Subgraph": "Low density lipoprotein subgraph"}, "source": 394, "target": 68, "key": 5}, {"relation": "increases", "evidence": "This processing is activated through a pathway involving the PDGF receptor, Src, and Rac1. ", "citation": {"type": "PubMed", "name": "J Biol Chem2004", "reference": "14766758"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "MAPK-JNK subgraph"}, "source": 397, "target": 68, "key": 0}, {"relation": "increases", "evidence": "This processing is activated through a pathway involving the PDGF receptor, Src, and Rac1. ", "citation": {"type": "PubMed", "name": "J Biol Chem2004", "reference": "14766758"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 397, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Here, we show that siRNA-mediated loss of calsyntenin-1 in cultured neurons alters APP processing to increase production of A. We also show that calsyntenin-1 is reduced in Alzheimer's disease brains and that the extent of this reduction correlates with increased A levels.", "citation": {"type": "PubMed", "name": "Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]", "reference": "22434822"}, "subject": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Axonal transport subgraph"}, "source": 423, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Here, we show that siRNA-mediated loss of calsyntenin-1 in cultured neurons alters APP processing to increase production of A. We also show that calsyntenin-1 is reduced in Alzheimer's disease brains and that the extent of this reduction correlates with increased A levels.", "citation": {"type": "PubMed", "name": "Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]", "reference": "22434822"}, "subject": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 423, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Here, we show that siRNA-mediated loss of calsyntenin-1 in cultured neurons alters APP processing to increase production of A. We also show that calsyntenin-1 is reduced in Alzheimer's disease brains and that the extent of this reduction correlates with increased A levels.", "citation": {"type": "PubMed", "name": "Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]", "reference": "22434822"}, "subject": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Calsyntenin subgraph"}, "source": 423, "target": 11, "key": 2}, {"relation": "increases", "evidence": " Together, these results indicate a role for calsyntenin-1 in Kinesin-1-dependent TGN exit and post-Golgi transport of APP-containing organelles and further suggest that distinct intracellular routes may exhibit different capacities for proteolytic processing of APP.", "citation": {"type": "PubMed", "name": "Traffic. 2009 May;10(5):572-89. Epub 2009 Jan 24.", "reference": "19192245"}, "subject": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "trans-Golgi Network"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Subgraph": "Calsyntenin subgraph"}, "source": 423, "target": 68, "key": 0}, {"relation": "increases", "evidence": " Together, these results indicate a role for calsyntenin-1 in Kinesin-1-dependent TGN exit and post-Golgi transport of APP-containing organelles and further suggest that distinct intracellular routes may exhibit different capacities for proteolytic processing of APP.", "citation": {"type": "PubMed", "name": "Traffic. 2009 May;10(5):572-89. Epub 2009 Jan 24.", "reference": "19192245"}, "subject": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "trans-Golgi Network"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 423, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Lysosomal dysfunction may be the earliest histological change in AD. Amyloid plaques are full of active lysosomal hydrolases, implying that plaques may originate from lysosomal rupture. Cathepsins D and E (intracellular aspartyl proteases) are considered to influence A peptides generation within the endosomallysosomal pathway because they exhibit - and -secretase like-activity [32]. For this reason, the endosomallysosomal pathway is a site for cleavage of the APP into smaller -amyloid-containing peptides, which are then degraded by cathepsins. Inhibition of cathepsins activity causes a rapid and pronounced build-up of potentially amyloidogenic protein fragments [33]. On the other hand, a failure to degrade aggregated Abeta_42 in late endosomes or secondary lysosomes was a mechanism that contributed to intracellular accumulation of A in AD. The cysteine protease cathepsin B in lysosomes degrades A peptides, especially the aggregation-prone species Abeta_42.", "citation": {"type": "PubMed", "name": "Acta Biochim Biophys Sin (Shanghai). 2009 Jun;41(6):437-45.", "reference": "19499146"}, "object": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 426, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Lysosomal dysfunction may be the earliest histological change in AD. Amyloid plaques are full of active lysosomal hydrolases, implying that plaques may originate from lysosomal rupture. Cathepsins D and E (intracellular aspartyl proteases) are considered to influence A peptides generation within the endosomallysosomal pathway because they exhibit - and -secretase like-activity [32]. For this reason, the endosomallysosomal pathway is a site for cleavage of the APP into smaller -amyloid-containing peptides, which are then degraded by cathepsins. Inhibition of cathepsins activity causes a rapid and pronounced build-up of potentially amyloidogenic protein fragments [33]. On the other hand, a failure to degrade aggregated Abeta_42 in late endosomes or secondary lysosomes was a mechanism that contributed to intracellular accumulation of A in AD. The cysteine protease cathepsin B in lysosomes degrades A peptides, especially the aggregation-prone species Abeta_42.", "citation": {"type": "PubMed", "name": "Acta Biochim Biophys Sin (Shanghai). 2009 Jun;41(6):437-45.", "reference": "19499146"}, "object": {"modifier": "Degradation"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 426, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Several lines of evidence suggest that cathepsin D, the major lysosomal/endosomal aspartic protease, may be involved in this process. ", "citation": {"type": "PubMed", "name": "International journal of biochemistry and cell biology1999", "reference": "10605825"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 426, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Several lines of evidence suggest that cathepsin D, the major lysosomal/endosomal aspartic protease, may be involved in this process. ", "citation": {"type": "PubMed", "name": "International journal of biochemistry and cell biology1999", "reference": "10605825"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Endosomal lysosomal subgraph"}, "source": 426, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Processing of beta-amyloid precursor protein by cathepsin D.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry1996", "reference": "8943232"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 426, "target": 68, "key": 2}, {"relation": "increases", "evidence": "Processing of beta-amyloid precursor protein by cathepsin D.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry1996", "reference": "8943232"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Endosomal lysosomal subgraph"}, "source": 426, "target": 68, "key": 3}, {"relation": "increases", "evidence": "NEP and IDE also contributed to IL-4-induced degradation of Abeta(1-42), b ecause their inhibitors, thiorphan and insulin, respectively, significantly suppressed this activity.", "citation": {"type": "PubMed", "name": "J Immunol2008", "reference": "18941241"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 438, "target": 11, "key": 0}, {"relation": "increases", "evidence": "NEP and IDE also contributed to IL-4-induced degradation of Abeta(1-42), b ecause their inhibitors, thiorphan and insulin, respectively, significantly suppressed this activity.", "citation": {"type": "PubMed", "name": "J Immunol2008", "reference": "18941241"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Interleukin signaling subgraph"}, "source": 438, "target": 11, "key": 1}, {"relation": "increases", "evidence": "NEP and IDE also contributed to IL-4-induced degradation of Abeta(1-42), b ecause their inhibitors, thiorphan and insulin, respectively, significantly suppressed this activity.", "citation": {"type": "PubMed", "name": "J Immunol2008", "reference": "18941241"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 438, "target": 11, "key": 2}, {"relation": "increases", "evidence": "The microtubule-associated protein tau plays a critical role in the pathogenesis of Alzheimer's disease (AD) and several related disorders collectively known as tauopathies.Development of tau pathology is associated with progressive neuronal loss and cognitive decline.", "citation": {"type": "PubMed", "name": "Methods Mol Biol. 2016;1303:143-60. doi: 10.1007/978-1-4939-2627-5_7.", "reference": "26235064"}, "annotations": {"Subgraph": "Tau protein subgraph"}, "source": 444, "target": 44, "key": 0}, {"relation": "increases", "evidence": "Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci. 2012 Apr;49(4):423-9", "reference": "22402435"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 447, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation.", "citation": {"type": "PubMed", "name": "Mol Cell Neurosci. 2012 Apr;49(4):423-9", "reference": "22402435"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 447, "target": 11, "key": 1}, {"relation": "increases", "evidence": "OBJECTIVE: Urinary-type plasminogen activator (uPA) binding to uPA receptor (uPAR) promotes the activation of matrix metalloproteinase-9 (MMP-9), which degrades amyloid beta protein (Abeta) in vitro.", "citation": {"type": "PubMed", "name": "Clin Neuropathol2001", "reference": "11327298"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 447, "target": 11, "key": 2}, {"relation": "increases", "evidence": "OBJECTIVE: Urinary-type plasminogen activator (uPA) binding to uPA receptor (uPAR) promotes the activation of matrix metalloproteinase-9 (MMP-9), which degrades amyloid beta protein (Abeta) in vitro.", "citation": {"type": "PubMed", "name": "Clin Neuropathol2001", "reference": "11327298"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 447, "target": 11, "key": 3}, {"relation": "increases", "evidence": "These findings suggest that MMP-9 can degrade fAbeta and may contribute to ongoing clearance of plaques from amyloid-laden brains.", "citation": {"type": "PubMed", "name": "J Biol Chem2006", "reference": "16787929"}, "object": {"modifier": "Degradation"}, "annotations": {}, "source": 447, "target": 11, "key": 4}, {"relation": "increases", "evidence": "Overexpression of MMP-9 or treatment of HEK/APP695 cells with activated recombinant MMP-9 resulted in enhanced secretion of soluble APP (sAPPalpha), a product of alpha-secretase cleavage, and reduction of Abeta release.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2007", "reference": "17761425"}, "annotations": {"Subgraph": "Matrix metalloproteinase subgraph"}, "source": 447, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Overexpression of MMP-9 or treatment of HEK/APP695 cells with activated recombinant MMP-9 resulted in enhanced secretion of soluble APP (sAPPalpha), a product of alpha-secretase cleavage, and reduction of Abeta release.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2007", "reference": "17761425"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 447, "target": 68, "key": 1}, {"relation": "increases", "evidence": "PAR-4 (prostate apoptosis response-4) is a leucine zipper protein that was initially identified to be associated with neuronal degeneration and aberrant Abeta production in pmodels of AD.", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "15671026"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 451, "target": 11, "key": 0}, {"relation": "increases", "evidence": "PAR-4 (prostate apoptosis response-4) is a leucine zipper protein that was initially identified to be associated with neuronal degeneration and aberrant Abeta production in pmodels of AD.", "citation": {"type": "PubMed", "name": "J Biol Chem2005", "reference": "15671026"}, "annotations": {"Subgraph": "Apoptosis signaling subgraph"}, "source": 451, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2009 May 22;455(3):191-4. doi: 10.1016/j.neulet.2009.03.066. Epub 2009 Mar 25.", "reference": "19429119"}, "annotations": {"Subgraph": "Leptin subgraph"}, "source": 474, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2009 May 22;455(3):191-4. doi: 10.1016/j.neulet.2009.03.066. Epub 2009 Mar 25.", "reference": "19429119"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 474, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Treatment with leptin reversed the 27-OHC-induced increase in Abeta and phosphorylated tau by decreasing the levels of BACE-1 and GSK-3beta respectively.", "citation": {"type": "PubMed", "name": "Journal of Alzheimer's disease2010", "reference": "20157255"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 474, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid- (A) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3 (GSK3) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3 to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3 activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3, or at Thr-668, the GSK3 phosphorylation site in APP, abolished the regulation of GSK3 activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3 kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "GSK3 subgraph"}, "source": 479, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid- (A) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3 (GSK3) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3 to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3 activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3, or at Thr-668, the GSK3 phosphorylation site in APP, abolished the regulation of GSK3 activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3 kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 479, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 479, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 479, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "To explore the molecular mechanism underlying AD, HTN, and CAA, we hypothesize a feedback signaling loop consisted of Pin1, eNOS, and A. Pin1 and eNOS mainly inhibit A deposition in cerebral vessels, cerebral microbleeds, and elevation of blood pressure, preventing the development of AD, HTN, and CAA, however, A plays an opposite role and aggravates these diseases.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Nitric oxide subgraph"}, "source": 479, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "To explore the molecular mechanism underlying AD, HTN, and CAA, we hypothesize a feedback signaling loop consisted of Pin1, eNOS, and A. Pin1 and eNOS mainly inhibit A deposition in cerebral vessels, cerebral microbleeds, and elevation of blood pressure, preventing the development of AD, HTN, and CAA, however, A plays an opposite role and aggravates these diseases.", "citation": {"type": "PubMed", "name": "Med Hypotheses. 2014 Feb;82(2):145-50", "reference": "24332564"}, "annotations": {"NervousSystem": "Cerebrum", "CardiovascularSystem": "Microvessels", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 479, "target": 11, "key": 5}, {"relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid- (A) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3 (GSK3) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3 to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3 activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3, or at Thr-668, the GSK3 phosphorylation site in APP, abolished the regulation of GSK3 activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3 kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "GSK3 subgraph"}, "source": 479, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid- (A) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3 (GSK3) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3 to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3 activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3, or at Thr-668, the GSK3 phosphorylation site in APP, abolished the regulation of GSK3 activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3 kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "object": {"modifier": "Degradation"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Amyloidogenic subgraph"}, "source": 479, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and ameliorate T2D, have become valuable candidates as disease modifying agents in the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta (A) peptide and tau phosphorylation in AD", "citation": {"type": "PubMed", "name": "Neuropharmacology. 2013 Sep;72:291-300. doi: 10.1016/j.neuropharm.2013.04.008. Epub 2013 Apr 17.", "reference": "23603201"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Tau protein subgraph"}, "source": 480, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and ameliorate T2D, have become valuable candidates as disease modifying agents in the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta (A) peptide and tau phosphorylation in AD", "citation": {"type": "PubMed", "name": "Neuropharmacology. 2013 Sep;72:291-300. doi: 10.1016/j.neuropharm.2013.04.008. Epub 2013 Apr 17.", "reference": "23603201"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Insulin signal transduction"}, "source": 480, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and ameliorate T2D, have become valuable candidates as disease modifying agents in the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta (A) peptide and tau phosphorylation in AD", "citation": {"type": "PubMed", "name": "Neuropharmacology. 2013 Sep;72:291-300. doi: 10.1016/j.neuropharm.2013.04.008. Epub 2013 Apr 17.", "reference": "23603201"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 480, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and ameliorate T2D, have become valuable candidates as disease modifying agents in the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta (A) peptide and tau phosphorylation in AD", "citation": {"type": "PubMed", "name": "Neuropharmacology. 2013 Sep;72:291-300. doi: 10.1016/j.neuropharm.2013.04.008. Epub 2013 Apr 17.", "reference": "23603201"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Glucagon subgraph"}, "source": 480, "target": 11, "key": 3}, {"relation": "decreases", "evidence": "GLP-1 possesses neurotropic properties and can reduce amyloid protein levels in the brain.", "citation": {"type": "PubMed", "name": "Neurosci Bull. 2007 Jan;23(1):58-65.", "reference": "17592527"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Neurotrophic subgraph"}, "source": 480, "target": 68, "key": 0}, {"relation": "decreases", "evidence": "GLP-1 possesses neurotropic properties and can reduce amyloid protein levels in the brain.", "citation": {"type": "PubMed", "name": "Neurosci Bull. 2007 Jan;23(1):58-65.", "reference": "17592527"}, "annotations": {"NervousSystem": "Brain", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 480, "target": 68, "key": 1}, {"relation": "decreases", "evidence": "We report here that (i) a single amino acid mutation at the Thr-668 residue of APP695, located 14 amino acids toward the amino-terminal end from the (682)YENPTY(687) motif, reduced the interaction between members of the Fe65 family of proteins and APP, whereas interaction of APP with the phosphotyrosine interaction domain of other APP binders such as X11-like and mammalian disabled-1 was not influenced by this mutation; (ii) the phosphorylation of APP at Thr-668 diminished the interaction of APP with Fe65 by causing a conformational change in the cytoplasmic domain that contains the Fe65-binding motif, YENPTY; and (iii) the expression of Fe65 slightly suppressed maturation of APP and decreased production of beta-amyloid (Abeta).", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2001", "reference": "11517218"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 481, "target": 11, "key": 0}, {"relation": "increases", "evidence": "APP-dependent transcription mediated by Fe65 is blocked by p75(NTR)", "citation": {"type": "PubMed", "name": "Ann Neurol2009", "reference": "19334058"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 481, "target": 68, "key": 0}, {"relation": "increases", "evidence": "APP-dependent transcription mediated by Fe65 is blocked by p75(NTR)", "citation": {"type": "PubMed", "name": "Ann Neurol2009", "reference": "19334058"}, "annotations": {"Subgraph": "Nerve growth factor subgraph"}, "source": 481, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2002", "reference": "12297508"}, "annotations": {"Subgraph": "Notch signaling subgraph"}, "source": 482, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2002", "reference": "12297508"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 482, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2002", "reference": "12297508"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 482, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2002", "reference": "12297508"}, "annotations": {"Subgraph": "Notch signaling subgraph"}, "source": 482, "target": 68, "key": 0}, {"relation": "increases", "evidence": "Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2002", "reference": "12297508"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 482, "target": 68, "key": 1}, {"relation": "increases", "evidence": "Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2002", "reference": "12297508"}, "annotations": {"Subgraph": "Gamma secretase subgraph"}, "source": 482, "target": 68, "key": 2}, {"relation": "increases", "evidence": "The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-1 (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1alpha and IL-1beta increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5'-untranslated region (5'-UTR) conferred translational regulation by IL-1alpha and IL-1beta to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5'-UTR)/CAT mRNAs were unchanged, whereas both base-line and IL-1-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5'-cap site and is homologous to related translational control elements in the 5'-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "J Biol Chem. 1999 Mar 5;274(10):6421-31.", "reference": "10037734"}, "annotations": {"NervousSystem": "Astrocytes", "Subgraph": "Amyloidogenic subgraph"}, "source": 483, "target": 68, "key": 0}, {"relation": "increases", "evidence": "The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-1 (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1alpha and IL-1beta increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5'-untranslated region (5'-UTR) conferred translational regulation by IL-1alpha and IL-1beta to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5'-UTR)/CAT mRNAs were unchanged, whereas both base-line and IL-1-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5'-cap site and is homologous to related translational control elements in the 5'-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.", "citation": {"type": "PubMed", "name": "J Biol Chem. 1999 Mar 5;274(10):6421-31.", "reference": "10037734"}, "annotations": {"NervousSystem": "Astrocytes", "Subgraph": "Interleukin signaling subgraph"}, "source": 483, "target": 68, "key": 1}, {"relation": "increases", "evidence": "These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.", "citation": {"type": "PubMed", "name": "Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.", "reference": "19394434"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Chemokine signaling subgraph"}, "source": 484, "target": 11, "key": 0}, {"relation": "increases", "evidence": "These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.", "citation": {"type": "PubMed", "name": "Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.", "reference": "19394434"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 484, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.", "citation": {"type": "PubMed", "name": "Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.", "reference": "19394434"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Chemokine signaling subgraph"}, "source": 484, "target": 46, "key": 0}, {"relation": "decreases", "evidence": "These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.", "citation": {"type": "PubMed", "name": "Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.", "reference": "19394434"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Amyloidogenic subgraph"}, "source": 484, "target": 46, "key": 1}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Endothelin subgraph"}, "source": 485, "target": 11, "key": 0}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 485, "target": 11, "key": 1}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 485, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Since A is secreted extracellularly, and deposits outside the neuronal cells in the AD brain, we took an approach to screen any secreted protease(s) in neuronal and non-neuronal cell culture media for the ability to degrade A. Among all secreted proteases from the cells, only IDE degraded A. We found that under physiological conditions IDE is secreted at high levels from the microglial cells, and degrades A extracellularly [73]. Purified IDE from rat liver and brain was shown to degrade A effectively. IDE is present in the soluble fractions from human brains, and binds and degrades A specifically [57] and [71]. Primary cultured neurons were also shown to clear A via extracellular IDE as well as IDE on the cell surface [90]. IDE from brain homogenates degrades different forms of A: A40, A42 and an A mutant in one type of AD (Dutch Variant 1-40 Q) [61] and [71]. A42 is the longer form of A and more abundant in the AD brain.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2006 Feb;27(2):190-8. Epub 2005 Feb 17.", "reference": "16399206"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Insulin signal transduction"}, "source": 485, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Since A is secreted extracellularly, and deposits outside the neuronal cells in the AD brain, we took an approach to screen any secreted protease(s) in neuronal and non-neuronal cell culture media for the ability to degrade A. Among all secreted proteases from the cells, only IDE degraded A. We found that under physiological conditions IDE is secreted at high levels from the microglial cells, and degrades A extracellularly [73]. Purified IDE from rat liver and brain was shown to degrade A effectively. IDE is present in the soluble fractions from human brains, and binds and degrades A specifically [57] and [71]. Primary cultured neurons were also shown to clear A via extracellular IDE as well as IDE on the cell surface [90]. IDE from brain homogenates degrades different forms of A: A40, A42 and an A mutant in one type of AD (Dutch Variant 1-40 Q) [61] and [71]. A42 is the longer form of A and more abundant in the AD brain.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2006 Feb;27(2):190-8. Epub 2005 Feb 17.", "reference": "16399206"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 485, "target": 11, "key": 4}, {"relation": "increases", "evidence": "These data suggest that NOS2 upregulation impairs amyloid  degradation through negative regulation of IDE activity and thus loss of NOS2 activity will positively influence amyloid  clearance.", "citation": {"type": "PubMed", "name": "J Neuroimmune Pharmacol. 2012 Mar;7(1):165-72", "reference": "22227962"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Nitric oxide subgraph"}, "source": 485, "target": 11, "key": 5}, {"relation": "increases", "evidence": "These data suggest that NOS2 upregulation impairs amyloid  degradation through negative regulation of IDE activity and thus loss of NOS2 activity will positively influence amyloid  clearance.", "citation": {"type": "PubMed", "name": "J Neuroimmune Pharmacol. 2012 Mar;7(1):165-72", "reference": "22227962"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 485, "target": 11, "key": 6}, {"relation": "increases", "evidence": "The amyloid hypothesis of AD suggests that  -amyloid accumulation is the  critical event  in development of disease (I 49,  I 50].  Lots  of research has been  done  on  the formation and accumulation of Al3, however, in the  last years  the mechanism' of  amyloid clearance came   into focus. For  Al3 clearance several mechanisms are  known (Fig.  2):  i) Enzy matic  degradation by activated microglia or  by  insulin   de grading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and  angiotensin converting  enzyme (ACE); ii) Receptor-mediated transport across the blood  brain  barrier (BBB) by  binding to  the  low-density  lipoprotein  receptor related protein (LRP) either  directly or after  binding to apol ipoprotein E (ApoE) and/or a2-macroglobulin (a2M)  to be delivered  to  peripheral sites   of  degradation, e.g.,   liver  and kidney.  (Review in [151 ]).  Concerning insulin   resistance it has  been  shown  that   IDE expression  is stimulated  by  the IR/lGF-1 R  cascade  (152]. ", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2009 Jun;6(3):213-23.", "reference": "19519303"}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer's disease (AD) as ACE functions to degrade amyloid- (A).", "citation": {"type": "PubMed", "name": "Alzheimers Res Ther. 2014 May 15;6(3):27", "reference": "24987467"}, "object": {"modifier": "Degradation"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer's disease (AD) as ACE functions to degrade amyloid- (A).", "citation": {"type": "PubMed", "name": "Alzheimers Res Ther. 2014 May 15;6(3):27", "reference": "24987467"}, "object": {"modifier": "Degradation"}, "annotations": {"MeSHDisease": "Alzheimer Disease", "Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Lower CSF ACE protein level, and to a lesser extent serum ACE protein level and CSF ACE activity, were associated with lower CSF A, indicating more brain A pathology; adjusted regression coefficients (B) (95% CI) per SD increase were 0.09 (0.04; 0.15), 0.06 (0.00; 0.12) and 0.05 (0.00; 0.11), respectively. Further, lower CSF ACE protein level was associated with lower CSF tau and ptau levels; adjusted B's (95% CI) per SD increase were 0.15 (0.06; 0.25) and 0.17 (0.10; 0.25), respectively.These results strengthen the hypothesis that ACE degrades A.", "citation": {"type": "PubMed", "name": "Alzheimers Res Ther. 2014 May 15;6(3):27", "reference": "24987467"}, "object": {"modifier": "Degradation"}, "annotations": {"FluidAndSecretion": "Serum", "NervousSystem": "Brain", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 3}, {"relation": "increases", "evidence": "Lower CSF ACE protein level, and to a lesser extent serum ACE protein level and CSF ACE activity, were associated with lower CSF A, indicating more brain A pathology; adjusted regression coefficients (B) (95% CI) per SD increase were 0.09 (0.04; 0.15), 0.06 (0.00; 0.12) and 0.05 (0.00; 0.11), respectively. Further, lower CSF ACE protein level was associated with lower CSF tau and ptau levels; adjusted B's (95% CI) per SD increase were 0.15 (0.06; 0.25) and 0.17 (0.10; 0.25), respectively.These results strengthen the hypothesis that ACE degrades A.", "citation": {"type": "PubMed", "name": "Alzheimers Res Ther. 2014 May 15;6(3):27", "reference": "24987467"}, "object": {"modifier": "Degradation"}, "annotations": {"FluidAndSecretion": "Serum", "NervousSystem": "Brain", "Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 4}, {"relation": "decreases", "evidence": "ACE was found to significantly inhibit A beta aggregation in a dose response manner.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11604391"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 5}, {"relation": "decreases", "evidence": "ACE was found to significantly inhibit A beta aggregation in a dose response manner.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11604391"}, "annotations": {"Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 6}, {"relation": "decreases", "evidence": "These findings led to the hypothesis that ACE may affect susceptibility to AD by degrading A beta and preventing the accumulation of amyloid plaques in vivo.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11604391"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "These findings led to the hypothesis that ACE may affect susceptibility to AD by degrading A beta and preventing the accumulation of amyloid plaques in vivo.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11604391"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 8}, {"relation": "decreases", "evidence": "The most striking fact was that ACE degraded A beta by cleaving A beta-(1-40) at the site Asp(7)-Ser(8).", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11604391"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 9}, {"relation": "decreases", "evidence": "The most striking fact was that ACE degraded A beta by cleaving A beta-(1-40) at the site Asp(7)-Ser(8).", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11604391"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 10}, {"relation": "decreases", "evidence": "ACE was found to significantly inhibit A beta aggregation in a dose response manner.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2001 Dec 21;276(51):47863-8. Epub 2001 Oct 16.", "reference": "11604391"}, "annotations": {"Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 11}, {"relation": "decreases", "evidence": "ACE was found to significantly inhibit A beta aggregation in a dose response manner.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2001 Dec 21;276(51):47863-8. Epub 2001 Oct 16.", "reference": "11604391"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 12}, {"relation": "decreases", "evidence": "The most striking fact was that ACE degraded A beta by cleaving A beta-(1-40) at the site Asp(7)-Ser(8).", "citation": {"type": "PubMed", "name": "J Biol Chem. 2001 Dec 21;276(51):47863-8. Epub 2001 Oct 16.", "reference": "11604391"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Renin-angiotensin subgraph"}, "source": 486, "target": 11, "key": 13}, {"relation": "decreases", "evidence": "The most striking fact was that ACE degraded A beta by cleaving A beta-(1-40) at the site Asp(7)-Ser(8).", "citation": {"type": "PubMed", "name": "J Biol Chem. 2001 Dec 21;276(51):47863-8. Epub 2001 Oct 16.", "reference": "11604391"}, "object": {"modifier": "Degradation"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 486, "target": 11, "key": 14}, {"relation": "increases", "evidence": "In addition, NF-B p65 expression leads to up-regulated -secretase cleavage and A production, while non-steroidal anti-inflammatory drugs (NSAIDs) inhibited BACE1 transcriptional activation induced by strong NF-B activator tumour necrosis factor-alpha (TNF-).", "citation": {"type": "PubMed", "name": "Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90", "reference": "21329555"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 487, "target": 11, "key": 0}, {"relation": "increases", "evidence": "In addition, NF-B p65 expression leads to up-regulated -secretase cleavage and A production, while non-steroidal anti-inflammatory drugs (NSAIDs) inhibited BACE1 transcriptional activation induced by strong NF-B activator tumour necrosis factor-alpha (TNF-).", "citation": {"type": "PubMed", "name": "Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90", "reference": "21329555"}, "annotations": {"Subgraph": "Nuclear factor Kappa beta subgraph"}, "source": 487, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "In contrast, enhanced FasL shedding, by recombinant MMP-7, completely protected neurons from Abeta neurotoxicity.", "citation": {"type": "PubMed", "name": "Curr Biol. 2002 Sep 17;12(18):1595-600", "reference": "12372252"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Matrix metalloproteinase subgraph"}, "source": 488, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "In contrast, enhanced FasL shedding, by recombinant MMP-7, completely protected neurons from Abeta neurotoxicity.", "citation": {"type": "PubMed", "name": "Curr Biol. 2002 Sep 17;12(18):1595-600", "reference": "12372252"}, "object": {"modifier": "Activity"}, "annotations": {"NervousSystem": "Neurons", "Subgraph": "Non-amyloidogenic subgraph"}, "source": 488, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Several proteases were shown to hydrolyze Abeta in vitro or in cell-based assays, and are likely candidates for a role in Abeta clearance in brain. Previous reports suggest that matrix metalloproteinases (MMPs) could be involved in such a mechanism.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2007 Aug;28(8):1215-20. Epub 2006 Jul 5", "reference": "16822591"}, "object": {"modifier": "Degradation"}, "annotations": {"NervousSystem": "Brain"}, "source": 489, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Here we show that glutaminyl cyclase (QC) catalyzes the formation of Abeta 3(pE)-40/42 after amyloidogenic processing of APP in two different cell lines, applying specific ELISAs and Western blotting based on urea-PAGE.", "citation": {"type": "PubMed", "name": "Biochemistry2008", "reference": "18570439"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 490, "target": 11, "key": 0}, {"relation": "increases", "evidence": "Here we show that glutaminyl cyclase (QC) catalyzes the formation of Abeta 3(pE)-40/42 after amyloidogenic processing of APP in two different cell lines, applying specific ELISAs and Western blotting based on urea-PAGE.", "citation": {"type": "PubMed", "name": "Biochemistry2008", "reference": "18570439"}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 490, "target": 11, "key": 1}, {"relation": "increases", "evidence": "Here we show that glutaminyl cyclase (QC) catalyzes the formation of Abeta 3(pE)-40/42 after amyloidogenic processing of APP in two different cell lines, applying specific ELISAs and Western blotting based on urea-PAGE. ", "citation": {"type": "PubMed", "name": "Biochemistry2008", "reference": "18570439"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 490, "target": 11, "key": 2}, {"relation": "decreases", "evidence": "We found that overexpression of endogenous calpain inhibitor calpastatin (CAST) under the control of the calcium/calpmodulin-dependent protein kinase II promoter in APP/PS1 mice caused a remarkable decrease of amyloid plaque burdens and prevented Tau phosphorylation and the loss of synapses.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 491, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "We found that overexpression of endogenous calpain inhibitor calpastatin (CAST) under the control of the calcium/calpmodulin-dependent protein kinase II promoter in APP/PS1 mice caused a remarkable decrease of amyloid plaque burdens and prevented Tau phosphorylation and the loss of synapses.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Calpastatin-calpain subgraph"}, "source": 491, "target": 11, "key": 1}, {"relation": "decreases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 491, "target": 11, "key": 2}, {"relation": "decreases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Calpastatin-calpain subgraph"}, "source": 491, "target": 11, "key": 3}, {"relation": "decreases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 491, "target": 11, "key": 4}, {"relation": "decreases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Beta secretase subgraph"}, "source": 491, "target": 11, "key": 5}, {"relation": "decreases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Calpastatin-calpain subgraph"}, "source": 491, "target": 11, "key": 6}, {"relation": "decreases", "evidence": " Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20595388"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 491, "target": 11, "key": 7}, {"relation": "decreases", "evidence": "The phosphotyrosine binding domain of the neuronal protein X11alpha/mint-1 binds to the C-terminus of amyloid precursor protein (APP) and inhibits catabolism to beta-amyloid (Abeta), but the mechanism of this effect is unclear.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2004", "reference": "14756819"}, "annotations": {"Subgraph": "Amyloidogenic subgraph"}, "source": 492, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "The phosphotyrosine binding domain of the neuronal protein X11alpha/mint-1 binds to the C-terminus of amyloid precursor protein (APP) and inhibits catabolism to beta-amyloid (Abeta), but the mechanism of this effect is unclear.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2004", "reference": "14756819"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 492, "target": 11, "key": 1}, {"relation": "decreases", "evidence": "The neuronal adaptor X11alpha interacts with the conserved -GYENPTY- sequence in the C-terminus of amyloid precursor protein (APP) or its Swedish mutation (APPswe) to inhibit Abeta40 and Abeta42 secretion.", "citation": {"type": "PubMed", "name": "Neuroscience2003", "reference": "12849748"}, "annotations": {"Subgraph": "Non-amyloidogenic subgraph"}, "source": 492, "target": 11, "key": 2}, {"relation": "increases", "evidence": "Down regulation of DNMT results in hypomethylation of BACE1 and APP which are involved in Abeta production and causes upregulation of their protein expression; in turn SP1 transcription factor increases which finally results in Abeta production.", "citation": {"type": "PubMed", "name": "Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.", "reference": "19245828"}, "annotations": {"Species": "10090"}, "source": 493, "target": 11, "key": 0}, {"relation": "decreases", "evidence": "The 5-HT4 receptor may play a role in memory and learning and 5-HT4 receptor activation has been suggested to modulate acetylcholine release and to reduce amyloid- (A) accumulation.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2011;26(3):457-66. doi: 10.3233/JAD-2011-110056.", "reference": "21673407"}, "annotations": {}, "source": 494, "target": 11, "key": 0}, {"relation": "increases", "evidence": "polymorphisms in three other genes (among others), apolipoprotein E (apoE), alpha2-macroglobulin (alpham), and the low density lipoprotein receptor-related protein (LRP), are implicated to contribute to AD pathogenesis", "citation": {"type": "PubMed", "name": "Microsc Res Tech. 2000 Aug 15;50(4):268-72.", "reference": "10936878"}, "annotations": {"Disease": "Alzheimer's disease", "Subgraph": "Low density lipoprotein subgraph"}, "source": 495, "target": 33, "key": 0}, {"relation": "increases", "evidence": "Lipoprotein lipase (LPL) assists lipid transport by transferring lipids between lipoprotein particles and cells. LPL binds apolipoprotein E (apoE) lipoprotein particles and a major apoE receptor, low density lipoprotein receptor related protein (LRP). Because apoE and LRP polymorphisms alter Alzheimer's disease (AD) risk, and LPL itself is found in AD amyloid plaques, we examined whether LPL variants also affect AD risk.", "citation": {"type": "PubMed", "name": "Microsc Res Tech. 2000 Aug 15;50(4):291-6.", "reference": "10936883"}, "annotations": {}, "source": 496, "target": 33, "key": 0}, {"relation": "directlyIncreases", "evidence": "absence of CPE leads to degeneration of the CA3 neurons and perturbation of the cytoarchitecture of the hippocampus. Ex vivo studies showed that overexpression of CPE in cultured hippocampal neurons protected them against H(2)O(2) oxidative-stress induced cell death. These findings taken together indicate that CPE is essential for the survival of adult hippocampal CA3 neurons to maintain normal cognitive function.", "citation": {"type": "PubMed", "name": "Hippocampus. 2008;18(10):1051-63", "reference": "18570185"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Response to oxidative stress"}, "source": 497, "target": 44, "key": 0}, {"relation": "directlyIncreases", "evidence": "absence of CPE leads to degeneration of the CA3 neurons and perturbation of the cytoarchitecture of the hippocampus. Ex vivo studies showed that overexpression of CPE in cultured hippocampal neurons protected them against H(2)O(2) oxidative-stress induced cell death. These findings taken together indicate that CPE is essential for the survival of adult hippocampal CA3 neurons to maintain normal cognitive function.", "citation": {"type": "PubMed", "name": "Hippocampus. 2008;18(10):1051-63", "reference": "18570185"}, "annotations": {"Condition": "Normal Healthy State", "Subgraph": "Protein biosynthesis subgraph"}, "source": 497, "target": 44, "key": 1}, {"relation": "directlyIncreases", "evidence": "absence of CPE leads to degeneration of the CA3 neurons and perturbation of the cytoarchitecture of the hippocampus. Ex vivo studies showed that overexpression of CPE in cultured hippocampal neurons protected them against H(2)O(2) oxidative-stress induced cell death. These findings taken together indicate that CPE is essential for the survival of adult hippocampal CA3 neurons to maintain normal cognitive function.", "citation": {"type": "PubMed", "name": "Hippocampus. 2008;18(10):1051-63", "reference": "18570185"}, "annotations": {"Subgraph": "Protein biosynthesis subgraph"}, "source": 497, "target": 44, "key": 2}, {"relation": "increases", "evidence": "Extracellular-signal regulated kinase 1/2 signaling (ERK1 and ERK2): The mitogen-activated protein kinase (MAPK) family of protein kinases is traditionally viewed as important kinases in transmitting extracellular membrane signals intothe nucleus. The 44 kDa ERK1 and 42 kDa ERK2 are members of the MAPK superfamily that specifically respond to A in brain cells [127]. ERK1 and ERK2 are known to be activated through dual phosphorylation by the MAPK/ERK on threonine and tyrosine in the Thr-Glu-Tyr sequence of the activation loop [128, 129]. ERK signaling is critical for memory and tightly regulated by many proteins. ERKs are critical for human learning as revealed by human mental retardation syndromes [130]. They are also known to contribute to molecular information processing in dendrites, to stabilize structural changes in dendritic spines and to interact with scaffolding and structural proteins at the synapse [131]. ERK is an important neuronal marker for activity through activation by cytosolic calcium and depolarization of the membrane [132, 133]. On phosphorylation and activation, ERKs phosphorylate other cytoplasmic effectors and are translocated into the nucleus where they phosphorylate transcription factors such as Myc, Fos, Jun, and Elk1 [104, 134]. Direct substrates of the ERKs includetwo members of the RSK family of protein serine-threonine kinases, RSK1 and RSK2. The transcription factor CREB is phosphorylated on serine 133 in vivo by RSK2 in NGF-stimulated PC12 cells [135]. The dependence of CREB phosphorylation on activation of the ERK pathway is suggested by inhibition of A-induced phosphorylation of CREB by piceatannol and the MEK inhibitor PD98059. Other kinases, such as protein kinase A (PKA) or Ca2+/calmodulin-dependent protein kinases [CAM kinases; 136] may also contribute to phosphorylation of cyclic AMP response element (CRE)-binding protein (CREB) in response to A but the complete inhibition of CREB phosphorylation by PD98059 suggests that the ERK pathway is the main signaling pathway elicited by A leading to transcriptional activation through CREB [137]. These data provide a mechanism by which A alters gene expression through the transcription factor CREB [137], possibly resulting in a ceiling of activation that limits further formation of new memories.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2010;22(3):741-63", "reference": "20847424"}, "subject": {"modifier": "Activity"}, "annotations": {"Subgraph": "MAPK-ERK subgraph"}, "source": 498, "target": 45, "key": 0}, {"relation": "increases", "evidence": "Some cholinesterase inhibitors (tacrine, donepezil, galantamine) are metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2007 Sep;4(4):479-500", "reference": "17908053"}, "object": {"modifier": "Activity"}, "annotations": {"Subgraph": "Cholesterol metabolism subgraph"}, "source": 499, "target": 50, "key": 0}]};
    </script>
    <script src="https://npmcdn.com/tether@1.2.4/dist/js/tether.min.js"></script>
    <script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.1.1/jquery.min.js"></script>
    <script type="text/javascript"
            src="https://cdnjs.cloudflare.com/ajax/libs/jqueryui/1.12.1/jquery-ui.min.js"></script>
    <script type="text/javascript"
            src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/4.0.0-alpha.6/js/bootstrap.min.js"></script>
    <script type="text/javascript"
            src="https://cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min.js"></script>
    <script type="text/javascript"
            src="https://cdnjs.cloudflare.com/ajax/libs/jquery-validate/1.16.0/jquery.validate.min.js"></script>
    <script type="text/javascript"
            src="https://cdnjs.cloudflare.com/ajax/libs/svg.js/2.4.0/svg.min.js"></script>
    <script type="text/javascript"
            src="https://cdnjs.cloudflare.com/ajax/libs/FileSaver.js/1.3.3/FileSaver.min.js"></script>
    <script type="text/javascript">
        // Initialize d3.js force to plot the networks from neo4j json
        function init_d3_force(graph) {

            //////////////////////////////
            // Main graph visualization //
            //////////////////////////////

            d = document;
            e = d.documentElement;
            g = d.getElementsByTagName('body')[0];


            // Graph uses 0.85 x 0.85 of the window size
            var w = $("#graph-chart").width(), h = w.innerHeight ||
                e.clientHeight || g.clientHeight;

            var focus_node = null, highlight_node = null;

            // Highlight color of the nodes
            var highlight_color = "#4EB2D4";

            // Size when zooming scale
            var size = d3.scalePow().exponent(1)
                .domain([1, 100])
                .range([8, 24]);

            // Simulation parameters
            var linkDistance = 100, fCharge = -1000, linkStrength = 0.7, collideStrength = 1;

            // Simulation defined with variables
            var simulation = d3.forceSimulation()
                .force("link", d3.forceLink()
                    .distance(linkDistance)
                    .strength(linkStrength)
                )
                .force("collide", d3.forceCollide()
                    .radius(function (d) {
                        return d.r + 10
                    })
                    .strength(collideStrength)
                )
                .force("charge", d3.forceManyBody()
                    .strength(fCharge)
                )
                .force("center", d3.forceCenter(w / 2, h / 2))
                .force("y", d3.forceY(0))
                .force("x", d3.forceX(0));

            // Pin down functionality
            var node_drag = d3.drag()
                .on("start", dragstarted)
                .on("drag", dragged)
                .on("end", dragended);

            function dragstarted(d) {
                if (!d3.event.active) simulation.alphaTarget(0.3).restart();
                d.fx = d.x;
                d.fy = d.y;
            }

            function dragged(d) {
                d.fx = d3.event.x;
                d.fy = d3.event.y;
            }

            function dragended(d) {
                if (!d3.event.active) simulation.alphaTarget(0);
            }

            function releasenode(d) {
                d.fx = null;
                d.fy = null;
            }

            //END Pin down functionality

            var color_circunferencia = "black";
            var default_link_color = "#888";
            var nominal_base_node_size = 8;
            // Normal and highlighted stroke of the links (double the width of the link when highlighted)
            var nominal_stroke = 1.5, highlighted_stroke = 3;
            // Zoom variables
            var min_zoom = 0.1, max_zoom = 10;
            var border = 1, bordercolor = 'black';

            var svg = d3.select("#graph-chart").append("svg")
                .attr("width", w)
                .attr("height", h);

            // // Create definition for arrowhead.
            svg.append("defs").append("marker")
                .attr("id", "arrowhead")
                .attr("viewBox", "0 -5 10 10")
                .attr("refX", 20)
                .attr("refY", 0)
                .attr("markerUnits", "strokeWidth")
                .attr("markerWidth", 6)
                .attr("markerHeight", 6)
                .attr("orient", "auto")
                .append("path")
                .attr("d", "M0,-5L10,0L0,5");

            // // Create definition for stub.
            svg.append("defs").append("marker")
                .attr("id", "stub")
                .attr("viewBox", "-1 -5 2 10")
                .attr("refX", 15)
                .attr("refY", 0)
                .attr("markerUnits", "strokeWidth")
                .attr("markerWidth", 6)
                .attr("markerHeight", 6)
                .attr("orient", "auto")
                .append("path")
                .attr("d", "M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z");

            // Background
            svg.append("rect")
                .attr("width", "100%")
                .attr("height", "100%")
                .attr("fill", "#ffffff")
                .style("pointer-events", "all")
                // Zoom + panning functionality
                .call(d3.zoom()
                    .scaleExtent([min_zoom, max_zoom])
                    .on("zoom", zoomed))
                .on("dblclick.zoom", null);


            function zoomed() {
                g.attr("transform", d3.event.transform);
            }


            // g = svg object where the graph will be appended
            var g = svg.append("g");

            var linkedByIndex = {};
            graph.links.forEach(function (d) {
                linkedByIndex[d.source + "," + d.target] = true;
            });

            function isConnected(a, b) {
                return linkedByIndex[a.index + "," + b.index] || linkedByIndex[b.index + "," + a.index] || a.index == b.index;
            }

            function ticked() {
                link
                    .attr("x1", function (d) {
                        return d.source.x;
                    })
                    .attr("y1", function (d) {
                        return d.source.y;
                    })
                    .attr("x2", function (d) {
                        return d.target.x;
                    })
                    .attr("y2", function (d) {
                        return d.target.y;
                    });

                node
                    .attr("transform", function (d) {
                        return "translate(" + d.x + ", " + d.y + ")";
                    });
            }


            simulation
                .nodes(graph.nodes)
                .on("tick", ticked);

            simulation.force("link")
                .links(graph.links);

            // Definition of links nodes text...

            var link = g.selectAll(".link")
                .data(graph.links)
                .enter().append("line")
                .style("stroke-width", nominal_stroke)
                .style("stroke", default_link_color)
                .attr("class", function (d) {
                    if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',
                            'positiveCorrelation'].indexOf(d.relation) >= 0) {
                        return "link link_continuous"
                    }
                    else {
                        return "link link_dashed"
                    }
                })
                .attr("marker-start", function (d) {
                    if ('positiveCorrelation' == d.relation) {
                        return "url(#arrowhead)"
                    }
                    else if ('negativeCorrelation' == d.relation) {
                        return "url(#stub)"
                    }
                    else {
                        return ""
                    }
                })
                .attr("marker-end", function (d) {
                    if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {
                        return "url(#arrowhead)"
                    }
                    else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {
                        return "url(#stub)"
                    }
                    else {
                        return ""
                    }
                });

            var node = g.selectAll(".nodes")
                .data(graph.nodes)
                .enter().append("g")
                .attr("class", "node")
                // Next two lines -> Pin down functionality
                .on('dblclick', releasenode)
                .call(node_drag);

            var circle = node.append("path")
                .attr("d", d3.symbol()
                    .size(function (d) {
                        return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);
                    })
                )
                .attr("class", function (d) {
                    return d.function
                })
                .style("stroke-width", nominal_stroke)
                .style("stroke", color_circunferencia);

            var text = node.append("text")
                .attr("class", "node-name")
                // .attr("id", nodehashes[d])
                .attr("fill", "black")
                .attr("dx", 12)
                .attr("dy", ".35em")
                .text(function (d) {
                    return d.name
                });

            // Highlight on mouseenter and back to normal on mouseout
            node.on("mouseenter", function (d) {
                set_highlight(d);
            })
                .on("mousedown", function () {
                    d3.event.stopPropagation();
                }).on("mouseout", function () {
                exit_highlight();
            });

            function exit_highlight() {
                highlight_node = null;
                if (focus_node === null) {
                    if (highlight_color != color_circunferencia) {
                        circle.style("stroke", color_circunferencia);
                        text.style("font-weight", "normal");
                        link.style("stroke-width", nominal_stroke);
                    }
                }
            }

            function set_highlight(d) {
                if (focus_node !== null) d = focus_node;
                highlight_node = d;

                if (highlight_color != color_circunferencia) {
                    circle.style("stroke", function (o) {
                        return isConnected(d, o) ? highlight_color : color_circunferencia;
                    });
                    text.style("font-weight", function (o) {
                        return isConnected(d, o) ? "bold" : "normal";
                    });
                    link.style("stroke-width", function (o) {
                        return o.source.index == d.index || o.target.index == d.index ? highlighted_stroke : nominal_stroke;
                    });
                }
            }

            // Freeze the graph when space is pressed
            function freezeGraph() {
                // Space button Triggers STOP
                if (d3.event.keyCode == 32) {
                    simulation.stop();
                }
            }

            // Search functionality to check if array exists in an array of arrays
            function searchForArray(haystack, needle) {
                var i, j, current;
                for (i = 0; i < haystack.length; ++i) {
                    if (needle.length === haystack[i].length) {
                        current = haystack[i];
                        for (j = 0; j < needle.length && needle[j] === current[j]; ++j);
                        if (j === needle.length)
                            return i;
                    }
                }
                return -1;
            }

            function reset_attributes_on_double_click() {

                // On double click reset attributes (Important disabling the zoom behavior of dbl click because it interferes with this)
                svg.on("dblclick", function () {
                    // SET default color
                    svg.selectAll(".link").style("stroke", default_link_color);
                    // SET default attributes //
                    svg.selectAll(".link, .node").style("visibility", "visible")
                        .style("opacity", "1");
                    // Show node names
                    svg.selectAll(".node-name").style("visibility", "visible").style("opacity", "1");
                });

            }

            function reset_attributes() {
                // Reset visibility and opacity
                svg.selectAll(".link, .node").style("visibility", "visible").style("opacity", "1");
                // Show node names
                svg.selectAll(".node-name").style("visibility", "visible").style("opacity", "1");
            }

            function hide_select_nodes_text(node_list, visualization) {
                // Filter the text to those not belonging to the list of node names

                var not_selected_names = g.selectAll(".node-name").filter(function (d) {
                    return node_list.indexOf(d.name) < 0;
                });

                if (visualization != true) {
                    //noinspection JSDuplicatedDeclaration
                    var visualization_option = "opacity", on = "1", off = "0.1";
                } else {
                    //noinspection JSDuplicatedDeclaration
                    var visualization_option = "visibility", on = "visible", off = "hidden";
                }

                // Change display property to 'none'
                $.each(not_selected_names._groups[0], function (index, value) {
                    value.style.setProperty(visualization_option, off);
                });
            }

            function hide_select_nodes_text_paths(data, visualization) {

                // Array with all nodes in all paths
                var nodes_in_paths = [];

                $.each(data, function (index, value) {
                    $.each(value, function (index, value) {
                        nodes_in_paths.push(value);
                    });
                });

                // Filter the text whose innerHTML is not belonging to the list of nodeIDs
                var not_selected_names = g.selectAll(".node-name").filter(function (d) {
                    return nodes_in_paths.indexOf(d.id) < 0;
                });

                if (visualization != true) {
                    //noinspection JSDuplicatedDeclaration
                    var visualization_option = "opacity", on = "1", off = "0.1";
                } else {
                    //noinspection JSDuplicatedDeclaration
                    var visualization_option = "visibility", on = "visible", off = "hidden";
                }

                // Change display property to 'none'
                $.each(not_selected_names._groups[0], function (index, value) {
                    value.style.setProperty(visualization_option, off);
                });
            }

            function selected_edge_highlight(edge) {

                // Array with names of the nodes in the selected edge
                var mapped_nodes_names = [];

                // Filtered not selected links
                var links_not_mapped = g.selectAll(".link").filter(function (el) {

                    if (el.label == edge) {
                        mapped_nodes_names.push(el.source.id);
                        mapped_nodes_names.push(el.target.id);
                    }

                    // Source and target should be present in the edge
                    return el.label != edge;
                });

                hide_select_nodes_text(mapped_nodes_names, false);

                var not_mapped_nodes_objects = node.filter(function (el) {
                    return mapped_nodes_names.indexOf(el.id) < 0;
                });

                not_mapped_nodes_objects.style("opacity", "0.1");
                links_not_mapped.style("opacity", "0.1");

            }

            // Highlight nodes from array of ids and change the opacity of the rest of nodes
            function selected_nodes_highlight(node_list) {

                hide_select_nodes_text(node_list, false);
                console.log('Node list');
                console.log(node_list);

                // Filter not mapped nodes to change opacity
                var not_mapped_nodes_objects = svg.selectAll(".node").filter(function (el) {
                    return searchForArray(node_list, el.id) < 0;
                });

                // Not mapped links
                var links_not_mapped = g.selectAll(".link").filter(function (el) {
                    // Source and target should be present in the edge

                    return !((searchForArray(node_list, el.source.id) >= 0 || searchForArray(node_list, el.target.id) >= 0));
                });

                not_mapped_nodes_objects.style("opacity", "0.1");
                links_not_mapped.style("opacity", "0.1");
            }

            function color_all_paths(data, visualization) {

                /**
                 * Returns a random integer between min (inclusive) and max (inclusive)
                 * Using Math.round() will give you a non-uniform distribution!
                 */
                function getRandomInt(min, max) {
                    return Math.floor(Math.random() * (max - min + 1)) + min;
                }

                // data: nested array with all nodes in each path
                // visualization: parameter with visualization info ('hide' || 'opaque)

                var link = g.selectAll(".link");

                ///////// Filter the nodes ////////

                // Array with all nodes in all paths
                var nodes_in_paths = [];

                $.each(data, function (index, value) {
                    $.each(value, function (index, value) {
                        nodes_in_paths.push(value);
                    });
                });

                // Filtering the nodes that are not in any of the paths
                var not_mapped_nodes_objects = svg.selectAll(".node").filter(function (el) {
                    return nodes_in_paths.indexOf(el.id) < 0;
                });

                if (visualization != true) {
                    //noinspection JSDuplicatedDeclaration
                    var visualization_option = "opacity", on = "1", off = "0.1";
                } else {
                    //noinspection JSDuplicatedDeclaration
                    var visualization_option = "visibility", on = "visible", off = "hidden";
                }
                not_mapped_nodes_objects.style(visualization_option, off);

                ///////// Colour links in each path differently and hide others ////////

                // Colour the links ( Max 21 paths )
                var color_list = ['#ff2200', ' #282040', ' #a68d7c', ' #332b1a', ' #435916', ' #00add9', ' #bfd0ff', ' #f200c2',
                    ' #990014', ' #d97b6c', ' #ff8800', ' #f2ffbf', ' #e5c339', ' #5ba629', ' #005947', ' #005580', ' #090040',
                    ' #8d36d9', ' #e5005c', ' #733941', ' #993d00', ' #80ffb2', ' #66421a', ' #e2f200', ' #20f200', ' #80fff6',
                    ' #002b40', ' #6e698c', ' #802079', ' #330014', ' #331400', ' #ffc480', ' #7ca682', ' #264a4d', ' #0074d9',
                    ' #220080', ' #d9a3d5', ' #f279aa'];

                // iter = number of paths ( Max 21 paths )
                if (data.length > color_list.length) {
                    //noinspection JSDuplicatedDeclaration
                    var iter = color_list.length;
                } else {
                    //noinspection JSDuplicatedDeclaration
                    var iter = data.length;
                }

                // First hide or set to opacity 0.1 all links
                link.style(visualization_option, off);

                // Make visible again all the edges that are in any of the paths
                var links_in_paths = [];

                for (var x = 0; x < iter; x++) {

                    // Push the array (each path) to a new one where all paths are stored
                    var path = link.filter(function (el) {
                        // Source and target should be present in the edge and the distance in the array should be one
                        return ((data[x].indexOf(el.source.id) >= 0 && data[x].indexOf(el.target.id) >= 0)
                        && (Math.abs(data[x].indexOf(el.source.id) - data[x].indexOf(el.target.id)) == 1));
                    });

                    links_in_paths.push(path);
                }

                // Only the links that are in any of the paths are visible
                for (var j = 0, len = links_in_paths.length; j < len; j++) {
                    links_in_paths[j].style(visualization_option, on);
                }

                // For each path give a different color
                for (var i = 0; i < iter; i++) {
                    var links_in_this_path = link.filter(function (el) {
                        // Source and target should be present in the edge and the distance in the array should be one
                        return ((data[i].indexOf(el.source.id) >= 0 && data[i].indexOf(el.target.id) >= 0)
                        && (Math.abs(data[i].indexOf(el.source.id) - data[i].indexOf(el.target.id)) == 1));
                    });

                    // Select randomly a color and apply to this path
                    links_in_this_path.style("stroke", color_list[getRandomInt(0, 21)]);
                }

            }

            // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is "Space" that triggers the freeze
            d3.select(window).on("keydown", freezeGraph);

            /////////////////////////
            // Additional features //
            /////////////////////////

            function download_link(response, name) {
                var element = document.createElement('a');
                element.setAttribute('href', 'data:text/plain;charset=utf-8,' + encodeURIComponent(response));
                element.setAttribute('download', name);
                element.style.display = 'none';
                document.body.appendChild(element);
                element.click();
                document.body.removeChild(element);
            }

            // Build the node multi-level dropdown
            $('#node-list').append("<ul id='node-list-ul' class='dropdown-menu node-dropdown' role='menu' " +
                "aria-labelledby='dropdownMenu' " + "class='no-bullets min-padding-left'></ul>");

            // Variable with all node names for shortest path autocompletion input
            var node_names = [];

            $.each(graph.nodes, function (key, value_array) {

                node_names.push(value_array.id);

                $("#node-list-ul").append("<li class='dropdown-submenu node_selector node-dropdown'><a id='" +
                    value_array.id + "'>" + value_array.name + "<ul class='dropdown-menu no-bullets min-padding-left'>" +
                    "<li>Name: " + value_array.name + "" + "</li><li>Namespace: " + value_array.namespace + "</li>" +
                    "<li>BEL function: " + value_array.function + "</li></ul></li>");
            });

            ///////////////////////////////////////
            // Build the edge multi-level dropdown
            ///////////////////////////////////////

            $('#edge-list').append("<ul id='edge-list-ul' class='dropdown-menu edge-dropdown' role='menu' " +
                "aria-labelledby='dropdownMenu' " + "class='no-bullets min-padding-left'></ul>");

            $.each(graph.links, function (key, value_array) {

                var pubmed_hyperlink = 'https://www.ncbi.nlm.nih.gov/pubmed/' + value_array.citation.reference;

                $("#edge-list-ul").append("<li class='dropdown-submenu edge_selector '><a id='value'>" +
                    value_array.source.name + ' ' + value_array.relation + ' ' + value_array.target.name +
                    "</a><ul class='dropdown-menu no-bullets min-padding-left edge-info'><li><span class='color_red'>" +
                    "From: </span>" + value_array.source.name + "</li><li><span class='color_red'>To: </span>" +
                    value_array.target.name + "</li><li><span class='color_red'>Relationship </span>" + value_array.relation +
                    "</li><li><span class='color_red'>PubMed: </span><a href='" + pubmed_hyperlink + "' target='_blank' " +
                    "style='color: blue; text-decoration: underline'>" + value_array.citation.reference + "</a></li><li>" +
                    "<span class='color_red'>Journal: </span>" + value_array.citation.name + "</li><li>" +
                    "<span class='color_red'>Evidence: </span>" + value_array.SupportingText + "+</li><li>" +
                    "<span class='color_red'>Context: </span>" + value_array.context + "" + "</li></ul></li>");

            });

            // Shortest path autocompletion input
            node_names = node_names.sort();

            $("#source-node").autocomplete({
                source: node_names,
                appendTo: "#info-graph"
            });

            $("#target-node").autocomplete({
                source: node_names,
                appendTo: "#info-graph"
            });

            // Select node in the graph from selector
            $(".node_selector").click(function () {

                reset_attributes();

                // $this=li, first element is the a with the id of the node
                var node_array = [$(this)[0].childNodes[0].id.split(',')];
                selected_nodes_highlight(node_array);
                reset_attributes_on_double_click();

            });

            // Update Node Dropdown
            $("#node-search").on("keyup", function () {
                // Get value from search form (fixing spaces and case insensitive
                var searchText = $(this).val();
                searchText = searchText.toLowerCase();
                searchText = searchText.replace(/\s+/g, '');

                $.each($('#node-list-ul')[0].childNodes, dropdown_update);
                function dropdown_update() {
                    var currentLiText = $(this).find("a")[0].innerHTML,
                        showCurrentLi = ((currentLiText.toLowerCase()).replace(/\s+/g, '')).indexOf(searchText) !== -1;
                    $(this).toggle(showCurrentLi);
                }
            });

            // Update Edge Dropdown
            $("#edge-search").on("keyup", function () {
                // Get value from search form (fixing spaces and case insensitive
                var searchText = $(this).val();
                searchText = searchText.toLowerCase();
                searchText = searchText.replace(/\s+/g, '');

                $.each($('#edge-list-ul')[0].childNodes, dropdown_update);
                function dropdown_update() {

                    var currentLiText = $(this).find("a")[0].innerHTML,
                        showCurrentLi = ((currentLiText.toLowerCase()).replace(/\s+/g, '')).indexOf(searchText) !== -1;
                    $(this).toggle(showCurrentLi);
                }
            });

            // Select node in the graph from selector
            $(".edge_selector").on("click", "#value", function () {
                console.log($(this)[0])

                reset_attributes();

                // textContent or innerHTML
                var edge_name = $(this)[0].innerHTML;
                selected_edge_highlight(edge_name);

                reset_attributes_on_double_click()
            });

            // Hide text in graph
            $("#hide_node_names").on("click", function () {
                svg.selectAll(".node-name").style("display", "none");
            });

            // Hide text in graph
            $("#restore_node_names").on("click", function () {
                svg.selectAll(".node-name").style("display", "block");
            });

            // Hide text in graph
            $("#restore").on("click", function () {
                reset_attributes();
            });
        }
        ;

        // Saves visualized network as image
        $("#save-svg-graph").click(function () {
            var graphName = "graph_image";
            var svgContainer = $("svg").svg(),
                svgGet = svgContainer.svg("get");
            svgGet = svgGet.toSVG();
            var blob = new Blob([svgGet], {type: "data:image/svg+xml;charset="});
            saveAs(blob, graphName + ".svg");
        });


    </script>
    <script type="text/javascript">
        $(document).ready(function () {
            init_d3_force(window.graph);
        });
    </script>

</head>
<body>
<div id="graph-chart">
</div>
</body>
</html>
